CA2488682A1 - Gene differentially expressed in breast and bladder cancer and encoded polypeptides - Google Patents

Gene differentially expressed in breast and bladder cancer and encoded polypeptides Download PDF

Info

Publication number
CA2488682A1
CA2488682A1 CA002488682A CA2488682A CA2488682A1 CA 2488682 A1 CA2488682 A1 CA 2488682A1 CA 002488682 A CA002488682 A CA 002488682A CA 2488682 A CA2488682 A CA 2488682A CA 2488682 A1 CA2488682 A1 CA 2488682A1
Authority
CA
Canada
Prior art keywords
seq
peptide
amino acids
analog
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002488682A
Other languages
French (fr)
Other versions
CA2488682C (en
Inventor
Maurice Zauderer
Elizabeth E. Evans
Melinda A. Borrello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Vaccinex Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2488682A1 publication Critical patent/CA2488682A1/en
Application granted granted Critical
Publication of CA2488682C publication Critical patent/CA2488682C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relat es to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 pepti de epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The presen t invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic composition s or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

GENE DIFFERENTIALLY EXPRESSED IN BREAST AND BLADDER
CANCER AND ENCODED POLYPEPTIDES
BACKGROUND OF THE INVENTION
Field of the Invention [0001] The present invention relates to a novel human gene that is differentially expressed in human breast and bladder carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35. This invention also relates to C35 polypeptides, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast and bladder carcinomas. . The present invention further relates to the formulation and use of the C35 gene and polypeptides in immunogenic compositions or vaccines, to induce antibody and cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
Background Art [0002] Cancer afflicts approximately 1.2 millionpeople in the United States each year. About 50% of these cancers are curable with surgery, radiation therapy, and chemotherapy. Despite significant technical advances in these three types of treatments, each year more than 500,000 people will die of cancer in the United States alone. (Jaffee, E. M., Ann. N. Y. Acad. Sci. 886:67-72 (1999)). Because most recurrences are at distant sites such as the liver, brain, bone, and lung, there is an urgent need for improved systemic therapies.
[0003] The goal of cancer treatment is to develop modalities that specifically target tumor cells, thereby avoiding unnecessary side effects to normal tissue.
Immunotherapy has the potential to provide an alternative systemic treatment for most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. One form of immunotherapy, vaccines, is particularly attractive because they can also provide for active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response.
[0004] The possibility that altered features of a tumor cell are recognized by the immune system as non-self and may induce protective immunity is the basis for attempts to develop cancer vaccines. Whether or not this is a viable strategy depends on how the features of a transformed cell are altered. Appreciation of the central role of mutation in tumor transformation gave rise to the hypothesis that tumor antigens arise as a result of random mutation in genetically unstable cells.
Although random mutations might prove immunogenic, it would be predicted that these would induce specific immunity unique for each tumor. This would be unfavorable for development of broadly effective tumor vaccines. An alternate hypothesis, however, is that a tumor antigen may arise as a result of systematic and reproducible tissue specific gene deregulation that is associated with the transformation process. This could give rise to qualitatively or quantitatively different expression of shared antigens in certain types of tumors that might be suitable targets for immunotherapy. Early results, demonstrating that the immunogenicity of some experimental tumors could be traced to random mutations (De Plaen, et al., P~~oc. Natl. Acad. Sci. USA 85: 2274-2278 (1988);
Srivastava, & Old, Imfnunol. Today 9:78 (1989)), clearly supported the first hypothesis. There is, however, no a priori reason why. random mutation and systematic gene deregulation could not both give rise to new immunogenic expression in tumors. Indeed, more recent studies in both experimental tumors (Sahasrabudhe et al., J. Immunol. 151:6202-6310 (1993); Torigoe et al., J.
Imnaunol. 147:3251 (1991)) and human melanoma (van Der Bruggen et al., Science X54:1643-1647 (1991 ); Brichard et al., J. Exp. Med. l 78:489-495 (1993);
Kawakami et al., P~oc. Natl_ Acad. Sci. USA 91:3515-3519 (1994); Boel et al., Immunity 2:167-175 (1995); Van den Eynde et al., J. Exp. Med. 182: 689-698 (1995)) have clearly demonstrated expression of shared tumor antigens encoded by deregulated normal genes. The identification of MAGE-1 and other antigens common to different human melanoma holds great promise for the future development of multiple tumor vaccines.
[0005] In spite of the progress in melanoma, very few shared antigens recognized by cytotoxic T cells have not been described for other human tumors. The major challenge is technological. The most widespread and to date most successful approach to identify immunogenic molecules uniquely expressed in tumor cells is to screen a cDNA library with tumor-specific CTLs (cytotoxic T
lymphocytes).
Application of this strategy has led to identification of several gene families expressed predominantly in human melanoma. Two major limitations of this approach, however, are that (1) screening requires labor intensive transfection of numerous small pools of recombinant DNA into separate target populations, which themselves often need to be modified to express one or more MHC
molecules required for antigen presentation, in order to assay T cell stimulation by a minor component of some pool; and (2) with the possible exception of renal cell carcinoma, tumor-specific CTLs have been very difficult to isolate from either tumor infiltrating lymphocytes (T1L) or PBL of patients with other types of tumors, especially the epithelial cell carcinomas that comprise greater than 80% of human tumors. It appears that there may be tissue specific properties that result in tumor-specific CTLs being sequestered in melanoma.
[0006] Direct immunization with tumor-specific gene products may be essential to elicit an immune response against some shared tumor antigens. It has been argued that, if a tumor expressed strong antigens, it should have been eradicated prior to clinical manifestation. Perhaps then, tumors express only weak antigens.
Immunologists have long been interested in the issue of what makes an antigen weak or strong. There have been two major hypotheses. Weak antigens may be poorly processed and fail to be presented effectively to T cells.
Alternatively, the number of T cells in the organism with appropriate specificity might be inadequate for a vigorous response (a so-called "hole in the repertoire").
Elucidation ofthe complex cellularprocess whereby antigenic peptides associate with MHC molecules for transport to the cell surface and presentation to T
cells has been one of the triumphs of modern immunology. These experiments have clearly established that failure of presentation due to processing defects or competition from other peptides could render a particular peptide less immunogenic. In contrast, it has, for technical reasons, been more difficult to establish that the frequency of clonal representation in the T cell repertoire is an important mechanism of low responsiveness. Recent studies demonstrating that the relationship between immunodominant and cryptic peptides of a protein antigen change in T cell receptor transgenic mice suggest, however, that the relative frequency of peptide-specific T cells can, indeed, be a determining factor in whether a particular peptide is cryptic or dominant in a T cell response.
This has encouraging implications for development of vaccines. With present day methods, it would be a complex and difficult undertaking to modify the way in which antigenic peptides of a tumor are processed and presented to T cells.
The relative frequency of a specific T cell population can, however, be directly and effectively increased by prior vaccination. This could, therefore, be the key manipulation required to render an otherwise cryptic response immunoprotective.
These considerations of cryptic or sub-dominant antigens have special relevance in relation to possible immune evasion by tumors through tolerance induction.
Evidence has been presented to suggest that tumor-specific T cells in the tumor-bearing host are anergic, possibly as a result of antigen presentation on non-professional APC (Morgan, D.J. et al., J. Immunol. 163:723-27 (1999);
Sotomayor, E.M. et al., Proc. Natl. Acad. Sci. U.SA. 96:11476-~1 (1999); Lee, P.P. et al., Nature Medicine 5:677-~5 (1999)). Prior tolerization of T cells specific for immunodominant antigens of a tumor may, therefore, account for the difficulty in developing successful strategies for immunotherapy of cancer.
These observations suggest that T cells specific for immunodominant tumor antigens are less likely to be effective for immunotherapy of established tumors because they are most likely to have been tolerized. It may, therefore, be that T cells specific for sub-dominant antigens or T cells that are initiallypresent at a lower frequency would prove more effective because they have escaped the tolerizing influence of a growing tumor.
[0007] Another major concern for the development of broadly effective human vaccines is the extreme polymorphism of HLA class I molecules. Class I
MHC:cellularpeptide complexes are the target antigens for specific CD8+ CTLs.
The cellular peptides, derived by degradation of endogenously synthesized proteins, are translocated into a pre-Golgi compartment where they bind to class I MHC molecules for transport to the cell surface. The CD 8 molecule contributes to the avidity of the interaction between T cell and target by binding to the a3 domain of the class I heavy chain. Since all endogenous proteins turn over, peptides derived from any cytoplasmic or nuclear protein may bind to an MHC
molecule and be transported for presentation at the cell surface. This allows T
cells to survey a much larger representation of cellular proteins than antibodies which are restricted to recognize conformational determinants of only those proteins that are either secreted or integrated at the cell membrane.
[0008] The T cell receptor antigen binding site interacts with determinants of both the peptide and the surrounding MHC. T cell specificity must, therefore, be defined in terms of an MHC:peptide complex. The specificity of peptide binding to MHC molecules is very broad and of relatively low affinity in comparison to the antigen binding sites of specific antibodies. Class I-bound peptides are generally 8-10 residues in length and accommodate amino acid side chains of restricted diversity at certain key positions that match pockets in the MHC
peptide binding site. These key features ofpeptides that bind to a particular MHC
molecule constitute a peptide binding motif.
[0009] Hence, there exists a need for methods to facilitate the induction and isolation of T cells specific for human tumors, cancers and infected cells and for methods to efficiently select the genes that encode the major target antigens recognized by these T cells in the proper MHC-context.

BRIEF SLJNIMARY OF THE INVENTION
[0010] The present invention relates to a novel polynucleotide, C35, that is differentially expressed in human breast and bladder carcinoma, and to the encoded polypeptide of C35. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing C35 polypeptides and polynucleotides. The present invention further relates to the formulation and use of C35 polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, and polynucleotides in immunogenic compositions to induce antibodies and cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene products. Also provided are diagnostic methods for detecting disorders relating to the C35 genes and polypeptides, including use as a prognostic marker for carcinomas, such as human breast carcinoma, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of C35.
[0011] Thus, in one embodiment, the invention relates to an isolated polypeptide comprising a peptide comprising two or more C3 S peptide epitopes, wherein said peptide is selected from the group consisting of amino acids T101 to V113 of SEQ ID N0:2, E100 to V113 of SEQ ID N0:2, G99 to V113 of SEQ ID N0:2, I93 to V113 of SEQ ID N0:2, D88 to V113 of SEQ ID N0:2, P84 to V113 of SEQ ID N0:2, K77 to V 113 of SEQ ID NO:2, Q72 to V 113 of SEQ ID N0:2, F65 to V 113 of SEQ ID NO:2, and L59 to V 113 of SEQ ID NO:2, and wherein said isolated polypeptide is not SEQ ID NO: 2, SEQ ID NO: 153, SEQ ID NO:
155, or amino acids E100 to 8109 of SEQ ID N0:2.
[0012] In another embodiment, the invention relates to an isolated polypeptide comprising at least one C35 peptide epitope analog, wherein said C35 peptide epitope analog is selected from the group consisting of for the peptide epitope G22 to C30 of SEQ ID N0:2 and FIG. 1B, the analogs with either alanine or glycine substituted for cysteine at the ninth amino acid residue; for the peptide epitope I25 to C33 of SEQ ID N0:2 and FIG.1B, the analogs with either alanine _7_ or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG. 1B, the analog with valine substituted for tyrosine at the ninth amino acid residue; for the peptide epitope Kl 04 to C 112 of SEQ ID N0:2 and FIG. l B, the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope K104 to V 113 of SEQ ID NO:2 and FIG. 1B, the analogs with alanine, serine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope I105 to Vl 13 of SEQ ID N0:2 and FIG. 1B, the analogs with either leucine or methionine substituted for threonine at the second amino acid residue and/or alanine, serine or glycine substituted for cysteine at the eighth amino acid residue; and for the peptide epitope N107 to L115 of SEQ ID NO:2 and FIG. 1B, the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue.
[0013] Preferably the isolated polypeptide of the invention is not more than amino acids in length, alternatively not more that 95 amino acids in length, alternatively not more than 90 amino acids in length, alternativelynot more than 85 amino acids in length, alternatively not more than 80 amino acids in length, alternatively not more than 75 amino acids in length, alternatively not more than 70 amino acids in length, alternatively not more than 65 amino acids in length, alternatively not more than 60 amino acids in length, alternatively not more than 55 amino acids in length, alternatively not more than 50 amino acids in length, alternatively not more than 45 amino acids in length, alternatively not more than 40 amino acids in length, or alternatively not more than 3 S amino acids in length.
[0014] In another embodiment, the invention relates to a fusion protein comprising an isolated peptide comprising two or more C35 peptide epitopes, wherein said isolated peptide is selected from the group consisting of amino acids T101 to V113 of SEQ ID N0:2, E100 to V113 of SEQ ID N0:2, G99 to V 113 of SEQ ID NO:2, I93 to V 113 of SEQ ID NO:2, D88 to V 113 of SEQ ID
N0:2, P84 to V113 of SEQ ID N0:2, K77 to V113 of SEQ ID N0:2, Q72 to V113 of SEQ ID N0:2, F65 to V113 of SEQ ID N0:2, and L59 to V113 of SEQ

_g_ ID N0:2. In a preferred embodiment, the fusion protein is a homopolymer of said isolated peptide. In another preferred embodiment, the fusion protein is a heteropolymer of said isolated polypeptides. In yet another embodiment, the fusion protein is fused to a T helper peptide. In still another embodiment, the fusion protein is fused to a carrier. In another embodiment, the fusion protein is linked to a lipid.
[0015] In another embodiment, the invention relates to an isolated polypeptide consisting oftwo or more C35 peptide epitopes, wherein said isolated polypeptide is selected from the group consisting of amino acids T101 to V113 of SEQ ID
N0:2, E100 to V113 of SEQ ID N0:2, G99 to V113 of SEQ ID N0:2, I93 to V113 of SEQ ID N0:2, D88 to V113 of SEQ ~ N0:2, P84 to V113 of SEQ ll~
N0:2, K77 to V 113 of SEQ ID NO:2, Q72 to V 113 of SEQ ID N0:2, F65 to V 113 of SEQ ID N0:2, and L59 to V 113 of SEQ ID N0:2, and wherein said isolated polypeptide is not SEQ ID NO: 2, SEQ ID NO: 153, SEQ ID NO: 155, or amino acids E100 to 8109 of SEQ ID NO:2.
[0016] In another embodiment, the invention relates to an isolated polypeptide comprising apeptide comprising at least one C35 peptide epitope analog, wherein said peptide is selected from the group consisting of the analog of peptide to V 113 of SEQ ~ N0:2 having either alarune or glycine substituted for the cysteine at the twelfth residue, the analog of peptide E100 to V113 of SEQ ID
NO:2 having either alanine or glycine substituted for the cysteine at the thirteenth residue, the analog ofpeptide G99 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for cysteine at the fourteenth residue, the analog of peptide I93 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the twentieth residue, the analog of peptide D88 to V113 of SEQ ID
N0:2 having either alanine or glycine substituted for the cysteine at the twenty-fifth residue, the analog of peptide P84 to V113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the twenty-ninth residue, the analog of peptide K77 to Vl 13 of SEQ ll~ N0:2 having either alanine or glycine substituted for the cysteine at the thirty-sixth residue, the analog of peptide Q72 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the forty-first residue, the analog of peptide F65 to V113 of SEQ
ID
N0:2 having either alanine or glycine substituted for the cysteine at the foriy-eighth residue, and the analog of peptide L59 to V113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue.
[0017] In another embodiment, the invention relates to a fusion protein comprising apeptide comprising at least one C35 peptide epitope analog, wherein said peptide is selected from the group consisting of for the peptide epitope to C30 of SEQ DJ N0:2 and FIG. 1B, the analogs with either alanine or glycine substituted for cysteine at the ninth amino acid residue; for the peptide epitope I25 to C33 of SEQ ID N0:2 and FIG. 1B, the analogs with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG. 1B, the analog with valine substituted for tyrosine at the ninth amino acid residue; for the peptide epitope K104 to C 112 of SEQ ID NO:2 and FIG.
lB, the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope K104 to V 113 of SEQ ID N0:2 and FIG. 1B, the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope I105 to V
113 of SEQ ID N0:2 and FIG. 1B, the analogs with either leucine, serine or methionine substituted for threonine at the second amino acid residue and/or alanine or glycine substituted for cysteine at the eighth amino acid residue; and for the peptide epitope N107 to V113 of SEQ ID N0:2 and FIG. 1B, the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue, the analog of peptide T101 to V113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the twelfth residue, the analog of peptide E100 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for cysteine at the thirteenth residue, the analog of peptide G99 to V 113 of SEQ
ID
N0:2 having either alanine or glycine substituted for cysteine at the fourteenth residue, the analog of peptide I93 to V 113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twentieth residue, the analog of peptide D88 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the twenty fifth residue, the analog of peptide P84 to V
113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the twenty-ninth residue, the analog of peptide K77 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the thirty sixth residue, the analog of peptide Q72 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the forty first residue, the analog of peptide F65 to V 113 of SEQ ID N0:2 having either alanine or glycine substituted for the cysteine at the forty-eighth residue, and the analog of peptide L59 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue. In a preferred embodiment, the fusion protein comprises a homopolymer of said peptide comprising at least one C35 peptide epitope analog.
In another preferred embodiment, the fusion protein comprises a heteropolymer of said peptide comprising at lesat one C35 peptide epitope analog.
[0018] In another embodiment, the invention relates to a composition comprising an isolated polypeptide or fusion protein of the invention and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE FIGURES
[0019] FIGS. lA and 1B. FIG. lA shows the DNA coding sequence (SEQ ID
NO:1) of C35. The sequence immediately upstream of the predicted ATG start codon is shown in lower case and conforms to the expected features described by Kozak, M., J. Bzol. Chem. 266(30):19867-19870 (1991). FIG. 1B shows the deduced amino acid sequence (SEQ ID N0:2) of C35.
[0020] FIGS. 2A-2C. FIG. 2A: C35 is overexpressed in Breast tumor cell lines.
Upper Panel: 300ng of poly A RNA from 3 week old human thymus, normal breast epithelial cell line H16N2 from patient 21, and 4 breast tumor cell lines derived one year apart from primary or metastatic nodules of the same patient 21;

21NT, 21PT 21MT1, and 21MT2, was resolved on a 1% agarose/formaldehyde gel and transferred to a GeneScreen membrane. This blot was hybridized with a 32P labeled C35 probe. Hybridization was detected by exposing the blot to film for 15 hours. Lower Panel: To quantitate RNA loading, the same blot was stripped and re-hybridized with a 32P labeled probe for Glyceraldehyde-3 Phosphate Dehydrogenase (GAPDH). For each sample the C35 signal was normalized to the GAPDH signal. The numbers represent the fold expression of C35 in each sample relative to H16N2. FIG. 2B: C35 is expressed at low levels in normal tissues. A Blot containing 1 microgram of poly A RNA from each of the indicated adult normal tissues (Clontech) was hybridized with a 32P
labeled C35 probe. Hybridization was detected by exposing the blot to film for 1 S
hours (upper panel), or 96 hours (lower panel). FIG. 2C. C35 is overexpressed in primary Breast tumors. A blot containing 2 micrograms of poly A RNA from 3 primary infiltrating ductal mammary carcinoma, T1, T2, T3 and 1 normal breast epithelium, N (Invitrogen) was hybridized with a 32P labeled C35 probe. To normalize loading a 3~P labeled beta-Actin probe was included in the hybridization mix. Hybridization was detected by exposing the blot to film for 6 hours. The numbers represent the fold expression of C35 in each sample relative to normal breast epithelium.
[0021] FIG. 3. Expression of C35 in Breast Tumor Cell Lines. C35 is overexpressed in different breast tumor cell lines. Upper Panel: 300ng of poly A
RNA from BT474 (ATCC HYB-20, mammary ductal carcinoma), SKBR3 (ATCC HTB-30, mammary adenocarcinoma), T47D (ATCC HTB-133, mammary ductal carcinoma), normal breast epithelial cell line H16N2 from patient 21, and 21-NT breast tumor cell line derived from primary tumor nodule of the same patient 21 was resolved on a 1% agaroselformaldehyde gel and transferred to a GeneScreen membrane. This blot was hybridized with a 32P
labeled C35 probe. Hybridization was detected by exposing the blot to film for 15 hours. Lower Panel: To quantitate RNA loading, the same blot was stripped and re-hybridized with a 3zP labeled probe for beta-actin. For each sample the C35 signal was normalized to the actin signal. The numbers represent the fold expression of C35 in each sample relative to H16N2.
[0022] FIGS. 4A-4C. Surface Expression of C35 Protein Detected by Flow Cytometry. 1 x 105 breast tumor cells were stained with 3.5 microliters of antiserum raised in BALB/c mice against Line 1 mouse tumor cells transduced with retrovirus encoding human C35 or control, pre-bleed BALB/c serum. After a 30 minute incubation, cells were washed twice with staining buffer (PAB) and incubated with FITC-goat anti-mouse IgG (1 ug/sample) for 30 minutes. S amples were washed and analyzed on an EPICS Elite flow cytometer. FIG. 4A: 21NT.
FIG. 4B: SKBR3. FIG. 4C: MDA-MB-231. These three breast tumor lines were selected to represent tumor cells that express high, intermediate and low levels of C35 RNA on Northern blots (see FIG. 3). Abbreviations: nms, ns;
normal mouse serum; C35; C35 immune serum.
[0023] FIGS. 5A and 5B. CML Selected Recombinant Vaccinia cDNA Clones Stimulate Tumor Specific CTL. FIG. 5A: CML Selected vaccinia clones were assayed for the ability, following infection of B/C.N, to stimulate tumor specific CTL to secrete interferon gamma. The amount of cytokine was measured by ELISA, and is represented as OD490 (1~. An OD490 of 1.4 is approximately equal to 4 ng/ml of IFNg, and an OD490 of 0.65 is approximately equal to 1 ng/ml of lFNg. FIG. 5B: CML selected clones sensitize host cells to lysis by tumor specific CTL. Monolayers of B/C.N in wells of a 6 well plate were infected with moi=1 of the indicated vaccinia virus clones. After 14 hours of infection the infected cells were harvested and along with the indicated control targets labeled with 5'Cr. Target cells were incubated with the indicated ratios of tumor specific Cytotoxic T Lymphocytes for 4 hours at 37°C and percentage specific lysis was determined (1 S). This experiment was repeated at least three times with similar results.
[0024] FIGS. 6A and 6B. The Tumor Antigen Is Encoded by a Ribosomal Protein L3 Gene. Sequence of H2.16 and rpL3 from amino acid position 45 to 56. FIG. 6A: The amino acid (in single letter code) and nucleotide sequence of cDNA clone rpL3 (GenBank Accession no. Y00225). FIG. 6B: A single nucleotide substitution at C 170T of the H2.16 tumor cDNA is the only sequence change relative to the published L3 ribosomal allele. This substitution results in a T54I amino acid substitution in the protein.
[0025] FIGS. 7A and 7B. Identification of the Peptide Epitope Recognized by the Tumor Specific CTL. FIG. 7A: CML assay to identify the peptide recognized by tumor specific CTL. Target cells were labeled with SICr (1 S). During the 5'Cr incubation samples of B/C.N cells were incubated with 1 p.M peptide L34g_ss(I54), 100 ~,M L3~g_56(T54) or 100~,M peptide L34s-sa(I54). Target cells were incubated with the indicated ratios of tumor specific Cytotoxic T Lymphocytes for 4 hours at 37°C and percentage specific lysis was determined. This experiment was repeated at least three times with similar results. FIG. 7B: Titration of peptide L348_ss (I54). Target cells were labeled with 5'Cr. During the 5'Cr incubation samples of B/C.N cells were incubated either with no peptide addition (D) or with the indicated concentrations (1 p,M, l OnM,1nM) of L348_ss(I54) (~), BCA 39 cells were inoluded as a positive control (1). Target cells were incubated with the indicated ratios of Tumor Specific Cytotoxic T Lymphocytes for 4 hours at 37 ° C
and percentage specific lysis was determined. The experiment was repeated twice with similar results. .
[0026] FIGS. 8A to 8C. Analysis of L3 Expressed by Each Cell Line. FIG. 8A:
Sau3AI map of published rpL3 and H2.16. Shown above is the Sau3AI
restriction map for the published ribosomal protein L3 gene (Top), and for H2.16 (Bottom). Digestion of cDNA for the published L3 sequence generates fragments of 200, 355, 348, 289, and 84bp. The pattern for H2.16 is identical except for an extra Sau3AI site at position 168 caused by the C170T. This results in a 168bp digestion product in place of the 200bp fragment. FIG. 8B: The BCA tumors express both L3 alleles. RT-PCR products generated from each cell line or from vH2. l 6 were generated using L3 specific primers and then digested with Sau3AI, and resolved on a 3% agarose gel for 2 hours at 80 volts. FIG. 8C: The T_m_m__unogenic L3 allele is expressed at greatly reduced levels in B/C.N, BCB
13, and Thymus. L3 specific RT-PCR products from each indicated sample were generated using a 32P end labeled 5 prime PCR primer. No PCR product was observed when RNA for each sample was used as template for PCR without cDNA synthesis, indicating that no sample was contaminated with genomic DNA. The PCR products were gel purified to ensure purity, digested with Sau3AI, and resolved on a 3% agarose gel for 15 hours at 60 volts. No PCR
product was observed in a control PCR sample that had no template added to it.
This result has been reproduced a total of 3 times.
[0027] FIGS. 9A to 9C. Immunization with iL3 is Itnmunoprotective. FIG. 9A:
Immunization with H2.16 induces tumor specific CTL. Balb/c mice (2/group) were immunized by subcutaneous inj ection with 5X106 pfu of vH2.16, or control vector v7.5/tk. S even days later splenocytes were harvested and restimulated with peptide L348_56(I54) (~~. Five days following the second restimulation the lymphocytes were tested in a chromium release assay as described in Figure 11.
The L34g_ss(I54) peptide was used at a 1 micromolar concentration, and the L3d8_ sb(T54) peptide was used at a 100 micromolar concentration. Similar results were obtained when the immunization experiment was repeated. FIGS. 9B and 9C:
Female Balb/cByJ mice were immunized as indicated (2~. The mice were challenged by SC injection with 200,000 viable BCA 34 tumor cells into the abdominal wall. Data is from day 35 post challenge. These data are representative of 4 independent experiments.
[0028] FIGS. l0A and 10B. FIG.10A: C35 coding sequence with translation; 5' and 3' untranslated regions are shown in lowercase letters. The predicted prenylation site, CVIL, at the 3' terminus is boxed. FIG. lOB: Genomic alignment of C35 gene on chromosome 17.
[0029] FIGS. 11A and 11B. C35 Expression in Breast Carcinoma. C35 was labeled with 32P in a random priming reaction and hybridized to Northern blots at 106 cpm/ml. Each blot was stripped and re-probed with GAPDH or Beta-actin to normalize mRNA loads. The numbers indicate densitometryratios normalized against GAPDH/Beta-actin. A value of 1 has been assigned to normal cell line H16N2, and all values are relative to the level of expression in the normal cell line. FIG. 11A: C35 expression in breast epithelial cell lines. FIG. 11B: C35 expression in primary breast tissue/tumors. 300 ng mRNA was electrophoresed on 0.8% alkaline agarose gels, then blotted to Genescreen Plus, except leftmost panel of B loaded with l ,ug mRNA from 3 primary tumors and 1 normal tissue control (Real Tumor Blots, Invitrogen). Similar exposures are shown for all blots.
[0030] FIG. 12. C35 Expression in Bladder Carcinoma. C35 was labeled with 3aP in a random priming reaction and hybridized to a Northern blot of tumor and normal RNA at 106 cpxn/ml. The blot was stripped and re-probed with Beta-actin to normalize mRNA loads. The numbers indicate densitometryratios normalized against Beta-actin. Values are relative to the level of expression in the normal bladder samples. 300 ng mRNA was electrophoresed on 0.8°1o alkaline agarose gels, then blotted to Genescreen Plus.
[0031] FIGS. 13A and 13B. FACS Analysis with Anti-C35 Antibodies. FIG.
13A: Breast cell lines were stained with (top panel) sera from mice immunized with Line 1 cells infected with C35 recombinant retrovirus, and (bottom panel) 2C3 purified monoclonal antibody or isotype control. FIG. 13B: Bladder cell lines stained with 2C3 purified monoclonal antibody or isotype control.
[0032] FIGS. 14A and 14B. Inhibition of Tumor Growth in Presence of 2C3 Antibody. 21NT breast tumor cells (FIG. 14A) or H16N2 normal breast epithelial cells (FIG. 14B) were incubated with the indicated concentrations of 2C3 anti-C35 monoclonal antibody or a non-specific isotype control antibody.
Cell growth was measured by XTT assay following 72 hour incubation in the presence or absence of antibodies.
[0033] FIGS.15A and 15B. CTL stimulated with C35 expressing dendritic cells specifically lyse C35+ Breast (21NT) and Bladder (ppT11A3) tumor cell lines, with minimal activity against normal breast (MEC), immortalized non-tumorigenic breast (H16N2) and bladder (SV-HUC) cell lines, or anNK sensitive cell line (K562). FIG. 15A: T cell line 4 was generated from normal human PBL. FIG. 15B: T cell clone lOG3 was selected from line 4 for C35-specific activity. Target cell lines MEC, ppTl lA3 and SV-HUC are naturally HLA-A2 positive. Target cell lines 21NT and H16N2 were transected with HLA-A2 to provide a required MHC restriction element.
(0034] FIGS. 16A and 16B. Cytokine Release from T Cell Clone lOG3 upon Stimulation with Targets. FIG. 16A: IFN-gamma secretion. FIG. 16B: TNF-alpha secretion. Breast and bladder target cell lines were distinguished by the presence or absence of expression of HLA-A2 and C35 tumor antigen, an amino terminal 50 amino acid fragment of C35 (C35-SOaa), or the irrelevant mouse L3 ribosomalprotein. Eachmarkerwaseitherendogenouslyexpressedorintroduced by transfection of an HLA-A2.1 construct (pSV2.A2), or by infection with a vaccinia recombinant of C35 (w.C35, w.C35-SOaa), L3 (w.L3), or HLA-A2 (w.A2) [0035] FIGS. 17A and 17B. Effect of anti-CD40 ligand antibody (anti-CD154) in blocking the reactivity of marine T cells to specific transplantation antigens.
DBA/2 (H-2d) mice were immunized with 10' C57B1/6 (H-2b) spleen cells intraperitoneally and, in addition, were injected with either saline or 0.5 mg monoclonal anti-CD40 ligand antibody (MR1, anti-CD 154, Phariningen 09021D) administered both at the time of immunization and two days later. On day 10 following immunization, spleen cells from these mice were removed and stimulated in vitro with either C57B1/6 or control allogeneic C3H (H-2~ spleen cells that had been irradiated (20 Gy). After 5 days of i~ vitro stimulation, C57B1/6 and C3H specific cytolytic responses were assayed at various effectoraarget ratios by $1Cr release assay from specific labeled targets, in this case, either C3H or C57B1/6 dendritic cells pulsed with syngeneic spleen cell lysates. Significant cytotoxicity was induced against the control C3H
alloantigens in both saline and anti-CD154 treated mice (FIG. 17A) whereas a cytotoxic response to C57B 1/6 was induced in the saline treated mice but not the anti-CD154 treated mice (FIG. 17B).
[0036) FIG. 18. GM-CSF Production by Line 4 After Stimulation with Native 21NT-A2 Tumor, H16N2-A2 Pulsed with Different C35 Peptides, or H16N2-A2 Infected with C35 Recombinant Vaccinia Virus. T cell line 4 was generated by stimulating normal donor T cells for 12 days each with autologous dendritic cells (DC) and then autologous monocytes infected with C35 recombinant vaccinia.virus. Weekly stimulation was continued with allo PBL and the 21NT
tumor transfected with HLA-A2/Kb (21NT-A2). For the experiment depicted here, the T cells were restimulated in vitro at 106 T cells per well with 5 x irradiated (2500 rads) H16N2-A2/Kb pulsed with lug/ml of C35 peptides 9-17, 77-85, 104-112, or 105-113 and 105 irradiated allo PBL per well with IL2 (20U/ml) and IL-7 (lOng/ml) in AIM-V/5% human AB serum. After two (2) rounds of stimulation for 7 days, T cells were tested for induction of GM-CSF
secretion following incubation with different stimulators pulsed or not pulsed with lug/ml of peptide or infected with vvC35 or vvWT at MOI = 1. T cells (5000) were incubated with 25000 of the various stimulator cells overnight in AIM-V/5% human AB serum in triplicate.
[0037] FIG. 19. C35-Specific ELISA of Hybridoma Supernatants. Results of a representative ELISA experiment involving hybridoma clones with demonstrated specificity for C35.
[0038] FIG. 20. Western Blot with C35-Specific Antibodies. Western Blot hnmunodetection was performed with supernatant from selected hybridoma clones. Antibodies from 4 hybridomas (1B3, 1F2, 3E10, 11B10) reacted specifically with hC35 protein in this assay. Results for antibodies 1B3,1F2, and 3E10 are shown.
[0039) FIG. 21. Immunohistochemistry with 1F2 Antibody. Monoclonal antibody 1F2 was shown to have utility for immunohistochemical staining of primary breast tumor sections. This Figure demonstrates that monoclonal antibody 1F2 can detect high levels of endogenous C35 expression in human breast tumors, with little or no staining of normal breast tissue.
Specifically, this Figure shows strong staining of a section of invasive breast adenocarcinoma from patient OlA6, while normal breast tissue from the same patient is negative.
DETAILED DESCRE'TION OF THE INVENTION
Definitions [0040] The following definitions are provided to facilitate understanding of certain terms used throughout this specification.
[0041] In the present invention, "isolated" refers to material removed from its native environment (e. g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
[0042] In the present invention, a "membrane" C35 protein is one expressed on the cell surface through either direct or indirect association with the lipid bilayer, including, in particular, through prenylation of a carboxyl-terminal amino acid motif. Prenylation involves the covalent modification of a protein by the addition of either a farnesyl or geranylgeranyl isoprenoid. Prenylation occurs on a cysteine residue located near the carboxyl-terminus of a protein. The C35 polypeptide contains the amino acids Cys-Val-Ile-Leu at positions 112-115, with the Leu being the C terminal residue of the polypeptide. The motif Cys-X-X-Leu, where "X" represents any aliphatic amino acid, results in the addition of a 20 carbon geranylgeranyl group onto the Cys residue. Generally, following addition of this lipid the three terminal amino acid residues are cleaved off the polypeptide, and the lipid group is methylated. Prenylation promotes the membrane localization of most proteins, with sequence motifs in the polypeptide being involved in directing the prenylated protein to the plasma, nuclear, or golgi membranes.

Prenylation plays a role in protein-protein interactions, and many prenylated proteins are involved in signal transduction. Examples of prenylated proteins include Ras and the nuclear lamin B. (Zhang, F.L. and Casey, P.J., Anh. Rev.
Biochem. 65:241-269 (1996)). The C35 protein has been detected on the surface of two breast tumor cell lines by fluorescence analysis employing as a primary reagent a mouse anti-human C35 antiserum (FIGS. 4A-4C).
[0043] In the present invention, a "secreted" C35 protein refers to a protein capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as a C35 protein released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the C35 secreted protein can undergo extracellularprocessing to produce a "mature" C35 protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
[0044] As used herein , a C35 "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:1. For example, the C35 polynucleotide can contain the nucleotide sequence of the full length cDNA
sequence, including the S' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
Moreover, as used herein, a C35 "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
[0045] In specific embodiments, the polynucleotides of the invention are less than 300 nt, 200 nt, 100 nt, 50 nt, 15 nt, 10 nt, or 7 nt in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of C35 coding sequence, but do not comprise all or a portion of any C35 intron. In another embodiment, the nucleic acid comprising C35 coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the C35 gene in the genome).
[0046] In the present invention, the full length C35 coding sequence is identified as SEQ m NO: 1.
[0047] A C35 "polynucleotide" also refers to isolated polynucleotides which encode the C35 polypeptides, and polynucleotides closely related thereto.
[0048] A C35 "polynucleotide" also refers to isolated polynucleotides which encode the amino acid sequence shown in SEQ m NO: 2, or a biologically active fragment thereof.
[0049] A C35 "polynucleotide" also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ m N0:1, the complement thereof, or the cDNA within the deposited clone.
"Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, Sx SSC (750 mM NaCI, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), Sx Denhardt's solution,10% dextran sulfate, and 2,0 ~,g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65°C.
[0050] Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA), or to a complementary stretch of T (or L~ residues, would not be included in the definition of "polynucleotide,"
since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
(0051] The C35 polynucleotide can be composed of any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, C35 polynucleotides can be composed of single-and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-and double-stranded regions, hybrid molecules comprising DNA and RNA that maybe single-stranded or, more typically, double-stranded or a mixture of single-and double-stranded regions. In addition, the C35 polynucleotides can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. C35 polynucleotides may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified"
bases include, for example, tritylated bases and unusual bases such as inosine.
A variety of modifications can be made to DNA and RNA; thus, "polynucleotide"
embraces chemically, enzymatically, or metabolically modified forms.
[0052] C35 polypeptides can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The C35 polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
Modifications can occur anywhere in the C35 polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given C35 polypeptide. Also, a given C35 polypeptide may contain many types of modifications. C35 polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic C35 polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, Proteins - Structure And Molecular Properties, 2nd Ed., T. E. Creighton, W. H.
Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, pgs.
1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NN1'Acad Sci 663:48-62 (1992).) [0053] "SEQ m NO: 1" refers to a C35 polynucleotide sequence while "SEQ ID
NO: 2" refers to a C35 polypeptide sequence.
[0054] A C35 polypeptide "having biological activity" refers to polypeptides exhibiting activity similar to, but not necessarily identical to, an activity of a C35 polypeptide, includingmature forms, as measured in aparticularbiological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the C35 polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the C35 polypeptide (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the C35 polypeptide.) C35 Polynucleotides and Polypeptides (0055] A 348 base pair fragment of C35 was initially isolated by subtractive hybridization of poly-A RNA from tumor and normal mammary epithelial cell lines derived from the same patient with primary and infiltrating intraductal mammary carcinoma. Band, V. et al., CanceY Res. 50:7351-7357 (1990).
Employing primers based on this sequence and that of an overlapping EST
sequence (Accession No. W57569), a cDNA that includes the full-length C35 coding sequence was then amplified and cloned from the BT-20 breast tumor cell line (ATCC, HTB-19). This C35 cDNA contains the entire coding region identified as SEQ m NO:l. The C35 clone includes, in addition to the 348 by coding sequence, 167 by of 3' untranslated region. The open reading frame begins at an N-terminal methionine located at nucleotide position 1, and ends at a stop codon at nucleotide position 348 (FIG. 1A). A representative clone containing all or most of the sequence for SEQ ID NO:l was deposited with the American Type Culture Collection ("ATCC") on August 1, 2000, and was given the ATCC Deposit Number PTA-2310. The ATCC is located at 10801 University Boulevard, Manassas, VA 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.
[0056] Therefore, SEQ ID NO: 1 and the translated SEQ ID NO: 2 are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO: 1 is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO: 1 or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:2 maybe used to generate antibodies which bind specifically to C35, or to stimulate T cells which are specific for C35 derived peptide epitopes in association with MHC
molecules on the cell surface.
[0057] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA
sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).
[0058] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:l and the predicted translated amino acid sequence identified as SEQ ID N0:2. The nucleotide sequence of the deposited C3 5 clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted C35 amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by the deposited clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human C35 cDNA, collecting the protein, and determining its sequence.
[0059] The present invention also relates to the C35 gene corresponding to SEQ
~ NO:1, or the deposited clone. The C35 gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the C35 gene from appropriate sources of genomic material.
[0060] Also provided in the present invention are species homologs of C35.
Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.
[0061] By "C35 polypeptide(s)" is meant all forms of C35 proteins and polypeptides described herein. The C35 polypeptides can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods.
Means for preparing such polypeptides are well understood in the art.
[0062] The C35 polypeptides may be in the form of the membrane protein or a secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.
[0063] C35 polypeptides are preferably provided in an isolated form, and preferably aresubstantiallypurified. ArecombinantlyproducedversionofaC35 polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988).
C35 polypeptides also can be purified from natural or recombinant sources using antibodies of the invention raised against the C35 protein in methods which are well known in the art.
(0064] In one embodiment, the present invention is directed to an isolated polypeptide capable of eliciting a cytotoxic T lymphocyte and/or helper T
lymphocyte response in ahuman subj ect, the isolated polypeptide comprising, or, alternatively, consisting of, one or more C35 peptide epitopes or C35 peptide epitope analogs. In a preferred embodiment, said one or more C35 peptide epitopes are selected from the group consisting of amino acids E4 to P 12 of SEQ
ID N0:2, amino acids S9 to V17 of SEQ 117 N0:2, amino acids S21 to Y29 of SEQ ID N0:2, G22 to C30 of SEQ ID N0:2, amino acids I25 to C33 of SEQ TD
N0:2, amino acids T38 to V46 of SEQ ID N0:2, amino acids G61 to I69 of SEQ
ID N0:2, amino acids T62 to N70 of SEQ ID N0:2, amino acids G63 to G71 of SEQ ID N0:2, amino acids F65 to L73 of SEQ ll~ N0:2, amino acids I67 to F75 of SEQ ID N0:2, amino acids K77 to Y85 of SEQ ID N0:2, amino acids Q72 to E86 of SEQ ID NO:2, amino acids G81 to L89 of SEQ ID NO:2, amino acids K104 to C112 of SEQ ID N0:2, amino acids K104 to V113 of SEQ ID N0:2, amino acids I105 to V113 of SEQ ID N0:2, and amino acids N107 to L115 of SEQ ID N0:2. In a preferred embodiment, the isolated polypeptides comprising one or more C35 peptide epitopes (e.g., one or more octamers, nonamers, decamers, l5mers, or 20mers in Tables 1-3 or 5-6) or C35 peptide epitope analogs (e.g., an analog listed in Table 4) are not more than 114 amino acids in length, more preferably not more than 110 amino acids in length, more preferably not more than 105 amino acids in length, more preferably not more than 100 amino acids in length, more preferably not more than 95 amino acids in length, more preferably not more than 90 amino acids in length, more preferably not more than 85 amino acids in length, more preferably not more than 80 amino acids in length, more preferably not more than 75 amino acids in length, more preferably not more than 70 amino acids in length, more preferably not more than 65 amino acids in length, more preferably not more than 60 amino acids in length, more preferably not more than 55 amino acids in length, more preferably not more than 50 amino acids in length, more preferably not more than 45 amino acids in length, more preferably not more than 40 amino acids in length, more preferablynot more than 35 amino acids in length, more preferablynot more than 30 amino acids in length, more preferably not more than 25 amino acids in length, more preferably 20 amino acids in length, more preferably 15 amino acids in length, more preferably 14, 13, 12, 11, 10, 9 or 8 amino acids in length. Of course, although not explicitly listed here, isolated polypeptides of any length between, for example, 8 and 100 amino acids, comprising C35 peptide epitopes or C35 peptide epitope analogs are likewise contemplated by the present invention. In a preferred embodiment, the isolated polypeptide is a fragment of the C35 polypeptide shown in SEQ ID NO:2 and FIG. 1B. In another embodiment, the present invention is directed to an isolated polypeptide capable of eliciting a cytotoxic T lymphocyte and/or helper T lymphocyte response in a human subject, the isolated polypeptide comprising, or, alternatively, consisting of multiple C35 peptide epitopes. In a particularly preferred embodiment, said multi-epitopepolypeptide is selected from the group consisting of amino acids T101 to V113 of SEQ ID N0:2, amino acids E100 to V113 of SEQ ID N0:2, amino acids G99 to V 113 of SEQ ID N0:2, amino acids I93 to V 113 of SEQ ID
N0:2, amino acids D88 to V113 of SEQ ID N0:2, amino acids P84 to V113 of SEQ ID N0:2, amino acids I~77 to V113 of SEQ ID N0:2, amino acids Q72 to V113 of SEQ ID N0:2, amino acids F65 to V113 of SEQ ID NO:2, and amino acids L59 to V 113 of SEQ ID NO:2. In another preferred embodiment, the present invention is directed to a fusion protein comprising at least one C35 peptide epitope listed in Tables 1-3 or 5-6, or a C35 peptide epitope analog listed in Table 4. In one embodiment, the at least one C35 peptide epitope or C35 peptide epitope analog is fused to a heterologous (i.e., non-C35) polypeptide.
In another preferred embodiment, said fusion protein comprises two or more C35 peptide epitopes or two or more C35 peptide epitope analogs, either as a homopolymer or a heteropolymer. In another preferred embodiment, the fusion proteins ofthe present invention comprise at least one C35 peptide epitope analog joined to at least one C35 peptide epitope. In a further embodiment, the epitopes/analogs are joined by an amino acid spacer or linker.
[0065] The present invention is further directed to a pharmaceutical composition for use as a vaccine comprising such isolated polypeptides and fusion proteins.
[0066) The present invention is further directed to a method for stimulating a cytotoxic T lymphocyte andlor a helper T lymphocyte response in a human patient comprising administering to said patient an immunogenically effective amount of the pharmaceutical composition of the invention.
Polynucleotide and Polypeptide Variants [0067] "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide, but retaining essential properties thereof.
Generally, variants are overall closely similar, and, in many regions, identical to the C35 polynucleotide or polypeptide.
[0068] By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the C35 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown of SEQ ~ NO:l, the ORF (open reading frame), or any fragment specified as described herein.
(0069] As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence or polypeptide sequence of the presence invention can be determined conventionallyusing known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al., Comp. App. Biosei. 6:237-245 (1990).
In a sequence alignment the query and subject sequences are both DNA
sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=l, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.
[0070] If the subj ect sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subj ect sequence when calculating percent identity. For subj ect sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence.
Whether a nucleotide is matchedlaligned is determined by results of the FASTDB
sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.
[0071] For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the .FASTDB alignment does not show a matchedlalignxnent of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subj ect sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.
[0072] By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subj ect polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% ofthe amino acid residues in the subject sequence may be inserted, deleted, or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
[0073] As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in SEQ ID N0:2 or to the amino acid sequence encoded by deposited DNA clone, can be determined conventionally using known computer programs.
A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB
computer program based on the algorithm of Brutlag et al., Co~rap. App.
Biosci.
6:237-245 (1990). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, JoiningPenalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.
[0074] If the subject sequence is shorter than the query sequence due to - or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for - and C-terminal truncations of the subj ect sequence when calculating global percent identity. For subj ect sequences truncated at the - and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are - and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matchedlaligned is determined by results of the FASTDB sequence alignment.
This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arnve at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the - and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes ofmanually adjusting the percent identity score.
That is, only query residue positions outside the farthest - and C-terminal residues of the subject sequence.
(0075] . For example, a 90 amino acid residue subj ect sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subj ect sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus.
The 10 unpaired residues represent 10% of the sequence (number of residues at the - and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB
program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the - or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the- and C-terminal ends of the subj ect sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.
[0076] The C35 variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide.

Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred.
C35 polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).
[0077] Naturally occurring C35 variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) Also, allelic variants can occur as "tandem alleles" which are highly homologous sequences that occur at different loci on chromosomes of an organism. These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.
[0078] Using known methods of protein engineering and recombinant DNA
technology, variants may be generated to improve or alter the characteristics of the C35 polypeptides. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein (Dobeli et al., J.
Biotechnology 7:199-216 (1988)).
[0079] Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-la. They used random mutagenesis to generate over 3,500 individual IL-la mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule.
Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.
[0080] Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the maj ority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking - or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.
[0081] Thus, the invention further includes C35 polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., ,Science X47:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.
[0082] The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated bynatural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.
X0083] The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) canbe used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.
[0084] As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu;
replacement of the amide residues Asn and Gln, replacement ofthe basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.
[0085] Besides conservative amino acid substitution, variants of C35 include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.
[0086] For example, C35 polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation.
Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin.
Exp. Immuhol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987);
Cleland et al., Crit. Rev. TherapeuticDrug Carrier Systems 10:307-377 (1993).) Polynucleotide and Polypeptide Fragments [0087] In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ m NO:1. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A
fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ m NO:1. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 50, 100, 150, 200, 250, 300 nucleotides) are preferred.
[0088] Moreover, representative examples of C35 polynucleotide fragments include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100,.101-150,151-200, 201-250, 251-300, or 301 to the end of SEQ ID
NO:1 or the cDNA contained in the deposited clone. In this context "about"
includes the particularly recited ranges, larger or smaller by several (S, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

[0089] In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:2 and FIG.1B or encoded by the cDNA
contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, or 101 to the end of the coding region. Moreover, polypeptide fragments can comprise about 7, 8, 9, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acids in length. In this context "about" includes the particularly recited ranges or lengths, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.
[0090] Preferred polypeptide fragments include the secreted C35 protein as well as the mature form. Further preferred polypeptide fragments include the secreted C35 protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. Further preferred polypeptide fragments include fragments ofthe C35 polypeptide comprising one ormore C35 peptide epitopes.
[0091] As mentioned above, even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other biological activities may still be retained.
Thus, the ability of shortened C35 muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a C35 mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, in the case of C35 peptide epitopes, peptides composed of as few as 9, 8, or even 7 C35 amino acid residues often evoke an immune response.
[.0092] Accordingly, the present invention further provides polypeptides having one or more residues deleted from the amino terminus of the C35 amino acid sequence shown in SEQ ID N0:2, up to the Threonine residue at position number 105 and polynucleotides encoding such polypeptides.
[0093] Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other biological activities may still be retained. Thus, the ability of the shortened C35 mutein to induce cytotoxic T
lymphocytes (CTLs) and/or helper T lymphocytes (HTLs) andlor to bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a C35 mutein with a large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities.
[0094] Accordingly, the present invention further provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the C35 polypeptide shown in SEQ ID N0:2, up to the valine residue at position number 10, and polynucleotides encoding such polypeptides [0095] Moreover, the invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini. In preferred embodiments, the invention is directed to peptides having residues: E4 to P
12, S9 to V17; V10 to V17; E16 to V23; E16 to R24; E16 to I25; S21 toY29; S21 to F35; G22 to C30; I25 to C33; C30 to T38; E31 to Y39; E36 to A43; A37 to A45;
A37 to V46; T38 to V46; Y39 to V46; S44 to I53; A45 to I53; G52 to L59; E54 to T62; S57 to F75; R58 to I67; L59 to V113; G61 to I69; T62 to N70, G63 to G71, G63 to F83; F65 to L73; F65 to Vl 13; E66 to L73; E66 to V74; I67 to F75;
K77 to Y85; K77 to Vl 13; Q72 to E86; Q72 to V113; G81 to L89; F83 to E103;
P84 to V 113; D88 to A96; D88 to V113; L89 to A96; A92 to T101; I93 to V 113;
R95 to L102; A96 to K104; G99 to V113, E100 to V113, T101 to V113; K104 to C112; K104 to V113; I105 to V113; I105 to I114; or N107 to,L115 of SEQ
ID N0:2 and polynucleotides encoding such polypeptides.
[0096] Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases.
,,[.0097] The human EST sequences referred to below were identified in a BLAST
search of the EST database. These sequences are believed to be partial sequences of the cDNA inserts identified in the recited GenBank accession numbers. No homologous sequences were identified in a search of the annotated GenBank database. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of matches. For example, an E value of 1 assigned to a hit can be interpreted as meaning that in a database of the current size one might expect to see 1 match with a similar score simply by chance.
[0098] For example, the following sequences are related to SEQ ID NO:l, GenBankAccessionNos.: AA971857 (SEQ ID N0:3); W57569 (SEQ ID N0:4);
AI288765 (SEQ ID NO:S ); W65390 (SEQ ID N0:6 ); W37432 (SEQ ll~ NO: 7);
N42748 (SEQ ID N0:8 ); AA971638 (SEQ ID NO:9 ); R22331 (SEQ ID NO:10);
AA308370 (SEQ ID NO:11 ); AA285089 (SEQ ID N0:12 ); R68901 (SEQ ID
N0:13 ); AA037285 (SEQ ID N0:14 ); H94832 (SEQ 117 NO:l 5); H96058 (SEQ
ID N0:16); H56522 (SEQ ID N0:17); AA935328 (SEQ ID N0:18); AW327450 (SEQ ID N0:19); AW406075 (SEQ ID N0:20); AW406223 (SEQ ID N0:21);
AI909652 (SEQ ll~ NO:22); AA026773 (SEQ ID NO: 23); H96055 (SEQ ID

N0:24); H12836 (SEQ m N0:25); 822401 (SEQ m N0:26); N34596 (SEQ m N0:27); W32121 (SEQ m N0:28); T84927 (SEQ m N0:29); 863575 (SEQ m N0:30); 823139 (SEQ m N0:31); AA337071 (SEQ m N0:32); AA813244 (SEQ m N0:33); AA313422 (SEQ m N0:34); N31910 (SEQ m N0:35);
N42693 (SEQ m N0:36); N32532 (SEQ m N0:37); AA375119 (SEQ m N0:38); 832153 (SEQ m N0:39); 823369 (SEQ m N0:40); AA393628 (SEQ
m N0:41); H12779 (SEQ m N0:42); AI083674 (SEQ m N0:43); AA284919 (SEQ m N0:44); AA375286 (SEQ m N0:45); AA830592 (SEQ m N0:46);
H95363 (SEQ m N0:47); T92052 (SEQ m N0:48); AI336555 (SEQ m N0:49); AI285284 (SEQ m NO:50); AA568537 (SEQ m NO:51); AI041967 (SEQ B7 N0:52); W44577 (SEQ m N0:53); 822332 (SEQ m N0:54); N27088 (SEQ m NO:55); H96418 (SEQ m N0:56); AI025384 (SEQ m N0:57);
AA707623 (SEQ m N0:58); AI051009 (SEQ m N0:59); AA026774 (SEQ m N0:60); W51792 (SEQ m N0:61); AI362693 (SEQ ID N0:62); AA911823 (SEQ m N0:63); H96422 (SEQ B? N0:64); AI800991 (SEQ m N0:65);
AI525314 (SEQ m N0:66); AI934846 (SEQ m N0:67); AI937133 (SEQ m N0:68); AW006797 (SEQ m N0:69); AI914716 (SEQ ~ N0:70); AI672936 (SEQ m N0:71); W61294 (SEQ m N0:72); AI199227 (SEQ m N0:73);
AI499727 (SEQ m N0:74); 832154 (SEQ m N0:75); AI439771 (SEQ m N0:76); AA872671 (SEQ m N0:77); AA502178 (SEQ m N0:78); N26715 (SEQ m N0:79); AA704668 (SEQ m N0:80); 868799 (SEQ m NO:81);
H56704 (SEQ m N0:82); AI360416 (SEQ m N0:83).
[0099] Thus, in one embodiment the present invention is directed to polynucleotides comprising the polynucleotide fragments and full-length polynucleotide (e.g. the coding region) described herein exclusive of one or more of the above-recited ESTs. Also, the nucleotide sequences in SEQ m N0: 152, SEQ m NO: 154, and SEQ m N0:156 are excluded from the present invention.
[0100] Also preferred are C35 polypeptide and polynucleotide fragments characterized by structural or functional domains. Preferred embodiments of the invention include fragments that comprise MHC binding epitopes andprenylation sites.
[0101] Other preferred fragments are biologically active C35 fragments.
Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the C35 polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.
Epitopes & Antibodies [0102] Cellular peptides derived by degradation of endogenously synthesized proteins are translocated into a pre-Golgi compartment where they bind to Class I or Class II MHC molecules for transport to the cell surface. These class I
MHC:peptide complexes are the target antigens for specific CD8+ cytotoxic T
cells. Since all endogenous proteins "turn over," peptides derived from any cytoplasmic or nuclear protein may bind to an MHC molecule and be transported for presentation at the cell surface. This allows T cells to survey a much larger representation of cellular proteins than antibodies which are restricted to recognize conformational determinants of only those proteins that are either secreted or integrated at the cell membrane. The T cell receptor antigen binding site interacts with determinants of both the peptide and the surrounding MHC.
T cell specificity must, therefore, be defined in terms of an MHC:peptide complex. The specificity of peptide binding to MHC molecules is very broad and of relatively low affinity in comparison to the antigen binding site of specific antibodies. Class I-bound peptides are generally 8-10 residues in length that accommodate amino acid side chains of restricted diversity at certain key positions that match pockets in the MHC peptide binding site. These key features of peptides that bind to a particular MHC molecule constitute a peptide binding motif.

[0103] The term "derived" when used to discuss a peptide epitope is a synonym for "prepared." A derived epitope can be isolated from a natural source, or it can be synthesized in accordance with standard protocols in the art. Synthetic epitopes can comprise artificial amino acids "amino acid mimetics," such as D
isomers of natural occurring L amino acids or non-natural amino acids such as cyclohexylalanine. A derivedlprepared epitope can be an analog of a native epitope.
[0104] An "epitope" is the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule.
Alternatively, an epitope can be defined as a set of amino acid residues which is involved in recognition by a particular immunoglobulin, or in the context of T
cells, those residues necessary for recognition by T cell receptor proteins and/or Major Histocompatibility Complex (MHC) receptors. Epitopes are present in nature, and can be isolated, purified or otherwise prepared/derived by humans.
For example, epitopes can be prepared by isolation from a natural source, or they can be synthesized in accordance with standard protocols in the art. Synthetic epitopes can comprise artificial amino acids "amino acid mimetics," such as D
isomers of natural occurring L amino acids or non-natural amino acids such as cyclohexylalanine. Throughout this disclosure, the terms epitope and peptide are often used interchangeably. Also, the term epitope as used herein is generally understood to encompass analogs of said epitopes.
[0105] It is to be appreciated that protein or polypeptide molecules that comprise one or more C35 peptide epitopes of the invention as well as additional amino acids) are still within the bounds of the invention. In certain embodiments, there is a limitation on the length of a polypeptide of the invention of, for example, not more than 114 amino acids, not more than 110 amino acids, not more than 100 amino acids, not more than 95 amino acids, not more than 90 amino acids, not more than 85 amino acids, not more than 80 amino acids, not more than 75 amino acids, not more than 70 amino acids, not more than 65 amino acids, not more than 60 amino acids, not more than 55 amino acids, not more than SO amino acids, not more than 45 amino acids, not more than 40 amino acids, not more than 35 amino acids, not more than 30 amino acids, not more than 25 amino acids, 20 amino acids, 15 amino acids, or 14, 13, 12, 1 l, 10, 9 or 8 amino acids. In some instances, the embodiment that is length-limited occurs when the protein/polypeptide comprising an epitope of the invention comprises a region (i.e., a contiguous series of amino acids) having 100% identity with a native sequence. In order to avoid the definition of epitope from reading, e.g., on whole natural molecules, there is a limitation on the length of any region that has 100%
identity with a native polypeptide sequence. Thus, for a polypeptide comprising an epitope of the invention and a region with 100% identity with the native polypeptide sequence, the region with 100% identity to the native sequence generally has a length of less than or equal to 114 amino acids, more often less than or equal to 100 amino acids, often less than or equal to 85 amino acids, often less than or equal to 75 amino acids, often less than or equal to 65 amino acids, and often less than or equal to 50 amino acids. In certain embodiments, the polypeptide of the invention comprises a peptide having a region with less than 50 amino acids that has 100% identity to a native peptide sequence, in any increment of amino acids (i.e., 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20,19,18,17,16,15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5) down to S amino acids. Preferably, such C35 polypeptide comprises one or more C35 peptide epitopes.
[0106] Accordingly, polypeptide or protein sequences longer than 100 amino acids are within the scope of the invention, so long as they do not comprise any contiguous sequence of more than 114 amino acids that have 100% identity with a native polypeptide sequence. For any polypeptide that has five contiguous residues or less that correspond to a native sequence, there is no limitation on the maximal length of that polypeptide in order to fall within the scope of the invention. In one embodiment, the polypeptide of the invention comprising one or more C35 peptide epitopes is less than 60 residues long in any increment down to eight amino acid residues.
[0107] An "immunogenic peptide" or "peptide epitope" is a peptide that will bind an HLA molecule and induce a cytotoxic T lymphocyte (CTL) response and/or a helper T lymphocyte (HTL) response. Thus, immunogenic peptides of the invention are capable of binding to an appropriate HLA molecule and thereafter inducing a cytotoxic T lymphocyte (CTL) response, or a helper T lymphocyte (HTL) response, to the peptide.
[0108] The term "motif' refers to a pattern of residues in an amino acid sequence of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 16 to about 25 amino acids for a class II
HLA
motif, which is recognized by a particular HLA molecule. Motifs are typically different for each HLA protein encoded by a given human HLA allele. These motifs often differ in their pattern of the primary and secondary anchor residues.
[0109] A "protective immune response" or "therapeutic immune response" refers to a cytotoxic T lymphocyte (CTL) and/or an helper T lymphocyte (HTL) response to an antigen derived from an pathogenic antigen (e.g., an antigen from an infectious agent or a tumor antigen), which in some way prevents or at least partially arrests disease symptoms, side effects or progression. The immune response may also include an antibody response which has been facilitated by the stimulation of helper T cells.
[0110] The term "residue" refers to an amino acid or amino acid mimetic incorporated into a peptide or protein by an amide bond or amide bond mimetic.
[0111] "Synthetic peptide" refers to a peptide that is not naturally occurnng, but is man-made using such methods as chemical synthesis or recombinant DNA
technology.
[0112] As used herein, a "vaccine" is a composition that contains one or more peptide epitopes of the invention, see, e.g., Tables 1-3 and 5-6, exclusive of peptide E-100 to R-109, and a pharmaceutically acceptable carrier. There are numerous embodiments of vaccines in accordance with the invention, such as by a cocktail of one or more peptides; apolyepitopic peptide comprising one or more peptides of the invention; or nucleic acids that encode such peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The "one or more peptides" or "one or more epitopes" can include, for example, at least 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 or more peptides or epitopes of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I-binding peptides of the invention can be linked to HLA class II-binding peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. Vaccines can comprise peptide pulsed antigen presenting cells, e.g., dendritic cells.
[0113] In a preferred embodiment, the isolated polypeptides of the present invention comprise or, alternatively, consist of one or more of the following peptide epitopes: amino acids E4 to P 12 of SEQ ID N0:2, amino acids S9 to V

of SEQ ID N0:2, amino acids S21 to Y29 of SEQ ID N0:2, G22 to C30 of SEQ
D7 NO: 2, amino acids I25 to C33 of SEQ ID N0:2, amino acids T38 to V46 of SEQ ID N0:2, amino acids G61 to I69 of SEQ ID N0:2, amino acids T62 to N70 of SEQ ID N0:2, amino acids G63 to G71 of SEQ ID N0:2, amino acids F65 to L73 of SEQ ID N0:2, amino acids I67 to F75 of SEQ ~ N0:2, amino acids K77 to Y85 of SEQ ID NO:2, amino acids Q72 to E86 of SEQ ID N0:2, amino acids G81 to L89 of SEQ ID N0:2, amino acids K104 to C 112 of SEQ ID N0:2, amino acids K104 to V113 of SEQ ID N0:2, amino acids I105 to V113 of SEQ ID
NO:2, or amino acids N107 to L115 of SEQ ID N0:2. In another embodiment, said polypeptides comprising or, alternatively, consisting of one or more C35 peptide epitopes are selected from the group consisting of: T101 to V 113 of SEQ
ID N0:2, G99 to V 113 of SEQ ID N0:2, E100 to V 113 of SEQ ll~ N0:2, I93 to V113 of SEQ ID N0:2, D88 to V113 of SEQ ID N0:2, P84 to V113 of SEQ ID
N0:2, K77 to V 113 of SEQ ID NO:2, Q72 to V 113 of SEQ ID NO:2, F65 to V 113 of SEQ ID N0:2, and L59 to V 113 of SEQ ID N0:2. It is contemplated that fragments of C35 peptide epitopes and polypeptides comprising fragments of C35 peptide epitopes of the invention will, in some instances, also be useful .
for stimulating a cytotoxic T lymphocyte response. Thus, the present invention includes fragments of the C35 peptide epitopes in which 1, 2, 3, 4, 5 or more amino acids of the peptide sequence provided have been deleted from either the amino terminus or the carboxy terminus of the peptide. In addition, it is contemplated that larger fragments of the C35 polypeptide that contain one or more of the peptide epitopes of the invention may also be used to stimulate a CTL
response in a patient. It is further contemplated that polypeptides that comprise one or more peptide epitopes of the present invention in addition to heterologous, i. e., non-C35, flanking sequences may also be used to stimulate a CTL
response.
[0114] In addition to the specific C35 peptide epitopes specifically listed above, many other peptide epitopes are contemplated by the present invention. Thus, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 8mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to T8; S2 to S9; G3 to V10; E4 to Al l; P5 to P12; G6 to P13; Q7 to P14; T8 to E15; S9 to E16; V10 to V17; Al l to E18; P12 to P19; P13 to G20; P14 to 521; E15 to G22; E16 to V23;
V17 to R24; E18 to I25; P19 to V26; G20 to V27; S21 to E28; G22 to Y29; V23 to C30; R24 to E31; I25 to P32; V26 to C33; V27 to G34; E28 to F35; Y29 to E36; C30 to A37; E31 to T38; P32 to Y39; C33 to L40; G34 to E41; F35 to L42;
E36 to A43; A37 to 544; T38 to A45; Y39 to V46; L40 to K47; E41 to E48; L42 to Q49; A43 to Y50; S44 to P51; A45 to G52; V46 to I53; K47 to E54; E48 to I55; Q49 to E56; Y50 to 557; P51 to R58; G52 to L59; I53 to G60; E54 to G61;
I55 to T62; E56 to G63; S57 to A64; R58 to F65; L59 to E66; G60 to I67; G61 to E68; T62 to I69; G63 to N70; A64 to G71; F65 to Q72; E66 to L73; I67 to V74; E68 to F75; I69 to 576; N70 to K77; G71 to L78; Q72 to E79; L73 to N80;
V74 to G81; F75 to G82; S76 to F83; K77 to P84; L78 to Y85; E79 to E86; N80 to K87; G81 to D88; G82 to L89; F83 to I90; P84 to E91; Y85 to A92; E86 to I93; K87 to R94; D88 to R95; L89 to A96; I90 to 597; E91 to N98; A92 to G99;

I93 to E100; R94 to TI01; R95 to L102; A96 to E103; S97 to K104; N98 to I105;
G99 to T106; E100 to N107; T101 to 5108; L102 to 8109; E103 to P110; K104 to P111; I105 to C112; T106 to V113; NI07 to I114; and 5108 to L115.
[0115] In a further embodiment, the isolated polypeptides ofthe present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 9mers (residues correspond to SEQ ID N0:2 and FIG.1B):
Ml to S9; S2 to V10; G3 to Al l; E4 to P12; PS to P13; G6 to P14; Q7 to E15;
T8 to E16; S9 to V17; V10 to E18; All to P19; P12 to G20; P13 to 521; P14 to G22; E15 to V23; E16 to R24; V17 to I25; E18 to V26; P19 to V27; G20 to E28;
S21 to Y29; G22 to C30; V23 to E31; R24 to P32; I25 to C33; V26 to G34; V27 to F35; E28 to E36; Y29 to A37; C30 to T38; E31 to Y39; P32 to L40; C33 to E41; G34 to L42; F35 to A43; E36 to 544; A37 to A45; T38 to V46; Y39 to K47;
L40 to E48; E41 to Q49; L42 to Y50; A43 to P51; S44 to G52; A45 to I53; V46 to E54; K47 to I55; E48 to E56; Q49 to 557; Y50 to R58; P51 to L59; G52 to G60; I53 to G61; E54 to T62; I55 to G63; E56 to A64; S57 to F65; R58 to E66;
L59 to I67; G60 to E68; G61 to I69; T62 to N70; G63 to G71; A64 to Q72; F65 to L73; E66 to V74; I67 to F75; E68 to 576; I69 to K77; N70 to L78; G71 to E79;
Q72 to N80; L73 to G81; V74 to G82; F75 to F83; S76 to P84; K77 to Y85; L78 to E86; E79 to K87; N80 to D88; G81 to L89; G82 to I90; F83 to E91; P84 to A92; Y85 to I93; E86 to R94; K87 to R95; D88 to A96; L89 to 597; I90 to N98;
E91 to G99; A92 to E100; I93 to T101; R94 to L102; R95 to E103; A96 to K104;
S97 to I105; N98 to T106; G99 to N107; E100 to 5108; T101 to 8109; L102 to P110; E103 to P111; K104 to C112; I105 to V113; T106 to I114; and N107 to L115.
[0116] In a further embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following lOmers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to V10; S2 to Al l; G3 to P12; E4 to P13; PS to P14; G6 to E15;
Q7 to E16; T8 to V17; S9 to E18; V10 to P19; A11 to G20P12 to 521; P13 to G22; P14 to V23; E15 to R24; E16'to I25; V17 to V26; E18 to V27; P19 to E28;

G20 to Y29; S21 to C30; G22 to E31; V23 to P32; R24 to C33; I25 to G34; V26 to F35; V27 to E36; E28 to A37; Y29 to T38; C30 to Y39; E31 to L40; P32 to E41; C33 to L42; G34 to A43; F35 to 544; E36 to A45; A37 to V46; T38 to K47;
Y39 to E48; L40 to Q49; E41 to Y50; L42 to P51; A43 to G52; S44 to I53; A45 to E54; V46 to I55; K47 to E56; E48 to 557; Q49 to R58; YSO to L59; P51 to G60; G52 to G61; I53 to T62; E54 to G63; I55 to A64; E56 to F65; S57 to E66;
R58 to I67; L59 to E68; G60 to I69; G61 to N70; T62 to G71; G63 to Q72; A64 to L73; F65 to V74; E66 to F75; I67 to 576; E68 to K77; I69 to L78; N70 to E79;
G71 to N80; Q72 to G81; L73 to G82; V74 to F83; F75 to P84; S76 to Y85; K77 to E86; L78 to K87; E79 to D88; N80 to L89; G81 to I90; G82 to E91; F83 to A92; P84 to I93; Y85 to R94; E86 to R95; K87 to A96; D88 to 597; L89 to N98;
I90 to G99; E91 to E100; A92 to T101; I93 to L102; R94 to E103; R95 to K104;
A96 to I105; S97 to T106; N98 to N107; G99 to 5108; E100 to 8109; T101 to P110; L102 to P111; E103 to 0112; K104 to V113; I105 to I114; T106 to L115.
[0117] In a further embodiment, the isolatedpolypeptides ofthepresent invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following llmers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to Al l; S2 to P12; G3 to P13; E4 to P14; PS to E15; G6 to E16;
Q7 to V17; T8 to E18; S9 to P19; V10 to G20; All to 521; P12 to G22; P13 to V23; P14 to R24; E15 to I25; E16 to V26; V17 to V27; E18 to E28; P19 to Y29;
G20 to C30; S21 to E31; G22 to P32; V23 to C33; R24 to G34; I25 to F35; V26 to E36; V27 to A37; E28 to T38; Y29 to Y39; C30 to L40; E31 to E41; P32 to L42; C33 to A43; G34 to 544; F35 to A45; E36 to V46; A37 to K47; T38 to E48;
Y39 to Q49; L40 to Y50; E41 to P51; L42 to G52; A43 to I53; S44 to E54; A45 to I55; V46 to E56; K47 to 557; E48 to R58; Q49 to L59; Y50 to G60; P51 to G61; G52 to T62; I53 to G63; E54 to A64; ISS to F65; E56 to E66; S57 to I67;
R58 to E68; L59 to I69; G60 to N70; G61 to G71; T62 to Q72; G63 to L73; A64 to V74; F65 to F75; E66 to 576; I67 to K77; E68 to L78; I69 to E79; N70 to N80;
G71 to G81; Q72 to G82; L73 to F83; V74 to P84; F75 to Y85; S76 to E86; K77 to K87; L78 to D88; E79 to L89; N80 to I90; G81 to E91; G82 to A92; F83 to I93; P84 to R94; Y85 to R95; E86 to A96; K87 to 597; D88 to N98; L89 to G99;
I90 to E100; E91 to T101; A92 to L102; I93 to E103; R94 to K104; R95 to I105;
A96 to T106; S97 to N107; N98 to 5108; G99 to 8109; E100 to P110; T101 to P111; L102 to C112; E103 to V113; K104 to I114; I105 to L115.
[0118] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, C35 peptide epitopes include the following l2mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to P12; S2 to P13; G3 to P14; E4 to E15; PS to E16; G6 to V17; Q7 to E18; T8 to P19; S9 to G20; V10 to 521; Al l to G22; P12 to V23; P13 to R24; P14 to I25;
E15 to V26; E16 to V27; V17 to E28; E18 to Y29; P19 to C30; G20 to E31; S21 to P32; G22 to C33; V23 to G34; R24 to F35; I25 to E36; V26 to A37; V27 to T38; E28 to Y39; Y29 to L40; C30 to E41; E31 to L42; P32 to A43; C33 to 544;
G34 to A45; F35 to V46; E36 to K47; A37 to E48; T38 to Q49; Y39 to Y50; L40 to P51; E41 to G52; L42 to I53; A43 to E54; S44 to I55; A45 to E56; V46 to 557;
K47 to R58; E48 to L59; Q49 to G60; Y50 to G61; P51 to T62; G52 to G63; I53 to A64; E54 to F65; I55 to E66; E56 to I67; S57 to E68; R58 to I69; L59 to N70;
G60 to G71; G61 to Q72; T62 to L73; G63 to V74; A64 to F75; F65 to 576; E66 to K77; I67 to L78; E68 to E79; I69 to N80; N70 to G81; G71 to G82; Q72 to F83; L73 to P84; V74 to Y85; F75 to E86; S76 to K87; K77 to D88; L78 to L89;
E79 to I90; N80 to E91; G81 to A92; G82 to I93; F83 to R94; P84 to R95; Y85 to A96; E86 to 597; K87 to N98; D88 to G99; L89 to E100; I90 to T101; E91 to L102; A92 to E103; I93 to K104; R94 to I105; R95 to T106; A96 to N107; S97 to 5108; N98 to 8109; G99 to P110; E100 to P111; T101 to 0112; L102 to V 113; E103 to I114; K104 to L115.
[0119] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following l3mers (residues correspond to SEQ ID N0:2 and FIG: 1B): Ml to P13; S2 to P14; G3 to E15; E4 to E16; PS to V17; G6 to E18;
Q7 to P19; T8 to G20; S9 to 521; V10 to G22; Al l to V23; P12 to R24; P13 to I25; P14 to V26; E15 to V27; E16 to E28; V17 to Y29; E18 to C30; P19 to E31;

G20 to P32; S21 to C33; G22 to G34; V23 to F35; R24 to E36; I25 to A37; V26 to T38; V27 to Y39; E28 to L40; Y29 to E41; C30 to L42; E31 to A43; P32 to 544; C33 to A45; G34 to V46; F35 to K47; E36 to E48; A37 to Q49; T38 to Y50;
Y39 to P51; L40 to G52; E41 to I53; L42 to E54; A43 to I55; S44 to E56; A45 to 557; V46 to R58; K47 to L59; E48 to G60; Q49 to G61; Y50 to T62; P51 to G63; G52 to A64; I53 to F65; E54 to E66; I55 to I67; E56 to E68; S57 to I69;
R58 to N70; L59 to G71; G60 to Q72; G61 to L73; T62 to V74; G63 to F75; A64 to 576; F65 to K77; E66 to L78; I67 to E79; E68 to N80; I69 to G81; N70 to G82; G71 to F83; Q72 to P84; L73 to Y85; V74 to E86; F75 to K87; S76 to D88;
K77 to L89; L78 to I90; E79 to E91; N80 to A92; G81 to I93; G82 to R94; F83 to R95; P84 to A96; Y85 to 597; E86 to N98; K87 to G99; D88 to E100; L89 to T101; I90 to L102; E91 to E103; A92 to K104; I93 to I105; R94 to T106; R95 to N107; A96 to 5108; S97 to 8109; N98 to P110; G99 to P111; E100 to C112;
T101toV113;L102toI114;E103toL115.
[0120] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following l4mers (residues correspond to SEQ ID N~:2 and FIG. 1B): Ml to P14; S2 to E15; G3 to E16; E4 to V17; P5 to E18; G6 to P19;
Q7 to G20; T8 to 521; S9 to G22; V10 to V23; Al l to R24; P12 to I25; P13 to V26; P14 to V27; E15 to E28; E16 to Y29; V17 to C30; E18 to E31; P19 to P32;
G20 to C33; S21 to G34; G22 to F35; V23 to E36; R24 to A37; I25 to T38; V26 to Y39; V27 to L40; E28 to E41; Y29 to L42; C30 to A43; E31 to 544; P32 to A45; C33 to V46; G34 to K47; F35 to E48; E36 to Q49; A37 to Y50; T38 to P51;
Y39 to G52; L40 to I53; E41 to E54; L42 to I55; A43 to E56; S44 to 557; A45 to R58; V46 to L59; K47 to G60; E48 to G61; Q49 to T62; Y50 to G63; P51 to A64; G52 to F65; I53 to E66; E54 to I67; I55 to E68; E56 to I69; S57 to N70;
R58 to G71; L59 to Q72; G60 to L73; G61 to V74; T62 to F75; G63 to 576; A64 to K77; F65 to L78; E66 to E79; I67 to N80; E68 to G81; I69 to G82; N70 to F83; G71 to P84; Q72 to Y85; L73 to E86; V74 to K87; F75 to D88; S76 to L89;
K77 to I90; L78 to E91; E79 to A92; N80 to I93; G81 to R94; G82 to R95; F83 to A96; P84 to S97; Y85 to N98; E86 to G99; K87 to E100; D88 to T101; L89 to L102; I90 to E103; E91 to K104; A92 to I105; I93 to T106; R94 to N107; R95 to 5108; A96 to 8109; S97 to P110; N98 to P111; G99 to 0112; E100 to V113;
T101 to Il 14; L102 to L115.
[0121] In anotherpreferred embodiment, the isolatedpolypeptides ofthepresent invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 1 Smers (residues correspond to SEQ ID NO:2 and FIG. 1B): Ml to E15; S2 to E16; G3 to V17; E4 to E18; PS to P19; G6 to G20;
Q7 to 521; T8 to G22; S9 to V23; V10 to R24; Al l to I25; P12 to V26; P13 to V27; P14 to E28; E15 to Y29; E16 to C30; V17 to E3I; E18 to P32; P19 to C33;
G20 to G34; S21 to F35; G22 to E36; V23 to A37; R24 to T38; I25 to Y39; V26 to L40; V27 to E41; E28 to L42; Y29 to A43; C30 to 544; E31 to A45; P32 to V46; C33 to K47; G34 to E48; F35 to Q49; E36 to Y50; A37 to P51; T38 to G52;
Y39 to I53; L40 to E54; E41 to I55; L42 to E56; A43 to 557; S44 to R58; A45 to L59; V46 to G60; K47 to G61; E48 to T62; Q49 to G63; Y50 to A64; P51 to F65; G52 to E66; I53 to I67; E54 to E68; I55 to I69; E56 to N70; S57 to G71;
R58 to Q72; L59 to L73; G60 to V74; G61 to F75; T62 to 576; G63 to K77; A64 to L78; F65 to E79; E66 to N80; I67 to G81; E68 to G82; I69 to F83; N70 to P84;
G71 to Y85; Q72 to E86; L73 to K87; V74 to D88; F75 to L89; S76 to I90; K77 to E91; L78 to A92; E79 to I93; N80 to R94; G81 to R95; G82 to A96; F83 to 597; P84 to N98; Y85 to G99; E86 to E100; K87 to T101; D88 to L102; L89 to E103; I90 to K104; E91 to I105; A92 to T106; I93 to N107; R94 to 5108; R95 to 8109; A96 to P110; S97 to P111; N98 to 0112; G99 to V113; E100 to Il l4;
T101 to L115.
[0122] In a further preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following l6mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to E16; S2 to V17; G3 to E18; E4 to P19; PS to G20; G6 to 521;
Q7 to G22; T8 to V23; S9 to R24; V10 to I25; All to V26; P12 to V27; P13 to E28; P14 to Y29; E15 to C30; E16 to E31; V17 to P32; E18 to C33; P19 to G34;

G20 to F35; S21 to E36; G22 to A37; V23 to T38; R24 to Y39; I25 to L40; V26 to E41; V27 to L42; E28 to A43; Y29 to 544; C30 to A45; E31 to V46; P32 to K47; C33 to E48; G34 to Q49; F35 to Y50; E36 to P51; A37 to G52; T38 to I53;
Y39 to E54; L40 to I55; E41 to E56; I~2 to S57; A43 to R58; S44 to L59; A45 to G60; V46 to G61; K47 to T62; E48 to G63; Q49 to A64; Y50 to F65; P51 to E66; G52 to I67; I53 to E68; E54 to I69; I55 to N70; E56 to G71; S57 to Q72;
R58 to L73; L59 to V74; G60 to F75; G61 to 576; T62 to K77; G63 to L78; A64 to E79; F65 to N80; E66 to G81; I67 to G82; E68 to F83; I69 to P84; N70 to Y85; G71 to E86; Q72 to K87; L73 to D88; V74 to L89; F75 to I90; S76 to E91;
K77 to A92; L78 to I93; E79 to R94; N80 to R95; G81 to A96; G82 to 597; F83 to N98; P84 to G99; Y85 to E100; E86 to T101; K87 to L102; D88 to E103; L89 to K104; I90 to I105; E91 to T106; A92 to N107; I93 to 5108; R94 to 8109; R95 to P110; A96 to P111; S97 to C112; N98 to V113; G99 to I114; E100 to L115.
[0123] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following l7mers: Ml to V 17; S2 to E18; G3 to P19; E4 to G20; PS to 521; G6 to G22; Q7 to V23; T8 to R24; S9 to I25; V 10 to V26; A11 to V27; P12 to E28; P13 to Y29; P14 to C30; E15 to E31; E16 to P32; V17 to C33; E18 to G34; P19 to F35; G20 to E36; S21 to A37; G22 to T38; V23 to Y39;
R24 to L40; I25 to E41; V26 to L42; V27 to A43; E28 to 544; Y29 to A45; C30 to V46; E31 to K47; P32 to E48; C33 to Q49; G34 to Y50; F35 to P51; E36 to G52; A37 to I53; T38 to E54; Y39 to I55; L40 to E56; E41 to 557; L42 to R58;
A43 to L59; S44 to G60; A45 to G61; V46 to T62; K47 to G63; E48 to A64; Q49 to F65; Y50 to E66; P51 to I67; G52 to E68; I53 to I69; E54 to N70; I55 to G71;
E56 to Q72; S57 to L73; R58 to V74; L59 to F75; G60 to 576; G61 to K77; T62 to L78; G63 to E79; A64 to N80; F65 to G81; E66 to G82; I67 to F83; E68 to P84; I69 to Y85; N70 to E86; G71 to K87; Q72 to D88; L73 to L89; V74 to I90;
F75 to E91; S76 to A92; K77 to I93; L78 to R94; E79 to R95; N80 to A96; G81 to 597; G82 to N98; F83 to G99; P84 to E100; Y85 to T101; E86 to L102; K87 to E103; D88 to K104; L89 to I105; I90 to T106; E91 to N107; A92 to 5108; I93 to 8109; R94 to P110; R95 to P111; A96 to 0112; S97 to V113; N98 to I114;
G99 to Ll 15.
[0124] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 18mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to E18; S2 to P19; G3 to G20; E4 to 521; PS to G22; G6 to V23;
Q7 to R24; T8 to I25; S9 to V26; V10 to V27; All to E28; P12 to Y29; P13 to C30; P14 to E31; E15 to P32; E16 to C33; V17 to G34; E18 to F35; P19 to E36;
G20 to A37; S21 to T38; G22 to Y39; V23 to L40; R24 to E41; I25 to L42; V26 to A43; V27 to 544; E28 to A45; Y29 to V46; C30 to K47; E31 to E48; P32 to Q49; C33 to Y50; G34 to P51; F35 to G52; E36 to I53; A37 to E54; T38 to I55;
Y39 to E56; L40 to 557; E41 to R58; L42 to L59; A43 to G60; S44 to G61; A45 to T62; V46 to G63; K47 to A64; E48 to F65; Q49 to E66; Y50 to I67; P51 to E68; G52 to I69; I53 to N70; E54 to G71; I55 to Q72; E56 to L73; S57 to V74;
R58 to F75; L59 to 576; G60 to K77; G61 to L78; T62 to E79; G63 to N80; A64 to G81; F65 to G82; E66 to F83; I67 to P84; E68 to Y85; I69 to E86; N70 to K87; G71 to D88; Q72 to L89; L73 to I90; V74 to E91; F75 to A92; S76 to I93;
K77 to R94; L78 to R95; E79 to A96; N80 to 597; G81 to N98; G82 to G99; F83 to E100; P84 to T101; Y85 to L102; E86 to E103; K87 to K104; D88 to I105;
L89 to T106; I90 to N107; E91 to 5108; A92 to 8109; I93 to P 110; R94 to P
111;
R95 to C112; A96 to V113; S97 to I114; N98 to L115.
[0125] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following l9mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to P19; S2 to G20; G3 to 521; E4 to G22; PS to V23; G6 to R24;
Q7 to I25; T8 to V26; S9 to V27; V10 to E28; Al l to Y29; P12 to C30; P13 to E31; P14 to P32; E15 to C33; E16 to G34; V17 to F35; E18 to E36; P19 to A37;
G20 to T38; S21 to Y39; G22 to L40; V23 to E41; R24 to L42; I25 to A43; V26 to 544; V27 to A45; E28 to V46; Y29 to K47; C30 to E48; E31 to Q49; P32 to Y50; C33 to P51; G34 to G52; F35 to I53; E36 to E54; A37 to I55; T38 to E56;

Y39 to 557; L40 to R58; E41 to L59; L42 to G60; A43 to G61; S44 to T62; A45 to G63; V46 to A64; K47 to F65; E48 to E66; Q49 to I67; Y50 to E68; P51 to I69; G52 to N70; I53 to G71; E54 to Q72; I55 to L73; E56 to V74; S57 to F75;
R58 to 576; L59 to K77; G60 to L78; G61 to E79; T62 to N80; G63 to G81; A64 to G82; F65 to F83; E66 to P84; I67 to Y85; E68 to E86; I69 to K87; N70 to D88; G71 to L89; Q72 to I90; L73 to E91; V74 to A92; F75 to I93; S76 to R94;
K77 to R95; L78 to A96; E79 to 597; N80 to N98; G81 to G99; G82 to E100;
F83 to T101; P84 to L102; Y85 to E103; E86 to K104; K87 to I105; D88 to T106; L89 to N107; I90 to 5108; E91 to 8109; A92 to P110; I93 to P111; R94 to C112; R95 to V113; A96 to I114; S97 to L115.
[0126] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 20mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to G20; S2 to 521; G3 to G22; E4 to V23; PS to R24; G6 to I25;
Q7 to V26; T8 to V27; S9 to E28; V10 to Y29; Al l to C30; P12 to E31; P13 to P32; P14 to C33; E15 to G34; E16 to F35; V17 to E36; E18 to A37; P19 to T38;
G20 to Y39; S21 to L40; G22 to E41; V23 to L42; R24 to A43; I25 to 544; V26 to A45; V27 to V46; E28 to K47; Y29 to E48; C30 to Q49; E31 to Y50; P32 to P51; C33 to G52; G34 to I53; F35 to E54; E36 to I55; A37 to E56; T38 to 557;
Y39 to R58; L40 to L59; E41 to G60; L42 to G61; A43 to T62; S44 to G63; A45 to A64; V46 to F65; K47 to E66; E48 to I67; Q49 to E68; Y50 to I69; P51 to N70; G52 to G71; I53 to Q72; E54 to L73; I55 to V74; E56 to F75; S57 to 576;
R58 to K77; L59 to L78; G60 to E79; G61 to N80; T62 to G81; G63 to G82; A64 to F83; F65 to P84; E66 to Y85; I67 to E86; E68 to K87; I69 to D88; N70 to L89;
G71 to I90; Q72 to E91; L73 to A92; V74 to I93; F75 to R94; S76 to R95; K77 to A96; L78 to 597; E79 to N98; N80 to G99; G81 to E100; G82 to T101; F83 to L102; P84 to E103; Y85 to K104; E86 to I105; K87 to T106; D88 to N107;
L89 to S 108; I90 to 8109; E91 to P110; A92 to P 111; I93 to Cl 12; R94 to V
113;
R95 to I114; A96 to Ll 15.

[0127] In anotherpreferred embodiment, the isolatedpolypeptides ofthepresent invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 2lmers (residues correspond to SEQ ID NO:2 and FIG. 1B): Ml to 521; S2 to G22; G3 to V23; E4 to R24; PS to I25; G6 to V26;
Q7 to V27; T8 to E28; S9 to Y29; V10 to C30; Al l to E31; P12 to P32; P13 to C33; P14 to G34; E15 to F35; E16 to E36; V17 to A37; E18 to T38; P19 to Y39;
G20 to L40; S21 to E41; G22 to L42; V23 to A43; R24 to 544; I25 to A45; V26 to V46; V27 to.K47; E28 to E48; Y29 to Q49; C30 to Y50; E31 to P51; P32 to G52; C33 to I53; G34 to E54; F35 to I55; E36 to E56; A37 to 557; T38 to R58;
Y39 to L59; L40 to G60; E41 to G61; L42 to T62; A43 to G63; S44 to A64; A45 to F65; V46 to E66; K47 to I67; E48 to E68; Q49 to I69; Y50 to N70; P51 to G71; G52 to Q72; I53 to L73; E54 to V74; I55 to F75; E56 to 576; S57 to K77;
R58 to L78; L59 to E79; G60 to N80; G61 to G81; T62 to G82; G63 to F83; A64 to P84; F65 to Y85; E66 to E86; I67 to K87; E68 to D88; I69 to L89; N70 to I90;
G71 to E91; Q72 to A92; L73 to I93; V74 to R94; F75 to R95; S76 to A96; K77 to 597; L78 to N98; E79 to G99; N80 to E100; G81 to T101; G82 to L102; F83 to E103; P84 to K104; Y85 to I105; E86 to T106; K87 to N107; D88 to 5108;
L89 to 8109; I90 to P110; E91 to P111; A92 to 0112; I93 to V113; R94 to I114;
R95 to L115.
[0128] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 22mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to G22; S2 to V23; G3 to R24; E4 to I26; PS to V26; G6 to V27;
Q7 to E28; T8 to Y29; S9 to C30; V10 to E31; Al l to P32; P12 to C33; P13 to G34; P14 to F35; E15 to E36; E16 to A37; V17 to T38; E18 to Y39; P19 to L40;
G20 to E41; S21 to IA.2; G22 to A43; V23 to 544; R24 to A45; I25 to V46; V26 to K47; V27 to E48; E28 to Q49; Y29 to YSO; C30 to P51; E31 to G52; P32 to I53; C33 to E54; G34 to I55; F35 to E56; E36 to 557; A37 to R58; T38 to L59;
Y39 to G60; L40 to G61; E41 to T62; L42 to G63; A43 to A64; S44 to F65; A45 to E66; V46 to I67; K47 to E68; E48 to I69; Q49 to N70; Y50 to G71; P51 to Q72; G52 to L73; I53 to V74; E54 to F75; I55 to 576; E56 to K77; S57 to L78;
R58 to E79; L59 to N80; G60 to G81; G61 to G82; T62 to F83; G63 to P84; A64 to Y85; F65 to E86; E66 to K87; I67 to D88; E68 to L89; I69 to I90; N70 to E91;
G71 to A92; Q72 to I93; L73 to R94; V74 to R95; F75 to A96; S76 to 597; K77 to N98; L78 to G99; E79 to E100; N80 to T101; G81 to L102; G82 to E103; F83 to K104; P84 to I105; Y85 to T106; E86 to N107; K87 to 5108; D88 to 8109;
L89 to P110; I90 to P111; E91 to C112; A92 to V113; I93 to I114; R94 to L115.
[0129] In another preferred embodiment, the isolatedpolypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 23mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to V23; S2 to R24; G3 to I25; E4 to V26; P5 to V27; G6 to E28;
Q7 to Y29; T8 to C30; S9 to E31; V10 to P32; Al l to C33; P12 to G34; P13 to F35; P14 to E36; El5 to A37; E16 to T38; V17 to Y39; E18 to L40; P19 to E41;
G20 to L42; S21 to A43; G22 to 544; V23 to A45; R24 to V46; I25 to K47; V26 to E48; V27 to Q49; E28 to Y50; Y29 to P51; C30 to G52; E31 to I53; P32 to E54; C33 to I55; G34 to E56; F35 to S57; E36 to R58; A37 to L59; T38 to G60;
Y39 to G61; L40 to T62; E41 to G63; L42 to A64; A43 to F65; S44 to E66; A45 to I67; V46 to E68; K47 to I69; E48 to N70; Q49 to G71; Y50 to Q72; P51 to L73; G52 to V74; I53 to F75; E54 to 576; I55 to K77; E56 to L78; S57 to E79;
R58 to N80; L59 to G81; G60 to G82; G61 to F83; T62 to P84; G63 to Y85; A64 to E86; F65 to K87; E66 to D88; I67 to L89; E68 to I90; I69 to E91; N70 to A92;
G71 to I93; Q72 to R94; L73 to R95; V74 to A96; F75 to 597; S76 to N98; K77 to G99; L78 to E100; E79 to T101; N80 to L102; G81 to E103; G82 to K104;
F83 to I105; P84 to T106; Y85 to N107; E86 to 5108; K87 to 8109; D88 to P110; L89 to P111; I90 to C112; E91 to V113; A92 to I114; I93 to L115.
[0130] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 24mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to R24; S2 to I25; G3 to V26; E4 to V27; P5 to E28; G6 to Y29;
Q7 to C30; T8 to E31; S9 to P32; V10 to C33; Al l to G34; P12 to F35; P13 to E36; P14 to A37; E15 to T38; E16 to Y39; V17 to L40; E18 to E41; P19 to L42;
G20 to A43; S21 to 544; G22 to A45; V23 to V46; R24 to K47; I25 to E48; V26 to Q49; V27 to Y50; E28 to P51; Y29 to G52; C30 to I53; E31 to E54; P32 to I55; C33 to E56; G34 to 557; F35 to R58; E36 to L59; A37 to G60; T38 to G61;
Y39 to T62; L40 to G63; E41 to A64; L42 to F65; A43 to E66; S44 to I67; A45 to E68; V46 to I69; K47 to N70; E48 to G71; Q49 to Q72; Y50 to L73; P51 to V74; G52 to F75; I53 to 576; E54 to K77; I55 to L78; E56 to E79; S57 to N80;
R58 to G81; L59 to G82; G60 to F83; G61 to P84; T62 to Y85; G63 to E86; A64 to K87; F65 to D88; E66 to L89; I67 to I90; E68 to E91; I69 to A92; N70 to I93;
G71 to R94; Q72 to R95; L73 to A96; V74 to 597; F75 to N98; S76 to G99; K77 to E100; L78 to T101; E79 to L102; N80 to E103; G81 to K104; G82 to I105;
F83 to T106; P84 to N107; Y85 to 5108; E86 to 8109; K87 to P110; D88 to PIl l; L89 to C112; I90 to V113; E91 to I114; A92 to L115.
[0131] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 25mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to I25; S2 to V26; G3 to V27; E4 to E28; PS to Y29; G6 to C30;
Q7 to E31; T8 to P32; S9 to C33; V10 to G34; All to F35; P12 to E36; P13 to A37; P14 to T38; E15 to Y39; E16 to L40; V17 to E41; E18 to L42; P19 to A43;
G20 to 544; S21 to A45; G22 to V46; V23 to K47; R24 to E48; I25 to Q49; V26 to Y50; V27 to P51; E28 to G52; Y29 to I53; C30 to E54; E31 to I55; P32 to E56; C33 to 557; G34 to R58; F35 to L59; E36 to G60; A37 to G61; T38 to T62;
Y39 to G63; L40 to A64; E41 to F65; L42 to E66; A43 to I67; S44 to E68; A45 to I69; V46 to N70; K47 to G71; E48 to Q72; Q49 to L73; Y50 to V74; P51 to F75; G52 to 576; I53 to K77; E54 to L78; I55 to E79; E56 to N80; S57 to G81;
R58 to G82; L59 to F83; G60 to P84; G61 to Y85; T62 to E86; G63 to K87; A64 to D88; F65 to L89; E66 to I90; I67 to E91; E68 to A92; I69 to I93; N70 to R94;
G71 to R95; Q72 to A96; L73 to S97; V74 to N98; F75 to G99; S76 to E100;
K77 to T101; L78 to L102; E79 to E103; N80 to K104; G81 to I105; G82 to T106; F83 to N107; P84 to 5108; Y85 to 8109; E86 to P110; K87 to P111; D88 to C112; L89 to V113; I90 to Ill4; E91 to L115.
[0132] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 26mers (residues correspond to SEQ ID N0:2 and FIG.1B): M1 to V26; S2 to V27; G3 to E28; E4 to Y29; PS to C30; G6 to E31;
Q7 to P32; T8 to C33; S9 to G34; V10 to F35; A11 to E36; P12 to A37; P13 to T38; P14 to Y39; E15 to L40; El6 to E41; V17 to L42; E18 to A43; P19 to 544;
G20 to A45; S21 to V46; G22 to K47; V23 to E48; R24 to Q49; I25 to Y50; V26 to P51; V27 to G52; E28 to I53; Y29 to E54; C30 to I55; E31 to E56; P32 to 557;
C33 to R58; G34 to L59; F35 to G60; E36 to G61; A37 to T62; T38 to G63; Y39 to A64; L40 to F65; E41 to E66; L42 to I67; A43 to E68; S44 to I69; A45 to N70;
V46 to G71; K47 to Q72; E48 to L73; Q49 to V74; Y50 to F75; P51 to 576; G52 to K77; I53 to L78; E54 to E79; I55 to N80; E56 to G81; S57 to G82; R58 to F83; L59 to P84; G60 to Y85; G61 to E86; T62 to K87; G63 to D88; A64 to L89;
F65 to I90; E66 to E91; I67 to A92; E68 to I93; I69 to R94; N70 to R95; G71 to A96; Q72 to 597; L73 to N98; V74 to G99; F75 to E100; S76 to T101; K77 to L102; L78 to E103; E79 to K104; N80 to I105; G81 to T106; G82 to N107; F83 to 5108; P84 to 8109; Y85 to P110; E86 to P111; K87 to C112; D88 to V113;
L89 to Il 14; I90 to Ll 15.
[0133] In another preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 27mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to V27; S2 to E28; G3 to Y29; E4 to C30; PS to E31; G6 to P32;
Q7 to C33; T8 to G34; S9 to F35; V10 to E36; All to A37; P12 to T38; P13 to Y39; P14 to L40; E15 to E41; E16 to L42; V17 to A43; E18 to 544; P19 to A45;
G20 to V46; S21 to K47; G22 to E48; V23 to Q49; R24 to Y50; I25 to P51; V26 to G52; V27 to I53; E28 to E54; Y29 to I55; C30 to E56; E31 to 557; P32 to R58; C33 to L59; G34 to G60; F35 to G61; E36 to T62; A37 to G63; T38 to A64;
Y39 to F65; L40 to E66; E41 to I67; L42 to E68; A43 to I69; S44 to N70; A45 to G71; V46 to Q72; K47 to L73; E48 to V74; Q49 to F75; Y50 to 576; P51 to K77; G52 to L78; I53 to E79; E54 to N80; I55 to G81; E56 to G82; S57 to F83;
R58 to P84; L59 to Y85; G60 to E86; G61 to K87; T62 to D88; G63 to L89; A64 to I90; F65 to E91; E66 to A92; I67 to I93; E68 to R94; I69 to R95; N70 to A96;
G71 to 597; Q72 to N98; L73 to G99; V74 to E100; F75 to T101; S76 to L102;
K77 to E103; L78 to K104; E79 to I105; N80 to T106; G81 to N107; G82 to 5108; F83 to 8109; P84 to Pl 10; Y85 to P111; E86 to C112; K87 to V113; D88 toI114;L89toL115.
[0134] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 28mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to E28; S2 to Y29; G3 to C30; E4 to E31; PS to P32; G6 to C33;
Q7 to G34; T8 to F35; S9 to E36; V10 to A37; Al l to T38; P12 to Y39; P13 to L40; P14 to E41; E15 to L42; E16 to A43; V17 to 544; E18 to A45; P19 to V46;
G20 to K47; S21 to E48; G22 to Q49; V23 to Y50; R24 to P51; I25 to G52; V26 to I53; V27 to E54; E28 to I55; Y29 to E56; C30 to 557; E31 to R58; P32 to L59;
C33 to G60; G34 to G61; F35 to T62; E36 to G63; A37 to A64; T38 to F65; Y39 to E66; L40 ~to I67; E41 to E68; L42 to I69; A43 to N70; S44 to G71; A45 to Q72; V46 to L73; K47 to V74; E48 to F75; Q49 to 576; YSO to K77; P51 to L78;
G52 to E79; I53 to N80; E54 to G81; I55 to G82; E56 to F83; S57 to P84; R58 to Y85; L59 to E86; G60 to K87; G61 to D88; T62 to L89; G63 to I90; A64 to E91; F65 to A92; E66 to I93; I67 to R94; E68 to R95; I69 to A96; N70 to 597;
G71 to N98; Q72 to G99; L73 to E100; V74 to T101; F75 to L102; S76 to E103;
K77 to K104; L78 to I105; E79 to T106; N80 to N107; G81 to 5108; G82 to 8109; F83 to P110; P84 to P111; Y85 to 0112; E86 to V113; K87 to I114; D88 to L115.
[0135] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 29mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to Y29; S2 to C30; G3 to E31; E4 to P32; PS to C33; G6 to G34;

Q7 to F35; T8 to E36; S9 to A37; V10 to T38; All to Y39; P12 to L40; P13 to E41; P 14 to L42; E 15 to A43; E 16 to 544; V 17 to A45; E 18 to V46; P 19 to K47;
G20 to E48; S21 to Q49; G22 to Y50; V23 to P51; R24 to G52; I25 to I53; V26 to E54; V27 to I55; E28 to E56; Y29 to 557; C30 to R58; E31 to L59; P32 to G60; C33 to G61; G34 to T62; F35 to G63; E36 to A64; A37 to F65; T38 to E66;
Y39 to I67; L40 to E68; E41 to I69; L42 to N70; A43 to G71; S44 to Q72; A45 to L73; V46 to V74; K47 to F75; E48 to 576; Q49 to K77; Y50 to L78; P51 to E79; G52 to N80; I53 to G81; E54 to G82; I55 to F83; E56 to P84; S57 to Y85;
R58 to E86; L59 to K87; G60 to D88; G61 to L89; T62 to I90; G63 to E91; A64 to A92; F65 to I93; E66 to R94; I67 to R95; E68 to A96; I69 to 597; N70 to N98;
G71 to G99; Q72 to E100; L73 to T101; V74 to L102; F75 to E103; S76 to K104;
K77 to I105; L78 to T106; E79 to N107; N80 to 5108; G81 to 8109; G82 to P110;F83toP111;P84toC112;Y85toV113;E86toI114;K87toL115.
[0136] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 30mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to C30; S2 to E31; G3 to P32; E4 to C33; PS to G34; G6 to F35;
Q7 to E36; T8 to A37; S9 to T38; V10 to Y39; Al l to L40; P12 to E41; P13 to L42; P14 to A43; E15 to 544; E16 to A45; V17 to V46; E18 to K47; P19 to E48;
G20 to Q49; S21 to Y50; G22 to P51; V23 to G52; R24 to I53; I25 to E54; V26 to I55; V27 to E56; E28 to 557; Y29 to R58; C30 to L59; E31 to G60; P32 to G61; C33 to T62; G34 to G63; F35 to A64; E36 to F65; A37 to E66; T38 to I67;
Y39 to E68; L40 to I69; E41 to N70; L42 to G71; A43 to Q72; S44 to L73; A45 to V74; V46 to F75; K47 to 576; E48 to K77; Q49 to L78; Y50 to E79; P51 to N80; G52 to G81; I53 to G82; E54 to F83; I55 to P84; E56 to Y85; S57 to E86;
R58 to K87; L59 to D88; G60 to L89; G61 to I90; T62 to E91; G63 to A92; A64 to I93; F65 to R94; E66 to R95; I67 to A96; E68 to 597; I69 to N98; N70 to G99;
G71 to E100; Q72 to T101; L73 to L102; V74 to E103; F75 to K104; S76 to I105; K77 to T106; L78 to N107; E79 to 5108; N80 to 8109; G81 to Pl 10; G82 to P111; F83 to 0112; P84 to V113; Y85 to I114; E86 to L115.

[0137] In another preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 3 lmers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to E31; S2 to P32; G3 to C33; E4 to G34; PS to F35; G6 to E36;
Q7 to A37; T8 to T38; S9 to Y39; V10 to L40; Al l to E41; P12 to L42; P13 to A43; P14 to 544; E15 to A45; E16 to V46; V17 to K47; E18 to E48; P19 to Q49;
G20 to Y50; S21 to P51; G22 to G52; V23 to I53; R24 to E54; I25 to I55; V26 to E56; V27 to 557; E28 to R58; Y29 to L59; C30 to G60; E31 to G61; P32 to T62; C33 to G63; G34 to A64; F35 to F65; E36 to E66; A37 to I67; T38 to E68;
Y39 to I69; I~1.0 to N70; E41 to G71; L42 to Q72; A43 to L73; S44 to V74; A45 'to F75; V46 to 576; K47 to K77; E48 to L78; Q49 to E79; Y50 to N80; P51 to G81; G52 to G82; I53 to F83; E54 to P84; I55 to.Y85; E56 to E86; S57 to K87;
R58 to D88; L59 to L89; G60 to I90; G61 to E91; T62 to A92; G63 to I93; A64 to R94; F65 to R95; E66 to A96; I67 to 597; E68 to N98; I69 to G99; N70 to E100; G71 to T101; Q72 to L102; L73 to E103; V74 to K104; F75 to I105; S76 to T106; K77 to N107; L78 to S 108; E79 to 8109; N80 to P 110; G81 to P 111;
G82 to C112; F83 to V113; P84 to I114 and Y85 to L115.
[0138] In another preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 32mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to P32; S2 to C33; G3 to G34; E4 to F35; PS to E36; G6 to A37;
Q7 to T38; T8 to Y39; S9 to LAO; V10 to E41; Al l to IA~2; P12 to A43; P13 to 544; P14 to A45; E15 to V46; E16 to K47; V17 to E48; El8 to Q49; P19 to Y50;
G20 to P51; S21 to G52; G22 to I53; V23 to E54; R24 to I55; I25 to E56; V26 to 557; V27 to R58; E28 to L59; Y29 to G60; C30 to G61; E31 to T62; P32 to G63; C33 to A64; G34 to F65; F35 to E66; E36 to I67; A37 to E68; T38 to I69;
Y39 to N70; L40 to G71; E41 to Q72; L42 to L73; A43 to V74; S44 to F75; A45 to 576; V46 to K77; K47 to L78; E48 to E79; Q49 to N80; Y50 to G81; P51 to G82; G52 to F83; I53 to P84; E54 to Y85; I55 to E86; E56 to K87; S57 to D88;
R58 to L89; L59 to I90; G60 to E91; G61 to A92; T62 to I93; G63 to R94; A64 to R95; F65 to A96; E66 to 597; I67 to N98; E68 to G99; I69 to E100; N70 to T101; G71 to L102; Q72 to E103; L73 to K104; V74 to I105; F75 to T106; S76 to N107; K77 to 5108; L78 to 8109; E79 to P110; N80 to P111; G81 to 0112;
G82 to V 113; F83 to Il 14 and P84 to Ll 15.
[0139] In another preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 33mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to C33; S2 to G34; G3 to F35; E4 to E36; PS to A37; G6 to T38;
Q7 to Y39; T8 to L40; S9 to E41; V10 to L42; Al l to A43; P12 to 544; P13 to A45; P14 to V46; El5 to K47; E16 to E48; V17 to Q49; E18 to Y50; P19 to P51;
G20 to G52; S21 to I53; G22 to E54; V23 to I55; R24 to E56; I25 to 557; V26 to R58; V27 to L59; E28 to G60; Y29 to G61; C30 to T62; E31 to G63; P32 to A64; C33 to F65; G34 to E66; F35 to I67; E36 to E68; A37 to I69; T38 to N70;
Y39 to G71; L40 to Q72; E41 to L73; IA.2 to V74; A43 to F75; S44 to 576; A45 to K77; V46 to L78; K47 to E79; E48 to N80; Q49 to G81; Y50 to G82; P51 to F83; G52 to P84; I53 to Y85; E54 to E86; I55 to K87; E56 to D88; S57 to L89;
RS8 to I90; L59 to E91; G60 to A92; G61 to I93; T62 to R94; G63 to R95; A64 to A96; F65 to 597; E66 to N98; I67 to G99; E68 to E100; I69 to T101; N70 to L102; G71 to E103; Q72 to K104; L73 to I105; V74 to T106; F75 to N107; S76 to 5108; K77 to 8109; L78 to P110; E79 to P111; N80 to C112; G81 to V113;
G82 to Il 14 and F83 to L115.
[0140] In another preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 34mers (residues correspond to SEQ ID N0:2 and FIG. 1B): M1 to G34; S2 to F35; G3 to E36; E4 to A37; PS to T38; G6 to Y39;
Q7 to L40; T8 to E41; S9 to L42; V10 to A43; All to 544; P12 to A45; P13 to V46; P14 to K47; E15 to E48; E16 to Q49; V17 to Y50; E18 to P51; P19 to G52;
G20 to I53; S21 to E54; G22 to ISS; V23 to E56; R24 to 557; I25 to R58; V26 to L59; V27 to G60; E28 to G61; Y29 to T62; C30 to G63; E31 to A64; P32 to F65;
C33 to E66; G34 to I67; F35 to E68; E36 to I69; A37 to N70; T38 to G71; Y39 to Q72; L40 to L73; E41 to V74; L42 to F75; A43 to 576; S44 to K77; A45 to L78; V46 to E79; K47 to N80; E48 to G81; Q49 to G82; Y50 to F83; P51 to P84;
G52 to Y85; I53 to E86; E54 to K87; I55 to D88; E56 to L89; S57 to I90; R58 to E91; L59 to A92; G60 to I93; G61 to R94; T62 to R95; G63 to A96; A64 to 597;
F65 to N98; E66 to G99; I67 to E100; E68 to T101; I69 to L102; N70 to E103;
G71 to K104; Q72 to I105; L73 to T106; V74 to N107; F75 to 5108; S76 to 8109; K77 to P110; L78 to P111; E79 to C112; N80 to V113; G81 to I114 and G82 to L115.
[0141] In another preferred embodiment,the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 35mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to F35; S2 to E36; G3 to A37; E4 to T38; PS to Y39; G6 to L40;
Q7 to E41; T8 to L42; S9 to A43; V10 to 544; A11 to A45; P12 to V46; P13 to K47; P14 to E48; E15 to Q49; E16 to Y50; V17 to P51; E18 to G52; P19 to I53;
G20 to E54; S21 to I55; G22 to E56; V23 to 557; R24 to R58; I25 to L59; V26 to G60; V27 to G61; E28 to T62; Y29 to G63; C30 to A64; E31 to F65; P32 to E66; C33 to I67; G34 to E68; F35 to I69; E36 to N70; A37 to G71; T38 to Q72;
Y39 to L73; L40 to V74; E41 to F75; L42 to 576; A43 to K77; S44 to L78; A45 to E79; V46 to N80; K47 to G81; E48 to G82; Q49 to F83; Y50 to P84; P51 to Y85; G52 to E86; I53 to K87; E54 to D88; I55 to L89; E56 to I90; S57 to E91;
R58 to A92; L59 to I93; G60 to R94; G61 to R95; T62 to A96; G63 to 597; A64 to N98; F65 to G99; E66 to E100; I67 to T101; E68 to L102; I69 to E103; N70 to K104; G71 to I105; Q72 to T106; L73 to N107; V74 to 5108; F75 to 8109;
S76 to P110; K77 to P111; L78 to C112; E79 to V113; N80 to I114; G81 to L115.
[0142] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 36mers (residues correspond to SEQ ID N0:2 and FIG. 1B):

Ml to E36; S2 to A37; G3 to T38; E4 to Y39; PS to L40; G6 to E41; Q7 to L42;
T8 to A43; S9 to 544; V 10 to A45; A11 to V46; P 12 to K47; P 13 to E48; P 14 to Q49; E15 to YSO; E16 to P51; V17 to G52; E18 to I53; P19 to E54; G20 to i55;
S21 to E56; G22 to 557; V23 to R58; R24 to L59; I25 to G60; V26 to G61; V27 to T62; E28 to G63; Y29 to A64; C30 to F65; E31 to E66; P32 to I67; C33 to E68; G34 to I69; F35 to N70; E36 to G71; A37 to Q72; T38 to L73; Y39 to V74;
L40 to F75; E41 to 576; L42 to K77; A43 to L78; S44 to E79; A45 to N80; V46 to G81; K47 to G82; E48 to F83; Q49 to P84; Y50 to Y85; P51 to E86; G52 to K87; I53 to D88; E54 to L89; I55 to I90; E56 to E91; S57 to A92; R58 to I93;
L59 to R94; G60 to R95; G61 to A96; T62 to 597; G63 to N98; A64 to G99; F65 to E100; E66 to T101; I67 to L102; E68 to E103; I69 to K104; N70 to I105; G71 to T106; Q72 to N107; L73 to 5108; V74 to 8109; F75 to P110; S76 to P111;
K77 to 0112; L78 to V113; E79 to I114; N80 to L115.
[0143) In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 37mers (residues correspond to SEQ ID NO:2 and FIG. 1 B):
M1 to A37; S2 to T38; G3 to Y39; E4 to L40; PS to E41; G6 to L42; Q7 to A43;
T8 to 544; S9 to A45; V 10 to V46; Al l to K47; P 12 to E48; P 13 to Q49; P 14 to Y50; E15 to P51; E16 to G52; V17 to I53; E18 to E54; P19 to I55; G20 to E56;
S21 to 557; G22 to R58; V23 to L59; R24 to G60; I25 to G61; V26 to T62; V27 to G63; E28 to A64; Y29 to F65; C30 to E66; E31 to I67; P32 to E68; C33 to I69; G34 to N70; F35 to G71; A37 to L73; T38 to V74; Y39 to F75; L40 to 576;
E41 to K77; L42 to L78; A43 to E79; S44 to N80; A45 to G81; V46 to G82; K47 to F83; E48 to P84; Q49 to Y85; Y50 to E86; P51 to K87; G52 to D88; I53 to L89; E54 to I90; I55 to E91; E56 to A92; S57 to I93; R58 to R94; L59 to R95;
G60 to A96; G61 to 597; T62 to N98; G63 to G99; A64 to E100; F65 to T101;
E66 to L102; I67 to E103; E68 to K104; I69 to I105; N70 to T106; G71 to N107;
Q72 to 5108; L73 to 8109; V74 to P110; F75 to P111; S76 to C112; K77 to V113; L78 to I114; E79 to L115.

[0144] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 38mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to T38; S2 to Y39; G3 to L40; E4 to E41; PS to L42; G6 to A43; Q7 to 544;
T8 to A45; S9 to V46; V10 to K47; All to E48; P12 to Q49; P13 to Y50; P14 to P51; E15 to G52; E16 to I53; V17 to E54; E18 to I55; Pl9 to E56; G20 to 557;
S21 to R58; G22 to L59; V23 to G60; R24 to G61; I25 to T62; V26 to G63; V27 to A64; E28 to F65; Y29 to E66; C30 to I67; E31 to E68; P32 to I69; C33 to N70; G34 to G71; F35 to Q72; E36 to L73; A37 to V74; T38 to F75; Y39 to 576;
L40 to K77; E41 to L78; L42 to E79; A43 to N80; S44 to G81; A45 to G82; V46 to F83; K47 to P84; E48 to Y85; Q49 to E86; Y50 to K87; P51 to D88; G52 to L89; I53 to I90; E54 to E91; I55 to A92; E56 to I93; S57 to R94; R58 to R95;
L59 to A96; G60 to 597; G61 to N98; T62 to G99; G63 to E100; A64 to T101;
F65 to L102; E66 to E103; I67 to K104; E68 to I105; I69 to T106; N70 to N107;
G71 to 5108; Q72 to 8109; L73 to P110; V74 to P111; F75 to C112; S76 to V113; K77 to I114; L78 to L115.
[0145] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 39mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to Y39; S2 to L40; G3 to E41; E4 to L42; PS to A43; G6 to 544; Q7 to A45;
T8 to V46; S9 to K47; V10 to E48; Al l to Q49; P12 to Y50; P13 to P51; P14 to G52; E15 to I53; El6 to E54; V17 to I55; E18 to E56; P19 to 557; G20 to R58;
S21 to L59; G22 to G60; V23 to G61; R24 to T62; I25 to G63; V26 to A64; V27 to F65; E28 to E66; Y29 to I67; C30 to E68; E31 to I69; P32 to N70; C33 to G71; G34 to Q72; F35 to L73; E36 to V74; A37 to F75; T38 to 576; Y39 to K77;
L40 to L78; E41 to E79; L42 to N80; A43 to G81; S44 to G82; A45 to F83; V46 to P84; K47 to Y85; E48 to E86; Q49 to K87; Y50 to D88; P51 to L89; G52 to I90; I53 to E91; E54 to A92; I55 to I93; E56 to R94; S57 to R95; R58 to A96;

L59 to 597; G60 to N98; G61 to G99; T62 to E100; G63 to T101; A64 to L102;
F65 to E103; E66 to K104; I67 to I105; E68 to T106; I69 to N107; N70 to 5108;
G71 to 8109; Q72 to P110; L73 to P111; V74 to C112; F75 to V113; S76 to 1114; K77 to L115.
[0146] In anotherpreferred embodiment, the isolatedpolypeptides ofthepresent invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 40mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to L40; S2 to E41; G3 to L42; E4 to A43; P5 to 544; G6 to A45; Q7 to V46;
T8 to K47; S9 to E48; V10 to Q49; Al l to Y50; P12 to P51; P13 to G52; P14 to I53; E15 to E54; E16 to I55; V17 to E56; E18 to 557; P19 to R58; G20 to L59;
S21 to G60; G22 to G61; V23 to T62; R24 to G63; I25 to A64; V26 to F65; V27 to E66; E28 to I67; Y29 to E68; C30 to I69; E31 to N70; P32 to G71; C33 to Q72; G34 to L73; F35 to V74; E36 to F75; A37 to 576; T38 to K77; Y39 to L78;
L40 to E79; E41 to N80; IA~2 to G81; A43 to G82; S44 to F83; A45 to P84; V46 to Y85; K47 to E86; E48 to K87; Q49 to D88; Y50 to L89; P51 to I90; G52 to E91; I53 to A92; E54 to I93; I55 to R94; E56 to R95; S57 to A96; R58 to 597;
L59 to N98; G60 to G99; G61 to E100; T62 to T101; G63 to L102; A64 to E103;
F65 to K104; E66 to I105; I67 to T106; E68 to N107; I69 to 5108; N70 to 8109;
G71 to P110; Q72 to P111; L73 to C112; V74 to V113; F75 to I114; S76 to L115.
[0147] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 4lmers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to E41; S2 to L42; G3 to A43; E4 to 544; P5 to A45; G6 to V46; Q7 to K47;
T8 to E48; S9 to Q49; V10 to Y50; Al l to P51; P12 to G52; P13 to I53; P14 to E54; E15 to I55; E16 to E56; V17 to 557; E18 to R58; P19 to L59; G20 to G60;
S21 to G61; G22 to T62; V23 to G63; R24 to A64; I25 to F65; V26 to E66; V27 to I67; E28 to E68;Y29 to I69; C30 to N70; E31 to G71; P32 to Q72; C33 to L73;

G34 to V74; F35 to F75; E36 to 576; A37 to K77; T38 to L78; Y39 to E79; L40 to N80; E41 to G81; L42 to G82; A43 to F83; S44 to P84; A45 to Y85; V46 to E86; K47 to K87; E48 to D88; Q49 to L89; Y50 to I90; P51 to E91; G52 to A92;
I53 to I93; E54 to R94; I55 to R95; E56 to A92; S57 to 597; R58 to N98; L59 to G99; G60 to E100; G61 to T101; T62 to L102; G63 to E103; A64 to K104; F65 to I105; E66 to T106; I67 to N107; E68 to 5108; I69 to 8109; N70 to P110; G71 to P111; Q72 to C112; L73 to V113; V74 to I114; F75 to L115.
[0148] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 42mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to L42; S2 to A43; G3 to 544; E4 to A45; PS to V46; G6 to K47; Q7 to E48;
T8 to Q49; S9 to Y50; V10 to P51; Al l to G52; P12 to I53; P13 to E54; P14 to I55; E15 to E56; E16 to 557; Vl7 to R58; E18 to L59; P19 to G60; G20 to G61;
S21 to T62; G22 to G63; V23 to A64; R24 to F65; I25 to E66; V26 to I67; V27 to E68; E28 to I69; Y29 to N70; C30 to G71; E31 to Q72; P32 to L73; C33 to V74; G34 to F75; F35 to 576; E36 to K77; A37 to L78; T38 to E79; Y39 to N80;
L40 to G81; E41 to G82; L42 to F83; A43 to P84; S44 to Y85; A45 to E86; V46 to K87; K47 to D88; E48 to L89; Q49 to I90; Y50 to E91; P51 to A92; G52 to I93; I53 to R94; E54 to R95; I55 to A96; E56 to 597; S57 to N98; R58 to G99;
L59 to E100; G60 to T10I; G61 to L102; T62 to E103; G63 to K104; A64 to I105; F65 to T106; E66 to N107; I67 to 5108; E68 to 8109; I69 to Pl 10; N70 to P111; G71 to 0112; Q72 to V113; L73 to I114; V74 to L115.
[0149] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 43mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):
M1 to A43; S2 to 544; G3 to A45; E4 to V46; PS to K47; G6 to E48; Q7 to Q49;
T8 to Y50; S9 to P51; V10 to G52; Al l to I53; P12 to E54; P13 to I55; P14 to E56; E15 to 557; E16 to R58; V17 to L59; E18 to G60; P19 to G61; G20 to T62;

S21 to G63; G22 to A64; V23 to F65; R24 to E66; I25 to I67; V26 to E68; V27 to I69; E28 to N70; Y29 to G71; C30 to Q72; E31 to L73; P32 to V74; C33 to F75; G34 to 576; F35 to K77; E36 to L78; A37 to E79; T38 to N80; Y39 to G81;
L40 to G82; E41 to F83; L42 to P84; A43 to Y85; S44 to E86; A45 to K87; V46 to D88; K47 to L89; E48 to I90; Q49 to E91; Y50 to A92; PS1 to I93; G52 to R94; I53 to R95; E54 to A96; I55 to 597; E56 to N98; S57 to G99; R58 to E100;
L59 to T101; G60 to L102; G61 to E103; T62 to K104; G63 to I105; A64 to T106; F65 to N107; E66 to 5108; I67 to 8109; E68 to P110; I69 to P111; N70 to 0112; G71 to V113; Q72 to I114; L73 to L115.
[0150] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 44mers (residues correspond to SEQ ll7 N0:2 and FIG. 1B):
Ml to 544; S2 to A45; G3 to V46; E4 to K47; PS to E48; G6 to Q49; Q7 to Y50;
T8 to P51; S9 to G52; V10 to I53; Al l to E54; P12 to I55; P13 to E56; P14 to 557; E15 to R58; E16 to L59; V 17 to G60; E18 to G61; P19 to T62; G20 to G63;
S21 to A64; G22 to F65; V23 to E66; R24 to I67; I25 to E68; V26 to I69; V27 to N70; E28 to G71; Y29 to Q72; C30 to L73; E31 to V74; P32 to F76; C33 to 576; G34 to K77; F35 to L78; E36 to E79; A37 to N80; T38 to G81; Y39 to G82;
L40 to F83; E41 to P84; L42 to Y85; A43 to E86; S44 to K87; A45 to D88; V46 to L89; K47 to I90; E48 to E91; Q49 to A92; Y50 to I93; P51 to R94; G52 to R95; I53 to A96; E54 to 597; I55 to N98; E56 to G99; S57 to E100; R58 to T101;
L59 to L102; G60 to E103; G61 to K104; T62 to I105; G63 to T106; A64 to N107; F65 to 5108; E66 to 8109; I67 to P110; E68 to P111; I69 to 0112; N70 to V113; G71 to I114; Q72 to L115.
[0151] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 45mers (residues correspond to SEQ ID N0:2 and FIG. 1B):

Ml to A45; S2 to V46; G3 to K47; E4 to E48; PS to Q49; G6 to Y50; Q7 to P51;
T8 to G52; S9 to I53; V10 to E54; All to I55; P12 to E56; P13 to 557; P14 to R58; E15 to L59; E16 to G60; V17 to G61; E18 to T62; P19 to G63; G20 to A64;
S21 to F65; G22 to E66; V23 to I67; R24 to E68; I25 to I69; V26 to N70; V27 to G71; E28 to Q72; Y29 to L73; C30 to V74; E31 to F75; P32 to 576; C33 to K77; G34 to L78; F35 to E79; E36 to N80; A37 to G81; T38 to G82; Y39 to F83;
L40 to P84; E41 to Y85; L42 to E86; A43 to K87; S44 to D88; A45 to L89; V46 to I90; K47 to E91; E48 to E92; Q49 to I93; Y50 to R94; P51 to R95; G52 to A96; I53 to 597; E54 to N98; I55 to G99; E56 to E100; S57 to T101; R58 to L102; L59 to E103; G60 to K104; G61 to K105; T62 to T106; G63 to N107; A64 to S 108; F65 to 8109; E66 to P 110; I67 to P 11 l; E68 to C 112; I69 to V
113; N70 to I114; G71 to L115.
[0152] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 46mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):
Ml to V46; S2 to K47; G3 to E48; E4 to Q49; PS to Y50; G6 to P51; Q7 to G52;
T8 to I53; S9 to E54; V10 to I55; All to E56; P12 to 557; P13 to R58; P14 to L59; E15 to G60; E16 to G61; V17 to T62; E18 to G63; P19 to A64; G20 to F65;
S21 to E66; G22 to I67; V23 to E68; R24 to I69; I25 to N70; V26 to G71; V27 to Q72; E28 to L73; Y29 to V74; C30 to F75; E31 to 576; P32 to K77; C33 to L78; G34 to E79; F35 to N80; E36 to G81; A37 to G82; T38 to F83; Y39 to P84;
L,40 to Y85; E41 to E86; L42 to K87; A43 to D88; S44 to L89; A45 to I90; V46 to E91; K47 to A92; E48 to I93; Q49 to R94; Y50 to R95; P51 to A96; G52 to 597; I53 to N98; E54 to G99; I55 to E100; E56 to T101; S57 to L102; R58 to E103; L59 to K104; G60 to I105; G61 to T106; T62 to N107; G63 to S 108; A64 to 8109; F65 to P110; E66 to P111; I67 to C112; E68 to V113; I69 to I114; N70 to L115 (0153] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 47mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to K47; S2 to E48; G3 to Q49; E4 to Y50; PS to PS 1; G6 to G52; Q7 to I53;
T8 to E54; S9 to I55; V10 to E56; All to 557; P12 to R58; P13 to L59; P14 to G60; E15 to G61; E16 to T62; Vl7 to G63; E18 to A64; P19 to F65; G20 to E66;
S21 to I67; G22 to E68; V23 to I69; R24 to N70; I25 to G71; V26 to Q72; V27 to L73; E28 to V74; Y29 to F75; C30 to 576; E31 to K77; P32 to L78; C33 to E79; G34 to N80; F35 to G81; E36 to G82; A37 to F83; T38 to P84; Y39 to Y85;
L40 to E86; E41 to K87; L42 to D88; A43 to L89; S44 to I90; A45 to E91; V46 to A92; K47 to I93; E48 to R94; Q49 to R95; Y50 to A96; P51 to 597; G52 to N98; I53 to G99; E54 to E100; I55 to T101; E56 to L102; S57 to E103; R58 to K104; L59 to I105; G60 to T106; G61 to N107; T62 to S108; G63 to 8109; A64 to P110; F65 to P111; E66 to 0112; I67 to V113; E68 to Ill4; I69 to L115 [0154] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 48mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):
Ml to E48; S2 to Q49; G3 to Y50; E4 to P51; PS to G52; G6 to I53; Q7 to E54;
T8 to I55; S9 to E56; V10 to 557; All to R58; P12 to L59; P13 to G60; P14 to G61; E15 to T62; E16 to G63; V17 to A64; E18 to F65; P19 to E66; G20 to I67;
S21 to E68; G22 to I69; V23 to N70; R24 o G71; I25 to Q72; V26 to L73; V27 to V74; E28 to F75; Y29 to 576; C30 to K77; E31 to L78; P32 to E79; C33 to N80; G34 to G81; F35 to G82; E36 to F83; A37 to P84; T38 to Y85; Y39 to E86;
L40 to K87; E41 to D88; L42 to L89; A43 to I90; S44 to E91; A45 to A92; V46 to I93; K47 to R94; E48 to R95; Q49 to A96; Y50 to 597; P51 to N98; G52 to G99; I53 to E100; E54 to T101; I55 to L102; E56 to E103; S57 to K104; R58 to I105; L59 to T106; G60 to N107; G61 to S108; T62 to 8109; G63 to P110; A64 to P111; F65 to C112; E66 to V113; I67 to Il l4; E68 to L115 [0155] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 49mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to Q49; S2 to Y50; G3 to P51; E4 to G52; PS to I53; G6 to E54; Q7 to I55;
T8 to E56; S9 to 557; V10 to R58; Al l to L59; P12 to G60; P13 to G61; P14 to T62; E15 to G63; E16 to A64; V17 to F65; El8 to E66; P19 to I67; G20 to E68;
S21 to I69; G22 to N70; V23 to G71; R24 to Q72; I25 to L73; V26 to V74; V27 to F75; E28 to 576; Y29 to K77; C30 to L78; E31 to E79; P32 to N80; C33 to G81; G34 to G82; F35 to F83; E36 to P84; A37 to Y85; T38 to E86; Y39 to K87;
L40 to D88; E41 to L89; L42 to I90; A43 to E91; S44 to A92; A45 to I93; V46 to R94; K47 to R95; E48 to A96; Q49 to 597; Y50 to N98; P51 to G99; G52 to E100; I53 to T101; E54 to L102; I55 to E103; E56 to K104; S57 to I105; R58 to T106; L59 to N107; G60 to 5108; G61 to 8109; T62 to P110; G63 to Pl 11; A64 to C112; F65 to V113; E66 to I114; I67 to L115 [0156] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following SOmers (residues correspond to SEQ ID N0:2 and FIG. 1 B):
M1 to Y50; S2 to P51; G3 to G52; E4 to I53; PS to E54; G6 to I55; Q7 to E56;
T8 to 557; S9 to R58; V10 to L59; Al l to G60; P12 to G61; P13 to T62; P14 to G63; E15 to A64; E16 to F65; V17 to E66; El8 to I67; P19 to E68; G20 to I69;
S21 to N70; G22 to G71; V23 to Q72; R24 to L73; I25 to V74; V26 to F75; V27 to 576; E28 to K77; Y29 to L78; C30 to E79; E31 to N80; P32 to G81; C33 to G82; G34 to F83; F35 to P84; E36 to Y85; A37 to E86; T38 to K87; Y39 to D88;
L40 to L89; E41 to I90; L42 to E91; A43 to A92; S44 to I93; A45 to R94; V46 to R95; K47 to A96; E48 to 597; Q49 to N98; Y50 to G99; P51 to E100; G52 to T101; I53 to L102; E54 to E103; I55 to K104; E56 to I105; S57 to T106; R58 to N107; L59 to 5108; G60 to 8109; G61 to P110; T62 to P111; G63 to 0112; A64 to V 113; F65 to I114; E66 to Ll 15 [0157] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide _71_ epitopes include the following S liners (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to P51; S2 to G52; G3 to I53; E4 to E54; PS to I55; G6 to E56; Q7 to 557;
T8 to R58; S9 to L59; V10 to G60; Al l to G61; P12 to T62; P13 to G63; P14 to A64; E15 to F65; E16 to E6,6; V17 to I67; E18 to E68; P19 to I69; G20 to N70;
S21 to G71; G22 to Q72; V23 to L73; R24 to V74; I25 to F75; V26 to S76; V27 to K77; E28 to L78; Y29 to E79; C30 to N80; E31 to G81; P32 to G82; C33 to F83; G34 to P84; F35 to Y85; E36 to E86; A37 to K87; T38 to D88; Y39 to L89;
L40 to I90; E41 to E91; L42 to A92; A43 to I93; S44 to R94; A45 to R95; V46 to A96; K47 to 597; E48 to N98; Q49 to G99; Y50 to E100; P51 to T101; G52 to L102; I53 to E103; E54 to K104; I55 to I105; E56 to T106; S57 to N107; R58 to 5108; L59 to 8109; G60 to P110; G61 to P111; T62 to C112; G63 to V113;
A64 to I114; F65 to L115 [0158] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 52rners (residues correspond to SEQ ID NO:2 and FIG. 1B):
Ml to G52; S2 to I53; G3 to E54; E4 to I55; PS to E56; G6 to 557; Q7 to R58;
T8 to L59; S9 to G60; V10 to G61; Al l to T62; P12 to G63; P13 to A64; P14 to F65; E1.5 to.E66; E16 to I67; V17 to E68; E18 to I69; P19 to N70; G20 to G71;
S21 to Q72; G22 to L73; V23 to V74; R24 to F75; I25 to 576; V26 to K77; V27 to L78; E28 to E79; Y29 to N80; C30 to G81; E31 to G82; P32 to F83; C33 to P84; G34 to Y85; F35 to E86; E36 to K87; A37 to D88; T38 to L89; Y39 to I90;
L40 to E91; E41 to A92; L42 to I93; A43 to R94; S44 to R95; A45 to A96; V46 to 597; K47 to N98; E48 to G99; Q49 to E100; Y50 to T101; P51 to L102; G52 to E103; I53 to K104; E54 to I105; I55 to T106; E56 to N107; S57 to 5108; R58 to Rl 09; L59 to P 110; G60 to P 111; G61 to C 112; T62 to V 113; G63 to Il 14;
A64 to L115 [0159] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide _72_ epitopes include the following 53mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to I53; S2 to E54; G3 to I55; E4 to E56; PS to 557; G6 to R58; Q7 to L59;
T8 to G60; S9 to G61; V10 to T62; Al l to G63; P12 to A64; P13 to F65; P14 to E66; El5 to I67; E16 to E68; V17 to I69; El8 to N70; P19 to G71; G20 to Q72;
S21 to L73; G22 to V74; V23 to F75; R24 to 576; I25 to K77; V26 to L78; V27 to E79; E28 to N80; Y29 to G81; C30 to G82; E31 to F83; P32 to P84; C33 to Y85; G34 to E86; F35 to K87; E36 to D88; A37 to L89; T38 to I90; Y39 to E91;
L40 to A92; ~E41 to I93; L42 to R94; A43 to R95; S44 to A96; A45 to 597; V46 to N98; K47 to G99; E48 to E100; Q49 to T101; Y50 to L102; P51 to E103; G52 to K104; I53 to I105; E54 to T106; I55 to N107; E56 to 5108; S57 to 8109; R58 to P110; L59 to P111; G60 to 0112; G61 to V113; T62 to I114; G63 to L115 (0160] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 54mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to E54; S2 to I55; G3 to E56; E4 to 557; P5 to R58; G6 to L59; Q7 to G60;
T8 to G61; S9 to T62; V10 to G63; Al l to A64; P12 to F65; P13 to E66; P14 to I67; E15 to E68; E16 to I69; V17 to N70; E18 to G71; P19 to Q72; G20 to L73;
S21 to V74; G22 to F75; V23 to 576; R24 to K77; I25 to L78; V26 to E79; V27 to N80; E28 to G81; Y29 to G82; C30 to F83; E31 to P84; P32 to Y85; C33 to E86; G34 to K87; F35 to D88; E36 to L89; A37 to I90; T38 to E91; Y39 to A92;
L40 to I93; E41 to R94; L42 to R95; A43 to A96; S44 to 597; A45 to N98; V46 to G99; K47 to E100; E48 to T101; Q49 to L102; Y50 to E103; P51 to K104;
G52 to I105; I53 to T106; E54 to N107; I55 to 5108; E56 to 8109; S57 to P110;
R58 to P111; L59 to C112; G60 to V113; G61 to I114; T62 to L115 [0161] In another preferred embodiment, the isolatedpolypeptides ofthe present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 55mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):

Ml to I55; S2 to E56; G3 to 557; E4 to R58; PS to L59; G6 to G60; Q7 to G61;
T8 to T62; S9 to G63; V10 to A64; Al l to F65; P12 to E66; P13 to I67; P14 to E68; E15 to I69; E16 to N70; V17 to G71; E18 to Q72; P19 to L73; G20 to V74;
S21 to F75; G22 to 576; V23 to K77; R24 to L78; I25 to E79; V26 to N80; V27 to G81; E28 to G82; Y29 to F83; C30 to P84; E31 to Y85; P32 to E86; C33 to K87; G34 to D88; F35 to L89; E36 to I90; A37 to E91; T38 to A92; Y39 to I93;
L40 to R94; E41 to R95; IA~2 to A96; A43 to 597; S44 to N98; A45 to G99; V46 to E100; K47 to T101; E48 to L102; Q49 to E103; Y50 to K104; P51 to I105;
G52 to T106; I53 to N107; E54 to 5108; I55 to 8109; E56 to P110; S57 to P111;
R58 to C112; L59 to V113; G60 to I114; G61 to L115 [0162] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 56mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to E56; S2 to 557; G3 to R58; E4 to L59; PS to G60; G6 to G61; Q7 to T62;
T8 to G63; S9 to A64; V10 to F65; Al l to E66; P12 to I67; P13 to E68; P14 to I69; E15 to N70; E16 to G71; V17 to Q72; E18 to L73; P19 to V74; G20 to F75;
S21 to 576; G22 to K77; V23 to L78; R24 to E79; I25 to N80; V26 to G81; V27 to G82; E28 to F83; Y29 to P84; C30 to Y85; E31 to E86; P32 to K87; C33 to D88; G34 to L89; F35 to I90; E36 to E91; A37 to A92; T38 to I93; Y39 to R94;
L40 to R95; E41 to A96; L42 to 597; A43 to N98; S44 to G99; A45 to E100;
V46 to T101; K47 to L102; E48 to E103; Q49 to K104; Y50 to I105; P51 to T106; G52 to N107; I53 to 5108; E54 to 8109; I55 to P110; E56 to P111; S57 to 0112; R58 to V113; L59 to Il l4; G60 to L115 [0163] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 57mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to 557; S2 to R58; G3 to L59; E4 to G60; PS to G61; G6 to T62; Q7 to G63;
T8 to A64; S9 to F65; V10 to E66; All to I67; P12 to E68; P13 to I69; P14 to N70; E15 to G71; E16 to Q72; V17 to L73; E18 to V74; P19 to F75; G20 to 576;
S2I to K77; G22 to L78; V23 to E79; R24 to N80; I25 to G81; V26 to G82; V27 to F83; E28 to P84; Y29 to Y85; C30 to E86; E31 to K87; P32 to D88; C33 to L89; G34 to I90; F35 to E91; E36 to A92; A37 to I93; T38 to R94; Y39 to R95;
L40 to A96; E41 to 597; L42 to N98; A43 to G99; S44 to E100; A45 to T101;
V46 to L102; K47 to E103; E48 to K104; Q49 to I105; Y50 to T106; P51 to N107; G52 to 5108; I53 to 8109; E54 to P110; I55 to P111; E56 to C112; S57 to V113; R58 to I114; L59 to L115 [0164] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 58mers (residues correspond to SEQ ID NO:2 and FIG. 1B):
Ml to R58; S2 to L59; G3 to G60; E4 to G61; PS to T62; G6 to G63; Q7 to A64;
T8 to F65; S9 to E66; V10 to I67; A11 to E68; P12 to I69; P13 to N70; P14 to G71; E15 to Q72; E16 to L73; V17 to V74; E18 to F75; P19 to 576; G20 to K77;
S21 to L78; G22 to E79; V23 to N80; R24 to G81; I25 to G82; V26 to F83; V27 to P84; E28 to Y85; Y29 to E86; C30 to K87; E31 to E88; P32 to L89; C33 to I90; G34 to E91; F35 to A92; E36 to I93; A37 to R94; T38 to R95; Y39 to A96;
L40 to 597; El to N98; L42 to G99; A43 to E100; S44 to T101; A45 to L102;
V46 to E103; K47 to K104; E48 to I105; Q49 to T106; Y50 to N107; P51 to 5108; G52 to 8109; I53 to P110; E54 to P111; I55 to C112; E56 to V113; S57 to Il 14; R58 to Ll 15 [0165] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 59mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to L59; S2 to G60; G3 to G61; E4 to T62; PS to G63; G6 to A64; Q7 to F65;
T8 to E66; S9 to I67; V10 to E68; Al l to I69; P12 to N70; P13 to G71; P14 to Q72; E15 to L73; E16 to V74; V17 to F75; E18 to 576; P19 to K77; G20 to L78;
S21 to E79; G22 to N80; V23 to G81; R24 to G82; I25 to F83; V26 to P84; V27 to Y85; E28 to E86; Y29 to K87; C30 to D88; E31 to L89; P32 to I90; C33 to E91; G34 to A92; F35 to I93; E36 to R94; A37 to R95; T38 to A96; Y39 to 597;
L40 to N98; E41 to G99; L42 to E100; A43 to T101; S44 to L102; A45 to E103;
V46 to K104; K47 to I105; E48 to T106; Q49 to N107; Y50 to 5108; P51 to 8109; G52 to P110; I53 to P111; E54 to C112; I55 to V113; E56 to Il 14; S57 to [0166] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 60mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to G60; S2 to G61; G3 to T62; E4 to G63; P5 to A64; G6 to F65; Q7 to E66;
T8 to I67; S9 to E68; V10 to I69; All to N70; P12 to G71; P13 to Q72; P14 to L73; E15 to V74; E16 to F75; V17 to 576; E18 to K77; P19 to L78; G20 to E79;
S21 to N80; G22 to G81; V23 to G82; R24 to F83; I25 to P84; V26 to Y85; V27 to E86; E28 to K87; Y29 to D88; C30 to L89; E31 to I90; P32 to E91; C33 to A92; G34 to I93; F35 to R94; E36 to R95; A37 to A96; T38 to 597; Y39 to N98;
L40 to G99; E41 to E100; L42 to T101; A43 to L102; S44 to E103; A45 to K104;
V46 to I105; K47 to T106; E48 to N107; Q49 to 5108; Y50 to 8109; P51 to P110;G52toP111;I53toC112;E54toV113;I55toI114;E56toL115 [0167] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 6lmers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to G61; S2 to T62; G3 to G63; E4 to A64; P5 to F65; G6 to E66; Q7 to I67;
T8 to E68; S9 to I69; V10 to N70; All to G71; P12 to Q72; P13 to L73; P14 to V74; El5 to F75; E16 to 576; V17 to K77; E18 to L78; P19 to E79; G20 to N80;
S21 to G81; G22 to G82; V23 to F83; R24 to P84; I25 to Y85; V26 to E86; V27 to K87; E28 to D88; Y29 to L89; C30 to I90; E31 to E91; P32 to A92; C33 to I93; G34 to R94; F35 to R95; E36 to A96; A37 to 597; T38 to N98; Y39 to G99;
L40 to E100; E41 to T101; L42 to L102; A43 to E103; S44 to K104; A45 to I105; V46 to T106; K47 to N107; E48 to 5108; Q49 to 8109; Y50 to P110; P51 to P111; G52 to C112; I53 to V113; E54 to I114; I55 to L115 [0168] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 62mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to T62; S2 to G63; G3 to A64; E4 to F65; P5 to E66; G6 to I67; Q7 to E68;
T8 to I69; S9 to N70; V10 to G71; A11 to Q72; P12 to L73; P13 to V74; P14 to F75; E15 to 576; E16 to K77; V17 to L78; E18 to E79; P19 to N80; G20 to G81;
S21 to G82; G22 to F83; V23 to P84; R24 to Y85; I25 to E86; V26 to K87; V27 to D88; E28 to L89; Y29 to I90; C30 to E91; E31 to A92; P32 to I93; C33 to R94; G34 to R95; F35 to A96; E36 to 597; A37 to N98; T38 to G99; Y39 to E100; L40 to T101; E41 to L102; L42 to E103; A43 to K104; S44 to I105; A45 to T106; V46 to N107; K47 to 5108; E48 to 8109; Q49 to P110; Y50 to P111;
P51 to C112; G52 to V113; I53 to I114; E54 to L115.
[0169] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 63mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to G63; S2 to A64; G3 to F65; E4 to E66; P5 to I67; G6 to E68; Q7 to I69;
T8 to N70; S9 to G71; V10 to Q72; A11 to L73; P12 to V74; P13 to F75; P14 to 576; E15 to K77; E16 to L78; V17 to E79; E18 to N80; P19 to G81; G20 to G82;
S21 to F83; G22 to P84; V23 to Y85; R24 to E86; I25 to K87; V26 to D88; V27 to L89; E28 to I90; Y29 to E91; C30 to A92; E31 to I93; P32 to R94; C33 to R95; G34 to A96; F35 to 597; E36 to N98; A37 to G99; T38 to E100; Y39 to T101; L40 to L102; E41 to E103; L42 to K104; A43 to I105; S44 to T106; A45 to N107; V46 to 5108; K47 to 8109; E48 to P110; Q49 to P111; Y50 to C112;
P51 to V 113; G52 to I114; I53 to Ll 15 [0170] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide _77_ epitopes include the following 64mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to A64; S2 to F65; G3 to E66; E4 to I67; PS to E68; G6 to I69; Q7 to N70;
T8 to G71; S9 to Q72; V10 to L73; Al l to V74; P12 to F75; P13 to 576; P14 to K77; E15 to L78; E16 to E79; V17 to N80; E18 to G81; P19 to G82; G20 to F83;
S21 to P84; G22 to Y85; V23 to E86; R24 to K87; I25 to D88; V26 to L89; V27 to I90; E28 to E91; Y29 to A92; C30 to I93; E31 to R94; P32 to R95; C33 to A96; G34 to 597; F35 to N98; E36 to G99; A37 to E100; T38 to T101; Y39 to L102; L40 to E103; E41 to K104; L42 to I105; A43 to T106; S44 to N107; A45 to 5108; V46 to 8109; K47 to P110; E48 to P111; Q49 to 0112; Y50 to V113;
P51 to Il l4; G52 to L115;
[0171] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 65mers (residues correspond to SEQ ID NO:2 and FIG. 1 B):
Ml to F65; S2 to E66; G3 to I67; E4 to E68; PS to I69; G6 to N70; Q7 to G71;
T8 to Q72; S9 to L73; V10 to V74; Al l to F75; P12 to 576; P13 to K77; P14 to L78; E15 to E79; E16 to N80; V17 to G81; E18 to G82; P19 to F83; G20 to P84;
S21 to Y85; G22 to E86; V23 to K87; R24 to D88; I25 to L89; V26 to I90; V27 to E91; E28 to A92; Y29 to I93; C30 to R94; E31 to R95; P32 to A96; C33 to 597; G34 to N98; F35 to G99; E36 to E100; A37 to T101; T38 to L102; Y39 to E103; L40 to K104; E41 to I105; L42 to T106; A43 to N107; S44 to 5108; A45 to 8109; V46 to P110; K47 to P111; E48 to C112; Q49 to V113; Y50 to I114;
P51 to L115;
[0172] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 66mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):
Ml to E66; S2 to I67; G3 to E68; E4 to I69; PS to N70; G6 to G71; Q7 to Q72;
T8 to L73; S9 to V74; V10 to F75; Al l to 576; P12 to K77; P13 to L78; P14 to _78_ E79; E15 to N80; E16 to G81; V17 to G82; E18 to F83; P19 to P84; G20 to Y85;
S21 to E86; G22 to K87; V23 to D88; R24 to L89; I25 to I90; V26 to E91; V27 to A92; E28 to I93; Y29 to R94; C30 to R95; E31 to A96; P32 to 597; C33 to N98; G34 to G99; F35 to E100; E36 to T101; A37 to L102; T38 to E103; Y39 to K104; L40 to I105; E41 to T106; L42 to N107; A43 to 5108; S44 to 8109;
A45 to P110; V46 to P111; K47 to C112; E48 to V113; Q49 to Il l4; Y50 to [0173] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 67rners (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to I67; S2 to E68; G3 to I69; E4 to N70; PS to G71; G6 to Q72; Q7 to L73;
T8 to V74; S9 to F75; V10 to 576; Al l to K77; P12 to L78; P13 to E79; P14 to N80; E15 to G81; E16 to G82; V17 to F83; E18 to P84; P19 to Y85; G20 to E86;
S21 to K87; G22 to D88; V23 to L89; R24 to I90; I25 to E91; V26 to A92; V27 to I93; E28 to R94; Y29 to R95; C30 to A96; E31 to 597; P32 to N98; C33 to G99; G34 to E100; F35 to T101; E36 to L102; A37 to E103; T38 to K104; Y39 to I105; L40 to T106; E41 to N107; L42 to S 108; A43 to 8109; S44 to P 110;

to P111; V46 to 0112; K47 to V113; E48 to Ill4; Q49 to L115;
[0174] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 68mers (residues correspond to SEQ ~ N0:2 and FIG. 1B):
M1 to E68; S2 to I69; G3 to N70; E4 to G71; PS to Q72; G6 to L73; Q7 to V74;
TS to F75; S9 to 576; V10 to K77; Al l to L78; P12 to E79; P13 to N80; P14 to G81; E15 to G82; E16 to F83; V17 to P84; E18 to Y85; P19 to E86; G20 to K87;
S21 to D88; G22 to L89; V23 to I90; R24 to E91; I25 to A92; V26 to I93; V27 to R94; E28 to R95; Y29 to A96; C30 to 597; E31 to N98; P32 to G99; C33 to E100; G34 to T101; F35 to L102; E36 to E103; A37 to K104; T38 to I105; Y39 _7g_ to T106; L40 to N107; E41 to 5108; L42 to 8109; A43 to P110; S44 to P111;
A45 to C112; V46 to V113; K47 to I114; E48 to L115;
[0175] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 69mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to I69; S2 to N70; G3 to G71; E4 to Q72; PS to L73; G6 to V74; Q7 to F75;
T8 to 576; S9 to K77; V10 to L78; Al l to E79; P12 to N80; P13 to G81; P14 to G82; E15 to F83; E16 to P84; V17 to Y85; E18 to E86; P19 to K87; G20 to D88;
S21 to L89; G22 to I90; V23 to E91; R24 to A92; I25 to I93; V26 to R94; V27 to R95; E28 to A96; Y29 to 597; C30 to N98; E31 to G99; P32 to E100; C33 to T101; G34 to L102; F35 to E103; E36 to K104; A37 to I105; T38 to T106; Y39 to N107; L40 to 5108; E41 to 8109; L42 to P110; A43 to P111; S44 to C112;
A45 to V 113; V46 to Il 14; K47 to Ll 15.
[0176] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 70mers (residues correspond to SEQ ~ N0:2 and FIG. 1B):
Ml to N70; S2 to G71; G3 to Q72; E4 to L73; PS to V74; G6 to F75; Q7 to 576;
T8 to K77; S9 to L78; V10 to E79; Al l to N80; P12 to G81; P13 to G82; P14 to F83; E15 to P84; E16 to Y85; V17 to E86; E18 to K87; P19 to D88; G20 to L89;
S21 to I90; G22 to E91; V23 to A92; R24 to I93; I25 to R94; V26 to R95; V27 to A96; E28 to 597; Y29 to N98; C30 to G99; E31 to E100; P32 to T101; C33 to L102; G34 to E103; F35 to K104; E36 to I105; A37 to T106; T38 to N107;
Y39 to 5108; LAO to 8109; E41 to P110; L42 to P111; A43 to C112; S44 to V113; A45 to I114; V46 to L115.
[0177] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 7lmers (residues correspond to SEQ ID N0:2 and FIG. 1 B):

Ml to G71; S2 to Q72; G3 to L73; E4 to V74; P5 to F75; G6 to 576; Q7 to K77;
T8 to L78; S9 to E79; V10 to N80; Al l to G81; P12 to G82; P13 to F83; P14 to P84; E15 to Y85; E16 to E86; Vl7 to K87; E18 to D88; P19 to L89; G20 to I90;
S21 to E91; G22 to A92; V23 to I93; R24 to R94; I25 to R95; V26 to A96; V27 to 597; E28 to N98; Y29 to G99; C30 to E100; E31 to T101; P32 to L102; C33 to E103; G34 to K104; F35 to I105; E36 to T106; A37 to N107; T38 to 5108;
Y39 to 8109; L40 to P110; E41 to P111; L42 to 0112; A43 to V113; S44 to Il 14; A45 to Ll 15.
[0178] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 72mers (residues correspond to SEQ iD N0:2 and FIG. 1B):
M1 to Q72; S2 to L73; G3 to V74; E4 to F75; P5 to 576; G6 to K77; Q7 to L78;
T8 to E79; S9 to N80; V10 to G81; Al l to G82; P12 to F83; P13 to P84; P14 to Y85; E15 to E86; E16 to K87; V17 to D88; E18 to L89; P19 to I90; G20 to E91;
S21 to A92; G22 to I93; V23 to R94; R24 to R95; I25 to A96; V26 to 597; V27 to N98; E28 to G99; Y29 to E100; C30 to T101; E31 to L102; P32 to E103; C33 to K104; G34 to I105; F35 to T106; E36 to N107; A37 to 5108; T38 to 8109;
Y39 to P 110; L40 to P 111; E41 to C 112; L42 to V 113; A43 to Il 14; S44 to Ll 15.
[0179] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 73mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to L73; S2 to V74; G3 to F75; E4 to 576; P5 to K77; G6 to L78; Q7 to E79;
T8 to N80; S9 to G81; V10 to G82; A11 to F83; P12 to P84; P13 to Y85; P14 to E86; E15 to K87; E16 to D88; V17 to L89; E18 to I90; P19 to E91; G20 to A92;
S21 to I93; G22 to R94; V23 to R95; R24 to A96; I25 to 597; V26 to N98; V27 to G99; E28 to E100; Y29 to T101; C30 to L102; E31 to E103; P32 to K104; C33 to I105; G34 to T106; F35 to N107; E36 to 5108; A37 to 8109; T38 to P110;
Y39 to P111; L40 to C112; E41 to V113; L42 to I114; A43 to L115;

[0180] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 74mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to V74; S2 to F75; G3 to 576; E4 to K77; PS to L78; G6 to E79; Q7 to N80;
T8 to G81; S9 to G82; V10 to F83; A11 to P84; P12 to Y85; P13 to E86; P14 to K87; E15 to D88; E16 to L89; V17 to I90; E18 to E91; P19 to A92; G20 to I93;
S21 to R94; G22 to R95; V23 to A96; R24 to 597; I25 to N98; V26 to G99; V27 to E100; E28 to T101; Y29 to L102; C30 to E103; E31 to K104; P32 to I105;
C33 to T106; G34 to N107; F35 to 5108; E36 to 8109; A37 to P110; T38 to P 111; Y39 to C 112; L40 to V 113; E41 to Il 14; L42 to L l 15.
[0181] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 75mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to F75; S2 to 576; G3 to K77; E4 to L78; PS to E79; G6 to N80; Q7 to G81;
T8 to G82; S9 to F83; V10 to P84; Al l to Y85; P12 to E86; P13 to K87; P14 to D88; E15 to L89; E16 to I90; Vl7 to E91; E18 to A92; P19 to I93; G20 to R94;
S21 to R95; G22 to A96; V23 to 597; R24 to N98; I25 to G99; V26 to E100; V27 to T101; E28 to L102; Y29 to E103; C30 to K104; E31 to I105; P32 to T106;
C33 to N107; G34 to 5108; F35 to 8109; E36 to P110; A37 to P111; T38 to 0112; Y39 to V113; L40 to I114; E41 to L115;
[0182] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 76mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to 576; S2 to K77; G3 to L78; E4 to E79; PS to N80; G6 to G81; Q7 to G82;
T8 to F83; S9 to P84; V10 to Y85; Al l to E86; P12 to K87; P13 to D88; P14 to L89; E15 to I90; E16 to E91; V17 to A92; E18 to I93; P19 to R94; G20 to R95;
S21 to A96; G22 to 597; V23 to N98; R24 to G99; I25 to E100; V26 to T101;

V27 to L102; E28 to E103; Y29 to K104; C30 to I105; E31 to T106; P32 to N107; C33 to 5108; G34 to 8109; F35 to P110; E36 to P111; A37 to Ci 12; T38 to V113; Y39 to I114; L40 to L115;
[0183) In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 77mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to K77; S2 to L78; G3 to E79; E4 to N80; PS to G81; G6 to G82; Q7 to F83;
T8 to P84; S9 to Y85; V10 to E86; Al l to K87; P12 to D88; P13 to L89; P14 to I90; E15 to E91; El6 to A92; Vi7 to I93; E18 to R94; P19 to R95; G20 to A96;
S21 to 597; G22 to N98; V23 to G99; R24 to E100; I25 to T101; V26 to L102;
V27 to E103; E28 to K104; Y29; I105; C30 to T106; E31 to N107; P32 to S 108;
C33 to 8109; G34 to P110; F35 to P111; E36 to C112; A37 to V113; T38 to Ii 14; Y39 to Ll 1 S;
[0184] In anotherpreferred embodiment, the isolatedpolypeptides ofthepresent invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 78mers (residues correspond to SEQ ID NO:2 and FIG. 1B):
M1 to L78; S2 to E79; G3 to N80; E4 to G81; PS to G82; G6 to F83; Q7 to P84;
T8 to Y85; S9 to E86; V10 to K87; Al l to D88; P12 to L89; P13 to I90; P14 to E91; E15 to A92; E16 to I93; V17 to R94; E18 to R95; P19 to A96; G20 to 597;
S21 to N98; G22 to G99; V23 to E100; R24 to T101; I25 to L102; V26 to E103;
V27 to K104; E28 to I105; Y29 to T106; C30 to N107; E31 to 5108; P32 to 8109; C33 to P110; G34 to P111; F35 to C112; E36 to V113; A37 to Il 14; T38 to L115.
(0185] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 79mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to E79; S2 to N80; G3 to G81; E4 to G82; PS to F83; G6 to P84; Q7 to Y85;
T8 to E86; S9 to K87; Vl0 to D88; Al l to L89; P12 to I90; P13 to E91; P14 to A92; E15 to I93; El6 to R94; V17 to R95; E18 to A96; P19 to 597; G20 to N98;
S21 to G99; G22 to E100; V23 to T101; R24 to L102; I25 to E103; V26 to K104;
V27 to I105; E28 to T106; Y29 to N107; C30 to 5108; E31 to 8109; P32 to P110; C33 to P111; G34 to C112; F35 to V113; E36 to I114; A37 to L115.
[0186] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 80mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to N80; S2 to G81; G3 to G82; E4 to F83; PS to P84; G6 to Y85; Q7 to E86;
T8 to K87; S9 to D88; V10 to L89; Al l to I90; P12 to E91; P13 to A92; P14 to I93; E15 to R94; E16 to R95; V17 to A96; E18 to 597; P19 to N98; G20 to G99;
S21 to E100; G22 to T101; V23 to L102; R24 to E103; I25 to K104; V26 to I105;
V27 to T106; E28 to N107; Y29 to 5108; C30 to 8109; E31 to P110; P32 to P111; C33 to 0112; G34 to V113; F35 to I114; E36 to L115.
[0187] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 8lrners (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to G81; S2 to G82; G3 to F83; E4 to P84; PS to Y85; G6 to E86; Q7 to K87;
T8 to D88; S9 to L89; V10 to I90; Al l to E91; P12 to A92; P13 to I93; P14 to R94; E15 to R95; E16 to A96; V17 to S97; E18 to N98; P19 to G99; G20 to E100; S21 to T101; G22 to L102; V23 to E103; R24 to K104; I25 to I105; V26 to T106; V27 to N107; E28 to 5108; Y29 to 8109; C30 to P110; E31 to P111;
P32 to 0112; C33 to V 113; G34 to I114; F35 to L115.
[0188] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 82mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to G82; S2 to F83; G3 to P84; E4 to Y85; PS to E86; G6 to K87; Q7 to D88;
T8 to L89; S9 to I90; V10 to E91; Al l to A92; P12 to I93; P13 to R94; P14 to R95; E15 to A96; El6 to 597; V17 to N98; E18 to G99; P19 to E100; G20 to T101; S21 to L102; G22 to E103; V23 to K104; R24 to I105; I25 to T106; V26 to N107; V27 to 5108; E28 to 8109; Y29 to P110; C30 to P111; E31 to C112;
P32 to V113; C33 to I114; G34 to L115.
(0189] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 83mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to F83; S2 to P84; G3 to Y85; E4 to E86; PS to K87; G6 to D88; Q7 to L89;
T8 to I90; S9 to E91; V10 to A92; Al l to I93; P12 to R94; P13 to R95; P14 to A96; E15 to 597; E16 to N98; V17 to G99; E18 to E100; P19 to T101; G20 to L102; S21 to E103; G22 to K104; V23 to I105; R24 to T106; I25 to N107; V26 to 5108; V27 to 8109; E28 to P110; Y29 to P111; C30 to 0112; E31 to V113;
P32 to I114; C33 to Ll 15.
[0190] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 84mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to P84; S2 to Y85; G3 to E86; E4 to K87; PS to D88; G6 to L89; Q7 to I90;
T8 to E91; S9 to A92; V10 to I93; All to R94; P12 to R95; P13 to A96; P14 to 597; E15 to N98; E16 to G99; V17 to E100; E18 to T101; P19 to L102; G20 to E103; S21 to K104; G22 to I105; V23 to T106; R24 to N107; I25 to 5108; V26 to 8109; V27 to P110; E28 to P111; Y29 to C112; C30 to V113; E31 to I114;
P32 to L115.
[0191] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 85mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to Y85; S2 to E86; G3 to K87; E4 to D88; PS to L89; G6 to I90; Q7 to E91;
T8 to A92; S9 to I93; V10 to R94; A11 to R95; P12 to A96; P13 to 597; P14 to N98; E15 to G99; E16 to E100; V17 to T101; E18 to L102; P19 to E103; G20 to K104; S21 to I105; G22 to T106; V23 to N107; R24 to S 108; I25 to 8109; V26 to P110; V27 to P111; E28 to 0112; Y29 to V113; C30 to I114; E31 to L115.
[0192] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 86mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to E86; S2 to K87; G3 to D88; E4 to L89; PS to I90; G6 to E91; Q7 to A92;
T8 to I93; S9 to R94; V10 to R95; Al l to A96; P12 to 597; P13 to N98; P14 to G99; E15 to E100; E16 to T101; V17 to L102; E18 to E103; P19 to K104; G20 to I105; S21 to T106; G22 to N107; V23 to S 108; R24 to 8109; I25 to P110; V26 to P111; V27 to C112; E28 to V113; Y29 to I114; C30 to L115.
[0193] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 87mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to K87; S2 to D88; G3 to L89; E4 to I90; PS to E91; G6 to A92; Q7 to I93;
T8 to R94; S9 to R95; V10 to A96; Al l to 597; P12 to N98; P13 to G99; P14 to E100; E15 to T101; E16 to L102; V17 to E103; E18 to K104; P19 to I105; G20 to T106; S21 to N107; G22 to 5108; V23 to 8109; R24 to P110; I25 to P111;
V26 to 0112; V27 to V113; E28 to I114; Y29 to L115.
[0194] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 88mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to D88; S2 to L89; G3 to I90; E4 to E91; PS to A92; G6 to I93; Q7 to R94;
T8 to R95; S9 to A96; V10 to 597; Al l to N98; P12 to G99; P13 to E100; P14 toT101;E15toL102;E16toE103;V17toK104;E18toIlO5;P19toT106;

_86_ G20 to N107; S21 to 5108; G22 to 8109; V23 to P110; R24 to P111; I25 to C112; V26 to V113; V27 to I114; E28 to L115.
[0195] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 89mers (residues correspond to SEQ Tl7 N0:2 and FIG. 1B):
Ml to L89; S2 to I90; G3 to E91; E4 to A92; PS to I93; G6 to R94; Q7 to R95;
T8 to A96; S9 to 597; V10 to N98; Al l to G99; P12 to E100; P13 to T101; P14 to L102; E15 to E103; E16 to K104; V17 to I105; E18 to T106; P19 to N107;
G20 to 5108; S21 to 8109; G22 to P110; V23 to P111; R24 to C112; I25 to V113; V26 to I114; V27 to L115.
[0196] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 90mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to I90; S2 to E91; G3 to A92; E4 to I93; PS to R94; G6 to R95; Q7 to A96;
T8 to 597; S9 to N98; V10 to G99; Al l to E100; P12 to T101; P13 to L102;
P14 to E103; E15 to K104; E16 to I105; Vl7 to T106; E18 to N107; P19 to 5108;
G20 to 8109; S21 to P110; G22 to P111; V23 to 0112; R24 to V113; I25 to I114; V26 to L115.
(0197] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 9lmers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to E91; S2 to A92; G3 to I93; E4 to R94; PS to R95; G6 to A96; Q7 to 597;
T8 to N98; S9 to G99; V10 to E100; All to T101; P12 to L102; P13 to E103;
P14 to K104; E15 to I105; E16 to T106; V17 to N107; E18 to 5108; P19 to 8109; G20 to P110; S21 to P111; G22 to 0112; V23 to V113; R24 to I114; I25 to L115.

_87_ [0198] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 92mers (residues correspond to SEQ U~ N0:2 and FIG. 1B):
Ml to A92; S2 to I93; G3 to R94; E4 to R95; PS to A96; G6 to 597; Q7 to N98;
T8 to G99; S9 to E100; V10 to T101; Al l to L102; P12 to E103; P13 to K104;
P 14 to I105; E15 to T106; E16 to N107; V 17 to S 108; E18 to 8109; P 19 to P
110;
G20 to P111; S21 to C112; G22 to V113; V23 to I114; R24 to L115.
[0199] In anotherpreferred embodiment, the isolatedpolypeptides ofthepresent invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 93mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to I93; S2 to R94; G3 to R95; E4 to A96; PS to 597; G6 to N98; Q7 to G99;
T8 to E100; S9 to T101; V10 to L102; Al l to E103; P12 to K104; P13 to I105;
P14 to T106; E15 to N107; E16 to 5108; V17 to 8109; E18 to P110; P19 to P111; G20 to C112; S21 to V113; G22 to I114; V23 to L115.
[0200] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 94mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to R94; S2 to R95; G3 to A96; E4 to 597; PS to N98; G6 to G99; Q7 to E100; T8 to T101; S9 to L102; V10 to E103; Al l to K104; P12 to I105; P13 to T106; P14 to N107; E15 to 5108; E16 to 8109; V17 to P110; E18 to P111; P19 to C112; G20 to Vl 13; S21 to I114; G22 to L115.
[0201] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 95mers (residues correspond to SEQ ID N0:2 and FIG. 1B): Ml to R95; S2 to A96; G3 to 597; E4 to N98; PS to G99; G6 to E100;
Q7 to T101; T8 to L102; S9 to E103; V10 to K104; All to I105; P12 to T106;

_88_ P13 to N107; P14 to 5108; E15 to 8109; E16 to P110; V17 to P111; E18 to C 112; P 19 to V 113; G20 to Il 14; S21 to Ll 15.
[0202] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 96mers (residues correspond to SEQ ~ N0:2 and FIG. 1B):
Ml to A96; S2 to 597; G3 to N98; E4 to G99; PS to E100; G6 to T101; Q7 to L102; T8 to E103; S9 to K104; V10 to I105; Al l to T106; P12 to N107; P13 to 5108;P14to8109;E15toP110;E16toP111;V17toC112;E18toV113;P19 to Il 14; G20 to L115.
[0203] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 97mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to 597; S2 to N98; G3 to G99; E4 to E100; PS to T101; G6 to L102; Q7 to E103; T8 to K104; S9 to I105; V10 to T106; Al l to N107; P12 to 5108; P13 to 8109;P14toP110;E15toP111;E16toC112;V17toV113;E18toI114;P19 to Ll 15.
[0204] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 98mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):
Ml to N98; S2 to G99; G3 to E100; E4 to T101; PS to L102; G6 to E103; Q7 to K104; T8 to I105; S9 to T106; V10 to N107; Al l to 5108; P12 to 8109; P13 to P110;P14toP111;E15toC112;E16toV113;V17toI114;E18toL115.
[0205] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 99mers (residues correspond to SEQ ID N0:2 and FIG. 1 B):

Ml to G99; S2 to E100; G3 to T101; E4 to L102; PS to E103; G6 to K104; Q7 to I105; T8 to T106; S9 to N107; V10 to 5108; Al l to 8109; P12 to P110; P13 toPIll;Pl4toC112;E15toV113;E16toI114;V17toL115.
[0206] In another preferred embodiment, the isolated polypeptides ofthe present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 100mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to E100; S2 to T101; G3 to L102; E4 to E103; PS to K104; G6 to I105; Q7 to T106; T8 to N107; S9 to 5108; V10 to 8109; A11 to P110; P12 to P111; P13 toC112;P14toV113;E15toI114;E16toL115.
(0207] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following lOlmers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to T101; S2 to L102; G3 to E103; E4 to K104; PS to I105; G6 to T106; Q7 to N107; T8 to 5108; S9 to 8109; V10 to P110; Al l to P111; P12 to 0112; P13 toV113;P14toI114;E15toL115.
[0208] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 102mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to L102; S2 to E103; G3 to K104; E4 to I105; PS to T106; G6 to N107; Q7 to 5108; T8 to 8109; S9 to P110; V10 to P111; Al l to C112; P12 to V113; P13 toI114;P14toL115.
[0209] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 103mers (residues correspond to SEQ E? NO:2 and FIG. 1B):

Ml to E 103; S2 to K104; G3 to I105; E4 to T106; PS to N107; G6 to 5108; Q7 toR109;T8toP110;S9toP111;V10toC112;A11toV113;P12toI114;P13 to L115.
(0210] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 104mers (residues correspond to SEQ m N0:2 and FIG. 1B):
M1 to K104; S2 to I105; G3 to T106; E4 to N107; PS to 5108; G6 to 8109; Q7 toP110;T8toP111;S9toC112;V10toV113;A11toI114;P12toL115.
[0211] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following l OSmers (residues correspond to SEQ ID NO:2 and FIG. 1B):
M1 to I105; S2 to T106; G3 to N107; E4 to 5108; PS to 8109; G6 to P110; Q7 toPlll;T8toC112;S9toV113;V10toI114;A11toL115.
[0212] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 106mers (residues correspond to SEQ ID NO:2 and FIG. 1B):
M1 to T106; S2 to N107; G3 to 5108; E4 to 8109; PS to P110; G6 to P111; Q7 toC112;T8toV113;S9toI114;V10toL115.
[0213] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 107mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to N107; S2 to 5108; G3 to 8109; E4 to P110; PS to P111; G6 to C112; Q7 toV113;T8toI114;S9toL115.
[0214] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 108mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to 5108; S2 to 8109; G3 to P110; E4 to P111; PS to C112; G6 to V113; Q7 to I114; T8 to L115.
[0215] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 109mers (residues correspond to SEQ ID NO:2 and FIG. 1B):
M 1 to 8109; S2 to P 110; G3 to P 111; E4 to C 112; P S to V 113; G6 to I114;

to L115.
[0216] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 110mers (residues correspond to SEQ ID NO:2 and FIG. 1B):
Ml to P110; S2 to P111; G3 to C112; E4 to V113; PS to I114; G6 to L115.
[0217] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 111mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
M1 to P111; S2 to C112; G3 to V113; E4 to I114; PS to L115.
[0218] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 112mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml to C112; S2 to V113; G3 to I114; E4 to L115.
[0219] In another preferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 113mers (residues correspond to SEQ ID N0:2 and FIG. 1B):
Ml toV113;S2toI114;G3toL115.

[0220] In anotherpreferred embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 114mers (residues correspond to SEQ ID NO:2 and FIG. 1B):
Ml to I114; S2 to L115.
Stimulation of CTL and HTL responses j0221] Much more about the mechanism by which T cells recognize antigens has been elucidated during the past ten years. In accordance with this understanding of the immune system, the present inventors have developed efficacious peptide epitope compositions that induce a therapeutic or prophylactic immune response to certain tumor associated antigens, when administered via various art-accepted modalities. Moreover, by use of the peptide epitopes of the invention, or by use of combinations of peptide epitopes in accordance with the principles disclosed herein, responses can be achieved in significant percentages of a non-genetically biased worldwide population. For an understanding of the value and efficacy of the claimed compositions, a brief review of immunology related technology is' provided.
[0222] A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al., Cell 47:1071, 1986;
Babbitt, B. P. et al., Natuz°e 317:359,1985; Townsend, A. and Bodmer, H., Annu.
Rev. Immunol. 7:601,1989; Germain, R. N., Annu. Rev. Imnzunol.11:403,1993).
Through the study of single amino acid substituted antigen analogs and the sequencing of endogenouslybound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified.
[0223] Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft of HLA molecules which accommodate, often on an allele-specific basis, residues borne bypeptide ligands;

these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D.R. Annu. Rev. Immunol. 13:587, 1995; Smith, et al., Immunity 4:203,1996; Fremont et al., Immunity 8:305,1998;
Stern et al., Structure 2:245,1994; Jones, E.Y. Curr. Opin. Immunol.
9:75,1997;
Brown, J. H. et al., Nature 364:33,1993; Guo, H. C. et al., Proc. Natl. Acad.
Sci.
USA 90:8053,1993; Guo, H. C. et al., Nature 360:364,1992; Silver, M. L. et al., Nature 360:367,1992; Matsumura, M. et al., Science 257:927,1992; Madden et al., Cell 70:1035, 1992; Fremont, D. H. et al., Science 257:919,1992; Saper, M.
A. , Bj orkman, P. J. and Wiley, D. C., J. Mol. Biol. 219:277,1991.) Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I
or class II supermotifs allows identification of regions within a protein that have the predicted ability to bind particular HLA antigen(s).
[0224] Moreover, the correlation of binding affinitywith immunogenicity, which is disclosed herein, is an important factor to be considered when evaluating candidate peptides. Thus, by a combination of motif searches of antigenic sequences, and by HLA-peptide binding assays, epitope-based vaccines have been identified. As appreciated by one in the art, after determining their binding affinity, additional work can be performed to select, amongst these vaccine peptides, e.g., epitopes can be selected having optional characteristics in terms of population coverage, antigenicity, and immunogenicity, etc.
[0225] Various strategies can be utilized to evaluate immunogenicity, including:
1 ) Evaluation ofprimary T cell cultures from normal individuals (see, e.g., Wentworth, P. A. et al., Mol. Immunol. 32:603,1995; Celis, E. et al., Proc.
Natl. Acad. Sci. LISA 91:2105,1994; Tsai, V. et al., J. Immuraol.
158:,1796,1997;
Kawashima, I. et al., Human Immunol. 59:1,1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subj ects with a test peptide in the presence of antigen presenting cells in vitro over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a SlCr-release assay involving peptide sensitized target cells, and/or target cells that generate antigen endogenously.

2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P.
A. et al., J. Immuhol. 26:97, 1996; Wentworth, P. A. et al., Iht. Immunol.
8:651, 1996; Alexander, J. et al., J. Immunol. 159:4753,1997); in this method, peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA
transgenic mice. Several weeks following immunization, splenocytes are removed and cultured in vitro in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a ~ 1 Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen.
3) Demonstration ofrecall T cell responses from individuals exposed to the disease, such as immune individuals who were effectively treated and recovered from disease, and/or from actively ill patients (see, e.g., Rehermann, B. et al., J. Exp. Med. 181:1047,1995; Doolan, D. L. et al., Immunity 7:97,1997;
Bertoni, R. et al., J. Clip. Invest. 100:503, 1997; Threlkeld, S. C. et al., J.
Immuhol. 159:1648, 1997; Diepolder, H. M. et al., J. Yirol. 71:6011, 1997). In applying this strategy, recall responses are detected by culturing PBL from subjects ih vitro for 1-2 weeks in the presence of a test peptide plus antigen presenting cells (APC) to allow activation of "mernor~' T cells, as compared to "naive" T cells. At the end of the culture period, T cell activity is detected using assays for T cell activity including SICr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.
[0226) The following describes the peptide epitopes and corresponding nucleic acids of the invention in more detail.
Binding Affinity of Peptide Epitopes for HLA Molecules [0227) As indicated herein, the large degree of HLA polymorphism is an important factor to be taken into account with the epitope-based approach to vaccine development. To address this factor, epitope selection encompassing identification of peptides capable of binding at high or intermediate affinity to multiple HLA molecules is preferably utilized, most preferably these epitopes bind at high or intermediate affinity to two or more allele-specific HLA
molecules.
[0228] CTL-inducing peptide epitopes of interest for vaccine compositions preferably include those that have an ICSO or binding affinity value for a class I
HLA molecules) of 500 nM or better (i.e., the value is <_ 500 nM). HTL-inducing peptide epitopes preferably include those that have an ICSO or binding affinity value for class II HLA molecules of 1000 nM or better, (i.e., the value is <_ 1,000 nM). For example, peptide binding is assessed by testing the capacity of a candidate peptide to bind to a purified HLA molecule in vitro. Peptides exhibiting high or intermediate affinity are then considered for farther analysis.
Selected peptides are generally tested on other members of the supertype family.
In preferred embodiments, peptides that exhibit cross-reactive binding are then used in cellular screening analyses or vaccines.
[0229] The relationship between binding affinity for HLA class I molecules and immunogenicity of discrete peptide epitopes on bound antigens has been determined. As disclosed in greater detail herein, higher HLA binding affinity is correlated with greater immunogenicity.
[0230] Greater immunogenicity can be manifested in several different ways.
Immunogenicity corresponds to whether an immune response is elicited at all, and to the vigor of any particular response, as well as to the extent of a population in which a response is elicited. For example, a peptide epitope might elicit an immune response in a diverse array of the population, yet in no instance produce a vigorous response. In accordance with these principles, close to 90% of high binding peptide have been found to elicit a response and thus be "immunogenic,"
as contrasted with about 50% of the peptides that bind with intermediate affinity.
(See, e.g., Schaeffer et al. PNAS 1985) Moreover, not only did peptides with higher binding affinity have an enhanced probability of generating an immune response, the generated response tended to be more vigorous than the response seen with weaker binding peptides. As a result, less peptide is required to elicit a similar biological effect if a high affinity binding peptide is used rather than a lower affinity one. Thus, in preferred embodiments ofthe invention, high affinity binding epitopes are used.
[0231] The correlation between binding affinity and immunogenicity was analyzed by two different experimental approaches (see, e.g., Sette, et al., J.
Immuyzol. 153:5586-5592, 1994)). In the first approach, the immunogenicity of potential epitopes ranging in HLA binding affinity over a 10,000-fold range was analyzed in HLA-A*0201 transgenic mice. In the second approach, the antigenicity of approximately 100 different hepatitis B virus (I~3~-derived potential epitopes, all carrying A*0201 binding motifs, was assessed by using PBL from acute hepatitis patients. Pursuant to these approaches, it was determined that an affinity threshold value of approximately 500 nM
(preferably 50 nM or less) determines the capacity of a peptide epitope to elicit a CTL
response. These data are true for class I binding affinity measurements for naturally processed peptide epitopes and for synthesized T cell epitopes.
These data also indicate the important role of determinant selection in the shaping of T
cell responses (see, e.g., Schaeffer et al. Proc. Natl. Acad. Sci. USA 86:4649-4653, 1989).
[0232] An affinity threshold associated with immunogenicity in the context of HLA class II (i.e., HLA DR) molecules has also been delineated (see, e.g., Southwood et al. J. Immunology 160:3363-3373,1998. In order to define a biologically significant threshold of HLA class II binding affinity, a database of the binding affinities of 32 DR-restricted epitopes for their restricting element (i.e., the HLA molecule that binds the epitope) was compiled. In approximately half of the cases (15 of 32 epitopes), DR restriction was associated with high binding affinities, i. e. binding affinity values of 100 nM or less. In the other half of the cases (16 of 32), DR restriction was associated with intermediate affinity (binding affinity values in the 100-1000 nM range). In only one of 32 cases was DR restriction associated with an ICso of 1000 nM or greater. Thus, 1000 nM is defined as an affinity threshold associated with immunogenicity in the context of DR molecules.
[0233] Vaccines of the present invention may also comprise epitopes that bind to MHC class II DR molecules. A greater degree of heterogeneity in both size and binding frame position of the motif, relative to the N and C termini of the peptide, exists for class II peptide ligands. This increased heterogeneity of HLA
class II peptide ligands is due to the structure of the binding groove of the HLA
class II molecule which, unlike its class I counterpart, is less physically constricted at both ends.
[0234] There are numerous additional supermotifs and motifs in addition to the A2 supermotif and the A2.1-allele specific motif. By inclusion of one or more epitopes from other motifs or supermotifs, enhanced population coverage for major global ethnicities can be obtained.
Peptide Analogs [0235] In general, CTL and HTL responses are not directed against all possible epitopes. Rather, they are restricted to a few "immunodominant" determinants (Zinkernagel, et al., Adv. Immuhol. 27:5159,1979; Bennink, et al., J. Exp.
Med.
168:19351939, 1988; Rawle, et al., J. Immuhol. 146:3977-3984, 1991). It has been recognized that immunodominance (Benacerraf, et al., Science 175:273-279, 1972) could be explained by either the ability of a given epitope to selectively bind a particular HLA protein (determinant selection theory) (Vitiello, et al., J.
Immunol. 131:1635, 1983); Rosenthal, et al., Nature 267:156-158, 1977), or to be selectively recognized by the existing TCR (T cell receptor) specificities (repertoire theory) (Klein, J., IMMUNOLOGY, THE SCIENCE OF SELFNONSELF
DISCRIMINATION, John Wiley & Sons, New York, pp. 270-310, 1982). It has been demonstrated that additional factors, mostly linked to processing events, can also play a key role in dictating, beyond strict immunogenicity, which of the many potential determinants will be presented as immunodominant (Sercarz, et al., Annu. Rev. Immunol. 11:729-766, 1993).
[0236] The concept of dominance and subdominance is relevant to immunotherapy of both infectious diseases and malignancies. For example, in the course of chronic viral disease, recruitment of subdominant epitopes can be important for successful clearance of the infection, especially if dominant CTL
or HTL specificities have been inactivated by functional tolerance, suppression, mutation of viruses and other mechanisms (Franco, et al., Curt. Opin. Immunol.
7:524-531, 1995). In the case of cancer and tumor antigens, CTLs recognizing at least some of the highest binding affinity peptides might be functionally inactivated. Lowerbinding affirittypeptides are preferentiallyrecognized at these times, and may therefore be preferred in therapeutic or prophylactic anti-cancer vaccines.
[0237] In particular, it has been noted that a significant number of epitopes derived from known non-viral tumor associated antigens (TAA) bind HLA class I with intermediate affinity (ICso in the 50-500 nM range) rather than at high affinity (ICSO of less than 50 nM).
[0238] For example, it has been found that 8 of 15 known TAA peptides recognized by tumor infiltrating lymphocytes (TIL) or CTL bound in the 50-500 nM range. (These data are in contrast with estimates that 90% of known viral antigens were bound by HLA class I molecules with ICSO of 50 nM or less, while only approximately 10% bound in the 50-500 nM range (Sette, et al., J.
Immunol., 153:558-5592, 1994). In the cancer setting this phenomenon is probably due to elimination or functional inhibition of the CTL recognizing several of the highest binding peptides, presumably because of T cell tolerization events.
[0239] Without intending to be bound by theory, it is believed that because T
cells to dominant epitopes may have been clonally deleted, and selecting subdominant epitopes may allow existing T cells to be recruited, which will then lead to a therapeutic or prophylactic response. However, the binding of HLA
molecules to subdominant epitopes is often less vigorous than to dominant ones.

[0240] Accordingly, there is a need to be able to modulate the binding affinity of particular immunogenic epitopes for one or more HLA molecules, to thereby modulate the immune response elicited by the peptide, for example to prepare analog peptides which elicit a more vigorous response. This ability to modulate both binding affinity and the resulting immune response in accordance with these principles greatly enhances the usefulness of peptide epitope-based vaccines and therapeutic agents.
[0241] Although peptides with suitable cross-reactivity among all alleles of a superfamily are identified by the screening procedures described above, cross-reactivity is not always as complete as possible, and in certain cases procedures to increase cross-reactivity of peptides can be useful; moreover, such procedures can also be used to modify other properties of the peptides such as binding affinity or peptide stability. Having established the general rules that govern cross-reactivity of peptides for HLA alleles within a given motif or supermotif, modification (i. e., analoging) of the structure of peptides of particular interest in order to achieve broader (or otherwise modified) HLA binding capacity can be performed. More specifically, peptides that exhibit the broadest cross-reactivity patterns, can be produced in accordance with the teachings herein.
[0242] In brief, the analoging strategy utilizes the motifs or supermotifs that correlate with binding to certain HLA molecules. Analog peptides can be created by substituting amino acid residues at primary anchor, secondary anchor, or at primary and secondary anchor positions. Generally, analogs axe made for peptides that already bear a motif or supermotif. For a number of the motifs or supernlotifs, residues are defined which are deleterious to binding to allele-specific HLA molecules or members of HLA supertypes that bind the respective motif or supermotif. Accordingly, removal of such residues that are detrimental to binding can be performed. For example, in the case of the A3 supertype, when all peptides that have such deleterious residues are removed from the population of peptides used in the analysis, the incidence of cross-reactivity increased from 22% to 37% (see, e.g., Sidney, J. et al., Hu. Immunol. 45:79, 1996). Examples of C35 peptide epitope analogs of the present invention are found in Table 4.
In a particularly preferred embodiment, the isolated polypeptides of the present invention comprise or, alternatively, consist ofthe following C35 peptide epitope analogs: for the peptide epitope G22 to C30 of SEQ ID N0:2 and FIG. 1B (i.e., GVIUWEYC), the analog with either alanine or glycine substituted for cysteine at the ninth amino acid residue (i.e., GVRIVVEYA or GVR1VVEYG); for the peptide epitope I25 to C33 of SEQ ID N0:2 and FIG.1B (i.e., IVVEYCEPC), the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue (i.e., IVVEYAEPC, IWEYCEPA IWEYGEPC, IWEYCEPG, IWEYAEPA, 1WEYAEPG, IWEYGEPA, IWEYGEPG); for the peptide epitope K77 to Y~5 of SEQ 117 NO: 2 and FIG. 1B (i.e., KLENGGFPY), the analog with valine substituted for tyrosine at the ninth amino acid residue (i.e., KLENGGFPVa; for peptide epitope K104 to 0112 of SEQ ~ N0:2 and FIG. 1B (i.e., KITNSRPPC), the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue (i.e., KITNSRPPL, KITNSRPPA, KITNSRPP~; for peptide epitope K104 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., KITNSRPPCV), the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue (i.e., KITNSRPPLV, KITNSRPPAV, KITNSRPPGV, KITNSRPPSV), for the peptide epitope I105 to V 113 of SEQ ll~ N0:2 and FIG.
1B (i.e., ITNSRPPCV), the analogs wherein either leucine or methionine is substituted for threonine at the second amino acid residue and/or alanine, serine or glycine is substituted for cysteine at the eighth amino acid residue (i.e., ILNSRPPCV, IMNSRPPCV, ITNSRPPAV, ITNSRPPGV, ILNSRPPAV, ILNSRPPGV, IMNSRPPAV, IMNSRPPGV, ILNSRPPSV, IMNSRPPSV, ITNSRPPSV), for the peptide epitope N107 to Ll 15 of SEQ ID N0:2 and FIG.
1B (i.e., NSRPPCV1L,), the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue (i.e., NSRPPAVIL, NSRPPGVIL). The invention is further directed to polypeptides comprising or, alternatively, consisting of one or more C3 S epitope analogs. In a preferred embodiment, the invention is directed to polypeptides comprising one or more C3 S epitope analogs and, in addition, one or more C35 peptide epitopes. In a particularly preferred embodiment, the invention is directed to a fusion protein comprising at least one C35 peptide epitope analog selected from the group consisting of for the peptide epitope G22 to C30 of SEQ I17 N0:2 and FIG. 1B (i.e., GVRIWEYC), the analog with either alanine or glycine substituted for cysteine at the ninth amino acid residue (i.e., GVRIWEYA or GVRIVVEY~; for the peptide epitope I25 to C33 of SEQ ll~ N0:2 and FIG.1B (i.e., IWEYCEPC), the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue andlor the ninth amino acid residue (i.e., 1VVEYAEPC, 1WEYCEPA, IWEYGEPC, 1WEYCEPG, IWEYAEPA, 1WEYAEPG, IWEYGEPA, IWEYGEP,G~; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG.
1B (i.e., KLENGGFPY), the analog with valine substituted for tyrosine at the ninth amino acid residue (i.e., KLENGGFP~; for peptide epitope K104 to Cl 12 of SEQ ID N0:2 and FIG. 1B (i.e., KITNSRPPC), the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue (i.e., KITNSRPPL, KITNSRPPA, KITNSRPPG); for peptide epitope K104 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., KITNSRPPCV), the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue (i.e., KITNSRPPLV, KITNSRPPAV, KITNSRPPGV, KITNSRPPSV); for the peptide epitope I105 to V 113 of SEQ ID N0:2 and FIG. 1B (i.e., ITNSRPPCV), the analogs wherein either leucine or methionine is substituted for threonine at the second amino acid residue and/or alanine, serine or glycine is substituted for cysteine at the eighth amino acid residue (i.e., ILNSRPPCV, IMNSRPPCV, ITNSRPPAV, IT'NSRPPGV, ILNSRPPAV, ILNSRPPGV, 1MNSRPPAV, IMNSRPPGV, ILNSRPPSV, IMNSRPPSV, ITNSRPPSV), for the peptide epitope N107 to L115 of SEQ ID NO:2 and FIG. 1B (i.e., NSRPPCVIL), the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue (i.e., NSRPPAVIL, NSRPPGVIL,), and at least one C35 peptide epitope selected from the group consisting of amino acids E4 to P 12 of SEQ ID

N0:2, S9 to V l7 of SEQ ID NO: 2, S21 to Y29 of SEQ ID NO:2, G22 to C30 of SEQ ID NO: 2, I25 to C33 of SEQ ID N0:2, T38 to V46 of SEQ ID NO:2, G61 to I69 of SEQ ID N0:2, T62 to N70 of SEQ ID N0:2, G63 to G71 of SEQ ID
N0:2, F65 to L73 of SEQ ID NO: 2, I67 to F75 of SEQ ID NO:2, K77 to Y85 of SEQ ID N0:2, Q72 to E86 of SEQ ID N0:2, G81 to L89 of SEQ ID N0:2, G99 to V 113 of SEQ ID N0:2, E 100 to V 113 of SEQ ID N0:2, Kl 04 to C 112 of SEQ
ID N0:2, K104 to V113 of SEQ ID NO: 2, I105 to V113 of SEQ ID NO:2, and N107 to L115 of SEQ ID N0:2.
[0243] Thus, one strategy to improve the cross-reactivity of peptides within a given supermotif is simply to delete one or more of the deleterious residues present within apeptide and substitute a small "neutral" residue such as Ala (that may not influence T cell recognition of the peptide). An enhanced likelihood of cross-reactivity is expected if, together with elimination of detrimental residues within a peptide, "preferred" residues associated with high affinity binding to an allele-specific HLA molecule or to multiple HLA molecules within a superfamily axe inserted.
[0244] To ensure that an analog peptide, when used as a vaccine, actually elicits a CTL response to the native epitope in viv~ (or, in the case of class II
epitopes, elicits helper T cells that cross-react with the wild type peptides), the analog peptide may be used to induce T cells in vitro from individuals of the appropriate HLA allele. Thereafter, the immunized cells' capacity to lyse wild type peptide sensitized target cells is evaluated. Alternatively, evaluation of the cells' activity can be evaluated by monitoring IFN release. Each of these cell monitoring strategies evaluate the recognition of the APC by the CTL. It will be desirable to use as antigen presenting cells, cells that have been either infected, or transfected with the appropriate genes, or, (generally only for class II epitopes, due to the different peptide processing pathway for HLA class I~, cells that have been pulsed with whole protein antigens, to establish whether endogenouslyproduced antigen is also recognized by the T cells induced by the analog peptide. It is to be noted that peptide/protein-pulsed dendritic cells can be used to present whole protein antigens for both HLA class I and class II.
[.0245] Another embodiment of the invention is to create analogs of weak binding peptides, to thereby ensure adequate numbers of cellular binders. Class I
binding peptides exhibiting binding affinities of 500-5000 nM, and carrying an acceptable but suboptimal primary anchor residue at one or both positions can be "fixed"
by substituting preferred anchor residues in accordance with the respective supertype. The analog peptides can then be tested for binding and/or cross-binding capacity.
[0246] Another embodiment of the invention is to create analogs of peptides that are already cross-reactive binders and are vaccine candidates, but which bind weakly to one or more alleles of a supertype. If the cross-reactive binder carries a suboptimal residue (less preferred or deleterious) at a primary or secondary anchor position, the peptide can be analoged by substituting out a deleterious residue and replacing it with a preferred or less preferred one, or by substituting out a less preferred residue and replacing it with a preferred one. The analog peptide can then be tested for cross-binding capacity.
[0247] Another embodiment for generating effectivepeptide analogs involves the substitution of residues that have an adverse impact on peptide stability or solubility in, e.g., a liquid environment. This substitution may occur at any position of the peptide epitope. For example, a cysteine (C) can be substituted out in favor of a-amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substituting a-amino butyric acid for C not only alleviates this problem, but actually improves binding and crossbinding capability in certain instances (see, e.g., the review by Sette et al., In: Persistent Viral Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999).
Substitution of cysteine with a-amino butyric acid may occur at any residue of a peptide epitope, i.e. at either anchor or non-anchor positions.

[0248] Moreover, it has been shown that in sets of A*0201 motif bearing peptides containing at least one preferred secondary anchor residue while avoiding the presence of any deleterious secondary anchor residues, 69% of the peptides will bind A*0201 with an ICso less than 500 nM (Ruppert, J. et al.
Cell 74:929,1993). The determination of what was a preferred or deleterious residue in Ruppert can be used to generate algorithms (see, e.g., 22). Such algorithms are flexible in that cut-off scores may be adjusted to select sets of peptides with greater or lower predicted binding properties, as desired.
[0249] C35 epiotpes containing cysteine residues have a tendency to dimerize with other cysteine containing peptides. Thus, an embodiment of the present invention is a composition comprising a peptide epitope of the invention (e.g.
a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of E100 to of SEQ ID N0:2) and a suitable reducing agent that protects the free sulfhydryl group of the cysteine residue but does not otherwise inhibit epitope binding.
In a preferred embodiment the composition comprises the peptide epitope ITNSRPPCV or KITNSRPPCV in combination with a suitable reducing agent:
Suitable reducing agents include, but are not limited to, TCEP and dithiothreitol (DTT).
[0250] Another embodiment of the invention is to create peptide epitope analogs in which the cysteine residues of the peptide epitope (e.g., a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of E100 to 8109 of SEQ ID N0:2) have been substituted with any other amino acid to facilitate synthesis. (See Zarling, A.L. et al., J. Exp. Med. 192(12): 1755-1762 (2000)).
Preferably, the cysteine residues are substituted with either alanine, serine or glycine residues, although any amino acid can be substituted provided that such substitution does not negatively effect binding to MHC or recognition by T cells. Thus, in a particularly preferred embodiment, the isolated polypeptides of the present invention comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope G22 to C30 of SEQ ID
N0:2 and FIG. 1B (i.e., GVRIWEYC), the analog with either alanine or glycine substituted for the cysteine at the ninth amino acid residue (i.e., GVRIWEYA or GVRIWEYG~; for the peptide epitope I25 to C33 of SEQ
ID N0:2 and FIG: 1B (i.e.,1WEYCEPC), the analog with either alaniize or glycine. substituted for the cysteine at the sixth amino acid residue andlor the ninth amino acid residue (i.e., IWEYAEPC or IVVEYGEPC or IVVEYCEPA or 1WEYCEPG or IWEYAEPA or IWEYAEPG or IWEYGEPA or IWEYGEPG); for the peptide epitope of I~104 to Cl 12 of SEQ ID N0:2 and FIG. 1B (i.e., KITNSRPPC) the analog with either alanine or glycine substituted for the cysteine at the ninth residue (i.e., KITNSRPPA
or KITNSRPP,G~; for the peptide epitope K104 to Vl 13 of SEQ ID N0:2 and FIG. 1B (i.e., KITNSRPPCV), the analog with either alanine, serine or glycine substituted for the cysteine at the ninth residue (i.e., KITNSRPPAV, I~ITNSRPPSV or KITNSRPPGV); for the peptide epitope I105 to V 113 of SEQ ID N0:2 and FIG. 1B (i.e., ITNSRPPCV), the analog with either alanine, serine or glycine substituted for the cysteine at the eighth residue (i.e., ITNSRPPAV, ITNSRPPSV or ITNSRPPGV); for the peptide epitope N107 to L115 (i.e., NSRPPCVIL,), the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue (i.e., NSRPPAVII,, NSRPPGVIL); for the multi-epitope peptide T101 to V113 of SEQ ID NO:2 and FIG. 1B (i.e., TLEK1TNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twelfth residue (i.e., TLEKITNSRPPAV or TLEKITNSRPPGV); for the mufti-epitope peptide E100 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., ETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the thirteenth amino acid residue (i.e., ETLEKITNSRPPAV, ETLEI~ITNSRPPGV), for the mufti-epitope peptide G99 to V113 of SEQ ID
N0:2 and FIG. 1B (i.e., GETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the fourteenth amino acid residue (i.e., GETLEKITNSRPPAV, GETLEKITNSRPPGV), for the mufti-epitope peptide I93 to V113 of SEQ ID NO:2 and FIG. 1B (i.e., IRR.ASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twentieth residue (i.e., IRRASNGETLEKITNSRPPAV or IItR.ASNGETLEKTTNSRPPGV); for the multi-epitope peptide D88 to V113 of SEQ ID NO:2 and FIG. 1B (i.e., DLIEAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twenty-fifth residue (i.e., DLIEAIRRASNGETLEKITNSRPPAV or DLIEAlItRASNGETLEKITNSRPPGV); for the multi-epitope peptide P84 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., PYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twenty-ninth residue (i.e., PYEKDLIEAIRRASNGETLEKITNSRPPAV or PYEKDLIEAB2RASNGETLEKITNSRPPGV); for the multi-epitope peptide K77 to L115 of SEQ ID N0:2 and FIG. 1B (i.e., KLENGGFPYEKDLIEAIRR.ASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the thirty sixth residue (i.e., KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPAV or KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPGV); for the multi-epitope peptide Q72 to L115of SEQ ID N0:2 and FIG. 1B (i.e., QLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the forty-first residue (i.e., QLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPAV
or QLVFSKL,ENGGFPYEKDLIEAIItRASNGETLEKITNSRPPGV); for the multi-epitope peptide F65 to L115 of SEQ ID N0:2 and FIG. 1B (i.e., FEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the forty eighth residue (i.e., FEIEINGQLVFSKLENGGFPYEKDL1EAIRRASNGETLEKITNSRPPAV or FEIEINGQLVFSKLENGGFPYEKDLIEAIRR.ASNGETLEKITNSRPPGV);
and for the multi-epitope peptide L59 to L115 of SEQ m N0:2 and FIG. 1B

(i.e., LGGTGAFEIEINGQLVFSI~LENGGFPYEKDLIEAIRRASNGETLEKI T NS
RPPCV), the analog with either alanine or glycine substituted for the cysteine at the fifty fourth residue (i.e., LGGTGAFEIEINGQLVFSKLENGGFPYEI~DLIEAIRRASNGETLEKITNS
RPPAV or LGGTGAFEIEINGQLVFSI~LENGGFPYEKDLIEAIRRASNGETLEKITNS
RPPGV) [0251] Another embodiment of the invention is to create peptide epitope analogs in which the cysteine residues of the peptide epitope (e.g., a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of E100 to 8109 of SEQ ID N0:2, having one or more cysteine residues) have been "cysteinylated" (i.e., reacted with a second cysteine residue). (See Pierce, R.A. et al., J. Immuhol.
163(12):6360-6364 (1999)). As used herein, the term "cysteinylated" describes a cysteine residue, within a peptide (e.g. peptide epitope) of the present invention, which has been reacted with a second free cysteine, i.e. a cysteine not part of a larger peptide, at the free sulffiydryl group thereby creating a disulfide bond (-SH
+ HS- _ -S-S-).
[0252] Thus, in aparticularlypreferred embodiment, the isolatedpolypeptides of the present invention comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope of I~104 to V113 of SEQ ID
N0:2 and FIG. 1B (i.e., KITNSRPPCV), the analog wherein the cysteine at the ninth residue has been cysteinylated and for the peptide epitope of I105 to V

of SEQ ID N0:2 and FIG.1B (i.e. ITNSRPPCV), the analog wherein the cysteine at the eighth residue has been cysteinylated.
[0253] Another embodiment of the invention is to create peptide epitope analogs in which the serine, threonine andlor tyrosine residues of the peptide epitope (e.g., a C35 peptide epitope listed in any of Tables 1-3 or S-6, exclusive of E100 to 8109 of SEQ ID N0:2) have been phosphorylated. Thus, in a particularly preferred embodiment, the isolated polypeptides of the present invention comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope E4 to P12 of SEQ ID N0:2 and FIG.
1B (i.e., EPGQTSVAP), the analog wherein the threonine at T8 andlor the serine at S9 have been phosphorylated; for the peptide epitope S9 to Vl7 of SEQ ID N0:2 and FIG. 1B (i.e., SVAPPPEEV), the analog wherein the serine at S9 has been phosporylated; for the peptide epitope S21 to Y29 of SEQ ID
N0:2 and FIG. 1B (i.e., SGVRIWEY), the analog wherein the serine at S21 and/or the tyrosine at Y29 are phosphorylated; for the peptide epitope G22 to C30 of SEQ ~ N0:2 and FIG. 1B (i.e., GVRIVVEYC), the analog wherein the tyrosine at Y29 is phosphorylated; for the peptide epitope T38 to V46 of SEQ ID N0:2 and FIG. 1B (i.e., TYLELASAV), the analog wherein the threonine at T38, the tyrosine at Y39, and/or the serine at S44 are phosphorylated; for the peptide epitope G61 to I69 (i.e., GTGAFEIEI), the analog wherein the threonine at T62 is phosphorylated); for the peptide epitope T62 to N70 of SEQ ID NO:2 and FIG. 1B (i.e., TGAFEIEIN), the analog wherein the threonine at T62 has been phosphorylated; for the peptide epitope I~77 to Y85 of SEQ ID N0:2 and FIG. 1B (i.e., KLENGGFPY), the analog wherein the tyrosine at Y85 is phosphorylated; for the peptide epitope Q72 to E86 of SEQ ID N0:2 and FIG. 1B (i.e., QLVFSI~LENGGFPYE), the analog wherein the serine at S76 and/or the tyrosine at Y85 are phosphorylated; for the peptide epitope G81 to L89 of SEQ ID N0:2 or FIG. 1B (i.e., GGFPYEI~DL), the analog wherein the tyrosine at Y85 is phosphorylated; for the peptide epitope K104 to 0112 of SEQ ID N0:2 and FIG. 1B (i.e., KITNSRPPC), the analog wherein the threonine at T106 andlor the serine at S 108 are phosphorylated; for the peptide epitope K104 to V 113 of SEQ ID
N0:2 and FIG. 1B (i.e., KITNSRPPCV), the analog wherein the threonine at T106 andlor the serine at 5108 are phosphorylated; for the peptide epitope I105 to Vl 13 (i.e., ITNSRPPCV), the analog wherein the threonine at T106 and/or the serine at S 108 are phosphorylated; for the peptide epitope N107 to L115 (i.e., NSRPPCVIL), the analog wherein the serine at 5108 is phosphorylated; for the polyepitopic peptide T101 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., TLEKITNSRPPCV), the analog wherein the threonines at T101 and T106 and/or the serine at 5108 are phosphorylated; for the polyepitopic peptide I93 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., IRRASNGETLEKITNSRPPCV), the analog wherein the serine at S97 andlor the threonine at T 101 and/or the threonine at T 106 and/or the serine at S

are phosphorylated; for the polyepitopic peptide D88 to V 113 of SEQ ID N0:2 and FIG. 1B (i.e., DLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the serine at S97 and/or the threonine at T101 and/or the threonine at T106 and/or the serine at 5108 are phosphorylated; for the polyepitopic peptide P84 to V113 of SEQ ID N0:2 and FIG.1B (i.e., PYEKDLIEAIRRASNGETLEI~ITNSRl'PCV), the analog wherein the tyrosine at Y85 and/or the serine at S97 and/or the threonine at T101 and/or the threonine at T106 andlor the serine at 5108 are phosphorylated; for the polyepitopic peptide K77 to V113 of SEQ ID NO:2 and FIG. 1B (i.e., KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the tyrosine at Y85 and/or the serine at S97 and/or the threonine at T101 andlor the threonine at T106 and/or the serine at 5108 are phosphorylated; for the polyepitopic peptide Q72 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., QLVFSKLENGGFPYEKDLIEAIRRASNGETLEI~ITNSRPPCV), the analog wherein the serine at S76 and/or the tyrosine at Y85 and/or the serine at S97 and/or the threonine at T101 and/or the threonine at T106 and/or the serine at S 108 are phosphorylated; for the polyepitopic peptide F65 to V 113 of SEQ ID
NO:2 and FIG. 1B (i.e., FEIE1NGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEI~ITNSRPPCV), the analog wherein the serine at S76 andlor the tyrosine at Y85 and/or the serine at S97 and/or the threonine at T101 and/or the threonine at T106 and/or the serine at 5108 are phosphorylated; for the polyepitopic peptide L59 to V113 of SEQ ID N0:2 and FIG. 1B (i.e., LGGTGAFEIEINGQLVFSKLENGGFPYEKDLIEAIRR.ASNGETLEI~ITNS

RPPC~, the analog wherein the threonine at T62 and/or the serine at S76 andlor the tyrosine at Y85 and/or the serine at S97 and/or the threonine at T 101 and/or the threonine at T 106 and/or the serine at S 10~ are phosphorylated.
[0254] Another embodiment of the invention is to create peptide epitope analogs in which the asparagine residues of the peptide epitope (e.g., a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of E100 to 8109 of SEQ ID N0:2) have been converted to asparEic acid after translation. (See S'lapper, J. C. et al., J. Exp. Med. 183(2):527-534 (1996)).
(0255] In preferred embodiments, the C35 peptide epitope analogs of the present invention contain multiple modifications provided that such modifications do not inhibit binding to MHC molecules or recognition by T
cells. Thus, preferred analogs include C35 peptide epitopes for which one or more residues have been modified as described herein to increase binding affinity to MHC molecules, one or more cysteine residues have been replaced with alanine or glycine residues to facilitate synthesis, and one or more serine, threonine or tyrosine residues have been phosphorylated.
[0256] Furthermore, additional amino acids can be added to the termini of a peptide epitope to provide for ease of linking peptide epitopes one to another, for coupling to a Garner support or larger polypeptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like.
Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide, particularly class I peptides. It is to be noted that modification at the carboxyl terminus of a CTL epitope may, in some cases, alter binding characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NHZ acylation, e.g., by alkanoyl (C1-CZO) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc., polyethylene-glycol modification (i.e., PEGylation) of the C-terminus, and the addition of a lipid tail (e.g., a pahnitoyl-lysine chain) to enhance presentation to T cells and immunogenicity.
(See Brinckerhoff, L.H. et al., Int. J. Cancer 83(3):326-334 (1999); Le Gal, F.A. et al., Iut. J. Cancer 98(2):221-227 (2002). N-terminal amides, in particular, will be more resistant to certain peptidases, thus preventing destruction of the peptide epitope in situ without affecting recognition. This will effectively increase the half life ofthe peptide epitope and enhance its ability to stimulate immune cells. In some instances these modifications may provide sites for linking to a support or other molecule.
Preparation of Peptide Epitopes [0257] Peptide epitopes in accordance with the invention can be prepared synthetically, by recombinant DNA technology or chemical synthesis, or from natural sources such as native tumors or pathogenic organisms. Peptide epitopes may be synthesized individually or as polyepitopic polypeptides (e.g., homopolymers or heteropolymers). Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides may be synthetically conjugated to native fragments or particles.
[0258] In addition, one or more non-C35 tumor associated peptides can be linked to one or more C35 peptide epitopes and/or C35 peptide epitope analogs to increase immune response via HLA class I and/or class II.
Especially preferred are polypeptides comprising a series of epitopes, known as "polytopes," and nucleic acids encoding same. The epitopes can be arranged in sequential or overlapping fashion (see, e.g., Thomson et al., PYOC.
Natl. Acad. Sci. USA 92:5845-5849 (1995); Gilbert et al., NaturelBiotechnology 15:1280-1284 (1997)), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generate individual epitopes which are recognized by the immune system for generation of immune responses.

[0259] Thus, for example, C35 peptide epitopes and C35 peptide epitope analogs can be combined with peptides from other tumor rejection antigens (e.g., by preparation of hybrid nucleic acids or polypeptides) to form "polytopes." (Zeng, G. et al., Proc. Natl. Acad. Sci. 98(7):3964-3969 (2001);
Zeng, G. et al., J. Immunol.165:1153-1159 (2000); Mancini, S. et al., J. Exp.
Med. 189(5):871-876 (1999)). Exemplary tumor associated antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including: MAGE-1, MADE-2, MADE-3, MAGE-4, MADE-5, MACE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, MAGE-12, MACE-13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGS-1, RAGE-l, LB33/MUM-1, PRAMS, NAG, MAGE-Xp2 IMAGE-B2), MAGE-Xp3 IMAGE-B3), MAGE-Xp4 IMAGE-B4), tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-Cl, MAGE-C2, NY-ESO-1, LAGS-1, SSX-1, SSX-2(HOM-MEL-40), SSX-l, SSX-4, SSX-5, SCP-1 and CT-7. For example, specific antigenic peptides characteristic of tumors include those listed in Table A.
Table A
Gehe MHC Peptide Position HLA-Cwl6 SAYGEPRKL 230-238 BAGS HLA-Cwl6 AAR.AVFLAL 2-10 GAGE-1,2 HLA-Cwl6 YRPRPRRY 9-16 GnT-V HLA-A2 VLPDVFIRC(V) 2-10/11 MLTM-1 HLA-B44 EEKL1WLF exon 2/intron EEKLS V VLF (wild-type) ARDPHSGHFV (wild-type) [3-cateninHLA-A24 SYLDSGIHF 29-37 SYLDSGIHS (wild-type) TyrosinaseHLA-A2 MLLAVLYCL 1-9 Melan-AM~"HLA-AZ (E)AAGIGILTV 26/27-35 gpl00P'ell'HLA-A2 KTWGQYWQV 154-162 PR.AME HLA-A24 LYVDSLFFL 301-309 MAGE-6 HLA-Cwl6 KISGGPRISYPL 292-303 [0260] Other examples of non-C35 HLA class I and HLA class II binding peptides will be known to one of ordinary skill in the art and can be used in the invention in a like manner to those disclosed herein. One of ordinary skill in the art canprepare polypeptides comprising one or more C35 peptide epitopes or C35 peptide epitope analogs and one or more of the aforementioned tumor rejection peptides, or nucleic acids encoding such polypeptides, according to standard procedures inmolecularbiology. Examples ofpolytopes comprising C35 peptide epitopes or C35 peptide epitope analogs of the present invention and various tumor rejection antigenic peptides are set forth in Tables B and C below.
[0261] Thus, polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response. The peptides can be joined directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art.
,,[0262] In a preferred embodiment, the isolated polypeptides of the present invention comprise one or more C35 peptide epitopes or C35 peptide epitope analogs linked to one or more tumor rej ection peptides. In a particularlypreferred embodiment, said one or more C35 peptide epitopes are selected from the group consisting of amino acids E4 to P12 of SEQ ID N0:2, amino acids S9 to V17 of SEQ ID N0:2, amino acids S21 to Y29 of SEQ ID N0:2, amino acids G22 to C30 of SEQ ID NO: 2, amino acids I25 to C33 of SEQ ll~ N0:2, amino acids T38 to V46 of SEQ ID N0:2, amino acids G61 to I69 of SEQ ID N0:2, amino acids T62 to N70 of SEQ ID N0:2, amino acids G63 to G71 of SEQ ID NO:2, amino acids F65 to L73 of SEQ ID N0:2, amino acids I67 to F75 of SEQ ID N0:2, amino acids K77 to Y85 of SEQ ID NO:2, amino acids Q72 to E86 of SEQ ID
N0:2, amino acids G81 to L89 of SEQ ID N0:2, amino acids K104 to 0112 of SEQ ID N0:2, amino acids K104 to V 113 of SEQ ID NO:2, amino acids I105 to V113 of SEQ ID N0:2, amino acids N107 to L115 of SEQ ID N0:2, amino acids T101 to V113 of SEQ 117 N0:2, amino acids E100 to V113 of SEQ 117 N0:2, amino acids G99 to V 113 of SEQ ID N0:2, amino acids I93 to V 113 of SEQ ID NO:2, amino acids D88 to V113 of SEQ ID N0:2, amino acids P84 to V 113 of SEQ ID NO:2, amino acids K77 to V 113 of SEQ 117 N0:2, amino acids Q72 to V 113 of SEQ ID N0:2, amino acids F65 to V 113 of SEQ ID N0:2, and L57 to V 113 of SEQ ID NO:2; and said one or more tumor rejection peptides are selected from the group consisting of the antigenic peptides shown in Table A.
[0263] In another embodiment, one or more non-C35 cell penetrating peptides can be linked to one or more C35 peptide epitopes and/or C35 peptide epitope analogs to enhance delivery of C35 peptide epitopes to cells, e.g., dendritic cells.
Especiallypreferred are polypeptides comprising a series of C35 peptide epitopes or C35 peptide epitope analogs and cell penetrating peptides, and nucleic acids encoding same. The epitopes and peptides can be arranged in sequential or overlapping fashion with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polypeptide is processed to generate individual C35 epitopes which are recognized by the immune system for generation of immune responses.
(0264] Thus, for example, C35 peptide epitopes and C35 peptide epitope analogs can be combined with cell-penetrating peptides. (Wang, R.-F. et al., Nature Biotechnology 20(2):149-154 (2002); Frankel, A.D. et al., Cell 55:1189-1193 (1988); Elliott, G. et al., Cell 88(2):223-233 (1997); Phelan, A. et al., Nature Biotechnology 16(5):440-443 (1998); Lin, Y.-Z. et al., J. Biol. Chem.
270(24):14255-14258 (1995); Rojas, M. et al., Nature Biotechnology 16(4):370-375 (1998)). Exemplary cell penetrating peptides that can be administered to enhance delivery of C35 peptides to cells, such as dendritic cells, include:
the Tat protein of human immunodeficiency virus, the HSV-1 structural protein VP22, and the 12-residue membrane-translocating sequence (MTS) modified from the 16-residue h region of the signal sequence of Kaposi fibroblast growth factor.
[0265] The one or more C35 peptide epitopes/analogs and one or more cell penetrating peptides can be joined together in various arrangements (e.g.
concatenated, overlapping). The resulting polypeptide (or nucleic acid encoding the polypeptide) can be administered in a standard immunization protocol, e.g.
to animals, to test the effectiveness of the polypeptide in stimulating, enhancing and/or provoking an immune response. The C35 peptide epitopes/analogs and one or more cell penetrating peptides can be joined directly or via the use of flanking sequences to form the polypeptides, and the use of such polypeptides as vaccines is well known in the art. Examples of polypeptides comprising C35 peptide epitopes or C35 peptide epitope analogs of the present invention and various cell penetrating peptides are set forth in Tables D and E below.

>~ >
n-i '~.a~'''' d E-~ Cx7 U
w x ~ ~ a ~' x t~
w d ~ a ~w ~w ~~ a~ a> >~~ ~w xw xw ~w a~ a~w yaw, aw W w ~w xw >~w ~ w0.' ~7a~..~ a,~ a~ ~a~.~ ~~w,, ~~., ~~ yaw-.
a>
o w ~ ~ r~ w ~ a vi ~ ~ ~ a > ~ v~ d > ran ~
~, wx w wa w w~ wa w w w~ w~ w~
~. w w wx w~ w~., w w~ w w~, w wa H ~ a~ ~ a~ ~ a, ~ w ~ a, ~., a~ ~ w a, a, a~ C7 w ~
a' w aE"', ~., tW7 aw.' as a~'.~ ~ a~.~ ate, a~.~ ~ ~ ~ ax~ a~..~ U' ~ a >~ d d ~ d ~ d ~ d ~ '" d d ~
W m W m vi v~ W cry w v~ ~ m rr~ rn v~ r~ d v~ v~ vi ~
d a.
M M M
N
O CJ U C7 ~U C~ N ' w ~ N c~G
w U
O O O O O
i, ~ ~ ~ ~ ~ 4.~ 4-~ O O O H
~, .~ O 00 .~ ~ O \O ON M M O
~O M ~ t~ ~ ii ri .~ M O~
E'~ ~ N .~ N .~ N 01 ~ N N
p., v~ m m vwn cwn v~ v~ v~ m b b b b b b U U U U U U U U U U U
cG ai cd aj c~ cG at cV cd c~ cC
'.~,' O O O O O O O O O O O
W .

O
°' a w w ~, >
w a U ~ d o~ >

A
a A
a A
a a Z ~ O' ~ ~ U
w ~w d d~~ ~ C~7wa~..~H
d w ~'wC7~wcw7C~.7~~~a w o~ww A ~ ~ ~~ d w ~A ~ a ~d aw w~ ~ o,W ~~ > ~~ ~ w ww w,~W ~~ ~~ ~~ aw.~ ~w ~d-'~ ~W v~w,W w~ ~~ o~awa rx w ~ ~1 ~ w ~ a., ~, w ' w E-~ w a... w w ~ a., N awi ~ aw a°' a~ a~ ~~ Cw7~ HAw-' ~''~ ~~ ~~ ~d w w~
~, w~ wd wq w~ w~ wv~ w~ wa w~ ww w~' wa ,~ Aw., a., ~ a., a aw-~ ~ aw.~ p~ aw-~ w aw..~ ~ aw..~ d aw..~ ~ aw..~ a aw, a~.~ aw-c, as a~ a a, a w a w ~ w j as C7 w H w ~'' as ~ as ~ as ~'' w ~ ~ ~-' ~ ~' a, a w a~ a, C7 a~ as ai ~ w ~
~, d a d ~ d E., d ~ d d w d A d ~ d ~ d ~, d a ~e ~w >~ ~~ ~a ~H >~ ~ ~a >a ~~ ~ ~a w v~d ~a v~A v~~ v~~ ~~ v~~ via ~~ via ~
ø~ N N N
~"~ _t~ ~ .~ ~ w w w w w w p ~ cc3 ~ ~' O O O O O ~ w Op.F~" O ~ 00000 ~ i H ~ H ~ ~ ~ ~ ~ ~ ~ ~ z H o ~ 0 0 0 0 0 0 0 p ~ p ~ ~ ~ ~ ~ o 0 N N ~t d' m m W O O oo ~ d' O~ O WO ..~ N l~
O ~O d' N V7 O o0 V'1 t O OWn (~ N ~n d' m .~ N N d- ~t m N
m w vmn m cwn m fn [n m w b b b b b b b b :'C b b b ,., r, ." ..~ ... r, .~ ,~ ., r.
U U U U U U U U U U U U
cG cd cd c~ cd cV cd c~i c~ ai c~ c~
~'., O O O O O O O O O O O O
U
d O
O
'Ly d M
U

c~
o' H ~ ~ ~ a a ~ a H
~ ~ ~ ~ ~ ~ ~ A
W A ~ P-I ~ W ~ ~ U
W
a '~ ~ ~ -~ ~ a ~ ~ -~ -a w aw Nw ~ ~~ ~ a~w a~ x a~ ~~ ~w ~x ~ pW., ~~'' pW~ ~ 'xU ~ ~ ~ ~ ~., W
~, ~ as ~ ~ ~ a~
o a ~c~ ~c~ ~~ a~ ~w~
~-wn rn w W ~ vs v~ W v~ w ~ ~ ~"' ~ v~ ~ C7 v~ ~ ~
Wx w ~ ~~ ~cx7 ~a ~~ W
L7 0., > a~
a~'-I ~ aw-i a ~ ate., CW7 a, r~ C~ ~ ~ ~ ~ ~ ~ a~
~ a d ~ a A ~ > ~ ~ > W ~ ~, a >a ~a a c~~ c~~
W rwn ~n d v~ v~ W v~ v~ ra W ~ w i7 ~ ran ~ ~ ~ ~ ~ c~r~ ~
M
1 I i c O O O ~ L7 ~U C7 L7 ~U .-I W
i oooca'~~ooooo~~~U
V1 M O , ~, O~ 00 l0 O~ ~O ~ 4-~
~"" ~O \O l~ pp ~D M l~ l~ l~ ~ W O O
.-i .-i .-i N
i i i , N ~--~ N '-, O O O N
~ (wn .-i O o0 .-i ~ O ~O N M
V7 ~ in 'C ~O M ~O lw0 i I .~ M
[.-1 .--i .-i .-r ' V .-, N ~~ N .-n N Ov .--n N
,~, m wo cd v~ m rn fn m m fn m ~n ~"bb ~l0bbbb'U'd:Gbb U U U U U U U U U U U U
c~ c~ aS cct N cd ai cG c~ ai cd ai .",000~000000000 W ..~
N
d °' z w a o W
a~ ~, >
N
U ~_ N U

A
a a A
a a a w ~ ~ ~ ~ N ~ w o' w ~ ~ ~ w o' ~w A a a aw ~ ~ a w r~
~a w W ~ A C7 a ~ ~ ~ ~"' H ~ ~ ~ w ~'' t7 A~ >w ~ w ~~ H w o A ~~ ~ ~w a°~ ~ ~~ o°~ ~~ ~~ ~'~ A
a ~' >
w ~",v' ~U Ww Waw ~~ Wa ~~ w~ H w~ W~ ww > ~ > 0' ~ c~,7 ? ~O, > w > ~ ~ ~ ~ C7 j a d A
t7 ~ c7 c7 w c7 Z ~ ~ c7 c7 H c7 ~ c7 c7 a c7 W rn rsm ~ vi ~ v~ O~ r~ ~l m '1~'~ v~ ;.4 cn ,~ ~n ~ en ~.7 ca ~
v ~.' F
y N N
Pi ~ U N ~ E E E E E W
.~ ~ .~ ~' O O O ~ O
.O O ~ O .~ p ' O O O O O
' ~ ~ ~ ~ ~ ~ ~ ~ ~
N O d- ~ ~-~ N N d~ d' cn ' O~ ~ ' ~ Wt' O1 O l~ ~D
Ei N ~ O ~O ~t N ~ O oo W l~ O
.-~ N v7 Wit' M ~-~ N N d' d' M
fn m m m m vwn cn en vwn v~
y, b ~f ~ b b b b b b b b b U U U U U U U U U U U U
cd N cd ai c~ c~ at of c~ of cd cd .~',00 0000000000 W
d O
d ~4 O
N
M
U

a w a H
i a W
a a ~ ~ ~ ~ ~ a "~-t ~'' ~ W ~ ~ ~ U
~' a o' ~ ~ xw ~w a~' ~ a a ~W
~, ~'a as a~ a~ a ~ d ~ ~ w o v~ w vW O' cn w w c7 ra C7 w ~ w ~
~ U ~..~ U ~ E-~ U U ~ U U y., U ~ U a U a U C7 W v~ W p~ W O° W ~ d ~w Wx ~~ >~ >a A ~~., P"' ~ ~ ~ ~ ~ r~
a c7 ~' c7 a c7 a c7 a a ~ d ~ d ~ ~ a ~ W
w ~ "~ c~ rn v~ vi v~ O' v~ c7 w C7 v~ c7 w C7 w c7 ~ c7 ~ c7 d ~b M
.-, .-r .-a ,~ W
' ~ ~ M M M
O O ~ ~ ~ 'U 'U C7 C7 C7 v a~ ~, ~ z ,n ~ ~ ~ 'U C7 '~ w w w w w o, w w w w w 0 0 0 0 o N o 0 0 0 0 ~ U
M t~ ,f7 M O .~ 01 DO ~O O~ ~O w w O ~O ~O ~O l~ pp ~O M (~ l~ l~ O O
-~ .--, .-, N .-1 N ,-, N
~,' M n , , , n , i i n p \O
N I~ t~ ~n t~ cn .-, O oo .-i h ov v-, ~mn ~n b ~ M vo Wo E~ N ~ ~ ~ ~ U ~--~ N ~ N ~ N Ov ~, vwn vwn m c~ m m v~ m m m w i.a 'd 'd b b 'd O b 'd 'd 'C~ 'd 'd 'd U U U U U U U U U U U U
at c~ c~ cd N ' cct cd cC c~ a3 N at O .~ . ~ .~ O ~" . . .
w at c~ c~ at a3 N c~ c~ c~
N
z a W U
o W
o U N

a a a a x t~ ~ w .,d ~U
w C7 ~ ~ a.~ U O' ~ C~ ~ w ~ C~.7 ~1 rn a a., w ~ w w ~1 w w W ~1 ~ ~ ° ~," a .-W7 ., a1 a H U w ~ ., ~ ~-i U rte; U a A
,~, v~ W ~ U
W i7 '-' W ~ ~ W Z C7 O' A c~7 ~" ~ w ~' j ~ H W
aw ao' a a ~ ~ H
a~ a~ d ~~ ~ ~ A W A
o~C~7~~~ ~~~C~7~~~~~~~~~ ~C7a U (-~ U ~ U ~ U '~ U W U '~ U A U C7 U ~' U ~ U d U
~ w ~ ~U., ~ ~ ~ ~ ~' ~ a ~ ~ ~ ~ ~ E-~ ~ a ~ W W~ WC~7 ~ W W~ Wa ~~ ~ Ww P~., ~d c. ~ x ~ ~ ~ ~ ~ a ~ a a ~ ~ ~ ~ t7 ~ H
~A q ~a ~a ~~ ~~ ~ ~~ o' ~w w c~~ ~~ ~~ t7~ ~~ ~o~ ~A ~~ c~~ ~~ ~~~ ~a d Pa N y ~ ~ ~ E
w w w cw O O -~ ~ ~~ ~ O O O O
o .~' ~ ~'''u g'u ~n ~'n ~U ci o o ~' o ~ 0 0 0 0 0 0 0 ~' ~ o ~ o ~, ON M c~~1 O cV ~ d' ~ '; tV N 'V' i ~ U ~O i o0 W f' 01 O l~
M ~ ~ O ~O d' N V7 O o0 h N N ~-~ N ~n eh M ~ N N ~t m m wn vwn ~n vwn m w m i, b b ~ b b 'd :G 'd 'd b z7 b U U U U U U U U U U U U
cd at cd c~ cci at c~ cG cd cV at cd ~'~, O O O O O O O O O ~ O O O
O
O
y d .., d ai M
U

c~
a a a U
a ~ ~ d ~' ~' p., a C7 w w '-' w H ~ ~ ~ ~ a L'7 a~ x ~ rte' a ~ ate.. ~
., ~ a, ~, aU a~ a a W ~ ~ P~ a U a ~ w ~ ~' a W rn W w ~ U
w~ w~U.., ~~ O' a~ ~~ ~a~, ~~ a~ aa~, xw ~WP~,~~~C7Lx7UWUCx7U
c, ~~ ~ ~ a ~ ~w caw ~~ ~W a, ~'a as a a a ~ ~~ ~~ a ° U~ U~ ~~ UU UU ~E~-~ U W~ U~ W" ~'~ ~a p'' ~ w ~ w ~ ~ ~ O' ~ O~ ~ ~ d ~ v~ w ~ W ~'' ~ a W ~7 ~ a ~ ~ ~ ~ W ~ W ~ U ~ U p-, U ~ U ~ U H
a. > C7 ~ ~ ~ a ~ ~' ate., w CW.7 ~'' ~ ~ ~ ~.., w ~a a ~a a ~A ~~ ~ W~ W
w c7 ~ c~ ~ c7 ~ c7 'v~~ c7 ~ t~ o' ~ ~ w ~ ~ ~ ~ ~ w M
W
.--~ ~ .-m-r W '° O O O O ~ '"' ~"' M M M
O O ~ ~ W W W W ~ ~ ~ ~ ~ O
z ~Z
'~ w w w w w w w ov w w w w w 0 0 0 0 0 0 o N o 0 0 0 0 01 M I~ v7 M O .~ 01 00 ~O Q, ~D
O O vO lO v0 ~ oD ~O N ~ N
~" i ~ n ~ ~ i ~ N i i i i i ~O .--~ N I~ l~ V~ l~ m .--i O o0 .--y t~ O O~ ~ .V'~- .V'~- ,-v'y 'd ~ N ~ N v0 H d- M N U
m cn vwn m fn m cC m m m wn b b b b b b b ~ b b b b b U U U U U U U U U U U U
cd cd cct cd ai at cd ' at at at cd c~
O ~~ ~ O o ~ .b . . . O
W at tG cG at c~ cC cd cG
N
°z °
a a w U
o ~, m~
M
V $ W
N
r-mr a a A
a A
a a a H ~ U w a w ax.~ ~ ~ a: °' O' aU, C~7 a w d c~ a a aw L~7 ~ Pq.~ W
PU., ~ W f~ U U pU., w U~ p'-~_, A ~ a ~ a W ~ U
a U ~ W U ~ ~ ~ w "~ U U Z ~ ~ A ~ w ~ ~ w W
~ ~ U ~ x w ran U ~ ~'' ~ ~ a ~.a''~., ~ ~' n-1 U ~' j U
~ ~w ~~ ~W a a Hm ~~ ~~' ~~ p,~'' o ~ ~ ~ ran ~ d ~ ~ ~ ~ ~ ~ ~ O'a w U ''~ U U H U ~'' U U U U ~' U a.. U A U '"' U a U
~, a~a a~ a~ a,~ a~~ w~, w aa~ aa~ a,~ a, w~~"
U ~ U ~ U U ~ U L7 U'~ U U ~ U ~' U ~ U ~ U w cs~ ~
ww wz >~ wH ~~ wa w ~ ~ ~ ~ ~ ~ ~ d ~ ~ ~ ~ ~ ~ ~ O° ~ ~.1 I~ N ~ ~ & E
N ~ w a.
U .~ ~ .~ ~' O O
~ C7 'U U' ~ ~ .~ ~ o ~ aW'D bD
°' o ~ o ~ 0 0 PG0.~1C~'J U~o s. ~ w o 0 0 ~ ~ o ~ o O O O N l~ ~ N O '~ O ~ N
.~ M O\ ~ O ~O d- N N O
E'~ N O~ .-1 N N ~ N ~n ~Y M .-~ N
,~, m m wwn m m m m v~ m m b 'd ~ b b '~ b b b ~G b U U U U U U U U U U U U
cd cd a3 cd c~ ai at c~ c~ N cG at .~',00 000000~0000 d O
U
~i M
U

a a w d ~ ~ a ~ °' d ~~., w ~ ~ ~ ~ ~ ~ ~ x a, H ~ a ~ ~ ~ a H H w a ~ ~ A
., ~ ° v ~ ~ ~ '~ aU-~ w aU, ., ran " a U W
~> ~>
~ U ~ P... r~ w , j U ~ W U W U U E-~ U
E-a P.~ a W w W fs, p., r/~ U O' U O~ ~ "'' P.~ ~ ~ ~ ~-1 C, U E-i U C7 y-w7 w ~ ~'' E-~ ~ ~ U ~ U ~ Lx7 ~ Q' ~ ~ v~
~ H~' ~w ~~ ~~ ~~ ~~ a~ w Ha ~a ~a ~w c~ ~ ~ ~ ~ ~'a ~a A
a aw a"-, a~ w ~w~ ~~ w w v~ v~ Uw ~~ ~~ Uo, ~o, °~~' o, >~ d >
w w w w a.. w w w d ~ ~a w> w~ w'" ww w~ wH wH w H ~x ~' ~x U w U d U ~ U a U A.., U '-' U '-"' U ~ '"'' a, >~~ W~ W~" WA W~ ~~ ~~ ~a ~ a~ w~
A ~ ~ >~ ~a ~a ~a a a~ ~~ a w ~~ ~a ~> ~a ~~ ~~ ~~ ~o~ ~ ~w H~ ~w M
Cdr ~ .~~ ~ .-i ~ .~ rr W
°' ~° O O O
w w w w W U~ C/~ cn C/~ W W W
o °o °o °o C7 W W W W ~ (~ (7 O o 0 o O O O o o N O O O
00 ~ ~n o~ m r ~n m o .=. ~ o0 0 00 ~O 00 O O ~O ~O ~O l~ pp ~O M l~
c ~t ~r ~' m c'm .~ . ~ ..-~ ,-~ N ,~ cy o r. vo ,~ N ~ ~ v~ t~ v~ .-~ 0 00 00 ~n n o o»n ~n v~ ~ b ~ c~
H N d' d" M N rr '.r .-n .--n V .-, N ..-~
fn m m w m m w fn m cC v~ m w ~' b b b b b b b b 27 b b b S. r, ..n ,~ ..-n .-~ ,-n ., ..-n O ..n U U U U U U U U U U U U
of cG at N cG ai cd c~ c~ ' N cd at O O O O O O O ~ O O ~ O O O
w .~ .
b N
o O
z ~.
a O v~
~a U
~a H E

A
a a aa, A
a a ~ ~ H ~ w v w a a ~' x ~ ~ ~ A~ >
ai ~ ~ w c7 ~ ~ ~ ~ ~' d t7 cn~Aaw~d~cn v, a a a ~,~ d a ~~ ~~ ~~ a~ ~ ~~ ~a a~,w ? ~ a ~ ~ E-~ ~ w d v~ ~-a ~ ~., ~ a W f.~
a~ ~~ a~ ~d ~ cx7~ ~~ ~~ ~~ ~ P~
~a ~w ~a ~~ a xw ~~ ~a ~a ~~ a a ~ a ~, w w ~ a d w w W a w ~ w ~ a ~a ~~ ~~ a~
a ~ a ~ ~ ~ ~ ~ ~ ~ ~ ~ w ~ U ~ w ~ aa.~ ~ A > H
~, d dx d,~ d~-' d d d d~.., d~ dd d da ~, rn ~ v~ C7 m v~ m r~ ~ rn ~ cn cn v~ v~ A v~ ~
d d ''' d ~' d ~ d d ~' d C7 d ''a d ~ d ~ d ~' d C7 w~ wP~ w~ w~ w w~ wA w~ ww wa w~ wa ~a ~ a ~ W ~ d ~ r~ U ~ ~ a w W E-~ w E-~ ~ Ei d E-~ ~ ~ v~ ~ d ~ v~ E-~ ~ ~ d ~ ~ ~ ~ E-M M
W W N
d Wrr~,°~'o.~o~f Cw.7CW.7~~ v.~ ~'o ~' i d d d 0 o W U ~ ~ n- ~ o ~ o s, ~ ~ w w o 0 0 ~ o ~ o O O O N ~ w N O d- O
O ~O CV M M ~ ~ I~ ~ d' F'~ N ~ ~ ~ ~-~ M O\ ~ O ~D ~t N
.--n N Ov .-~ N N ~-~ N V~ d~ M
v~ vw wn fn m m ~.n mo m m D'~fb b bbbb'~b~bb ~.
U U U U U U U U U U U U
a1 t~ ai c~ cd N N c~i ai of at cd 0 0 0 0 0 0 . 0 0 0 0 0 0 W ..
a~
O, b P~
~n M
U

a a a ~ ~ ~ a >
a d ~ w C~7 c~7 ~ ~ C~7 ~ ~ H
H ~ a ~ a w A ~ a a d o,~ -~ a °~ ~ ~ ~ a ~ w ~ ~~ ~o~ a' d ~d drdn aw ~d ~w c~7a ~a ~'a ~W ~a ~W ~W H
Pew c~~
~> a~' ~~ ~~ >~ a~ v a >H
d~ dH d~a d~ ~w d~ do' dO' d'_'' a m rn w v~ ~ r~ E-~ rn rn w r~ ~ r~ E~ m E--wn ~ E-~
dp' d dw dd d~ da dw d'-' d~ d~
o, a~ a~ act aH a~ a~ a~ a~ a as w wa wa, w~ w~ w w~ w~ w~ wa ~, a~ aw a,~ a~ ate, as a ~ a ~a a a ~~ ~a ~a ~a a w H~ H~ H~ ~a ~> a ~~x H~ H~ Ha v~
M
°' '° O O O O ~
W ~ ~ ~ ~ ~ W
0 0 0 0 o W
0 0 o O o 0 ~n ~ ~ ~ w ~ ~ z O O O O O o O o O O O N
N t~ oo ~D v~ O~ M ~ ~n M O .
y0 ..-~ oo ~O oo O O ~O vD v0 t~ op N N c/- ~f' M M .-n .--n .-i .~ N
n n ~ ~ ~ i d' Q~ O tW0 .-, N t~ l~ V7 t~ v~
m O oo ~n l O OWn W o ~ ~f E-~ .~ N N ~t ~t M N .-~ ,~ .~ r, V
,~, v~ vwn vw wn v~ vo vmn v~ cct b ~ b b b ~ b b b b b .~ '. .H ~ .~ .r '.
U U U U U U U U U U U
cd cd at cV c~i cG ni cG cd cd ai ,~,' O O O O O ' O O O O O O
w O
d U
pi M
U

H ~ ~ w cx7 a~
H W C7 a' P, C5 a ~E~ ~ a~ a~ xW ~~ ~.;~ H~ ~~ w~ U~ w~W
Hw aw ~ w ~~W t'~w aw w w~ ~~ ~~ w~ ~a~ ~w ~ xc7 ~w o ~,~ ~c~ ~~ ~~ AH
~H ~H H ~H ~c~ ~H ~ ~H A~ aH a~ aH
~ ~ c5 a ~ w ~ ~ ~ ~ H o, ~ ~ ~ ~., w c7 a~ ~~' v~ w~.., ~a ~~ ~~ ~ ~E-' ~E~ ~w ~U yaw ~x ~~ ~~ ~~ ~c~ ~a ~~ ~~ ~c~
wF~.. ww w~ wa.~ w~ w~ w w wx w~ w> w~
~ w ~ C7 ~ a~ d c7 ~ P' ~ ~ ~ r~ ~ ~ ~ a~ ~ q ~ ~ ~ w o°'e H ~ E~-~ ~ H j H ,.~a H w N H E~-~ p., H ~ H ~ E~-~ a H w W c7 W c7 v~ L7 W L7 w C'7 ~ C7 ~ C~ ~ C7 rn L7 ~ C7 m C7 ~ C7 ~
d b .-. ~ m m m o Cw7 CW7 cW.7 ~ Cw7 W d- ~ ~ o A
0 0 0 0 ~ ~ c.~ ~. o O O p N l ~ N
O 00 .~ ~ ~ \O N M M
m ~o ~ ~ ~ ~ ~-~ m ov ~ o N ~-~ N ~-~ N O~ .-~ N N ~ N
~, v~ vwn m m w cn fn m en m cn y, b b b b b b b b b b b T1 .-n ..r ~ .-~ .~ .~ .r .-i .a ~.-n U U U U U U U U U U U U
at p c~ cd c~ aS c~3 p ai ai p N
~"',00 00~00000000 U
W '~
y N
O Z
Q, H
a :° w w w ~w H
d H

A
a a A
a a a a ~ °, ~ ~ ~ a °~ ~ ~ w ~ d ~~., w ~ ~ d A ~ w E-~ a o°w o'w ~ c~
w A
wH ~c7 a~ w >w H~ ~aw ww wf~ ~w o'w ~O'c~,7~~~aw..~wa~,w~~~~~w~d~~~w aa~.''a~~~cH7o'c~7~c~7~H~H~~~~~~~c~7 Zc~7 ~~ ~H ~~ AH
° o, a a~ ~a-, fir" ,...,,~ ~ ~.,~ ~E,, ~a ~w dw ~~ ~~, ~p, Z ~; ~ ~ ~ ~ ~ ~ w ~ ~ ~ E-~ f~ ~ ~ w ~ ~ ~ H ~ H
w wa wc~ w w w~, w~ w wa w w~ w~
a Hz H~ H~ HH H~ Ha HA ~~ H~ H~ Ha Ha w c~~ ~A c~~ ~~ e~~ c~~ c~a c~~ c~a c~~x c~~ c~~
U N
~_ s E a ~ W ~ O O
0 0 0 0 0 ~ w o v~ ~ 0 0 0 0 o U' mo ~a' g'n~n~Og"D~'nW~~Z
o ~ 0 0 0 0 0 0 0 0 0 p o ~ ° ~ ~ ono ~ ~ o 0 .-, .-.
00 ~ d' Ov O l~ ~D ~ N l~ l~
~O 'd' N in O o0 v~ l~ O O~ ~n [-i ~n d- M ~-~ N N ~fi d' M N
b ~ b b b b b ~ ~ b b b .~ .., .~ " .~ a U U U U U U U U U U U U
c~ at cG cd cd at cC c~ cd c~ cC c~
'~', O O O O O O O O O O O O
d U
O
U
w G:.
d ~i M
U

a a ~' H x H w ~ w P~ ~ ~ w °a ~ ~a as as ~~ ~;a ~a ~w ~ x a, a ~ ~ E~-~ ~ w ~ ~ ~ w ~ a, ~ ~ ~ ~ C7 O ac7 ~,, w~ C7'~T'~ w~ ~~ ~w ~ ~~ ~~ a.,w A
~, vsH a ~1w ~w Pew ~w w~ w ~ ~,w ° o'H ~ w~ ~w w w~ ~a ~a ~w rii~ d vow ~ o° a~ a~ a~ as a~ as a~ a a~ a~
a ,~
a a wd w~ w~ wa w~ wd w~ w~ wd w~
W C7 d rn w w w ~ w w w w w M
.-i M M M
, , v , , O , , '.", w w ~ C7 C7 C7 C7 C7 N
w w O N O O O O O
M O . ~, 01 00 ~D O~ ~ c,.., W O O O
N ~ N ,-~, O O O N I
, , , , , , , ~nWnrrOOO.-r~o~ONMC~1 h V'1 b l0 M ~O l~ l0 , , ~ M Q~
(-i .-~ .-~ V .-a N .~ N ~-~ N Ov ~ N N
cn v~ aW nn m v~ m v~ v~ v~ v~ m y" b b O b 'O b b 'b ~ 'd b b 'b O U U U U U U U U U U U U
cd at ' cc3 cc3 td ccf cd cd c~ cd c~ cct O O O O O O O O O O O O
y N
O
w z ~.
a b w a ~a p c~
M
M
v '~ w ~w w w a ca ~, w a o~
d ran w e~ d ~ ~ ~ a ti a '~w AA
w a ~ ~ C7 c7 ~ ~ w L-1 a °a > a ~~ a as aw Aw ~, a ~ ~a ~ ~ as ~c~
w'~ ww ~w as ~ ~a H a~ ~t~ w o~o~ c.~7~7 ~~ ~~ t~7~ H~ ~W "'~ t~'7w o ~~ P..,l~ ao' ~''" ~~ ~w o~ ~,~ caw ~~ P~~ e~w w ~, ~ca.~ ~w O~~ A~ ~W as ~~ a~ q~ aw as a a a a ~ ~, H ~ w ~ wa w w ~~ ~ ~~ ~o° w wc7 ~ w w~
W w~ w~ wo' w~ w~ w~ w~ w~ wa w~ wa w~~
Ow F ~ ~_ U
ai U cad E ~ E E 6 w f~" .~ ~.~ d' 00000 Vr C ~ O .~. p ~ O~ O O O O

o -~' o ~ 0 0 0 0 0 0 0 °~ °~~o°~o~oNOO~Mo N O ~t O .~ N N d' 'd' M M
~O ~ oO ~, d' Ov O l~ ~ .~ N
O ~O ~f- N h O o0 h I O O~
N ~n d' M ~-~ N N d' d' M N
yn cn m m v~ m m m ~w wn v~
y, b °'d b b b 27 b b b b b b .-m.. ,..n .. ...n .-n .. .,.., ~ .w U U U U U U U U U U U U
~~ cc! cd cd ai ai N cG cG ai cd at a3 ~"., ~ O O O O O O O O O O O O
U
N
O
U

U
M
U

t7 w a o, ~ ~ ~ ~ a ~ ~ H
a ~ a a -a a a a ~ ~ ~ ~ a ~ ~ ~ w a~
~a ~a ~a ~a ~~ wa ~~ a H~ wt~ ~~ wc~
as ~w ~w a w~ ~W w~ ~~ ~W w v ~~ ~~ ~~ w~ ~a ~a awl ~
a d a or a o' a~ aW a~ aw a~ a~ a~ a a w a w a w a a Wld ~I~ ~I~ Vila ~ ~ c~
w w v~ w c~ w O' ~n ~ w ~ v~ ~ w ~ w M
..-, ,-, .-, ,-. w O O O O ~ '~ M M M
i i O O O O O
i l~ V1 M p .~ O\ 00 vO 01 ~O ~ O
~"' ~D ~D ~O l~ pp ~O M l~ l~ t~ 4"~ 4-~ O
.-~ .-~ N .-, N .-i N .-, O O p i ~ ~ ~ i l~ I ~ I~ m .~ O oo .-i ~ o ~O cV
V1 N N V~ b ~O M ~O lW0 ~ i [-W--i .--i .--~ .--i V .~ N .-n N .~ N Ov m v~ fn wn aW n vw wn v~ v~ v~ m b b 2J b T~ b b 21 b b b b .,-n ~., ...n ., O .,-n ,-n ,r ., ,-, ,.. .r -,-v U U U U U U U U U U U U
cd ccf c~ cd cd ai N c~ ai of ai ai .,0000~00000000 w .~
N
O O
H
.p L1~
W
N N
w O
U
~ W

-1~2-a A
a a a U w ~ ~ ~ a a, ~ ~ ~ a; a a ~ ~ o, w ate, H
a '-.~ a ~ ~1 t7 ~ a a ~a °~ U ~ w ~ ~ ~ q ~~ ~ ~ ~~ >
x ~~ ~'a a ~1~~ AA ~~ ~ ~~ ~"a Ha aw as as °~~~ as ~c~ H~
~ ~w a~ a~ ~a~ ~~ ~~ ~~ ~~ a~ a v ~~ ~a ~w o~a AA ~~ ~a ~~ ~~ a~
a a ~z ~o, a~ ~~ ~w ~~ ~H
a. x ~ ~ ~ a a ~ ~ ~ H
c7 a~ c7 ~ c7 ~ t7 ~., c7 a c~ ~ c7 ~ c7 ~ c7 t7 w e7 ~ ~7 w W~ ~~ ~~ W~ ~o~ ~~ ~~ w~ w~
H
Q1 cad U ~ ~ E E E ~ E
C . .~ ~ .~ d' O O O O O
'd' a~ ~ O ,~ p ~ ~ O O O O
.~ ~ o .~ ~ ~"n g'u ~"n g'o ~'o ~, U ci o o ~' o ~ 0 0 0 0 0 ,. o o ~' ~ o ~ o M M 4 cV O V~' O~ .~ N N d~ d' 00 ~ d' O\ O I~ ~O
Ei N N ~ N ~ ~ m ~ N N Wd D, ~n vmn vm wn m v~ m m m y, b b 'd b b b b b 21 b b b -~ .'-n -.-m. .-n ,.-n ,-n ..-~ ', .., -., U U U U U U U U U U U U
cV N cti cd cd cd ai of at cd cU c~
'~', O O O O O O O O O O O O
d O
O
b L7.
d M
M
U

a w v a a ~ a ~ ~' ~ ~' a a ~ a w tw7 a ~ ~ N w w c'~ w a a >~
.,a ~ ~ w ~ °'~ ~d C7 a ~a ~a v H vow a~ ate, aw xw ~w w~ ~ a a.~ ~~ ~) xw ~w ~w t7 C7 aw w a ~ ~ ~ ~ ~ a a ~ C7 t7 w C7 ~ ~ ~ ~'' ~ ~ C~7 ~. ~c~ ~~ ~~ 3~ acs ~ ~z ~z ~z ~z Pw ~z as a~ ~~ a ~w ~W ~w aw w w v v' ~p~ gyp' ('~~ p~ w'~' w w~ wa w~ wa a a ~ a ~ a ~ a ~ ~ ~7 ~ ~7 ~ e~ ~ c7 ~ c7 ~ t7 a ~ t~H caw ~~ caw c~ c~ ~ ~a z~ z~ z~ z~ zP z~
a w~ w~ w~ wa ww w w ~a f~~x ~~ ~~ ~os ~ ~w ~~ ~w ~xw ~x~
z3 M
p, .-, .-~ ,-~ ~ W
P~.i w 'D C7 ,--~ .~ M M M
O O O O
w W W W W ~ C7 C7 C7 C7 C7 z 0 0 0 0 oN o a o 0 0 O~ M l~ ~1 M O .~ O~ 00 ~O 01 t0 0 0 ~ ~ ~o t~ oo ~o M t~ n ~ '''' M M .-n ~ .--n .-~ N .-r N .--n N .-r O
i ~ ~ ~ ~ i ~ i ~ i p "~ .--~ N l~ l~ V) l~ v~ ~ O o0 .-~
O 01 V7 V7 V1 ~ b \O M ~O l~ ~O 'i E-t M N .-~ ..-~ .~ .-i V .~ N .~ N .-~ N
>, ~n m fn vm wn ai m wu m m y, 'd 'G b b b b p ~ ~ ~l 'b ~ b U U U U U U U U U U U U
td cd cd ccf cC c~ ' cd cC cd cd cd cd b cG c~ at N
O, O
° z w a a w m z U ~ W

A
a a A
'a w a ~ d ~' x ~ ~ ., ~ A ~ ~ va c7 w a, C7 ~ ~ a, ~., p, w C7 cs'AAaa-'dw~cw.7aH~a~..~
a ~ ,z., ~ A Z ~ ~ ~ W
~a~..~ ~w ~~..~,,~ Va~.~ wad'., aW ~W a~~.., ~w >~
~w Cw7 ~C~.7 ~w a~ ~tw7 z~ O'A L7w ~~ ww ~Cw.7 o ~z ~W AW Az aw ~z aw ~a ~~ aW o'~ ~z a ,~w d~ ~~ ~z ~ W ww a~
d w w w ~ w a.. w a, w ~ a, a w ~ w ~ a.. H
w w w~ w~ w~ w w~ wA w> w w~ w c7 ~ ~ ~7 ~n t7 ~ ~7 a c7 ~ c7 z ~7 a c7 c7 c7 ~ ~ w c7 ~
c~ ~ ~x t~~ ~> c~ ~~' c~a ~a c~a z~ z~ z~ zA z~ z~. za z~ z~ z~ za z~, w ~~ ~~ ~~ ~~ ~~ ~~ ~a ~A
N N F _. ... ..
v~ m ~, N
U .~ ~ .~ ~~ O O O
W ,~ ~ . ~ O_ O_ O
CW7 ~ A ~ .~ .~ o ~ ~ g'o ~"n ~''u U cue. o o ~ o ~ 0 0 0 ~, 4, 0 0 0 ~' ~; o ~ o O N t~ Q N O ~t O .-~ N N
i i y0 N cn M ~ ~ ~ op ~ ~t Ov O
M O~ n O ~O d- N V1 O 00 E1 O~ .-~ N N ~-~ N ~n d- M .-~ N N
fn m cn m v~ m cn m m vmn m b b b b b ~~ b b b ~f b U U U U U U U U U U U U
cG of CC cG N cd at cd ai c~ c~ cG
'.~,' O O O O O O O O O O O O
d N
O
d w U
M
U

a a d ~ ate, ca~7 w a H ~ a tw7 ~ d ~ H ~ ~ "w ~~ ~ w a ~ a w a ~ a~ a~, a a ~ H~ w~ ~~ wc~
w 0., cry d c7 w C7 C7 c7 w ~ C7 ~
w ~~ ,..a~., w caw ~~ H~ z z ~z A ~z aw ww w~, ~t~ o~c~ o~w raw w ~w ~w >W aw ~z ~z H~ ~~ ~ w~ ~'~ w~ w~
o AW ~W ~z ~w ~w ~z az .,., a w vW a ~ a w ~ w p., w w w ~ w ~, a~x a ~w ~~ a w v z~ z z~ z~
~ wr; ~w w~ wo° wo' w''-' o° w~ w~ wa w~
~' c~~ ~~ ~a p, c7 E-~ C7 ~ C7 ~ L7 ~ C7 t7 C7 ,~ ~ v~ E-1 vi w v~ 1-~ vW
w C7 r~ w C7 wA w~ w w~ w~ w~ w~ a ~ ~~ ~A
w ~a ~~ ~~ ~x~ ~x'v~~ ~~ ~a ~ a~w a~ aw aw M
w ~ ~ .~ .-1 ,~ .~ w i i 1 i ~ ~ M M
Lr" O O
w w W o ~ o ~ ~ c7 C7 ~ c7 -1 ~ ~-1 ~-1 4-, ~-1 0, ~ ~-1 ~~-1 4-, 0 0 0 0 0 0 0 o N o 0 0 0 ~O In O\ M h v1 M O .~ Ov o0 ~O O~
0 l0 00 O O ~O ~O ~D t~ pp ~O M l~ l~
~, 'd' ~1' M M ,--~ .-, r-m--I N .-i (~j ~ (V
1 1 7 1 I I 1 1 1 1 i 1 rl N ~. ~ V7 ~ V1 N O 00 r-1 V1 l~ O O~ v1 V1 IWn b l0 M ~O l~
H d' d' M N .~ .~ .-~ .~ v .-i N ~ N
w vwn m rn fn m at vw wn cn .d b ~ b b b b p b b b b ~, U U U U U U U U U U U U
cd cd at a3 cd cc3 cG cC ' c~ c~ cd c~
,.d cti c~ c~
N
z~
o a~
:o w ~z M w U N
~a as A
a a ~' A
A
a ~ ~ ~ o, U w a~~, a ~ x ~ ~ ~~ ~iw w O'~ C7 ., ~ ~ '~ ., ~ A a w ~ ~ A Cw.7 ~ ., ~, ..~ ~vw, > ~ ~~ c7 t7 w t~ ~ ~ w xFw aa~'.~ ~"'~ ~~ ~~ -~W,, U~ w~ ~~ Aw °W aw L7 ~ ~ w C7 ~ ~ a, W,~ ~1 wC~7 ~~ ~w Cw7 ~t~7 ~~ >~ ~Cw.7 ax ~v~ aw ~c~7 ~w W ~z ~,W aw q~ aw w~ a~ ~~ ~~ ~w ~w ~ ~~ ~W ~ ~w a~ Aa ~w w~ w~ w~ ~ w w~ wax w A w~' ~~' c, w w~ wrn w~ w w w~ w a,d ww a..~ w,..a o wa w w w wa wF~ w war w w~ w w ~ '~
~, za z~ z zH z~ z z ; zw za zA z za ~, wx wa w~ w w w~ w w w w w w~
~x~ ~x~ ~ ~~ ~c~ ~xa ~x a, ~ rs~ v~ v~ v~ x ~n cry v~ > ~n ~ r~ ~n v~ v~
~A ~A ~a >a W a~ a~ a~ a~ a~ a~ a~ a~w ao, aA a~ a~
.'., d M N N
c~ p ~ E
o C7 .-~ ~ ~, y ~ -~ ~~ o ~' ~Wd'Nmp.f~O~O
d ~ v e-U'~. .o ~ ~, ~ '~p'' p~o' 0 0 0 .~ ~ o ~ o p p O N l~ 4'' N O ~I- O .-i O ~ ~ M Q\ ~ O 1p 'd N
H ~ N Ov .-~ N N .-~ N ~wY M
w nn cn v~ (n m m w m wn D' b b b ~ b b ~ 'b 'b b b b x.
U U U U U U U U U U U U
at ai a3 at c~ ai cV at cC N cC cd ~., O O O O O O O O O O O O
O
d pi M
U

c7 a a w r~ > ~ Vo, r~~dCr~7wcP,7HdH
w Cw,7 C~,7 >~ ~ C7 ~ ~ H
a ~ a W~
o° w ~~ ..~ ~ a ~ a ~ a a w ,~~ > a ~ w ~ v~ O' t7 ~ E~~,, H ~ ~a yi ~ w ~ ~ w O' w w w > ~ ~'w' c7 c7 a ~'" ~ ~ ~ ~ ~ w ~ w w a, w w C'~ H c~7 >~ L7 t" w ~C~7WzAw~w ~~w~W
~w ~w a~ ~~ ~w ~~ ~~ ~W o,w a. w ~ w !-'~ ar ~ w ~ a.. ~ a-~ a w a a.~ ~ w o w w wa wa w w w w w a ~ a c7 c~ c~ a ~ a c~ a c~ a c~ a a C7 t7 C7 C7 > C7 c7 t7 w C7 c7 w w° z> z~ z~ zw za z~ z~ z~ z~
w~, wH wa w ww w~ wa wa w a ~w ~a>, ~d ~" m ~ cs~ O m E-~ v~ >~ v~ ~ cri ~ v~ ~ v~ rn a w ~~ ~~ ~a a> ~~ a~ ~~ ~~ as a M
°' '° O O O O ~
Pi ~ E E E
C.' O O O O w 0 0 0 0 0 ~ O
z 0 0 0 0 0 0 0 0 0 o N
y~ t~ oo ~ ~n a, m t~ ~n m o .._', ~ oo v0 00 0 o vo W O ~ op N N ~t d- m m ~ .-~ .~ .-~ N
01 O tW0 .~ N l~ l~ V1 t~
O o0 V7 t~ O O\ ~ h V1 V1 b h N N ~Y ~t m N .~ .--~ .-~ .-~ ' p mm v~ v~ v~ v~ cn m v~ cG
y.~',bb~d:db ~fb ~J ~f~0 O O .~ .~ O O O
W c~ c~ c~ c~ c~ as a~
Q.
O
d Ci~
a~
Pi M
M
U

a x a H ~ v w a~
Cx7a~x~~a A ~ ~ ~ ~w ~ ~ ~ A A a a a ~ ~ w d a w ~;a °a ~;a as as as "~ Ha ~a ~~ Ua w~
H~ w~ ~~, w~ ww ~~ w ~ xa, ~,w ~. ~ ~~ ~,~, raw v w~ ~~ ~~ a~ ~~ ~~ ~~ ~~ ~> ~~ ~Z~
a~ a a a> as as act aH a a~ as aw ~ ~x ~
w c7 w a~ ~ w w w w w ~ w ~ w a w a~.,w a~.,tw7 ~a, ~C7 ~~ a~-~~ a~.~~ a~.~ w~ a~.~~
Cw.7 A Lw.7 ~ Cw.7 j cw,7 a cw.7 w Cw7 ~ Cw7 ~ Cw.7 ~' cw.7 WU Cw.7 ~ Cw7 a cw,7 ''~
W C7 w C7 v~ C7 W c7 w L7 ~ C7 ~ c7 L7 ran c7 ~ c7 v~ c7 ~ C7 a, ~--~ M M M
O U' C7 CJ C7 C7 N ' N v~
O
A
0 0 0 0 ~ ~ ~ v ~ 0 0 s. ~ °M° ~ ~ ~ ~ 4..~ 0 0 0 .~' d;
O v0 N M M O N
O o0 r, l~ .-~ .-~ ~ ~ ~ p~ ~O
'~D M ~O (~. v0 ~ i .--~ M 01 i O
N .-i N .-r N Ov .-~ N N ~~ N
vmn m m cn v~ m vmn m m [n b b b ~ b b b b 'd b b b ",~ U U U U U U U ~U U U U U
cd cC cG N c~ c~i c~ c~ cd cd cC c~
~.,"00 0000000000 N
O
;~ z a O
~~ ~
M aw U 'w o c7 a a a U, z a ? '_'~ w a ~ ~ ~ v '~ ~' d a w ~ a v a ~i a wa~~a~~L~.7C~7 A ~ a . ~ w ~~ o~a ~~ ~~ °a ~ ~ ~~ '~ ~ w a ~1c~.7 ~ c7 a a c7 ~ a w w ~ ~ ~ ~ ~'' a w c~, a~ w o a~~'''''''~'~~~o' ~ s~ ~p~., ~~ ~o'a~..~ ww ~w ~w ~~ ~w w c7 w ~ ~ ,..~ ~ w v~ c~.7 ~ t~7 ~ w ~C~7n-7~~~~~~'-'~~wcanC~7 a~ as a~7 as a~ ad a~ av, as a~ acs acs d A 3 t" ~ a w ~., ~n o' o°
~~., ~~, ~~ ~H ~~ ~w ~ ~H
~ wo' c~ w~ ww wd w~ wa ~ w~
c. ~ a ~"' a ~ G~ ~'' C7 ~ ~ ~' L7 ~ E-as ,~ a~ ~ a, a~ as ~, a~ a, a, c7 a~ ~ a~ a, ~ w a, ~
~ Z c~7 ~ tw7 ~ cw7 ~ tw7 q cw7 a Cw7 ~ ~ a Cw7 ~ C~'.7 ~ cw7 a Cw7 '~
W C7 O' C~ ~ C7 ~ C7 x C7 ~ c7 ~ c7 ,-a c7 ~ c7 a c'? ~ c7 rn L7 ran b p'' ~ ~ ~ ~ w ~ ~ w W ~ O
o ~ '~ ~ °o °o °o °o °o O ~ ,-. ,-, ,--~ ,-, ,.-.

O O
o;° "~~ o~o~ooo r' oo '~'' v. oN'v o VJ ~t N ~n O oo ~n ~ O
H N d' M .-, N N d' d' M N .'-i .-n m wn v~ m m va mu vmn m b b b b b b :'d b b b b TJ
V U U U U U U U U U U U
ccf c~ N t~ cct c~ cC ni N cd N at '~', O O O O O O O O O O O O
N
O
i~
U
'b i~
isi M
U

a H
x a a c~ a ~ w x ~ a~ ~ ~ x c~
W ~ P, H d ~"' ., W ., r~" ~ ., w "' U U ~ U ~ U ~~-7 ri, F-1 U ~ E-~ U ~ O.U., ., rn x~
o a~ ~ a~~,~ ~~ a~~,~
~~ ~~ ~~ w~ ~~
d rs~ ~ U ~ U ~l U ;,~ U ~ U ~, U U ~ U
a~ x a~ as a, a, ~ a~ ,~ a~ w as ~ as C7 ~ w ~ C7 w ~s, A
a w C~7 d ri ~ w ~ ~ ~ ~ ~ w :d m CJ ~"..' '~-i M M M

CJ U' 'U CJ U" .-i z ~° ~ ~ ~ ~ ~ ~ ~ W
oN o 0 0 0 0 c°~ '" o c°°n ~ °' i° ~ ~ 0 0 0 .-n .-~ N .--n N .--n N .-, O O O N t~
n ~ _i i p t0 N M M
VWn y0 o v0 lW0 '; ' ~' ,..~, (-~ r' ~"'' ti '"' N .-i N .-~ N Ov .-i N N
m rn cct (n m m fn fm wn m vwn b b ~ b b b b b b ~ ~ b b ,~"~ U U U U U U U U U U U U
td c~ ' c~ c~ ai cd at cd cV of at td N
z ~.
a b w U
y N_ p.., Qi U

a a a a a a a r~r~
U w ~ ~, ~ 9 H H v~ a a; °~ o~ ~ c~7 a w c~w7 z.~7 a p'' ww ~~ A~ ~~ a~ r~n~ H'z' ~~ ~~ waU-~
a~ A ~ w ~~ v~ c5~ ~' r~
a w ~~' a ~ a~ ~ ~ tw.7 ~°' H
v~ a a~ a~ ~a ~~ ~~ H
o ~a ~~ as ~A ~~ ~o' ~~ ~~ a~ ~~ a~
U U U U P-' U ~ U U U U E..., U a U w U w U ra ~ w ~ a.~ a, ~ a, A as ~ w w ~ w ~ w H a~ m as w a, ~a w ~~ ~~ ~xa ~A ~~ ~x ~x~ ~~ ~a ~~ ~a b H
,r ~.
~1 Cd U t~ ~ ~ ~ P" a.
O O O O O
~O .~ ~O ~ ~ O O O O
o .
0 0 ~ o ~ o o Q o 0 0 0 o~.-~~o~o~o~ooo N Od'O~NNd'd~MM
oo ~ d' o~ O l~ ~D ~-~ N
~N ~d~-cNn~-~~~NNd'~~N
cwn m v~ vwn cn ~n v~ m v~ m y, b b b b b b ~ b .O b b b '. 'a ~.-.n ,-, ~ ., ., .-~ ,-n .r 'a .., ""~ U U U U U U U U U U U U
cd cd at cC c~ cG cG c~ of cE c~ cd a~
CL
O
a>
.o +;
C, Pi N
M
U

U ~ ~ ~ a ~ a H
x '" ~ U H~ ~ ~ C~7 ~ ~ v~
rWWn a ~ ~ ~ ~ j a U~ UU HUB ~ ~~ ~U aU ''~~ ~a'' ~U ~''~ ~U
a~ yaw a W~ ~~ ~~ a W
U d U p~ U ~ p~ U v~ U U ~ U .-1 U x; U ~ U ~ U
~ w as w ~ ~, a.. x w ~ w a a-~ a.~ w a w a.~
W ~a ~'~ ~o' ~ ~~ ~x~ ~~ ~w 'C7 M
.~, .--~ ,-~ .--~ W
m cn m oW W W W~~CW.7CW.7LW.7C7 W
0 0 0 o N o 0 0 0 o W U
_~
S. y0 ~ I~ 00 ~O M ~ ~ ~ 4-r 4i O
.--n .-, .--~ N ~ cy r, N ..-, O O O
.~, ~ ~ ~ ~ ~ ~ i ~ ~ O l0 N
V'1 I~ v~ .~-i O oO .--y~ .-n .--W
.~ V~ ~ V7 V1 '.'O lp M \O t~ \D ~ W
[~ .--n .--~ .-, .-W V .,-i N .-r N ~-~ N Ov v~ v~ fn wn c~ cwn vwn m vmn v~
~", b ~ b ~d O b b b b ~ b b b U U U U U U U U U U U U
cC cd N c~ cd cd a3 of cC cd aS cV
,~ O 0 0 0 ~~ 0 0 0 0 0 0 0 0 N
z a w >
o U
M F1, Qi ,-i I
U ~
o_ A
d a A
a a U w ''~ ~ ~ ~ w d w ~~., H
aU c~ ~ x ~'aawa"~'~a~~~o'wAa w ,.~
w~U~aU.~~~~~A~~U~aa''~->~~~.,U~aU,waU.~
~ U ~ E-~ vi a~.~~ A~ d~
w ~ ~ aa..~ ~ A ~ ~ ~ ~ ~ W ~ A
~A >~ ~~ ~ ~~ >~
U x U U U U U ~ U ~l U ~ U ~ U ~, U ,~ U w w ~ w ~ w a w ~ a~ ~ a.. a w~ ~ ~ a ~ w ~ ~ ~ ~ a~ C7 ~. ~x ~~ ~~ ~~ ~a ~a ~d w ~x~ ~x~ ~x~ ~x~ ~xa ~xA ~x~' ~~ ~x~ ~x~ ~xa b N N H '. .. .. _.
cC ~ 8 ~ 8 8 p U ~~ ~ ~~ Q~, O O O O O
O_ O O_ O_ O
d r~ o ~ 't'',-I' ~ O
d- O O ~ O ~ O O O O O
7., O O ~ ~ O ~ O
N t~ ~ N O ~t O ~ N N ~t ~t M M 01 ~O ~i 00 ~ V~ O\ O [~ l0 M 01 ~ O ~O ~t N ~n O o0 Ei N N ~-~ N v~ ~t M ~-~ N N 'dwt w m m m m vmn v~ m fn m m b b b b ~ b b b b b b U U U U U U U U U U U U
cd cG ict at cG cU cC ai a! cC cd cd '~,~' O O O O O O O O O O O O
d U
G1.
O

'~
d M
U

'"a w U
a ~ a ~ ~ ~ a a t~.7 ~ ~ ~ ~' a a ~ a c~7 ~ ~ ~ ~ w ~ ~ w w a~ a~ a a ~ A
~ o,a~.~ o,~ Ha ~ ~~ °> ~~ aU a~ a a a~
as a'' U w U v~ U p~ U p~ U ~ ~ ~ rn ~ ~ ~ a ~ a ~ ,'~~', ~ d ~, v~c~ ~ ~~ ~a ~a ~a a w ~xa ~x~ ~~ ~x~ ~xa ~ ~w ~~ ~w ~w -, .-, .-. .-. w ' ' ' ' U .~ .-~ M M M
O O O ~ ~ 'wU Cw"J Cw.7 C.w7 Cw7 z ~Z°
O O O O O O N O O O O O
av M ~ v, M o r, a, ao ~ ov 0 0 ~o ~ ~O ~ ~ ~ M ~ ~ t~
C M M .--~ .-~ .~ .-~ N .-.-~ O
i ~ n ~ ~ N ~i Nt~l~Vlt~cn.~OOo O 01 ~ h v1 V7 'G ~O M ~O l~ ~ i' Ei 'M N .~ .-~ .-, .-~ ' V .~ N .~ N .-~ N
w m m~ v~ v~ cc3 m m m m m w b b b b b b ~ ~ b b b b ~" .-~ ~ .-, ., ,~ .~ O .-n ., ,-n ,-n ,-n U U U U U U U U U U U U
cd c~ c0 c~ at c~f ~ cd c~3 cd at cd ai ~', O O O O O O ~ O O O O O O
U b N

z ~, a M
,..., U
-, w M
U

w d a A
a a a >a U
H
a~ ~ ~ A"; ~ d ~ ~ C7 w A q a ~ ~~ ~ ~ ~ C7 .,c~n~~ ~ wC~.7~aA.,~ ~> a a H~ ~~ ~~ a~ w~ a~
U ~ ((~~ ~ U U U z ra ~ ~ w ~ rJ ~, w ~~~~ai~a~x~zw~p'p~Ca~.7a~,~~w~~
~H ~w ~~ as ~~ ~a ~'A ~~ ~'o, q~ a~
~ r U U U C7 U ~ U J'' U U ~ U ~1 U ~ U ~ U ~ U ~
wa w~ wo, ww w~
~w v~ ~ ~ ~ v~
N O
N cad ~ N E E E
p ~ x -~ ~ ~~ ~ .~ Q,' O O O
O O y~ O~" O O
cd L~7 ~ q ri- o o ~, ~ ~ ~ ~'u 0 0 ~ o o ~ ~ p ~ p O N t ~, \O N M M O N ~ ~ ~ '; N cV
,~ .--~ ~ ~ i ~ l0 ~ 00 ~ d' 01 O
"''NN~OVO
E"i ~ .--~ N V~ due' m .~-~ O o0 N N
b ~ b ~ b b b b ~ b b b U U U U U U U
cat cV N c~ at tai cC cV ~ cG c~
'~", O O O O O O O O O O O O
d O
Y
w d M
U

m a w ~ ;~ a d a ~ ~' p~ H ~ aH-~ ~ w C7 w w H ~' a ~ ~ H ~ H ~ ~ ~ a A ~ ~ ~' a ~ a ~ ~~ °> ~;~
°~ ~ ~ ~ a ~ w U ~~ ~p~
vi U a ~ ~ w U P., U ~ H ~ vs H ~ W
H~ ~~' w~ ~~ °~r~ °~~ ~aU-~ ~ w~ ~~ w~
~, ~ ~ ~ ~ ~ a ~w >w >w ~w ~a as a~ ~~ a Ua Ua Ua Ua a w a ,~ a ~., w w H a.~ H w H w H
° a ~ a ran a ~ "~ ~ m U ra U O' H U ~ ~, a'' ~ a ~ w > w > v~ > p~ > O~ > ~ p~ ~ v~ r~
aU.,~ aU,c7 aU.~,.w~ w~ aU.~~ w~ aU.,~ ~ ~~ ~w ~a a w~ w~ w~ wa ~O~ ~ Hw Hen Hw Hw m .-~ W
P.~ ~ ~ W ~° O O O O 'U ,.-~ .wn m r i i O ~ w v~ ~ ~ ~ w W W w W W w w U O_ O_ w w ~ ~ ~ ~, 0 0 0 0 0 0 0 o N o 0 0 0 V1 01 M t~ V7 M O .~ 01 00 ~O 01 00 O O v0 ~C ~ ~ 00 ~ N .-~~ N
~I,' d' m M ~ ~ ~ i N ~ i i lW0 .~ N l~ h V 1 Iwn .-~ O 00 N t~ O OW 1 ~n V7 V7 b v0 M v0 l~
H d' d' M N .--~ .~ ~ .--~ V .-~ N ~ N
cwn m fn v~ m m m at wn m y b ~ ~ ~ b b b b ~ b b b b U U U U U U U U U U U U
CG cd cG cct cG cd ttl c~ ' ccf cV cd c~
N
O
.'., ~. a ~
w M ?_ v °a E-~ H

A
a A
a a H
a A r~r~ d a. w~ o'~ d a ~, ~ H
~~ a~ w~
ah.,'' PU-~ d U ~ ~ U ~ PU-i U ~ P.~ U ~ ~ ~ ~ '~ ~ P-i ~w aa~ ~ z~ ~w a,~ x~' ~ ~~, ~ aw a a w~' as A a a~ a~ z~ ~o, ~~' ~~x P., o a ~w ~ ~w ~a ~~ ~w ~w ~~' ~~ ~~x U E-~ U a U W U a U E'' U W U a U U p'' U ~1 U W U F'' a,~ a.~H a.~,~ a.~ w~ wa a.~H w~ w~ ww a,a w>
~x ~H ~~ ~w ~~ ~q ~a °
w wn a r~ m r~ ~ ra ~ zn ~ v~ ~ cn d v~ yn ~
~A ~~ ~w ~a ~~' ~"" ~C7 W H ~ H ~ H ~ H r~'n H q H ~ H ~ Ea-~ d H O° H A H ~ H
d w U U H
M ~n v~
W c~ N E
N °' s~ ~ . ° .~ ~, .~ ';; o W!=1 W't+ ~ °.~ o c7 ~ ~i .~ .~, ~ ~, -w o °
A
Pa C7 ~ ~U", °- ~ o .~~' o ~ o ,. '~° ~, w o 0 0 ~ o ~ o O O O N l~ 0 N O d' O
O ~o N m m t d' ~-, ~i ~~ M Ov ~ O ~O '~t N h N O~ .-~ N N '-i N ~n d' m b b b ~~ b ~ b b b b ~C b .w " " .-, " 'r N .-n N .H N H
""w U U U U U U U U U U U U
c~ cd c~ cd cd at of c~ c~ N cG cd ~., O O O O O O O O O O O O
O
b Qi M
U

a a v H ~ ~ a ~ a a H
H
a ~ a d w A ~ ~ ~~ a ~ ate, "> > ~ ~ a ~ w v .,~ .,o' ~ U
Uw ~ ~ w U ~ a~ ~~ dU ~ U
ww ~~ Nab. ~~ ~~ ~~ H~ Hw ~w a~ w~ A
a. ~~ ~ a~ w ~~ a ~W ~~x ~'~x _~, ~W ~W ~~ ~ ~a ~a ~~ ~a ~a a ~ U ~ U ~ ~ U
~w ~w ~v~
yn w r~ ~ ra r~ v~ v~ w v~ rn H v~ E., ~ ~ E-~
w~ ww wA w~ w~ w~ wa wa w~ a w H~ H~ Ha H~ Ha H~ H~ H~ Ha ;b M
W E E E E ~ ~ ~' 'i.'OO OO
O O O O O
~ g'u ~''u ~''n g"n w 'y w ~ ~ ~..~ w w ~ ~+.~ ~ ~ ov 0 0 0 0 0 0 0 0 0 o N
ono ~ ono 0 0 ° r, ,..-~ r, oN', o ~ ~ ,m-,' N ~ ~ ~n t~ v 0 00 ~n ~ o o, ~n ~n ~n ~n b E~ cV cV ~t d' m N ~-, .--~ ,-, b b b b b b b b b ~: _ N cUd ~ ~ N ~ cad ~ c~G
O O O O O O O O O O
W .
d °
ar a~
a~
P~
~n M
U

a a H x d ~~ ~ a ~ ~ ~~ ~ arm., ~ ~ a w U a ~ a U ~-'a., PU-~ d U ~; ~ H U ~ pU.., tn ~ U ~ w U
a, ~ w ~ ~., ~ w~ L7 a~. a w ~ ~ ~ ran ~ ~ aU.i a ~ ~ a'' H~ w~ ~~ ~, ~,~ ~~ ~ x~
a a d~ ~~ a~ ~~ ~~ ~~ a~~.,~ ~ ~~ a ~w >W >~ ~w ~W ~w ~~ >w ~a >~ ~w >w U ~l U a U w U ~ U ~ U a U w U a U ~' U w U a U a P.r P-. E-i P..i ~, w P, W P-i E-~ P-r ,~ P-r E-i w W w a w E'' w H
~W ~~ ~~ ~~ ~w v~ r~ v~ ~ vi Z v~ ~ rn z m U r~ vs vs ~n c~ r~ z v~
w w w w w w w w w w w w o a a a a a as a a~ a a a a w Hue, H H~ Ha Ha H~ H~ H H~ H~ ~c~ Hw w w~ w w wx w w~ w w w w w c~x ~ ~~ t~~ c~~ ~a c~ c~ ~~ c~~ c~a c~~
z~ zW z~ z~, zw z~ z~ z zx z~ z> z~
b w m m c~~ °' W W W W W N
w w w L] C~ ~ ~ V
O O O O O ~ ~ ~ n- O O
Fa ~ M ~ ~ l~ 4"~ 4-.~ O O O
N .-, N '-, O O p N l 0 N
~ O oo .-~ I
m ~ t~ ~ ~ m o~ °~ o [-i .-i N ~ N .-~ N ~ .~ N N ~-~ N
~, ~n v~ m v~ m fn m m wn m m y, b b b b b b b b 'z7 b b b ~.-n ..u ." ...-n .-~ ., ...n -.w ..r U U U U U U U U U U U U
cC cct c~3 4i c~i c~ at a3 cC of aS c~
~., O O O O O O O O O O O O
U
N
°' z° ~
°' z H
°' w ~a ø, o W
°
~ ~_ ~
M ,' U
m O~' ~ U

A
w d a a a a a H
w > d ~ w H a w a ~ A ~ ~ a c7~ ~~ ~ >~ ~~ ~~ ~~ ~ a~ a~ a a U w U
A .,~ ~°~ w a ~ ~ ~ U~ U ~ w dw dU
A ~ ~ U ~ ~ ~ ~ a, H w ~ E-~ ~ E-~
aw o°a da, ~w ~ a~ aw aw ~~ a ~a ~z ~~ ~~ ~~ ~~ ~w ~a ~a ~~ ~H >H >w U ~ U U W U U w U a U H U H U w U w U w U a w a.~ a~ w w a.~ a w H a, w w w a~ a w ~ w U w E-~
~w ~z ~W ~~ ~z ~z ~n ~ rn ~1 v~ U ~ rn v~ C7 r~ ~ v~ ~ v~ ~ v~ r~ ~n v~ ~
~. ~w ~a ~~ ~
wc~ w~, w w w w w w w wa wa w ° Ha HA H~ ~~' H H~ H~ H~ H H~ H~
w w~ w'~' w~ w w~" wH wa ww ww w~ wo' W
p7 ~ c7 ~ c7 ~ c7 ~ c7 w c7 ~ ~7 ~ t~ ~ ~ a c7 ~ c7 H c7 ~' ~a ~ ~~ ~a ~~ ~~ r~n~
W ~a ~A ~~ ~~ ~~ ~~ ~~ ~> ~~ ~~ ~~ ~~
...
~, ° H ~ ~ ~ ~ 0 0 w ~, ~ ~ ~ ~ ~ ~ ~ w '°
0 0 0 0 o w o ,~ o ~ 0 0 0 0 0 ~ ~ , , ~ o .~ ~ ~ ~ ~ ~ ~''n w ~ Z
' o ~ 0 0 0 0 0 0 0 0 0 ~,o~ o~~o°°o~o'~'ooo ° O d~ O .~ N N ~t ~t M m y. , , , , , , , , , 00 , et Ov O tWD .--~ N I t~
to wt N ~n O oo ~n t~ O oW ~n H ~n ~t cn .--, N N d' d' cn N .-m., vwn [n fn m cn vmn m cw on b b b b b b ~ b ~ b b b ..-n .1 .-, " H .r .-n ~ ..-n H
""~ U U U U U U U U U U U U
at N c~ cd cc3 N cd cd N cG cV cd .
a>
a.

w a~
.,., W
M
U

a H

a~ a~ H~ ~~ v a U ~ U U a U '~ U x; P., ~ U ~"' ~ U ~ P., U
~ a~
a~ wW
~ ~'~ ~~ ~w ~,a >w >~ >w a~,..w..t U,w-1U,..w..lUaUaUHUaHUwUaUE"'Uw F P, E-~ P-i E-~ P, ~., P~ E"' w W w w w E-~ w w w a o'~x ~ ~~ ~~ ~~ ~~ ~~ ~~ ~w ~ w cn v~ rn m Z rn ~ cs~ Z rn ~ v~ Z rn ~ v~ C7 w ~z a a a a a~ a a~ a a~ a a ra ~ ~, d E.., ~ E-, d H ~ E-~ ~ F' ~ E-~ H ~ E-~ '~ E-~ d o ~ w~ w~ w~ w~ wa w~ w~ w(~ wa w c~a c~a c~ c~a ~ c~a t~~ ~a c~ c~~
w~ w z~ zA za zP z~ zq za z~ z~ za Pa H ~ d '~ ~ '~' '~ ~ '~ a '~ ~ cn ~ ~n ~ cn r~ ~ v~ A
z~ H ~H ~W ~~ ~~ ~~ ~> ~~ ~ ~x W~q, W~ WP ~ W~ W~ W~ WA
w ~' d~ AwAc~n~~~wA~~~~~A~Ad W
M
, ~," .-, .-. w a; ~ , 0 o~w, ~~w, ~ tw7 ~ tw7 eW7 Cw7 w y a ~ ~ ~ ~ ~ ~ U
d d ~ U C2 0 o N o 0 0 0 0 ~ U
o ~ ~ oMO ~ o~, ~ <,-m+, 0 0 0 O ,~ .~-~ N .-, N .-yy ,~ O O p N l~
, , _, , , _, , ,~ ~ b ~O pM ~D I~ ~ O ~ ~.~ n1 Q1 v .-i N .-a N ~ N Ov .-~ N N
b b O 'C b 'C b ;b 'd 'd ,'b :b U U .~ U U U U U U U U U U
CV tc3 n~ C~ CG CG al cd Cd cd cd CG
N [~
zw w ~ w a b W .-' ~ U
~ w W
U
Aaz A
a a A
a a w ~ ~ ~ ~ ~ ~ ~ ~ w cw7 w p., d U w a, a a ~w ~~ ~ o' C7 ~ w cn ~" > ~ A ° ~ ~ ~ ~ aa, w ~ a m ~ ~ ~~ dU d ~ ~ U ~ U a ~ aU, ~ aU., U ~ ~ ~' ~ w ~ U E-~ U a w rw w w o'w ~~ ~~ ~~' ~~ H~
a~ '~~ zw ~~ ~~ ~~x ~w ~w ~z ~~ >~x ~a ~~ ~w U a U ~1 U ~ U U W U W U w U a U H U E-~ U a U w w H w w w a, a a., w a w (-~ P-~ w P.~ W w w U
~w vi ~ r~ Z r~ ~ v~ d v~ ~ r~ v~ vi C7 m Z v~ ~ r~ ~ vi v~
~x ~x x~ a ~ A ~x ~ ~ ~ ~x ~ ~x ~x ~x a~ a~ a~ wo~ w a~ a~ a~ wd ~~ a~ a~
~w o w~ w~ wo' wv~ w~ wa ww w~ wa wa w w a c~ a c~ w c~ A e~ ~ ~ c~ ~ c~ a c~ A c~ c~ ~ ~
za zA z~ z~ za z~ za zr~ z z~ z z v~ a v~ w vi a vi A v~ A v~ O' vi ~ rn ~ v~ ~ vi v~ ~n q rn ~;
~w ~~ ~~ ~~~., ~a ~a~.~
c. ~ a ~d ~c~
wa ww ~, ~ w wO' w w~ w w~ wc7 ~a ~~ ~ ~ ~~ ~ ~w w ~~ A~ Ao~ AA a~ a~ a~ ~~ as a> ~a A
U U U
W ~ y ~ E E E E E W
Ci .~ ~ .~ ~' O O O O O Ur O ,~ p ~ O~ O O O O
O N
~~ m O ~ O ~ O O O O O O O
4~ 4~
O W '-~ o ~O W D '."~ oo ~O o~0 O O
CVOd'O.~,CVCV~'d'MM
~O ~ 00 W d- O\ O l~ ~D .~ N
o wd- N ~n o 00 ~ ~ o o, .-~ N ~1 d- M ~ N N V' d' M N
fn v~ vm vwn cwn m vwn m b b b b b b b b b b b b a .-n ~,--n ~.~ .~ .-n .~ ,-n .r ,-m-~
U U U U U U U U U U U U
c~ c~ cd of cd cd ai N c~ ai cat c~
'~", O O O O O O O O O O O O
U
C1.
O
.,., CL
U
b U
M
U

a a ~ ~ E-~
U ~ ~ ~ w ~ ~' O' ~ ~ w U E-~ ~ E-~ W
'~' d ~ j a ~ ~ a, H
a ~ w ~'~ ~~ av a~ xPU., dU ~~ ~U
w~ .,~ .,d ~ ~~'' ~w ~~,., ~~ c7~ a~ ~U~ ~w ate' a~
a~ ~w ~a Va ~a ~~ ~H ~a ~w ~
a a a w a, E-~ w E-~ a~ E., w a.~ w a.~ H a, a a.~
UW Uw aW ~ ~z ~z ~z ~~ ~~ ~z ~~ ~z w~ w~ w~ a~ ad a~ w ~'i' d Hd Hd E-aid E1 W H'~"~
w(~ w~ ww wa wa w~ ~d ~a w~ w~ a~ A za za za z z~ z z~ z a "~'~ d H d FJ~ rry rry vy vn v~ ~ v~ ~ v~ ~ vy a Q, ~ ~ ~ ~ czn ~ ~ d ~ d w d ~ ~ ~ d '~.W~' d ~ d ~ d H
a a ~H ~ ~ ~~ ~~ a~ a~ a~ a~ a~ ~
oa as as as a ~d ~d ~> ~a W ~1 ea ~1 v~ f~ O' v~ a. w a, v~ a, w w w ~ ~ a~-~ ~ a~.~ ~ a~.~ ~
"C1 M
w C7 C7 C7 C7 ~ N W
~Z Z ~°
O O O O N O O O O O
twn M o ~ o~ oo ~o ov ~ ~,_, w o ~O ~O ~O t~ 00 ~D M t~ t~ l~ O O
-~ ~ .~ N .-, N r" N '-' p ~O
i _i ~ i _i h ~ ~ b v0 o v0 l~ ~O ri [-r .-~ .-, .--i ~ V .-, N .-, N .-~ N Ov m vmn v~ cd w fw wn mo m v~
y" ~1 b b ~f o :G :d 'U ~ b b 'd b U U U U U U U U U U U U
ai cd cd N ' c~ cG ca cB cd N cC cd O O O O O. O O O O O O O
W .~ . . . ~
N E'~
ow z~
a~
~xU
m a U 'w a~~a a w w a a w~ ~ ~ o~
a w a ~" vi a ~ ~ H H
w ~ ~ ~ r~ ~ O' ~ c~.7 L7 w A a a.. dU w w ~ ~ A
~~~ as ~~ a~ a~,~ ~ >~ a a a ~Uw v'U ~~ wU d~ ~~ "'~~ ~w r~n~ HU ~~ waU, w ~ ~ w a ~ a, ~ ~ a w C7 aU, ~, ~ w ~ ~~., a'' d ~ C7 x ~~ ~~, ~~ aw a a ~ H~
w ~ a ~ ~ "-' a a~ w~ Zw ~~ ~~ ~ a~ w~
~w ~ ~ H~ ~~ ~~ qW aw >a >~ ~w >w az ~z >~ ~w ~ a UE' Uw Ua U~-1 U~ U~ U W UW Uw Ua U~ U
P-i w ~ Pa a P, E"' P1 E~ w P~ pi ~ p1 ,~. P.~
~w ~z ~w z w~ w w~ w w wax w a~ a~ ad a~ a~ aw a aW a~ a~ a~ a~
N Er~" Ei ~ E--~ w E-~ ~ E-~ E-~ ~., H ~ E-~ ~ E-~ ~ H d E-~ E-1 wa w w~ w(~ w~ wa, w~ wa ww w~ w~ wa L7 C7 ~ C~ ~ t7 a C7 P, C7 (~ C7 ~ C7 z~x za z zq z~ za za z~
~w ~a ~~ ~~ ~~ ~~x ~~x ~w ~w a ~ ~ ~ ~ ~ d ~ ~ ~ ~ ~ w U ~ ~~, ~~ ~ a ~~ ~~ d~
a~ a~ as ax a~ as act as aw a~ a~ a~
~ ~A ~~ ~a, ~a ~~ ~~ ~~ ~p~ ~a~.~
wa wa w~ ~ w w~ w ww wA
a ~w ~ ~~ ~~' ~H ~q ~~ ~a ~a W w ~ a, v~ w ~ w ~ w O' a.~ L-1 w 'h'~ w ~ a, ~ a, w a a, ~
..
H
E
o a, -~ ~ .~ ~ 0 0 0 0 0 .~ 0 0 0 0 0 .~'o.~~ ~ng'u~'ng'ug'n ° o ~' o ~ o 0 0 0 0 i.. O O ~ d' p N 4'' N l 00 ~O V'1 O 4-~ ,~ O ~ r-' 00 ~O o0 m M O N O ~ ~ N N dwt H N N ~ O v0 ~t N ~ O
N ~n ~t cn .-~ N N d' vwn m fn m v~ fn wn vwn m ~ b b b b b ~ b b ~ b b N ~ ~ cUC cUd ~ N ~ cUG
''.,000000000000 W
O
O
'L3 P~I
M
M

>. ~ a Cx7~x~.a, a a x H W ~ w a > ~ ~ w a a ~ ~ ~ ~' w ~~ ~ ~~ ~
d ~ ~~ a~ ~~ a~ a~ ~U
C7 ~ ~' xaU..~ ~w aU w Cx7 aw rn a ~ > :~ P..
d a ~ w U ~rn ~p' ~w Va.~ U> H~ m ~ ~ ~~ a w~ ~~ a~ a~ ~~ ~ ~w ~W ~~ ~w ~a ~w a w ~~ ~~ ~w ~Cw7 ~z ~tw7 a ~ Ea'' ~ Z ~ z ~ O ~ z ~ v~ ~ z w ~, ~, ~ v~ v~
H ~w ~w w z ~H ~~ ~~ ~w a~,w ~ a~ a~ a~ w~ a~ a z a a~ a~ w~ a~ a~
wd wa wa w~ wW ~ ~w w ~w ~w ~cw7 ~w t7~ ~~ c~~ c~a ~a ~ ~c~ ~ W~ W~ W~ Wc~
z z z z z w c. ~'~ ~'~ ~'~ ~'~ ~'~ ~ az az aZ aW aw aW
~a ~~ ~~ a ~~ ~~ ~w U U H U ~ ~ ~ ~ ~ ~ ~ a a d ~, ~ a ~ ~ ~, ~, rs~ as ~ a, as a a, x ai ~
r-~T-w (~~ ~F, ~H ~ ~, wx w w~ w w~ wa 3 ~H ~w z~ z~ z~ z~ zq z~
~v' ~a ~a ~a a w~ w~ W~ w~ w~ w W wa a.~~ a.av~ wv~ a.~o' tn ~w ~v~ ~w ~w ;b M
Q, ~ ~ ~ ~ W
'° O O O O ~ '-' '-' cn cn m Pi W
WWWWW~'U'U'U'U'U
z z ~~° ~ Z
w O O O O O O N O O O O o o~ m ~ ~n m o r, o~ oo ~ o~
i.' O O ~O ~D ~O l~ 00 ~O M l~ l~ l~
cn cn .-m, .--a ,-~ N .-. N ..-~ N ,-~ O
i ~ ~ ~ ~ n ~ ~ r ~ ~ O
N l~ I~ ~n tWn .~ O 00 .--W~
O 01 V7 ~n ~n ~n b ~D M v0 (~ ~O 'i E~~ M N .-~ .-~ .-~ .-~ V .-~ N ,-a N ..-~ N
P, ~n m w cn m m cct v~ m m ~ v~ 'n cn y" b b b b 'C b o b ~ b b b b U U U U U U U U U U U U
cct cG cd cd cd cG ' cd c~ c~ cd c~ cd .~', O O O O O O ~ O O O O O O
N

~w~
o ~ w cn w ~, r" C7 U

a A
a E-~ ~ U w a r~ d w U aw ~ O°
a a ~'w .,~ ~~ ~' a U ~ aU.~ ~ ~ U ~ w V
~ P.~ w Z ~ O' W ~ ~ ~ ~ ~ U
P, r'~ x~ ~, ~~ ~~ aw a °'~' a ~w ~ ~w ~W >~ ~w ~w ~z U W U ~-1 U ~ U w U ~ U a U ~ U ~ U W U W U W
a.. a w E-~ w w a~ a w w E-~ a. w w w w a ~w ~~ ~~ ~W ~~ ~~ ~~ ~ ~w ~z v~ ~ vi z v~ ~ r~ c7 m Z ~n z v~ vi ~ rr~ ~ r~ v~ v~ C7 ~x ~ ~x W Wa W~ w w~ w a a~ a~ a~ a~ a~ a~ aw ~ a~
N~ H~ H~ H~ HW H~ Nw H~ ~~ ~~ H~
wd w~ wa w w~ w~ w~, ww w~ wa w c~W ~a t~ ~~ c~a tea caw ~w caw c~~
za zq z~ za z~ z~ zw z~ za z za ~z ~z rp"'=., ~Cw7 ~~ ~w ~w ~W ~~ ~~ ~Cw.7 ~a~.., ~ d ~ ~ w ~ C7 ~ ~ d ~ ~ A ~ w ~ c7 ~ w ~7 ~ z az aW ~w ~w ~w ~W ~a ~~ ~z ~w ~w w A
p"' a, w a, w '~ w U w w p"' as ~ as a, w w w w~ w~ w~ w~ w~ wA w~ w~ w~
C7 ~ c7 c7 v~ C7 ~ c7 p7 x C7 z c7 d C7 c~ C7 c7 w c~x c~~ ~ c~~ c~a c~aa c~~ c~°~
z~ z~ z~ zr~ z~ z~, z ~ z~w z z za w ~~ ~~ ~~ ~~ ~~ ~~ ~a°' ~~~
C, t_.
y N N
N ~ U ~ w w t~
.~ U .~ ~ y ~ p_ O_ CW7~~.~~~~ .~ ~~~''n f~, C~.7 ~ U ei o w 4-., s, w o 0 0 ~; o ~ o 0 N ~ O N O et O ~ N
l0 N m M ~ ~ l ~ pp ~, cf' Ov (-1 O~ .~-~ N N ~-~ ON ~1 due' M V1 O
y, b b b b b b 'd b b b b U U U U U U U U U U U
at at cd ai c~ cG cd cd N c~ c~
~, O ~ O O O O O ~ ~ O O O
.~ ..

a, M

a a w a x x w a ~ d U H ~ ate., ~ w > d ~ w ~ ~ a ~ ~ A
A ~ ~ ~' ~a ~ ~ v ~~ ~~ aU
w U .,~ .,d ~ H ~ W
aU w ~ w ~ ~ w d a, ~ U ~ U ~ a., ~ a, v~
~ H~ ~
w~ A~ ~~ ~ ~~ a~ ~~ ~~ ~ ~H ~~ ~H
a~ a~ aW
W >a ~aa ~~ ~H >H >w >W
Ua UH UH U~ UW Uw Ua Ua ~ ~~ ~~, a, H w W a.. W w F, w ~ a, ~ w E~ w H
~z ~z w~
~x ~ ~x ~ a c7a ~7a c~a w w w w w~ w~ w w z z z a~ a~ a~ a~ a~ a~ a a~
Wa Wa W~ W~ w w C~ ~ C7 a C7 L7 ~ C7 ~ C7 ~ C7 a C7 a ~ ~ ate, w z z~ z~x z z z z z w w w w d c~
w a-~ w w ~ ~ ~ a z a ~ a z ~c~ ~c~ ~w ~w w w w w z aW ~w az Wa Ww ~~ ~~ w C~7a C~7a C~7a ~U ~U ~~ U Z~ z z~
w H w a a., w w w w v~ w o' w O' w d w ~ w ~ w a w~ wH w~ ww w~ wH wH w~ H
Cv C7 p_, C7 ~ C7 C7 C7 a C7 ~ C7 ~ C7 ~ C7 ~ ~ ~ C7 ~~,, C7 ~ C7 H t~ ~ c7 ~ c7 ~ c7 ~ C7 ~ c7 a ~ ~ ~ ~ ~ ~ w w z~, z~ z~ z z z z~ za ~, ww wa w~ w w~" wa wa w~ a a a a ~ ~ a a a a~ ~~ ~~ a w ~~ ~xa ~x> ~xa ~x~ ~~ ~x~ ~a ~> w ~ w ~C M
i t~. ~ ~ ~ .-. .-~ .-, .-. w C O O p '~ w ~ ~ ~ o ~'~ fil W W
0 0 0 0_ z ~ z~°
w ~ ~ ~ ~ ~~ ~, 0 0 0 0 0 0 0 0 o N o 0 0 00 ~ ~n o~ M mn M o ,-~ o, o0 O 00 ~D 00 O O ~O ~O ~O t~ ap ~O M I~
N d' Wit' M M .-i .-, ..-i .-~ N .-i CV
i i ~ i i ~ i i i i O l~ ~ ~--~ N l~ t~ ~ t~ v~ .--~ ~ O o0 00 ~!1 l~ O O\ ~ .-v'y ~-~r H N d' d' M N U
,7., fn m cn m wn m vwn cW n m m y" b b b b b b b ~ b o b b b U U U U U U U U U U U U
a c~ cd N c~ c~ c~S N cG ai c~ cd cd ~"' O O O O O O O ~ O O ~O O O
Zw~
o ~'' W
~a.~ ~ w H
~ ~ cw7 o a ~
M
~ U
V ~ j ~ a, W

~a~
ao°a ~

a x ~ H ~ ~ w a a ~ ~ ~ a a a, ~ ~ ~, c~ ~ ~ a;
c7 ~ ~ rn d ~ w av~,~Aawda~
aU a~ Hj ~~ ~ a~ w~
rri ~ U U
a U x w d U ~; ~ U ~ w U ~ w ~ U
w ~ a ~, U Pa C7 P~ ~ w w~ ~~ ~~ ~ ~~ r~"~ ~~ ~~ a w a ~w ~w >w ~~ ?w ~a >~ ~w ~w > z Ua Uw Uv-1 U~' Uw U~ U~-1 U
ate., w ~ ~ a.. W a, N ~, W w ~ a, -~-~ w w w W as ~t~ ~z ~w ~z ~~ ~c~ ~z ~z ~ d w a w w w w w w w a~ ad a~ a a~ ad a~ ~ a~ a Hd Hf~ Hd H~ HW H~ Hd ~~ Hd H w w~3 wa w~ wd w~ wa w w~ w[~ w t7 a ~ c~ a c~ ~ ~ a ~ c~ ~ c~ a c~ a c~ w z~ z~ z~ za zq z~ za z~ zq z w vow v~~ ~w ~~ ~q~ v~ ~w ~tw.7 ~w ~~ ~w ~cw7 ~~ ~~ ~w ~ w d c5 d ~ d c7 d ~., d ~ d ~ d w d C7 d ~ d ~ ~z (~~ ~c~ ~c~ t~z az aw az a~ az aw a~ az a~ a ~x~ ~x~ ~~ ~w ~x~ ~~ ~xW ~x~ ~~ ~ a ~' ~F~ ~~' ~~ ~~ ~~ ~~ ~'~' a, a~ ~ a~ w ~ a, cn as ~ w w a, ~ a, ~ w d o w wa w w w wa w~ w w w ~., t7a ~ c~a ~~ ~a c~ tea ~a c~a c~
c~ c~ ~ ~ c~ a c~ ~ ~ ~ c~ ~ c~
w za za zd z z~ zw~ z~ z ; zw z ~'~
~, w wx wa w~ w w~ w~ w~, w w ~c~ ~a ~~ ~ ~a~
o, cn ~' v~ A v~ v~ v~ r~ ~ r~ v~ v~ ~ v~ r~ a c7 bC r~-1 a ~ W ~ ~ ~ ~, ~ 0., ~ ~, ~ ,Sa., i-~-1 a ~~-1 w W w ~ d ~ vi d ~ ~ d O'z m m o wU" wU" N , dd ~Lw7~ ~ '~ o Cw.7 Cw.7 ~ ~ .~ .~' o d d ~, o o ~ ~ ~ ~ n- ~ o 4.. 0 0 0 ;~ o r, O O p N l~ ~ N O
O ~O CV M M ~ ~ I~
H N ~° ~ ~ .-~ M o~ ~ O ~fl .-a N Ov ~ N N ~-~ N V'1 '~' b b b b b b b b b b iw V
cOG N
'~", O O O O O O ~ O O O
d d G1.
O
r d 'b w A, N
M
U

a d d ~ t~7 L7 w w H
H a w A a ~P ~ a A ~' ~ ,..~ a ~ a a a r~r~~ E~-'~ ~~U wU~ w> ~ ~ d U
A ~ U ~ U cn U P, w d w~
r~ U W ~ Ea- U W ~ W U fa-' ~ ~ W
~w ~ ~ ~W ~W
w ~z ~ ~ ~z ~~ ~~ ~~ ~z w ~ w~ w a ~, a~ a a~ a~ ~ a~ a~ a ~ a H~ H~ ~~ H~ H~ H f~ H
a w wW w wa w w a w c7 w c7 f~ c7 t7 ~ c~ a c7 a ~7 c7 ~ C7 c7 ''~
z ~ za z ~ za zq z~ z~ za z ~ z ~a~..~ ~w w w ~ w ~ ~ w ~ w ~ w ~
z ~~ ~c~ ~z ~lz t~~ ~ z t~ z ~x a ~w ~ ~x ~W ~w w ~ w w ~ w w~ w~, w~
w a, ~ a.~ as w a, w w a~ w a w a o w ~ w w a w~ w~ wa wa w~ w w ~ c~ ~ c~ a ~ ~ c~ ~ c~
w~ ~a ~ ~ ~~~ ~ c~ ~~ ~"~ ~ a c~ ~~
w° z A~ za z a z~ z~ z~ zw za z ~ z ~, W q W w W ~ w H w a W ~ W w W v~ w p O'a~,~C7~ ~~w o, v~ a ~1 rry-1 v~ U m j v~ t7 m E-~ r~ ~ v~ v1 rs~ v~
~ > ~ ~ A ~ W ~ A ~ ~ ~ ~ ~ ~ ~ a W a Aa a~ a ~ aH a~ as a~ as a ~ a ,a a ~, Or E ~ ~ ~ ~ ~ ."~
Pi ~ E E E E E W
0 0 0 ~O o o_ o_ o_ _o _O

° ~ ~ ono ~ o~0 0 0 ~t O .-n N N 'd' ~t M M
d' 01 O I~ ~D .-~ ' v p N h EiV~' M ~ NON~~oMN .
b b b b b b b ~b ~"., O O O O O O O O O O
d CL
O
.a O
b ~4 O
M
U

A ~ w ~ w a O' ~ ~ > > w w a U x ~ ~ ~' ~ ~ a a a ~"
a~ ~>o° ~ ~ ~ ~ ~ ~ ~ a ~ w a ~ a > a ~ a ~ H
~' w ~ w ~ w ~ W ~ w a~w a~w w ~ w ~ w ~ w ~ w w W W W a a ~ a c~ a w w a r-~~~. c.~7 w t~7 f~ ~ f~ ~ ~3 z ~w ~W ~ ~ ~ ~ a a w w w ~ w ~ w ~ w w a, w o, w ~' ~ H~ ~ w ~ ~ ~ ~~ ~ Ax ~ w a ~ ~ ~ w v~ ~ C7 ~ a.a ~ ~ C7 a x ~ ~x ~ ~~ ~ ~a ~ ~~ w ~e as as ax w ~c~ w ~w w >x w a w w~
W rr~ o' v~ a w w H w v~ w w w c7 w w ~ w M
.-~ .~ W

.--i ~ M M M
i 1 1 I 1 IU ~ L7 C7 z z z ,°
0 oN o 0 0 0 0 in M o r-. o~ oo ~ oWo ~O ~O l~ 00 ~O M l~ l~ t~
.-1 .-r .--n N .~ N .-n N .~

1~ i 1 b v0 OM ~ t~
H .-~ .--~ .-i ~ .-, N .~ N .--1 p., vwn m c~ rn m w (wn b :'d b O ~d 'd a7 'd 'd i.
.., ... .~. ..a cOG ~ ~ ' cVV cOG
~", O O O ~ O O ~ O O O
N w [~
~w~
c. d ~ d w~~~
~ w ~ U
b o ~ ~ a.
~a~~
~a~
~w~w wwwa q a w ~ > U i~ ~ >
H v ~ w ~ v v U w r~~aU, v~~~AU'~r~a~~n a > a ~ > a > ~ ~ w ~ a ~ a U
p., W pU.., pU., ~W per., ~ pU., E'~-~ PU..i W P~-i W
C7 w C7 C7 w ~ ~ ~ ~ ~ z a ~ a a ~ w W a ~ a ~ w w ~ w ~ w a w a w ~ w ~ w a w ~ Cw.7 ~ ~ ~ ~ w d ~ ~ w ~ c7 W L7 w ~x z ~x w a ~x ~ z ~ w ~ w w ~ ~x ~ ~ ~ ~ ~ ~ ~ ~x w ~ w ~ w ~ w ~ w ~ w c7 z ~ z ~ z ~ z ~ z ~ z ~ z w ~ (~ ~ w ~ ~ ~ w ~ w ~ w w w a w t~ ~ c7 ~ c"~ ~ C7 ~ ~ c7 ~ c7 ~ a t7 ~ w G'" ~ ~ ~ ~ ~ ~ ~ w ~ ~ ~ ~ ~1 ~ U ~ a,, w ~'~ w w a w ~x w ~~ w as w w W w d~ w ~ w v~~ w dw wnc7 w ~~ w a.
a~
N

R~1 Pa (] ~ C2 O O
J., 4-a 4-~ O O O
O O O c,.., O_ vp N M M O N
E"'~ N 01 .~-, M 01 O
N N .--~ N
b b b b b b b ~," O O O O O O O
O
N
Q, O
d b w G7, a~
P~
M
M

a, U a ~ ~ ~ >~, ~ A
A ~ ~ ~ ~ a v H ~ ~a a H ~ v z ~ ~ ~ H ~ ~ ~ °' ~ W ~ A
w ~ a w ~ W ~ H
U~ P-,~w~ P,H Pi wW
z y a w ~' w ~ w w w w a a a ~ a ~ a w ~ w w w ~ w ~ w ~ w w w z ~ ~ ~ z ~ z ~ z a z a z a ~ ~, ~ ~ ~ ~ ~ w w ~ ~ ~ ~ ~ w w ~ cww7 w d w d d ~ ~ U ~ U
c~
z ~x ~ ~ W ~ ~ ~ w ~ w w ww~~ cw7 cw7a ~~ ~a w ~ w a ~ c7 ~, z ~w ~ a~ z a z ~ ~ c~ z w w~, o~ w ~ ~ w c~ w W w ~ w ~ w w ~a ~ a~.,A ~ ~ ~ ~ ~ W ~ w ~ w a w q A w w W~ p~ ~ w ~ w w Ao' a ~ a ~' a w a > a ~ a ~ ~ ~ c~ c~ ~ a a c~ ~ ~ ~ ~ H ~
°~ ~ a~ ~ ~a~ ~ ~ ~ ~ ~ ~ ~,~ ~ ~a zo° ~ ~~ w w H~ w Aw w a> w dad W w O~ ~I w ~ UI w '~'~ w ~ L7 w F-, a, w ~ w w a H
d N H - ~ .~
N E ~k E E
C, O O O O
O O O O O
~ O
O ~ O O O O
s. O N p N l~ oo vp O
O ~ O
N N ~Y
Ov O I~
H ~ '~d' m ~ O o0 v7 N N ~t b b b b b b b N ~ N ~ VN
"., 0 0 0 0 0 0 0 O
Gl~
O
y O
r C1~
P~
M
M
U

~' ~' a ~ a w ~ ~'~" a pU., U U
ca w , j ~ ~ a a'' U U E-~ ~ rs~
a ~ ~ ~ ~ ~ °, w ~x a ~ ~ ~ a H
a a ~x ~ H ~ H ~ w o' w cW7 H ~ w w w U a > a z c~ ~ H ~ ~ ~ ~ ~ W
z w ~ z ~7 w ~z w ~ w w w w ~ w ~ w a a w a ~ a a a ~ a ~ a ~
w a w w w w a w ~ w ~) w c~ ~ c~ a c~ ~ ~ ~ c~
cw7~a~.~~~~~~w~ww w Z ~ ~ ~ ~ ~ z ~ t~.7 w ~
w a a a c~
z ~ z ~ z W z W z ~ z ~ w~
W
p. '-' W W
p~ w ~ ~ ~ ~ ~ ~ ~ ~ w ~
a ~ a w a ~ a a aw a a a ~ o~a c~ ~ ~ c~ a c~ ~ ~ c~ ~ U c~
~ w ~~ ~ ~a ~ ~~ ~ ~a ~ ~a ~ aH ~
a~ w ~w w ~'~ w a~ w a~ W a~ a W w ~~ w as w ~t7 w ~~ w v~~ w o M
a~ n s~, ~ ,-, ,-~ .-. .-, W
0 ~ 0 w W w w w w W~
'1.r' O
O O_ ~ ~ v w ~ ~ z 0 0 0 0 0 0 o N
o'~0 0 0 ~ ~ ~ ° o O r. ..-~ .-. ....~ ~y d' M M
n _~
l~ O O\ ~ ~ V'1 ~ b H d' M N ~ .--~ .-~ .-', v~ m m m v~ fn wn ai ~, b b b b b :'O 'O
cUd cOG cOG N cOd '~", O O O O O O O
O

O
w d 'b i~
Gl.
d pi M
U

a.~ as U w C7 a~. w w a ~ a ~ w a a ~ H ~ a W UW ~Ea-~ UW ~ Cw.7 ~w p., C7 a, ~ w W a,, C7 ~ z w C7 w d w d w ~ ~ d a W ~ d a ~ a ~ ~ ~ a z w w w w ~ ~ w ~7 ~ ~ ~ W ~ ~ c7 w ~a ~ ~ w ~x ~ ~ w w a w ,.~.a w ~ w ~ w a c~ z ~ z w ~ w ~ w ~ w ~ w (~ w H H ~ N ~ ~ W ~ H
u., w a H
a. ~ ~ H ~ t7 ~ ~ a c~7 '~a ~ ~a ~ a~ ~ as ~' w ~'~ W ~~ w ax w a~ w x~ w cx.7 ~ ~ a.~ cw7 ~ x C7 W~ ~ ~ ~ H j a ~,, t7 H ~1 c7 w ~ c7 ~ ~ C7 ~ 3 ~ ~ w E1 w d E-~ C7 d E-~ w H ~ a H E
d>I ~ ~~w ~ a~I
w a w~ a v~~ a w~l a w~ ax ~w a v w c~
M M M
w w w w w ~r O O O O O
O
O o0 . ~, t~
~O M ~O t~ ~O
E1 .~ N .~ N .-~ N
b b b b b b .S~"., O O ~ O O O O
O
c~1 o z'aW_a~

°'zx~
~nww~
o w ~ W
d ~ w w H
~; ~ cd7 C~7 Lw7 U ?c~7W~
aa~~

Pa ~ ~ ~ ~ U P, ~.; Pi w ~ ~ ~ ~x a w ~ H ~ w > w H ~ H
pU,, E-~ U W C7 U ~ ~ W U W
~, ~ ~ z ~ W ~ z ~' z A.1 H a W ~ H
a WW d E., ,..., W W d W
W a ~ w ~ W ~ w w ~ W a ~ W a W a W a z a ~ ~ ~ ~ z '~ ~ z w ~ ~ a~.~ ~ w ~ w w Cw7 t7 w C7 c7 t~ ~ a w ~ ~ ~ t~
w a C~ w ~ w a w c7 ~ c~ z ~ ~ a ~ c~
w ~ ~ ~ ~ w w ~ w ~ w w w a ~ a ~ a ~, a c~
o c~ ~ ~ ~ ~ caw ~
a~' W >~ ~ ~~, ~ a~, ~ aw w t~.7 a, ~
~~~, C~''~ ~ ~ C~7 z ~ ~ x ~ C~7 rUn A C~"~ ~ a C~.7 H ~ H ~,a~, H ~d H Aa H a c~7 a~
a CU7 ~ ~ CU7 a~'.~ ~I C7 w ~ U) C7 ~ ~ L7 a ~I C7 w >I
W a ~ I a m U ,~ x w a ~ ~I a ~ U a ~ U
a~
Pa N
4~
w i., 4-~ O O O
O N t~ ~ N
t'~1 ~ ~ O
(-i O~ ~-~ N N ~-~ N
?' b 'G b b 'C b c~ ' ~
N cvd ~ cUG
~'00-O 000 d L~
O
a~
'O
N
M
U

z ~ a ~ ~ ~ °' a ~ ~ W d a ~ ~ z ~ ~ ~ w a ~ w w ~ W ~ H
w ~ z ~ w z a W ~ w a ~ w a ~ ~ W~ ~ H w ~ w H ~ ~ w a z ~ ~ a ~ ~ ~ ~ ~ a z z ~ ~ w ~ w w d r~ w a w ~ ~ ~3 z w w ~ w '~' w a a..
c7 w ~o' w ~~ w ~ w ~ w ~. w w r~
as ~ ~ a H
as ~ A~ ~ ~ ~ ad c~ ~ c~
A ~' ~ a a ~ o~~ ~ a ~ ~ d ~
w ~a wA A~ w ~~ w ~a w ~w w Ha, a; z~ ~0' o~U ~ C7a ~ ~,~ ~ ~' j ~ a~,a~.~
a. ~ d a ate.. ~ ~ a ~ ~ H j ~ ~ H ~ ~ o~ C7 C7 w ~ H ~ ~ ~ ~ E-~ p~ A E-~ a, a w aaa, a~ aA ~~ a ~~i a~ ~a~,~ ~ ~>I a H
tE E
Q~, O O O
O .~ m O_ O_ O_ y O
O ~ O O O
O O ~ O ~ N N
y.
~O d' N ~ O o00 H N ~h M ~ N N
~' b b b ~ b b ~, cUd ~ ~ ~ c~G N
~,' O ~ O O O O O

O
a~
r a~
Pi M
U

v ~ r~ ~ x ~ w v' ~ m a ~ ~ ~ ~ ~ d A ~ a ~ ~ ~ ~ . w ~ w v H ~ H ~ w ~ w v W ~ a a, w ,z., w a w ~ w c7 > H
z ~ w ~ z ~ z ~ w z ~ ~ ~ ~ ~ z a d a d ~ ~ a w a w w w d H a ~' a w w ~x z ~ w ~ ~ ~ ~ ~ w a w ~ ~ w ~ w t~
P, cZn ~w'' ~ Cw7 ~ Cw.7 w z ~ z ~ ~ w z w z w ~ ~ ~ ~x w~ w~
''a ~ a w ~ ~ a ~ a c~
c~ ~ ~ ~ a c~ ~ c~ c~
w w w w w ~ w ~ w ~ w w w a ~a ~ ~w ~ H
c ~ C~.7 ~ ~ C~7 ~ (~ ~ ~ a ~ C7 a a t7 C7 as ~ a~ ~ ~ ~ awl ~ aH ~ c~~
~w Hew ri~~ waw '~'c~.7w dew Cd7 Ed-~ q Cd7 ~ ~ ~ ran A L~.7 ~ ~ Ld7 ~ ~ C~.7 c7a H ~~ H ~~ ~a ~~ Ha ~~ H ~a a c~7 ~ A ~ ~ ~ > t7 ~ ~ ~ c7 w a ~ c7 w as a~~ aw ~~) a a>I a~ ~~~ ao~ ~aw,~ a ...
°' '° o 0 , w ~ w w w w w 0 0 0 ~ , , ~'u ~'n a, o~0 0 0 O d' d' M M .-~ .-i c~
v~ t~ o ~ v~ ~n E-~ ~t ~t M N
y~', b b b b b b O U U U U U U
c~ cd cV cd cd cG
,~," O O O
d O
r .'., O
r d ai N
M
U

H
w a W
w z v' ~' d d w a w Z
a x ~ H
~a w w A
C7 d d ~ a ~ w a ~~ ~~ ~~ a~ a~ xaU, C7 w m ~ w ~ a.. x a-, ~ ~ C7 ~ a w ~ U a., (7 a~
w a~ ww ~~ ~ ~~ ~w a~ ~w ~w ~~ ~w ~a >w >~ >w H ~ ~ U a U a U a U ~ U E-~ U a U W U U
o L7 ~ a., ~ w E-~ ~ a.. E-~ w ~, w w W w E-~ p'' ''~ ~ C7 ~'p a~ w ~CW7 ~CW.7 ~zj ~Cw7 ~~ ~Lw7 ~W W C'7 a x d a~ ~~ ~ ~a ~~ ~a ~a a~ ~a~, wH wW w~ w~ w~' w~ w~ w wx °' a aw act a~ a~ aP~ a~ a~ a~
~a a~ Ha H~ H~ H~ H H H ~'~ H
a> ,~~ wd wd w wa ww wd w w~, w W a o' UI v~ z ~7 w t7 ~ ~7 w c~ w e7 ~ ~7 d t7 ~ c7 v~ t7 d w p., O O C7 ,-~ ..., m m m o W W ~ CW.7 Cw7 CW.7 Cw.7 CW.7 W ~r "' ~ d d ~ U
0 o N o 0 0 0 o W O
o ,-~ ov oo ~ ov ~ z,.., c,.., 0 0 i ~ ~ i ~ i ~-~, N ~ N ~ N '-' O vO N M
V7 l~ cn ~--i O oo .--y~ r, .--~ v .-n M
N ~ N ~ N ~ ~ N
v~ vo c~ m wn cn vwn m m w y, :d b o b b b ~f b b b b b U U U U U U U U U U U
cC cti cC cct cG cC cd cct c0 c~ cat ~',O 0~000000000 N
~. z ~ U
W

M
v ~a ~w c7 c7 A
a a A
a a o~
Uwa~'~ ~~~..,wc~7 a; ~ A ~ a ~'' a C7 O' U C7 a a ~'~ ~~ ~ ~ ~ ~ A
..a > a a a~ w ~ ~ ~~ ~ U
o' w aw a A ~~' ~
a H ? ~ f~ r 'a~ ~w ~~ ~ ~W ww ~
w w w ~ a w ~ a aw ~ a U W ~ W j w ~ w U ~ U H ~ a ~ w w a w H w E-~ w ~' as ~ a~ a a~ O' w ~ w w a-~ w a, ~, w ~
~w ~a ~A ~~ ~o° ~~ a~ ~~ ~~ ~a ww ~t7 ~~ ~ ~~ ~ ~~ ~o~ w ww ~~ ~ ~a Via, a~ a~ w~ as a~ a~ a~ ~a ~~ a~ a~ aA a~
Ha Ha ~a H~ H~ H~ H ~ dw H~ H~ H Hue, cw~~ ~~ ~a ~~ ~~ ~~ ~~ ~~ ~a ~> ~~a c~w7~x v w o ~ o ~ °o °o °o °o °o y ~ ~ .~ r. ,~ r-, v ~ E~ o E~ a o t,.., "~ ~''n ~'n g'n ~ g'n a, n- ~ o E~ o ~ 0 0 0 0 0 0 0 oE~~,; o~ o~~o~o~o~ooo p tV ~ d' O~ .~ N N d' d' M M
i ~ l0 n ~ i '~h Q1 O l~ t0 ~--n N
Ov ~ O vO ~t N W O oo v~ I~ O O~
N .~ N cwt M .~ N N dwt M N
wn fn v~ m m vm wn v~ vw wn 'b b 27 ~c7 n7 b b b "d b T7 b b .r, .,.., .'., .'., .'., .,~
U U U U U ~U U U U ~U U ~U U
cd cd cct cct cG cC ai cC N at tt3 c~ of O O O O O O O O O O O O O

w v a o, ~ ~ ~ ~ a ~ ~ H
x a ~ a a ~ ~ ~ E~-~ w ~ ~ ~ ~ a, aj a a ~ a H ~ ~ w ~ ~ ~w aaU, ~ ~ ~U U aU a~ xa~..~ dU ~.;~ ~U ~aU, ~w ~w >H >w aw ~ ~ ~~ w~ ~~x ~w ~x ~~ ~~ ~w Uw Ua Ua ~w ~w ~w w a ~w ~w ~a ~ L7 ~ E-~ ~ E-~ p.., U U a U a U a U E~ U a U G.ra U a U E' ~c~7 ~~ w w~ w~ ~W '2'w ~~ ~a ~r3 ~H ~w d ~x~ ~x~ ~~ ~ ~c~7 w~ w3 wa ~ ~~ ~xw a~ a~ as ~ w~~1 w~ ww w~ wP~ w~ w~ w~, w~r~
wa wa wa ,.aa Hd H~ H> Ha Hw E~ w~ w~ wd ~a v~ ww w~ ww vww w~ w 'M
i -., ,--, .--, w OOOO~"'""'c'~MM
w w w w~ ~ c~
A
O O O O N O O O O O
M l~ l~ l~ ~"~ 4~ O O
.-, .~ N .-~ N .~ N .-~ O O O N
i i ~ ~ ~ ~ ~ i l~ ~ v» w-, O oo .-, ~ Oy0 N M
W ~n vWn T1 vp m ~O l~ ~O i ~ .-, m .-n .-~ .-r .-r V .--yV ~-n cV .-~ N 01 .-, N
w m m fn cd wu v~ fn mn v~ fn m :'C b b b ~ b b b b b b ~ b ~3 U U U U U U U U U U U U U
c~ c~ cd cV a3 c~ aS at c~ c~ c~ c~ N
O O O O ~~ O O O O O O O O O
a v a ~x °o '\' a wzw A
a A
a a v w a ~' d a ~ a w~~~~., O~ U C7 ~' a ~d a~ ~ ~ ~ ~ a W
a~ w~ a~ ~~ .,~ aU ~ ~~ ~~ ~~ as U ~ PU-~ pU,, ~ ~ A ~ ~ ? a' r~ U E-~ U a w ~ p-' fs.~ U v' aW c~~ ~~ ~~' ~~ H~ ~
v~ O' ~ W ~ rn a~ ate' dH ~w ~w ~~ ~w ~o' ~~ ~w ~~ ~~ ~w ~w ~~ ~w UW Ua U~W.1 Ud U~ U W U~' UW Ua U~-a, UEa-~ UW UW
a, a w H w E-~ w ~ w A w a w W a~ a a, W w W w ~ w W a.. a W H
~O' ~~ ~~ ~w ~p~"~ ~~ ~C~ ~a ~x~ ~~ ~xa ~a ~d ~~ ~~ x~c~ ~xH ~~' ~~' aA as as as a~ a~ a~ as aw aA a~ a~ a~
w~ w~ w~ w~ wA w~ w~ w~ w~ wa w> wa w~
w w w w w ~ W
N v~ ~t v~ Q,' O O O O O Ur O O O O O
O
~.r Pi O H~ O ~ O O O O O O O
O H ~ O ~ O ~ ~ o~O ~ ~ O O
fV Od-O~~N Nd'd't'~1M
00 ~ 'd' O~ O l~ ~O ~ N
O1 i O ~O C1' N V7 O a0 V7 t~ O O\
N .~ N V'~ ~t m .-~ N N V d- in N
'~7 b b 'b b T1 b b b b b b 'Ci .'., .'., .'., . r, .'., .'., .'., .'., .'., .'., U U U ~U U U U U ~U U U ~U U
cd ~i at c~ at c~ ai ai cd ai ai N c~
O O O O O O O O O O O O O

w a a H a H

> a ~ H

a H

a >H ~w ~w n~ w aU~ atea a . a , , -,, .~ ~.. E

~ ~

H H H a a w ~ w ~ w a M
i ~w h w w ~ 4-.~
O O O ov O
N

~n m .-r .--m , i ~ ~ N
N ~ h i ~
b w m w o b b b N
b b w a x ~ ~ a ~ a H
H w A ~ w ~ w ~ ~ ~ A a a ~a~..~ ~a~~, x w ~'~ ~
a-' w w x a w ~' ~ c~ a.. w x w ~ ~' ~ w ~ c7 ~ ~ w C7 ~ w cw7 W7 ~ w ~ C7 C7 ~ a~ c7 o aw ~w ~'z ~w ~W ~w ~z ~W ~ w az ~w ~w ~~ ~~ ~~ ~w a'' w v~ a.. w w a a1 x a.. d w ~ w a.~ x w ~' a., U
~wxw~waw~w~~aCw7~tw7 Cw7 ~cw7~Cw7a E-~ p" c~7 H C~7 W L~7 ~ C~7 w t~.7 ~' C7 ~ C7 c7 c7 ~ c7 v~ c7 >
z~ z~ z~ z~ zP z~ z~ z z ~ zA zd w M M M
o Cw7 Cw7 Cw7 Cw7 Cw7 °' d d d d w w w d-A

°m° ~ ~ ~ w v-.~ O O O Ei N ,-, N ,-~ O O O N l p O ~ ~ ~ O ~O N M M
lp M ~O l~ ~O ~i 'i .~ M O\
H .-~ N .-~ N .-r N O~ .-, N N
~, vwn v~ fn fn m m m v~ m m y, b ,'d b b ~ b b b b b b U U U U U U U U U U U
cd cti as as cG c~ cG c~ c~ cC cd ~' O O O O O O O O O O O
U
a d o, ~' oo .~G' :b ~.
w ~ C7 oN.°~~.~C7 op~ ~rz M
v ~z ~ ~~x o°
- a A
a w a ~ d ~ w ~ a ., a ~1 ~ ~ ~ ~ ~ ~ ~ w ~ E
O" a, C7 U w C~~7 C~7 ~ C7 d w ~-1 ~ "' w~ ~W ~w aA ~~ ~z ~~ ~~ H~ ~z ~c ~z ~z w o' d c~ w c~ z c~ c~ w w o aw ~a ~~ Nz ~ aW ww Aw ~w ~W ~ a ~w w~ w~ w~ w~ w~ w~ w~' wH w~ ww w"' wa c7 ~ c7 z ~7 a ~7 t7 L7 ~7 w ~ ~ ~7 ~ ~ c7 L7 a ~ ~ c7 ", c7 ~7 a c7 a ~7 d c7 ~ c7 j c7 ~ ~7 H c7 ~ ~7 ~ c7 ~ c7 ~
z~ za z~ z~ z za z~ zc~ z~ z z~ z~
W ~ ~ ~ ~ ~ A ~ d +~ -.
N
a.wa~.w~w O O .~ O ~ O O O O O
v--i .--mr .-~ rr ° ~' ~ ~''n g'n g'n g'n g"n Pa ~ Z
~ H ~ H °
w w ~ w w w w w w w w o H o 0 0 0 0 0 0 0 0 w w od; o~ °~,~~o°°o~o~ooo N O d- O .-~ N N d- dwn M
~O ~ 00 ~, d' 01 O t~ ~O .-~ N l~
O v0 'd' N h O o0 V7 t~ O 01 v7 Ei N Fwd- m .-. N N ~t ~t m N
p., w ~n vwn fn fn v~ m m vw wn ~, b b b b b b 'd b b b b b U U U U U U U U U U U U
ai cd cc3 at c~i cd c~ c~ c~ N c~ c~
~", O O O O O O O O O O O O
b0 O
G~
U
O
.,r G1.
W
M
U

c~
a d ~ ran ~ a H x ~ x ~ ~ a ~ x w ~ a, ~ w a~.i t7 . a~ c7 ~ rr~
.,~ .,O' ~ ~~ ~ ~ "w "a .,~ ~ .,ran w ~w w ~~ ~ apa., a~ x~ ~~ ~~ ~'w x~
a~ ~z az ~ ~' w ~~' w ~vi aw a w~ ~~ ~w w ~ a ~
~'~', wo' w~ ~' ~~ aa.~~ aa.,~ ~''~ aa..~~ ~a aa.,'"
~ ~, o, L~ ~ C7 ,~ ~ ~ ~ ~ ~ ~ ~ ~ ~ rn v~ ca ~ vi v~ ~
W ~ r~ri ~ ~ ~ w w ~ vi a w a, r, .., ,-c~ m m OW, ~ W'U C7 CW7 U C~7 C7 d ~ 'WU ~ ~ A

1., ~ ~ O ~ ~O M ~ ~ ~ 4-~ 4-~ O O
.-a N .--~ N .--r N ,~ O O O N
L~" i i i ~
I~ .~ .--~ O oo ~ l~ ~ .~ M
E V7 V7 V1 00 ~O M ~O l~ ~ N ~ .-a N
.-~ N .~ N .--i N
y~ v~ m v~ vwn m v~ r~ m v~ vm m b ~ b b b b 'b b 27 b b ..i ,~ ,-, .-n ~.~ ~...n ~ ..ma U U U U U U U U U U U U U
at N ai cV cd cd cd c~ N c~ N cd ai ~,' O O O O O O O O O O O O O

N
U
4~
O U
O N ~
N
.-r bU . b C,.~~cVu o d- .~ v o ..
O_ N ~., ~~ P~
c,.., 'b c~f w oz y o~ ...~~
d~ ~ ~~

A
a a A
a A
A
a a w d ~' ~ ~ a ~ a O~w ~ a w Cw7 ~ ~' w ~~ A ~ ~ °~ a w ~ as ~~ a~ ~'~ ~ ~~ ~~ ~~ a w ~~ Aq ~~ ~~ ~~",~., Hw C7 ~ yn ~ ~ ~ w O' p~ C7 ~ ~, ~ w ~ ~ ~ ~ ~' (~ cn a o' a a~ ~~ a~
a a~ a a av~ as a a~ aH as aw aw as ~ a, ~ a~ a~ d a~ ~ a, ~ a~ ~ a, ~ as a, H a~ ~n w w a ~. ~~ ~~ ~~ ~a ~o' ~~ da ~~ ~~ ~H ~a~ ~
a ~w ~z ~~ ~~ ~H ~~ ~w ~a w ~x~ ~~ ~x~ ~o~ ~xc~ ~~ ~x~ ~x~ ~~ ~xa ~> ~xa ...
w ~ ~ ~ E ~ ~ w -~ ~ ~ ~ 0 0 0 0 0 o '~ ~ o .~ o ~ O o 0 o O
H
'° n. ° o H o ~ 0 0 0 0 0 0 s, o H .~-~ ~ ~ ~ ~ .,~-~ ono ~ o~0 0 0 cV O ~d' ~ ~ N N d' d' M
, 00 Wd' O\ O l ~O
H N ' O ~O d' N ~n O o0 vW O
N cwt M ~-~ N N ~t ~t M
m vwn fn vwn m wo v~ ~n v~
y, b b b b b b b b b b 21 b .i .~ .~ ...n N ...n .~ .-n .-n ~ .w U U U U U U U U U U U U
c~ a3 c~i c~S a3 c~ ni c~ ai c~ N cd O O O O O O O O O O O O
iC
w .~
bA
O
L', U
O
r .., C, w M
M
U

w n-1 v ~ a o, H ~ ~ a Ca,7 E-~ ~ Cx7 ~ ~ ~ w a H
a a aaw.~ waa, .,a .,O' ~ ~~ °~ ~ ~~ a~ a a~ xa, dd ~
~z ~a ~z ~
a ~w ~~ a v wd ~~ ~wd a~ wa ~a a a~ as a~ ~ >~ ~ ~a ~a ~x »
w~ ~H ~H ~~ H dcx7 d~ ~c~7 d~ d~ da d~
w a~ a., w w w ~ w a..
a ~a ~a a z~ z~ z~ za zw z~ z~
w ~x~x ~~ ~~ ~o~ ~ dw ~~ ~w dw M
w U lp O O O O ~ ~ ~ M M M
W C/~ C/1 V~ C/1 W W W W W N
O (7 W W W W ~ C7 C7 C7 CJ C7 OOOOONOOOOO~Ur ~" O ~ ~O ~ l~ ~O M ~ l~ t~
O M .-~ .-~ .~ .~ N .-i N ,~ N .~ O O
~r"ii~inn~i~~O~O
N t~ l ~n t fn ,-, O oo .~ t O\ V'1 N V7 V'7 'C ~O M ~D l~ ~O
E~N~~''-~~-~'V~N~N~NOv m w fn m v~ c~ [n m w m vw wn ~" b b b ;'d ,'b O 'd ~ b b 'b 'b b U U U U U U U U U U U U
at cC c~ ai tai ' c~ c~ a3 cd of cd ai ~," O O O O O ~ O O O O O O O
w .~
+~
p O N N cd M U ;b p, O N O .~ c~i 7-n c~
4-~ cG ~ 4~ O
I3~ c,._, 0 b .-d 'd '~ . Pr w O z a-U. Fr" ~
o q ~ ~ ~ ~ .~ v~
U ~~r~, ~'o ~,~z ~ W .~ ~ ~ .a on a ~ v~

A
a a A
a A
A
a a a ~ a ~.
d ~ ~ d a ~'' ~ > d > ~ r~ > a A v a ~ a~-~ q ~ ~ ~ d w ., A
w~ a~ Az ad a~..~ c~~7~ ~~~., a~ ~ ~d o,A ~~ ~~ wad., p., e, ~ ~ ~ ran ~ ~ ~ ~ ~ ,,.~.~ w a ~ d d Z j ~ t7 R; E-~ v~
~ wz ~~ a~ ~,~ a ~~ ~ ~a a~
~w ~~ ~~ ~~ ~a ~~ ~~ >~
a~
d d~ ~~ ~~' ~ ~~ ~~ da d~ ~w, dj a-, ~ a... ~ as ~a a, ~ w a a.. a a~ C7 r~ v~ ca cn A cn a m ~ rri a en ~ m ~ rn O' vi r~
z~ z~ za za zw z~ z~~, zH z~ z~ zW zA
W d ~ d ~ d ~ d ~ d ~ d ~ d I-1 d h d ~ d 1-I d ~ d a N
.N
W
N N
o ~~ ~ .o .~ .o ~ °o O °o °o .~., W d' a> ~', o ~, . 'a A ~ o ~ ~ w ~ g'n ~ g'n ~''n U cue. ~ o E-~ o 4~ 4-~ W ~ d- O N ~ N t oo v0 i. O O O ~ ,WO ~ N N d' O
NM m O~ ~; app, d'OVOI~
M Ov Oi O v0 d' N ,.~.., N N d' N N ~ N ~ d' c'~1 y wn ~n cn fn m vwn v~ vmn m b b b b b b b b b b b ., ,.-m.~ ,-m., ~.-m. .a ~..
U U U U U U U U U U U U
cd c~ cd cd a3 c~ cd ai cd cd at cV
~., O O O O O O O O O O O O
U
b0 O
C."
U
G1.
O
.,.., C7~
W
I
M
U

w a a ~ ~ a a ~ a ~' ~ ~ ~ ~,..~ '~
aCw7~~~H Et7-~wC~~7~w d aa..~ ~ w ~ ..~ .,a ~ ~'a, w ~ ~ a ~ xa.~
wa,, ~~ a~ a~ ~a~, G~
a porn vi ~ E-~~ w~ ~~ r~~ wv~
o ~z ~~. ~a ~d ~~ a~ ~ w~n ~~ ~~ 3~
~ ~a aw as a~ w ~w ~~ w~ a o v~ a ~ ~~ ~~ o'H v ~ ~ a w ~ w ~ ~n ~ p~ > p~ ~ p~ ~ ra ~ ~ ~ ~ a a~.~ C7 ate... a a~, ~ a~.~ ~ a~.~ H a~.~ ~ H ~ ~ ~ ~ ~.' ~ a-' ~ w a. ~ ~'' ~ ~ ~ C7 ~ ~ ~ ~ ~ a ~ ~ ~ ~ tw7 ~ w ~ c~
w d~ da a~x d~ d~ da ~ ~w ~~ ~~w ~w ~ZS M
'''' ~ ~ .-.i ,-, ~ W
i .-n ~ M M M
O p ~Z ~ ~ ~Z
w ~ w a, ~ ~, 0 0 0 0 0 0 o N o 0 0 0 0 V7 Qv M t~ V'1 M O ,~ Q\ 00 l0 01 ~O
O oo O O v0 ~O ~O ~ oo ~ N ~ N
M M ~ i i ~ N ~ ~ i i y0 .-, N t I~ ~n Lwn .-~ O o0 .-~ t~
E'~ 'd O N .~-n .~-~ .~-r .-~.y'~ ~ N ~ N \O
U
v~ vwn cwn m m c~ m vw wn cn b :-O :'d b b b b O b b b :'d 'd O U U U U U U U U U U U U
~~ c~ cG at at at N cd ' cd at cV cd cC
0 0 0 0 0 0 0 ~ 0 0 0 0 0 o ~
tin o ~-Mit~~~c~o~
.-n Y O U 4-y, ~ 'L7 O
~ a..~-. tU-~ ~ N
C' ~ ~ N c~ b oz.~ ~ ~ ~ ~~d .n o .~ -~
U ~ O' ..~ a°~ .~ ~ ~ .d Cl~ ~ ~ c~ ~ U cUC

A
a a A
> ~ a a vl~U,,wz~ ~r~n c7 w A a w a~ A~ ~ ~ a H~ ~~ ~~ ~~ w~ a~ A~ ~~ a~
d ~~ d w ~a.~ d ~ ~1~ ~d ~ ~ ap' a ~ d'~' w d ~ aw o ~ ~ ~ ~ ~ ~ ~ ~ ~ a '~ w v' ~~ d~ ~ ~ ~~ ~~
w > ~ ~ ~ ~ ~ > ~ ~ ~ ~ U ~ w ~, d,.a d~' d d~ d~ d~ d~ d~ dA d'~'~ d~ dv~
~. a, w ~ a, w a.. w ,,~ w w Z w a.. w w w ~x w ~d ~~ ~~ ~d ~~ ~~ ~~ ~o~ ~A
N N F
..
N ~ E E
N ~~ ~ ~~ d o 0 .--i O W ~ ~ ~ O .~ O ~ O O
a~ (~ 'U A ~ ~ H ~ H a~
d~ ~ ~ U cue- ~ o I-~ o ~ 0 0 o.., 4..~ w o 0 o E-~ '~; o ~ o O N t~ Q N O d~ O .~ N
.~ m O~ ~ O ~ ~ N ~ O
H N O~ .-~ N N ~ N V~ d' M ~ N
m cn m cwn fn v~ m m vw wn b ~ b b ~ b b b b b b b U U U U U U U U U U U U
ai cd N at c~ ccS cC cct at at cd cC
~., O O O O O O O O O O O O
bA
O
CCl d d O
W
N
M
U

c~
a v CA''7CH.7 ~'~~~H~H Cx7~WCx7 °j > ~ ~~ a ~ w > .,~n "~ ~ d Ed-~ ~ad. rw"A~'' wd ~~ ~~ dd Hd 'i' ~~~" ~ ~>
aw r~~ E"'~ ~~ ~~ ~ xw ~a'~'., aQ, o. ate., ~ ~ 'i' ~ 'i' v~ ~ a, ~ ~ ~ ~ ~ w ~ ~
w a a~ ~~ a ~w ~~ o~ w a~ > d ~ ~ ~ ~ ~ a ~ ~ > ~ ~ ~ > ~ U ~ w ~
H a w w ~ a a a >~ >
~ x a, ~c7 ~H ~~' ~U' ~~ ~~ ~~ ~a ~ a~H a~~ a~~
v~ p., v~ C7 v~ ~ v~ r~ y wn yn a ~ ~ r,~ r~ ~'' M
y, P.i ~ E ~ w ~ ~ ~ ~ ~ ~ w w w a. w O O O O ~ ~ W W W W ~ ~ ~ C~J
0 0 0 0 0 0 0 0 o N o 0 0 00 l0 ~i'1 01 M l~ ~ M O ,~ O\ 00 ~O
00 ~O 00 O O ~O \O ~O l~ pp ~O M I~
N ~f' ~t M M .-r .--n ,~ .-a N ,--yy ,-n i ~ i ~ i "~, O l~ ~O ~ N l~ l~ ~!1 l~ .-r O o0 00 V1 l~ O O~ V1 ~ V1 V7 ~O M ~D
H N 'd. d' M N ,--~ .--~ .-~ ,--i V .-~ N
w cwn m w v~ fn m fn c~ m vmn . ~ b b b b b b b b b b b b .r .~ ... .-n .-, ... ,.. O .r ,..n U U U U U U U U U U U U
a cV cd at cC of cd cV cd c~ ai c~ at ."000000000~000 bA O .~ ~ N
M ~ N b b4 .
N
O ,N, 0 0 w o Z ~ .A.
M O
d ~ ~ 'ai a a a a a a Cx7 d H ~ c~ U w w ~ ~ ax, ~ ~ ~ ~;a a~ ~ a A a a aw d a a w a~ a~ H~ ~~ ~~ a~ wj a~ A
xw d,~ ~~ ~ ~la., v~~ ~~ ~ a~-~ ~~ a..
a~'~ ~ ~~ ~a, ~a~ ~~ ~w as ~w ~v~ v~ ~~ v~ ~~ A~ >dv~ w~" ao~ ~~ ~~ e7~
a~ w a ~a ~ ~H d v~H a dw O'a A 'c~'a,-, o' ~ d ~ ~ > > ~ ~ '~ ~ ~ ~ > ~ ~ ~ ~ a r~ ~ v~ ~ v~ a cn v~ vo C7 r~ ~ v~ ~-' v~ ~ rn vWl v~ ~ v~
Pi W H P1 ~ Pi P-1 P~i ~ Pi ~ P-1 P., P1 ~ Pi ~ P.~ ~ P-y/
r~~ ~ ~~ ~ ~a., ~
vi v~ q vi a v~ a v~ a v~ ~, vi v w ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~' ~ ~ ~ ~ ~ a ~ ~ ~ ~-t Lw.7 Cw7 .N~" .~ ~ .~ ~ .~ ' o o .~ o , w ~ ~ ~ d cW7~~A ~.~H~~H~
d d ~ 0 4.. 4..., ~+., 0 0 ~ U n- ~ o (~ o ~ o 'o ~ ~ 0 0 o H ~; o ~ o O O O N t~ ~ N O ~t O
O , , , M O\ ~ O ~D d' N N
N ~ N Ov .~ N N .~ N N d' M .--, wwn m w cn v~ vm v~ fn m v~
b b b 27 'ry b b b b ~C b b b .a .~ ~ .. ~ .~ " ~ ., '. ., U U U U U U U U U U U U U
ai c~ cd N c~ ai cC cd at cV cd c~ cC
O O O O O O O O O O O O O
.

c7 a H ~ ~ ~ a °' ate, H ~' ~ ~ H

a a~
w ~ ~ ~ c7 a ~ w ~ ~ ~ ~7 ~ ~,, c7 o a ~ ~ z ~ ~ ~a o c~
c~ ~ a ~
O' ~ ~ ~ ~ ~ en ~ ~ d U ~ U ~ U
~a ~a ~ a a ~ w ate, o a ~ ~ z ox o~ o~ o~ ~~ ~a o~ o~ o~ oa 0 0 0 oW
_ o 0 0 ~ C7 ~W ~ w W C7 a~
0 0 0 0 0 0 0 0 0 ~ 0 0 0 N r. oo vo ~n ov M ~ ~n M O ~n 0o v0 00 O O ~O vD v0 t~ Gv N N dy' M M ~ ~ ~ ~ N
i v ~ ~ i ~ ~ ~ ~ i ~
d' Ov O (w0 ~ N l~ l~ V1 I~ ~-~
U1 O oo V~ l~ O 01 V1 ~Wn W o0 N N d' ~t M N ~ ~ ~ .~ N
b b b ~ b b b b ~ ~ b b ..n ., .r H .. .-n .. ., '. .H ., U U U U U U U U U U U U
c~ cC c~Y c~ cV c~ cG cd cU cd c~ cct p ~ G p ~', G'r ~ G G G G

-1~4-A
a a A
~, w A
A
,..~.a ~ ~ ~ a a x ~ E-, ~ U w ~ rri a~~,, 'i'~'~ ~aO' ~; a o, A a a a~ a~ ~ H~ ~~ ~ a~ w~ a~ A
w ~ ~ ~ ~ ~ ~ ~ ~ A
A
W~
~a > ~ ~ > ~~, ~ ~w ~ ~A ~~ ~o' v~ a w x; v~ ~ vy v~ r~ x rs~ v~ U rep v~ v~ ca v~ a v~
a~ w ~ a~ a a, a~ a, ~ w ~ a~ ~ a~ ~ a, ~ a~ ~
a, ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ d c7 v~ yn v~ v~ ~ ra rn ~ rn ~ ~n ~ u~ rn a rn v~ ra ~
w ~ ~ ~ ~ ~ ~ "~ v~ "~ ~ ~ cn ~ ~ ~ ~ ~ O' ~ ~1 w w a~ ~ ~ ~ o W d. ~ o .~ o ~ o H
O O~' d'~UC2O OE'i O
O
4-i O O O H~ ~ O ~ O
N ~., O O p N l ~~"' N O ~t O
(~ ~O ~ .~ m Qv ~ ~O v0 due- N h N .-- N Ov .~ N N ..-~ N v1 d' M
'~J Z7 b b b b b z7 b b b b b .., .~ '. " .~ '. ..~
U U U U U U U U U U U U U
cc3 cd c~ ca of a3 cC at at cd N N cG
O O O O O O O O O O O O O

c~
a U
H ~ ~ w p~.., a °' '"' 'n~~" ~~~ ~Cw.7.a~
W q a ~ ., ~ ~ a p-~ ~ ~'' a ~ w v~, v~ d ~ w ., ran d~ ~~ ~~ aj ~w U~ v~ ~~ ~ ~d ~ ~d w a~..~ ~ ~ F' ~ c7 ~ ,..~'',a a'' ~ v~ v~ ~ O p.., x w ~'~ ~~ ~~ ~~ a~ ~ ~ ~ w~
w~ A~ a~ ~~ ~~ a~ a~ a~ a ~ ~>
vi ~, v~ ~ o' ~ w w C7 rn C7 w ~
~ U ~ U ~ E-~ U d ~ d v~ v~ F., ra ,,~ tn w v~ w rn r~ rn O' v~ p~ v~ d ~ v~ ~ ~ ~ a a, ~ a~ r-~ ~., w r~ a.. ~, a, a.. ~, a, ~, a.. ~ E1 x W
H w ~a a a ~a ~a ~x~ ~a ~x~ ~x~ ~~ x~~ v~ ~w ~~ caw M
i .-.i .-~ .-, .-~ w '° O O O O ~ '-' '~ M
0 0 0 0 ~ w 0 0 0 °
~'o ~'n ~'n ~ ~ w 4-, w 4-.~ ~ ~ ~ v-~ ~+
O O O O O O O O O O N O O O
00 ~O N Q1 M l~ ~ M O ,~ O\
00 ~O oD O O ~O ~O ~O l~ pp ~O M I~
N N ~ dwt m M .--~ .--~ .-~ .~ N .~ N
Ov O IWO ~~ N I l~ V1 t~ m .~ O o0 N N d' ~ ~ N .-N-i .~-n ,~-~ ~ .b ~ N \O
U
[n m w m vw wn fn cn v~ ai vwn fn b b b b b ~ b b b b O b b U U U U U U U U U U U U U
c~ cC cd a3 cd cd c~ c~ N ai a3 cd ' O O ~ O O O O O O O ~O O O
N
a ,~
o.~.~-o U
N .~ o o W
o N °~' o ~ ~ ~~
~z ~~~

A
a o°
A
a A
z a ~ d ~ ~ U w a~ ~ ~ ~ ~ ~ ~ 0.; d O° ~~., c~7 A a a w w ~w a~, ~ ~~ H~ ~ ~ ~;~ ~~ wi~ a ~w a c~ ~ ~ ~ a, A a a Wt7 ~~ ~ c7 ~ a ~w ~A
w~ ~~ a ~~ ~nc5 d w ~~ ~a w o'a AA ~c7 ~x ~ ~ ~ ~ w A a a ~ ~ H
>a ~ ~~, ~ ~ a ~ ~z t7 w c7 ~ ~7 ~ c7 ~ c7 cn c7 ~ ~ r~ c7 ~ c7 ~ c7 O' t7 ~-1 ~7 ~
M M ~ U
~UC7 N °'~~ ~ ~d O .~ o CW,7CW7CW.7q v.~E-~~~,H
d d ~ o 0 0 ~ U c2 ~ o E~ o 'o ~ ~ 0 0 o Ei d; o ~ o O O O N ~ ~ N O ~t O
O i O ~O N M cM ~ ~ l~ ~ ~t cn O~ ~ O ~O d' N
N .-~ N ~ ~ N N .-~ N ~n ~f' M
fn v~ vwn m m fn m cn cn m v~
b b b b b b b b b b b b U U U U U U U U U U U U
cG al ai cd a3 c~ N cd c~ cd c~ ai c7 a w a w ~ H d '-w C~7 a a, A ~ q ~ ~ ~ '~ ~ , a ~w ~~ Hid., ~~' ~'~ w~~,, ~ o~w o~w H
w w ~ ~ H ~ ~ ~ w ~ ~ C'7 W ~~ ~w ~C7 ~t7 a~ a ~ a as a a a ~, ~> ~H ~a ww ~,w stn ~,o~ ~a ~ a w~ ww w~ wH ~~ wa w~ w~ ~ w~ H
>~
a w A w~ ~c~" ~ ~ a a ,~ a ~ ~a ~a ~a a c~~ c~~ ~a ~> c~a c~~x ~~ c~~ c~a b '° O O O O ''"
0 0 0 0 0 ~ w '" '" '" '"

g"n a, 00 ~ vi ov cn t~ ~n m o ~n N N ~ ~ O O vD ~O v0 l~ Ov .-, .-~ .~ N
v ~ ~ ~ , ~, N I~ l~ h I
OO0oh~00v~.~-~~~N
N N d' d' M N
~n vwn m m m m wn ~n b b 'b 'b b ~ b b b b b b .. -'.
U U U U U U U U U U U U
cG cV a3 cC at c~ of cd cd cV at c~f O ~ O O O O O O O O O O
. . . _ E-~ ~ U w x ~ ~ a ~ x H w ~ ~ P~ ~ ~ a~
a w '~' A a w -w ~~ ar~, ~ ~ ~~ ~ ~ ~ ~~ ~d c~nad.~ pd., ~'d a~ 'a~'~ ~w ~~ gad... ~ w ~~ Uad.~ w~
d ~ w ~ ~ ~' ~ ~ » d w ...., w ~ ~ d ~ x v~
a.~w ~~' w~' ~w ~ ~w .~~ ~w w Ej ~1~"' a> ww d ~ a~ w~ d~ w ~~ ~ ~ ~, a~ w w~ ~~ w~ y ~ a ~~ ~H ~~ ~a w a~,~ ~a ~a ~~ ~a ~~ ~ ~ ~ ~~' wx w wx w~ wt~ w w w w w~ w w d~ d~ d~7 d due, d~ d~ d d ~' d~ da d~
w cw7 w w ~' t~7 ~' w ~'' ~ ~ r" ~ ~ ~" A w d w a, ~W ~~ ~~ ~w ~~ ~~ ~~ ~~ ~ ~ ~~ ~~ >~
.-i M M M cad . U
V
0 0 0 0 o d d ~ U ~- ~, o N ~-~ N .-~ O O O N t ~'"p N
O ~O N M M
v0 M v0 t~ ~ N Oy .-~ N N ~~ N
N ~ N
m vwn 'n cn v~ m wn v~ vo m T7 b b b 'c7 b b b b b zf b ..
U U U U U U U U U U U U
cd cC a1 at N cd cG N cd cd cG N
.
cC a5 at cG c~
N
w ~ U sv o .~ ~ o Pd.~
M ~
M '~.~'~d ° .~ W
w ..~ b ° r! -'~' ~ v an .~ ~ a~
,~, ~ m F~."b d p x m A
a a A
a a a ~ ~ ~ v d ~A a ~ ~ ~ a ~ a c~ ~ ~ H ~ a a poi., W ra ~ j ~ ~ O' w ,.~.a ~ q ~ ~ ~ ~ '~
H a > ~ a~ a~ a a ~w A~ ~~ ~~ ~~ H~ ~W ww w~ ~~ a~ a~ Hw f~ t7 w ~ w E-~ d w aw ate' ~~ aW w~ ~~ ~~ ~~ a~ ~w ~w ~j ~'W WW ~w ~w ~W ~~ ~~ ~w > ~ ~ Via., ~ q ~ ~ ~ ~ j ~ a ~ ~a,, ~ yd d d ~ ~ ~ ~ ~ d w ~ a d w ~ a-, a~ a, a, c" w E-~ w a w r" a, w a.. a., o' w o' a, w wA w~ w~ w w> wH w ww w wH wH w d w ~ w ~ ~ ~ ~ ~ a ~ a~.., ~ '", ~a ~~ ~~ ~~ ~~ ~~ ~~' ~~' ~~' ~c~ ~~ ~~ ~a w> wa w ~ w w w~ w~ w~ wa ~w A ~ ~~ >~ ~a a ~a ~> ~a ~
, , W W W
o ~ °o °o °o °o °o ~ , , , H
E-~ O ~ O O O O O O O O O O
N p N t~ 00 lp V7 01 M l~ h M
~O v0 .-~ oo ~O oo O O ~O ~ ~O
O d' O .~ N N V ~Y cf1 M .~ .-~ .-, ~ i oo ~, d' 01 O I~ ~O ~ ~ ~ , , ~D ~t N N O o0 h I~ O ~ h h ~n ~t m .-~ N N dwt m N
~n ~n v~ wn v~ ~n m ~n ~n v~ v~ m b b ~ b ~ b b ~ b b ~ ~ b ., .. ., ., .. ., ~ ., '., " ~ ..
U U U U U U U U U U U U U
c~ at aiaS c~ c~ ai ai c~ aS ai cC cct O O O , . . ' x x w a x d H C7 U '"~w x a ~ a H
C7 j d~Aa~~~~a'~'.,~aaw ~ ad.~ ~ Pd., ~' d a ~ ~ P'' d ~ ~; ~ ~' ~ ~ ~ v~ d U ad., ~'' ad..~
a ~ ~ ~ ~ is c~, d~
d ~ d ~ ~ ~ a ~ w ~ d ~ ~ ~ w ~ ~ ~ ~ a ~ w ~
w v~ w w ~ d a ~ v~ v~ ~ a d w, d v~ d ~ d a d a d x d d d d ~ d d d as x as a.~ as a.~ ~ as a as w w ~ as ~ w ~ a.~
~w ~cx7 ~~ ~a~ ~> ~~ ~ ~x ~~ ~j ~w~
v~ ~ v~ ~ v~ ~ v~ ~ v~ r~ v~ ~ v~ rr~ ~ vs r~ d v~
~a ~w ~~ ~w ~w ~~ ~~ ~~ ~~ ~d ~
b M .-m--~ M M M
O U' C7 C7 C7 C7 C7 'y . °
w w ~ ~ .
'U C7 A v '~ E-~
0 0 0 0 0 0 o d d ~ U e2 ° o 0.1 C7 c,.., c,.., w m ~ ~ ~ 4..~ ~ 0 0 o E-~ rr;
~-~ cV ~ N .~ tV .~ O O O N l~ p N
O o0 ~ 00 ~O M ~D l~ ~O O ~ .-~ M 01 ~ O
.-i N .w N ..-~ N .--i N Ov .-~ N N .-, N
v~ m m vwn v~ vu v~ m vwn m v~
b b b '~7 b b 'i7 b b b b b n7 .. H .., a .a .. ., .r U U U U U U U U U U U U U U
c~ N at ai ai ai c~ at cd c~ cC c~ cd cd O O O O O O O O O O O O O O
N
. U
O
rN.,cd NN
--~ by .
.,.., .a d' ,~ U
Q ~ O
~Q'~"'~P~
d ~ m 'W .s A
a~ d w a A
a w A
a a a ~ o' ~ ~ ~ ~ a ~ a H
rwn ~ ~ .,~ ~ W a ~ ~ .,~ ~a r~ a ~ ~ a~ a~ a a ~-1 ~ ~ a~.~ ~ ~ v~ a~ ~' P-' H ~ r~ ~ w as ~' ~ O' ~ O' a~ ~ as w ~v~ H~
as Zcw7 ~~~., ~~ ~~ ~~ a~ ~~ ~~ ~~ ~~ ~w a~
~a ~~ ~~ ~a ~~ ~~ a~ ~~, a~ ~~ ~~ ~~ o'H
a~ A a~, ~ a~..~ a~.~ v~ a~..~ H adi ~ a~.~ ~ a~.., w ate., ~ a ~a ~a ~ ~ ~~ ~ ~~ ~ ~ ~ ~t~ ~ ~ ~a ~xo~ ~xA ~~ ~x~ ~x~ ~x~ ~xa ~x~ ~xa ~x~ ~~ ~x~ ~xa v ~ 0 0 0 ~O o 'W~'' w v~ vmn 0 0 0 0 0 ~ w w w z ~, o ~ 0 0 0 0 0 0 0 0 0 0 ''-' N '''' N ~ oo vo ~n ov m t~ v~ cn ~p ~ ~ r.-~ oo ~0 0o O o ~a r, .~ ,-~ .-, d'O~ ~ NN~d'MCn ~ ~ i W O ~ d' Ov O l~ ~O .~ N l~ l~ ~n-v0 ~' N V1 O o0 V1 I~ O OWn ~n h N ~ M .-~ N N dwt M N .w b b '~~ '~ b b b 't7 b :'C 'b b b .H .1 .H N ~ .r .a .., N ~ .-n -N .., U U U U U U U U U U U U U
ai c~ c~i N N cG cd c~S N cd cd at cG

H
M
W
O
O N
O , ~, ;' N
~b '~ U
m cV
b c~
c~

w H H ~ w p~ ~ '~' ~ ~ > rx a, ~ ~' ~ ~'' ~ O~
a w w ~ ~ ~ ~ U W ~ ~ ~
x a' O'w ~
W7 a > ~ w H aw..~ ~q., d ~ L7 a; ~ ~ w ~ ~ p., ~ ~ O' ~ A w wHH~~~~'z~
a~x~W~~~~x ~~~.,H~~ ~~aa~~~E''H
~a xHv~H
~w~~~ ~,C~7aa~~~x~~
a ~ ~~a~w~H~~z~
c~aa~
~~~a~ ~a ~x~~~o,A~
v~ ~ v~ H w r" ~ d ~ ~1 ~
~>~~~ a~,~H~ ~~H~~
U vy a ~ rx rA''n a~-~ P'' ~ ~ E, ~ ~ ~ pi zs E,w ~dc7 AC'7H~H ,~~
r~r~ c~.7 ~ d~ ~ ~ ~ ~ w w w~~~~ ~~~~~de.7d>'~
a ~rx~>a~ a v ~~~~o, ~~~xH~~a~~
~A~~~ A~a~H~~~~~
~~~>A ~.>~~~~ ~~~. ~w o ~~w~x~ ww~c~~a~o~~~
A b ~c~,7a~,cw7z ~w~daW~~~~
"'a ~ ~~~~~ ~~ww~a~.~~W~~a wwo~a,~ ~~~~W~~~~A w~
W ~~~~z~~~
~a ,tea ~~~~H H~~~~~~~~
W ~ ~ w w > ~ f~ > E-~ a ~ a ~ ~ ~
., p N O
H
i.i pi ~ bD ,3~ O H
U U
~i ~ p, V ~ N 4i _O
U ~ °' N v~
~a ~ '~, ~,y +.. ~U.~N
.fl N N 0 G~, ~ '~+~' W P~.i x ~ ~ o w N
z y a M
~w U
~d a\

H ~z ~~>x Wa~,~H~Hrxa ~ E~-~ x C7 W >~ ~ a. U ~ A ~ ~ a r~aa~
'"d~w >~z>»1o'w~
a, H > ~ H ~ C7 ~~> axAw °~~~A~ wH~~~~~~a,,~'~~>
c~7~a~~ ~aH.,wEH-i~~~~H
> >
~~H~~
~~~a~x~~~
a~~,~~~~ oy~a~~~aa~
~t~o~~~H~~w ~ ~H C7 ~ d~ q ~ dt~7 a a ~a~>~
~>~~~
U per., ~ ~ ~ '~ r~'n ~ ~ ~ ~ ~'' a~.a ~' ~~ a~.~
Pq-~p~.,rHn~HP~,~~~~
a H ~ r~ ~1 a. ~~a~~ C~7~~d~~'C~'.7U'a~
W w W ~ c7 ~ ate', ~ ~ ~ ~" ~ a a'' a "' ~,>~~~~~~~~
,~a~~~~~'~a~~
A~a~~~>~~~
o ~~~~~ WW~~~~~o,~H ~w ~x~~o~w~~~~
~wH~> a ~, a AHD>~w~~>
~~~~a ~~~aA'~~~a ° ~~'~~~ ~~'~~~~~~~~ a ~~~Aw ~cc77~tw7Z~A~>A w~
~~~Z~ ~a ~~~~~~~ a a, ~ U' ~ ~ ~ pr rs~ L7 ~ w w ~~~~~ ~A~Ha~a~~~ ~

on ,s~ o y V o ~ ~ v a Pi a» v d a, ~ ~ ~ o ~'n a~ .~n ~, ~, _.~ ~ v ~, ~ °' o H
W P~ i~'' o N
z a w ow M
V

wHH~ ~rx z~d~>x ~H~~ Waa~,~~~~rxa ~aa> o'wA
~~x~w ~~~~~~~~z ~d~w~ '' o~~aa~
~'~' ~ ~ ~ ~ ~ ~
~a x ~~az~~~x~w x ~~aA~~~~w~
~~~'~, w~A~p~C~7aa~
~~xx~~~~A~
~~~~d Hr~~~a~c~~aA~
Ana a~~~~~~ H
~~~a~'w~H~~
d a~a,~~ dr~na~-~°'~'~'a~.~a''~~ d a o. ~ ~ a ~ ~ ~ ~ pq., ~ ~ ~ ~ ~ p, H a ww~~~ w~~~~~'-a~~~ a V ~' ~ x E-~ ~n a~ r~
~A~U' ,.~a~aw,~~H~~ C~7 a-; U
w~ ~P~~~~~~ aw v ~~~~a ~~~~Aw~~~
AHU~~W~~~
~~~~aa ~A~~A~~~~a ° U '~ w' ~ ~ cn ~ a' ~ ~ ~ A ~ U ~ U a w~~dW ~~~wwc~7~~>A w~
~" ~~~~U ~a ~~~~ ~~ a ~a.~~ ~d~p~,~rp~rnC7~ww w ~~~~~ ~A~Ha~ad~d ~
...
du .~1 0 0 p ~ ~ U U
O
W d G~ U cH N 4~
p a"
f/~ ~ O
N
d ~ U . v~ cc3 .D N N
W P.r '~' ~ °' ~ ..fl m o N
z a ~ U
o~
p W
U m U

w~H~ W~a~~~~H~a ~~~~~~jHa a'~~>W~a~~
w ~ ~ H ~, ~ H ~ c7 E-~ C7 ~ Z ~ ~ ~ ~ ~ w ~ ~~., a~.~ U
°~~~A~ ~H~H~ ~z~
a.. w E-~ ~ ~ w E-L~7 ~ ~A ~ O'~' x ~ w w d ~
~~~a~~~~H
a~a~~~~~~w a ~ a>
~~aA~H~~w aP~.~wHaEw'' C7a~.~a~-~A~dLC77,.~aa~
~~~o,~ ~~~x~~~~r~~
A
U ~~~ ~~ r~n~~~~~'a~..~~~a~-> ~ ~ ~ ~ ~ ~ ~ ~ ate... ~ H ~
w o a~~~H ~ad~~~~H~w AHOY ~>~~~~~~a~ a W ~''a~.~~~~ v~,C~7a -~~- ~~.,~aa~.,a~
a~
w ~ ~ A ~ > ~ ~ ~ ~ ~ A d ~ a a H ~ t7 w~a~~a~~~~ ~w o ~~w~~ w~Oaw~a~H aU
~x~~~w~~'~~
wH
~a~x~~ ~AwU~~~~~A a A
o ~~~Ha ~~~~ ~w ~
P., aU,A~~ L~7 ~~~A~ A aU,a w Wa ~Z H~~'~a~~~~z w ~~~~~ ~A>Na~a~~~
b v cd, w tn ,s~ 0 0 p ~ ~ U U
t~ f~ d"
U ~ °' ~ ~ _~ o ~'n R. °' ~ ~ v .~ .d o W .~°', x N
a~ Z
O
R, w M
U oW
m U
U W

~~x~w ~~~~~A~Ha a> aw~w~~>
a ~ d ~ U ~ w p~~
o'~aa~a, ~~~~w~a~~,aA.,U
C~,7~~~~ ~a~.~wHE~-,~~~E~
aa~~~xa>
a.. ~ a, a v~ c7 ~~~A~a~~z ~~d~d Ha~,~ ~~~aw~
a~~~~~~~~~
v ~~~a ~ H

.a, ~ ~ ~ ~ ~ ~ ~ ~ c7 '~' a a w w~~~~ ~~a~~~aa~,~~ a~.~
aw..~ ~ ~ ~1 H ~ ~ ~ ~ ~ ~ A ~ a x~
A~p,~H~~d t,~7 ° w~~ ~~w a a >~~~~ ~~c~~o,~~~~~
~~,w~~~~~~~ '~
o, ~ w d~~aw ~t~7~~z~w~~~
WdwzU ~,.~a ~~>~~~~ Wa H
w H~~~r~ ~A~Ha~a~~~
'"
a~ .~
U U
P,,i V S~ .~ ~ '~ 4c~
_ Y
O
C/~ vl O
~p Y
-1-. C7 ~ ft3 r~
w Qi t~-i ~ ~ O
N
z w a a. w w U
~ W

E

»~~ Wr~~zr~a~>x tw7H~H ~°~dc~7~'~~~~.,a ~Hx~w a~~~~qo,~~x rxaa> ~w ~wHw H~L7 H~~Z
o°~aa~ wHH~~
a v~ C7 A C7 H v~ H H ~ z >
w w ~ C7 w a~"'., >
a.~ ran ~ ~ ~ L'~7 ~ w ~ a~ E~-~ x a ~~~A~ a~aA~~~~w~
A ~ ~ ~ w c~ ~ ~ q ~ ~ ~ d z ~~~a~
~~a~~ ~~H~~~~~q~
~~N~~
v H>~~'~
w~~ ~~a~,a~~~~~P~ w ~~a~~' w ~ ~ ~ j ~ ti ~
~aw..~~~~1 ~~W~~~~~ ~ a x~~a ~qd~~ w~~~~~ v~x~ a.

~wH~a~'~~~~ ~
~~~>~
HA~Ha ~~~ ~~w~v~
~WO~~~x ~~~~a~Aw~A ~
w~'~Aw ~a >~~'~~~~ ~a ~aa~z~ r~~~~ol~c7~ww ~
w ~~~~> ~A~Ha~~~~~ ~
.'., '" ~~° ~
on .s~ o ~o '~ ~ U U
Q+ U p, 0 t~ y ~+~r ~'o .r a~ ~o C, .d .~-m..
y '.G ~ ~ ~ °> o W P~.~ ~ ~ °~' o N
z a w w v ~. w ~H

wHH~ Wa3~~~H~a ~ aN, w ~ ~ ~ ~ w ~ ~ ? ~' a aHxc7w awA~aW~~z rx a ,..~ >
~~H~~~dC~~7 ~dd~~0'a~.aaA,U
a~aa~ wHH~w ~Hv~Hw~ ~H
L7dd~l~ o,ww~w a.,w ~~H~~ ~~xa~WHH~
H ~ ~ a'' ~ c7 ~ w ~ a' f~-~ x '.-' W
U, a z d t7 aC7~A~~~ a>
zn ~ d ~ C7 d d q ~ ~ ~ ~ ~
~~N~~~~~q~
w ~>d~~ ~w~~~td7~d~~
~da~.,d~ a~..~aE-'..~~~~~~d Ha~~~ ~~~a~'~~H~~
w~~ dr~na~"O'~vA'',d~''' i,, as a > w d ~ W
'G, ~~ddd ~~~~~~~~a~ a ~.,w~n~~ r~~a~~d~ad.,arr~
w>~~~ ~v~d ? ~ d en ~x a aW. ~~'~~a -~~
~ A ~ ~ ~ A ~ ~'d ~ H~' ~A ~ w~ddd~ v~~~ a a ~ ~ ~ ~ ~ w W ~ ~ ~ q ~ d ~ Ed-~ ~ C7 x ~' d z a ~ a~ ~ > A w ~ d d d a ~~"~a~,Cw7z jwH~a~~'°'~~ ~
d f~ H U ~ W ~ ~ ~ ~~-1 w ~A~w~A~~~~a ~
>w ~' ~A~~ ~~~~~~A~U~ ~a w a ~d~~0'~c7~wW
W w~~a~.i> ~~~E~-~~a-1~~~~~ w~
.'., a~
ornf ,.c~ o H
p ~ ~ U U
~i U ~, U ~ N 4~
4a CS' C/W n O
U
r.. y +.. ~ U .~ cc3 "G '~ ~ ~ N O
H
ww x N

z a w ~a °a U
a~
,w ~w ww wHN~ Wa~~H~N~a ~~w~ ~~~ww~>Ha °~~~Z>a~a~x ~ c~7 ~ Z ~ ~ ~ ~ > t7 O'~ ~ U
~H~Hw~~~H
w w ~ w > ~ w c~~~~~ O~~x~~w~~x ~~H~w'd r~n~~a~~~r~nH
H~~~~ ~~~z~~~x~w a~
~~~~~w a~~~~o~~~z ~~~o'~ ~~~~~~~~A~
aw~v~ Hwv~°~
a~ H
v ~~a~~
~~~a~a0.'., w~~
o A~a~~ ~~A~~~~~~H
w ~~~~~ ~~a~~~~~~'~ a w w ~ ~ ~ ~ ~ ~ ~ C7 ~ ~ ~ ~ ~ a ~ c7 > q ~w~~a q w w ~ ~w ~ a ~ ~ ~ ~ ~ ~ ~ ~
a~
~~a~- Cw7Z ~wH~~w j"'~ a~,~
waHC.>>~~~~A a ~~>Ha ~~~~~'~w~~a a ~wo~~~x >~~~w~qw~A ~>
a~~Aw ~~w~z~~~ ~ '~a C7awwU ~~~~~~C~.7~~W ~
w ~~ww> ~~~Ha~a~~~
.o on ,r4 o w p ~ 0 U U
Ai ~ Q t~ N 4~
U ~

~'n +, Y
~I C1 U ~~ CC3 W P~Wi N
O

a ~a w~

wHH~ ~a~z-~~~>x a ~ O' w ~~a~w ~~Acw.Ww~~z ~~~>w~o°w~
~~~z ac7aa > o~~r~w ~~~~w~~z>
wH
~~H~~
~~~a~~~~H
a~~,~~~~ o,~az~~~x~w ~~,~A~ ~~o°A~~~~a~
~~~~~a~aa~
w ~~a~.,~~ ~~w~~~~~~w~
w r~ C7 a ~ ~; a, ~ a~ ~ ~ a, E1 ~ d U ~ v~ ~d ~ c7 r~ w ~ A ~ ~ a, ~ ~ w ~>~x~
w~~ ~C7dp~~v~~~,~ w o ~~o~~~ ~a~>~~~~~w wr~d ~ ~~qd v~w~,aH a a. ~ ~ U' ~ ~ va ~ ~ ~ ~ ~ ~ ~ ~' V ~~~~qa ~~~~~v~,~~d~ a w~~~
c ~ ~ w w > a ~ p~~ ~ H "' ~ ~ ~
~w~xd~~~~~~x o ~~~"~~~ w~~~~~~~w.,~~
w ~ ~ w w ~~~~x~a ~aW~~~~~~a ~ ~ ~ ~ a C7 v~ ~ ~ ~ ~ q ~ ~ ~~O' d ~~a~ U
w~aw~ ~~~~aa,AwwA ~a ~a~~~
z> z ~a~~~>~~~a za w ~x~~~~ ~a>H~~a~~~ ~~a .'., .f~, N . ~ Q, N
~ Pi 4~-~
S~ U .~ ~ .~1 O
yv Pi U ø, U 4y N cN
~ N
U ~ ~ ~ ~ ~ °
~'o a~ ~o a~ v ... ~s W ~ ''~~ ~ ~ ~ .o o~
N

z :.
a 'c, w °w U
t~ W

~~~a~ wo~a~.~~~oeA~
o'~aa~ ~~Awz~~~~
~~o~~~
~ Q > w ~ ~ ~ H
rs~w~rxrn w~,~,~'p~~wE_-A~~~~ ~a~,w~ac~;~;x~w a, ~x~w~~~a~
~~a~.~~~ ~rx~a>H~ w i~ ~ ~ v~ ~ w ~ ~ ~ ~ a a~~a~~~~~w~
a~a~~~~~,~~
~~d~~ .~~~~~~~H~~
~~~,~
v ~~a~~d ~~~AW~~~aH a ~ ~ '"' ~ ~ ~ w ~ ~ ~ ~ ~ ~ a~
w ~~ d~a~..~a~~>~dd a ~W~dA C~.7>~~~w~a~~
W ~ ~1 ~ U O° ~ C~7 a ~ ~~., > d C7 ~n a.~ q w ~ ~ cn ~ ~ ~ ~ ~ ~ ~ w ~~1 ~>~ ~~aw-~~~ ~a~.~
~~aw.,~~~,~a~~ a w~~~~wW~~~ ~w ~a~~~Z ~a,~ ~~ >
w~ A
~~~~r~~~~U°~
~o w~>~a ~wH~a~~w~~ ~, a, a~., w p' ~ ~ A E-a U > c7 ~
~A~~A~~a~~a L~7 w w~~~~ ~~~~~~~~~z wa ~ww~a~~
o. ~ w ~ E~-~ ~ ~ a w ~ ~ ~ ~~"' ~ ~
~~~>~~A~Ha w a ~ ~ ~ C~ ~ ~ ~ H aa~,~A aa, .., .c zw .s~ 0 0 p ~~ ~ U U
ai Q, 0 c~ N
~." p ~ ~ C'3 U ~ ~ ~ ~ ~ a ~'n Or ~ ~ t-a 'S~ ~ .-O ~ N O
'+'~ t-~
W W r~i ~ ~ O W
N
o ~ w a~
M
U
W
o° a ~H~~' w~~~H~H~o~
H ~' a~ ~
dHx~ua ~~~waq>Ha ~~~a> a~z~~~o~~~
as H w ~ H d c7 H~L~7d~ ~~~>~~'~AU
aC7aa~ rx > w ~z>
wwH wH
~~a~~ aHx~w~~~~
a~~~~H
a~'', ~P~., ~a r~p.,wH
~' H
a~~A~~~xa>
~~~°'A~a~~~~
>~~~ Hw~~a~~~~a v ~~ ~c~.7 ~w~q~H~~~"~~
H
a~~~d ~~~o~~~~~~.,~~ w ~H
~~~~~~~~aH a w~~~~ ~'~a~~~a~d~ a v ~x~>a ~~~~~~~~
a~o,~HH~a~~
a ~~~'~ a~w~~ ~
b rn ~ w ~ W ~ ~ ~ A w ~ E-~ a W
~ w a~~ a~, ~~~dz ~wH~°~w~~~~ acw7 ~~r-HT-~w~~~~~P~ ~a~.~
o ~~~Ha ~~~~ ~W
w w~~~ ~~~~~~A~w~ ~
~a w Cw.7~~aw,~ ~~~..,~a~. ~rr~~~cw7Z Cw7~
w t~~~~rx ~~~Ha~a~~~ ~
..., b N v c~"
by 00 ,.c1 o r-y W ~ U o ~U o P; c o °' U ~ °' r. ~n ~ ~s a~ ~o *' .fl ~ a~ .
~ o W a, '~~'' ~ °~' o N

z O
a c. w w ~a M O
V
a~
c~ ~

wHH~
E" ~ C7 ~ ~1 ~ H a a~'~>~'wa~~
H~~~
a~~A~ ~~~'~~ ~z>
~ c7 O'w ad ~ w ~ w ~ ~ ~
C7 w ~ A ~ ~ ~ x a ~ cw7 ~ ~ ~
~~Hx~
o,~az ~~x~w a~~~~a>
r~na~,dA~ C~7d~A~pc~7dW~~
a ~c~na~' ~p~''.,H~~r,~~~Ca.7~~
A ~ r~ ~ ~ ~ w H
w c7>~1 w~H ~Hw~x v ~~a ~ ~w~q ate, a-~~a~,~~Aa~.~~~~ a, A~d~~ ~~A ~~a~,~~H
°' ww~~~ ~~a '~'~r~n~a~ a wW~~~ H~~'dd~~~~dd ~W'~~a ~w~~~~~~~~~
a C~7~~~ w~~~~a~w~~ ~aU..~
V ~ ~ ~ ~ ~ ~ ~ ~ ~ A ~ ~ d ~ ~ a ~~a~,cw7~ ~WHdaw~~~ a~,~
x o' UW'Ha ~~~ aw w~a ~a ~~~dZ.~~~~~~ ~a ~~'a~~~ ~d~~~~c~7~wa w ~x'~~a~,> ~a~Ha~a~~~ ~
.., N ,o sue, Pa '''' on ,.ci o p ~ o U U
C/~ m O
'~; ~ c~i C7 .-r ~ U .~
N
o ~
W P.~ ''~'', ~. a w w o ~n cv U
M .-~ P..~
U U
O N
~°z~

CW"7 H ~ ~' w ~''' '2r E-' ,~' E~ ~ d H ~' a, ~ ~ A ~ E.., a ~ ~'' w ~ H ~ c7 > ~ ~
~~qwUwx~~
d ~ w ~ U w A O'a, a >~~~~~H~~
~L7dz ~aaw~v~°'~AU
~~~A~
~C7o~w~ Cw.7HwH~~~~~
~~H~~
aA''.., ~ a~., a ~ O' ~~H~~ a~~a ~~aa~
a,~a~~~ a~c~~~~~~w ~~~w~o'c~~z~
w ci, rsa a f~ rn a ~ a a ~wH~~~c~o'q~
~aa>cn v~w~~~~~~~~
a, r~n~a~.,~~
~ c~7 H ~ ~ ~'' ~ 'x d a ~
c ~~O'~E-~ ~a~'d~w~~~
~d~~ ~7~~~ ~~~o'~ a '~ ~ ~ v~
a ~q~~~ A
~~w ~ w~ ~~q~a ~' a U ~ ~ ~ ~ a ~ ~ ~ > A ~' ~ ~
xx o'w~
~~~~~a ~a~~~~~w~~~a ~
a. HA~~a ~~~> A~~' d~
A
w ~Waa~,~ ~~'~~~~~w~A Ua ~~~~w ~a ~d~~a w ~~~~~ ~A~Ha~~~x>~ ~x~
N .O
by ~ Pi ~U ,t1 O s-, (~i ~ O O
O .~ O to cUC
Pi ø, o ~ ~ 4-, U ~ °' ~'o °' ~ ~o _~ ~ a~ ~ a~
U -a~' U ~~
.fl N N
C, W P~ x ~. a w w ~n M U
M ~ p.., U
rsi O N
x°z~

A
o'HxC7w awa~,UUw~~a ~~~~w~0'aa~
~~~w~ ~~~~a~qv ac.~7aa~ ~d~~
~ c7 pe ~' d ~,~~w~~~~
c7 d d ~ cn 0' pi C7 > W d d r~
~~H~~ r~n~~a~~~r~nE~
E~- p_, ~ ~ p.., H~ Cd.7 d z ~ ~ ''w~ ~ w aC~7 O'~ ~ ~ ~ ~ a A C7 H ~ ~ w ~ ~ d Ew-~ ~ ad.~ ~ q ~ d t7 a a wwv~a ~a.~H~dd~"C7q~
~ ~ d ~ ~ v~ a~ ~ a,, ~ C7 p~ w v~
a a~ > rn H a~ ra ~ ~ ~ d d ~ ~
L~7~~~~ ~ H~ ~~Hrx~
v ~~a ~ ~~~A~Ha~'',~~~
H»~~ ~~~a~~~H~~
~a~.a~~,,~~~~
H d ~w"'~~''add ~~~~~~~~a~
w~~~y a,~,d~c7~7ad~~
a ~q~~~ a~aw,~~~~"-~ ~
.p t7 ~~wwa ~w~~~~~~~
~~d~ w~~~P~a~w~d ~
~ d H d U x C7 ~ ~ ~ ~ ~ ~ ~ A ~ ~p., as ~ a ~~P~-~Cw.7~ j W E~'-~~aw j'i'b ~rs~
~~~>~ ~AW~~~~~~~
~~~Ha a~ ~ ~ x ~ ~ ~...a w w w f~ ? a v~ ~ P-' ~ ~ v~ ~ ~ ~ ~ ~ ~ ~ w 'w'a v~ ~
H x w ~~~~~ ~~>Ha~a~d~
on ,.c~ o U U
° ~ o p Pi d p, V c~~., a~ 4 ~_, ~ +~
y ~ v~ ~ a' U a ~ ~ ~ ~ o ~'n '~ v~ ~, ~ +~
r: ~ +~ ~ v .~o ~
~_ ~ ~ a> o p., ?~4 a~
W W r~' ~' ,.
o N
z v w U '~

r, wa~~~w~'~~
a ~ d t7 d c7 p,~ ~ Z ~ ~ w ~ ~ ~ a~ ~ >
~ ~ ~0~~
~HH~w~HH~
~ ~ w H Ea-~ ~ aH.~ w EH-~
H ~ ~ ~ w p~H x ~ w O'~" x ~ W
aA.~~~~ r~'n~ a~~C~ ''4~
H~~W~H~~z z ~~~o~H
~~dwa~~dw~~~
~C~7~~~ Hp~..,~~r'''H~~
F4 H ~ ~ ~ C~7 pA., ~ H ~ ~ P~-~ ~ H ~~
U ~ w ~ ~w~~~~ad"~~~
.n a ~ p.., ~ d ~1 C7 H ~ H ~1 C7 H ~ -T~-~
P~ H O' d H w yn a w w ~n a o W~~~'~~ ~a~a~~a~~~
a. ~~~~A ~~~d~r~nd~ ~ a >~ ~~ ~~~~~~~d~~ d U ~ ~ ~ w ~ ~'' ~ ~ ~ H ~
c C~7 ~ ~ ~ q a ~ d~ H ~ ~ ~~ H
y ~ ~ d ~ ~ A ~ d ~ ~ A H d ~ a ww~~>ww~~~ a~
U ~ a ~ ~ ~ a.. C7 ~ q ~ w C7 ~ f~ a ~dH~~ ~,x~ a~,xr~do~ >
~AW~~~A~w~ dH
~wo,~~ ww~~r wwd>W ~
w ~~~Aw ~v~~~~vd~~ ~a a a~EH-~~~ H~~''~o~,aH~da~.~~ a w Hrxww ~A~Ha~e~~Ha H
a;
a U o :~ ~ o U U
p.~ ~ p. o _, ~ _o _ °' ~
U ~ ~ ~ ~ ,~ ~,o C~3 ~ +..
~.~, ~ ~ .fl N N
Q, '+~ c-~
w f~ r~i ~, ~ O 4~
N
z d ~a c. v~ p~
w o cn m v~
U
oa H H

~~7awd Wx>~~~»d~
c~w~
~~~'~a~, a~~~wa~x~w c7 x ~ a ~~~>~~~~w~
A~H~H WH~~ a~aa w w rs~ a ~ ~ ~ a ~ C7 ~1 ~~xa>~~a~~
~~",,~~z~~~~~~
~>~~'~ ~~o-A~~~~~~
w ~ ~ ~ ~ ~ ~ ~ A cA''7 H
~~a~~ ~w~~~~~~a~ a w w>~~~
v ~~~~~ ~~~A~~~~~~ >
~r~~ ca ~~~~'~~ w~~ ~>
r~ ww ~ ~a~ a~~ H ~U
~ ~' ~p.., ~ > C~ ~ ~ U
w ~C~~7~~~ ~C~.7'"~'~~v'~~~ ~ a V ~ ~ "~ ~ Z ~, > ~ ~ ~ ~ ~ ~ ? A a a~~~~ wH~a ~w ~~~Ha ~w~~~~~~~~~ ~>w v ~wo~~~x w>~~~~~a~,~ aU,c~
~~~Aw ~awrC7>~'~'w ~a~a~,H >~~'~~~~~~~
Ww ~a W ~ H H ~ ~ ~ ~ > ~ NI ~ ~ a~.t o a ~ E-~ vW"' ~ v~ P-~ ~ ~ A E"'' a ''a Wx~~~w ~~~wa~W~g~ Wa ~ ~ ~ c7 ~ ~ ~ a ~ t7 Z a ~d~>xa~a~z~ ~'~' w ~aa~~A~ ~~>Ha~~~a>
c~d~
s~~. w .~ ~o .s~ o ~, .~, V O
P~I ~ ø, V ~ N
C~
C/~
~ "y--~
°~ o W P.m~i ~ a. '+~. ~..~
o N

o a~
~a o ~
v ~z >~
.>
°' ~ U

~x~~~. wo~Hx~w a~.~ ~'~' W~da'' C7~~aa>
~ H ~ ~ ~~ ~ ~ ~ ~,~ ~ a a ~~~a~ ~~>~~~o,~~
W ~ ~ d ~l ~
~ H ~ ~ a ~ ~ H ~ ~
~ ~ x a j A ~ ~ ~ ~
H ~ ~ ~ ~ ~ ~ ~ A
~~O'~~ ~~ca7A°r~PaC7H~w d a ww~aH a w ~ ~wHr~~~7~~1~~ a ~~~~a~,~C~7a~~
~~H~~
a, ~ ~ ~ ~' W x a.. >
v~ a~ ~ ~ ~ ~ v ~ ~ a~.~ ~ ~ p~., ~ a H q H o~ d E~-~ ~ w v~ ~ ~ d~ ~ ~ ~d d ~'~~'~z ~'~~~~ww~~~ a~
~~~~~~W~~o° ~w ~~~a,~ ~~~~~~A~j~ ~cw7 ~'~ q w ~ ~ ~d E~-~ ~ ran a~'' ~ ~ w ~
~'>~~> ~~v~ ~xt7~za v ~~,~'~j WW~~~~'a~' w~~~~ ~WH~o'~~~~~ w~
w~H~~w Z~t~7 a z~
~~~~z~ ~~'~~~~~~~w ~'a c~
~~a,~~~~~~~
~a~ ~> da rrn~~. p~", P" ~ ~ H ~'' E1 ~ ~ W ~ H~ (~-i ~~1 ~-W, W ~~a~.~~a~.~~ ~~~HaEa-~~a~.,w~
..., on ,.q o N
U U
O a Qi d ø, V t,~i N W
~~"' '~" ~ ~ ~ C
N
~a a" .~ ~ fn O
y 's c~ V~ e> a~ . ran y A. 'J ~ ~ '+~O O
O w N
~a o a~
...
~z w U
A ~

v~ w d ~ p~ r~ w~ ~ ~ ~ E-~ C7 d Z
~~dw at~.7aw~~
C~7 > a ~~ a~ ~ ~ a ~ w H ~ ~
~Cd7a rdn ~~w~~z"w~~~
a,v~d~x wHd~wa ~' ~~w H ~Hw~~~~~A~
a~w~d ~wxa~~~H~H
Axa ~ v~~~a ~c7~o,~ a w~d~ H~d~~ d ~' a a d >
~~~''~>~ ~r~nCa7A~t~r~7~q>rdn a ~w~~a ~AW~~ ~~~~~~>~
a, ~i ~ ~ ~ ~ ~ ~ ~ A ~ d ~ d ~ ate...
V ~C~7~~W ~ad.~~~~~a~,~~A
~a~.~~~~'w~~~~
a~~~~w ~a ~w ~w ~a~~~ ~~wxH~~~waW
~w~ q~o°~~~~~'~~
a w ~ d ~ ~ ~ r~ ~ ~ ~ ~ ~ ~ > ~ ~ w H~~~'~ ww~~~~A~Ha ~a ~a~'~aw ~W~~~'~wo~~
~E~-~Cd7~aw~
o ~~~La.7~~ C7v~d ~'''~~~~~ ~d tn v~ w ~ a.~ E" d ~c~ad.,ap~ >~~~~W~~~a~~' ~>
~ ~ a'' ~ ~ a C7 °' ~~~~~~ ~a~>~wa~~x~~ ~a a ~~~~~~ H~~~~Zv c~7 a w a.~wdw~a.~ ~~~Harnxd~w~ w~
..., w .~ on ,~ o s, p p~ ~ p, o U ~ °' '~ ~'n Ca ~
N N o C, ~
...
W P~~~ 'r~' ~ °v~' 0 4~-a N
°z~
o a w ode, U
~a a~ww ~e~7a~~ W O'p~.,~~~'~~
~w ~~~xN a~~~a~,~~~A~
>w a yd~d ~ ~'H~~'~~aH
wHa~d wHH~w~~a~,a~ >
~~w~~~7>~~~ a, a~xc~ ~~~ ~ a wAH~~ ~~~w~~'~~~~
~A~>a x ~ ~~x~
a~aa~a ~~H ~U
a~aA~A~o~~~ aw wx~
~~~q~w~~'~~
w ~~~~~~~x~~~' ~~w~~> w A ~> dH
~1 w w ~1 UWr~a~.~~ A~E~.., WwW~?w UCw7 wwv~a~~~~~~
o ~a~~~~ ~,,.~~a~av'~~~ww ~v~
~w> ~~~~~~aw~z w~~H~ ~~a~~H~~~~ Ww A~Na as tin W m E~-i ~ C7 w W ~ ~ ~ ~ H
a ~~~ a~ ~~°'~~~w°'~~ zw ~w.,~~~~~a~~,,~U
o ~o~~aa~ w~~~~z .~ ~
U ~~p,~~ ~w~?~1~~~~w.,j '-'Z
b ~~d~~~ ~w~~~WW~H~ ww ac7~~~ a ~ ~~~w~~W~,Hx~
~a~,~H~~ ~~~~~z~~ a~ ~a w~w"a~.,dq~ ~~dww'~'~~~Z~ w~
C7 ~1 ~ H ~ E., v~ C7 w ~ z Q° ~ a a ~ C7 u., C7 w r~ ~ a ~'' ~ ~ a rs~ C7 A v~ L7 a W ~ ~ a~, ~ ~ ~ ~ ~ ~ ~ d ~ ~ dA ~ W
w ~t~»~~ ~~~~a~~~H~~ ~x~
C N v b0 ~ Pi ~' 4a ,F~ by .r~ O i..~
0 ~ ~ U U
W
U ~ °' '~ ~'n a~'~ ~ w .N
e, .~ .fl ~ u~ ~
a., .~ °
W Pa '~~'' ~ ~ o N
z~w o a oa~.~w U ~~H
~wz x~~

a~~~H Woy~~a~H~w ~w~~~~ ~~~wz~'~~a~ a w~~~j a~~'~~~~Aa~
C7 a ~ ~ w ~ ~ v~ ~ w ~wqH~~ ~H~~~~>~~~
~Hx~W~~w~~
~~~w~~w~a~~
~~~~z ~~~z~w>~~~
w~c~~ a~
~~aA~~~~~~
~w W Ri ',~ ,~ p., ~ P-i W ~ W
z U ~za~~~ ~~~~~~~~~a w ~ ~ L7 d a~ ~ a ~ ~ z o w~~~H ~a~d~H~~~~ w~
N ~ w w ,.1 ~~~xC7~ v L~7~
~n z v~ c7 a a~ v~ ~ C7 ~ H
v ~~~~z~ ~'~~x~~~~aU
~a~~a~ ~~a~~~~~~~
~'~~'~~Ww~N~ ww W~~~>a~~~~ a~
V ~ ~ aA"'., ~ ~ ~ ~ aW-~ C7 ~ ~1 W ~ H w ,,~
E'' ~ x c~: ~ O' C7 ~' p~ x C5 W
b ~,~~~~ ~w~~~z~~~a>
w ran a~..~ ~ A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ W ~ ~ w o ~~a~..~~a~ ~~~ ~~dr~n~a~ C~7 ~~~~~W~~aq~ W
~a~~~~H~~'~~ ~a ~,~H~a A
w ~~~~x~ ~a~Ha~~~~~~ a ...
w .~ on .s~ o 0 p ~ ~ U U
Qi ~ ø, ' U ci~ N 4~
C~
v C~ V~ N N . ~
"' C~ ~' ~ U ~ of N N
a, > ~ ~~ ,~
W P.~
o Nax o~q~
z ~.
d~ a H
oZCw7 can m~~
V '.'' O' o" w a, ~wxc~>
~x~da ~°~~~w~i ~~~~
>~~~~
~ ~ as ~ > ~ ~d ~ W q ~ ad ~ a ~~d~''~ Cw7~~~WW~~r~~ >~
~w~-W~ w w,.~w ~a~~ ~~xaj~~~>A a ~~~w~~A~~a ~a °'~~A~~~~~A ~w ~~aw~~~~ ~ wz ~ p~"'., H ~ ~ ~ ~ ~ ~ W ~ v~
~ ~ ~ ~ ~ ~n d ~ ~
V H~~wE~-~ ~a~..~~A~~~~H~ a~
wa~x~w ~~~aH~W~~z w~
~~~~a~ ~~~a~~~~Aw 0'c~7 a a ~ ~ ~ a d ~ ~ a~ Z ~
w ~~c~7~a~ ~~a~x ~~~H
~,~~~~wwd~~ ww V ~~a~.~HE'.'~ ~~w~~a~~
a ~w~wa~- as w E-~iwr~E~-o~ ~
a ~, 'i' p~ ~ ~1 ~ w ~ ~ C7 ~ ~ ~' C7 ~ ~ w C7 ~~w~~H ~~~~r~
v~ a wxr~do~
a. a~a~~~ ~~~~~W~~~~~ w,w °' P~ ~ w w aH~~~~ ~~~~~~aA,~H~~ ~aa ~, ~ > ~wwp.,w~a., ~ ~w x Ei v~ C7 Pi a ~A~o~d~ ~a~d~~~C7~~H ~a~
W ~ ~ ~ ~ ~ F" ~ ~ aP~., °' W v~ ~ a~, d ~ ~ ~ a w ww~~~A ~~1>Haa~a~d~ w~~
.'., a p ~ ~ o v Pa a> p. o 1 r, O
O
a. .~
.. ~ ~ n~ a~ o o W F~.i '"~~4'' O ~ ~
~z~
pw~
o a~
w v ~o,~~
~w~~
wwww ww~~w .v~~, C7~ w d O ~' d ~ ~ w aa, ~ a ~ w ~ ~' ~ U
~~dza ~~AwWq~a~d a~
~~~..,a~.,cw7Z da'',~jwwW~~~
w a~ > ~ ~ L7 ~~~~'CH7~WH~~ ~w C7 E" rHr~ c7 ww~a~qww~
~waw~ a~x~ww~~>
~~a~,~~ ~
~~~az..~H a~aa~~e~~~z P.., a, ~ a ~ p, A ~ ~ a C~7~~q~H~~..,~~~
w da, ~' ~ ui ~~~~~~~a~w ~ ~ a", ~ ~ ~ a~ ~1 U v' w ~c ~~'~aa~ ~'~H~w~~~~~
vi C7 ~1 v~ ~ v~ a ~'' o a~~~q~ ~a~a~Ww~~'H Ww c, ~ ~, a""', ~ ~ ~ ~ d ~ d ~ w ~ ~ ~ ~ w ~~c~~~~ ~~a~xz~~~a~
~~~d~rnU'd W ~a ~ x ~ ~ ~ w cw7~~H~~ ~ aw,~~~ ~C7aa~
z~~~a~ a~~'~H~a~o,~w~
w~a~~~ ~,~~~~w~~~r~~ wW
o ~~>~~~ w~~~P~a~~H~~
~~>~~~ ~A~~~~~~~~~
a, r~ ~ w w w ~ ~ a W ~ ~ O' ~ ~ ~ ~ ~ ~ q ~ ~ a~.~ ~ a H ~ 0.' a..
° d ~ ~ z~~~a~
w~'~~~~ ~~w~~w ~w~~ waa ~~~~~~ ~~'~~z~~d~~~ ~,.waa °' ~~x~~a ~a~~~W~~~a~x Ha a C7 ~ ~ U ~ H ~ ~ a~., a a N~ ~ ~ ~ ~
W a ~ ~1 W w A ~ ~1 ~ H a ~ P.r v~ i.~ (-~ a .'., w° .o °~.
eu ,.~ o H
~ ~ o P~ a~ p, o c a, ~ ~ ~ o ~~~ d +~ c~ v . i at .fl ~ a~ o W P~.~ x o O ~ ~ ~
z~~~
0 o,~a~
o w ~ ~
~~wW
v a o; ~ Z cW7 aaa~

~~~aw ~r~~z~C~~~~
~~~~~a~aw a~,~z~ ~~Aw ~wa~t~
~ ~ C7p, ~ a w a' U ~ ~ aZ-~ H
'~z>
C7a~.~a~,wv~ ~ww>wwdH~
~aa'. c~"~~ ~EH- vH,E~w~~f.~~'~
~HxH~xrxxa~
a~~~aa ~~~aw H ~wz C7a~.~a~,y~~~~'~~
~'~
w~o°~~ ~a.~~ ww~,~aH a C7 ~ ~ a ~ ~ v~ a., a~dd~~Add a ~w~~a ~~~~~w~a~~
wA~~~ ~c~a~xH~~~c~
~~~>~ ~~~~~~~W~H ~
pe H q ~ ~~ ~ a ~a~~~Z ~~~~~w~~~~ a~
WW~~~~x~>~ ~
~~'~~a~wH~°~ ~a UWP~',~'.~ ~AH~U~~qWw~ UCw.7 ~~..;; ~W ~ ~ q ran ran ~
~~a~,q~ ~~w~~~~~Za v'a ~~~~z~a~~~ ~
as wo~~x~ ~~d~a~~>~a w~
~xxa~ ~~>HaU~wx~~Z ~
.'., N t~ O
.O
~0 ,~
bA ,t/ O t-~
p, O _ a> ~ H a~
c~ C/~ m O
N
N +~
U .c~"n .cad ~ °' o x o N
z U
O' w w a~
o M
~w Wa~~~Aa~~x a~~~~a~~~
z>~ z ~ C7 a ~ ~ ~ ~ w N ~.-a ~ ~ w H
a w~~~a~~~~
~~~~Wa~~~w ~~H~ a~ ~>~~ a>
~ a~.~ ~ A ~ ~ d ~ w H d ~ w a~aa~a~aa~
av~~7a~~~'~7A~
~c~aw~~~o~w~
~~~~~~a~~a~
w ~~a~H q~H3N~~H~W
w H a ~~~a~~~~o'~
~~A~~~~a~~ a ~w~~o' ~~a ~'~~a ~
d U
~~a~,~~ y~a~NA~a~H aw ~~~'~~w~~'~~ a ~W~~A~x~>a j H~~ a x do'~wx~o~ ~a H
~ ~ U ~ ~ A W U ~ U PW..' pi d ~ ~ pa ~ ~ ~ p., 'U ~ ~ ~ Pi ~
a ~~~~z~~~~z ~
.~ ~a ~>
wo~~x~7 ~A~~a~l~>~a w~

00 ,.cf o s ~ U o v ~ ~
vy, o~
c~
~, ~ cps ~'n a> p n~ ~ aWn U ' ~ CC
~~ o B' .fl ''~~L', ~ ~ 0 4~
N
z w .w o H
W W

w E-~ H ~, v~ ~ ~ Z v~ ~ ~ ~ w' w~
~~aa> o'~~v>q~x~z ~c~7~z~ ww~~7o~xAw ~~a~H
~a~,N~~
A~'~~~ H~~z~aHx~w a~Cw.7~~~~~a~
A~H~w ~~aw~H~ w~
w ~~~aH ~d~a~p~~az A x~~~~,~A~
~,~H~ ~H~
A~Hw~~w H ~ ~ ~
w ~ ~ ~ ~7 ~ O'~ ~ ~ ~
o A ~ d ~ ~ ~ ~ A ~ ~ ~ ~ ~ H a w w~~~~ ~~a~~~~a~,a~
~x~~a -~a~a~~~~~~.~~ ~d q~~~~~~~~H
ci ~~~., ~ j~~w~a~aw.~~~
W ,~ ~~a~.~~~ ~~~do'W~a~~ ~z W ~ >~ ~A~U~~w~>A 'a~x ,.a ~ ~,~~xa ~A~~A~~~ o, as ~
wAa~~ ~~~~w~~~~q w ~~~c7z~~~ ~ ~a w~~~~ ~~~~~~~~~W w~
x w ~x~~~~ ~~~Ha~a~~~
N .O p., b-0 ,.~! O 0 ~ O ~ ~ U U
pi ~ ~, ~ ~°r y W
G~
C. .~~' C/~ v~ °
~ a S~ N .--~ ~ U .~ c~-~~V
.~ N U
W P°'.m-,~' o d o ~ i °
i o ,~
o. ~ no ~' :~ ~~
W ~ ,~ ~ ° Cw.7 ,~ o '~ C7 U oo~ Paz ~z ~~w ~dd~~A~~a ~~x~w a~~~~w~~~
~~z>~~aw w E-~ ~ E-~ d C7 d ~ w a., ~, ~ ~ O' ~ q w o°~aa~
dC7o'~w"' ~o~'.~wE-~~~~~~~' C7 ~ ~ A ~ o° ~ x c7 > w ~ ~ ~
~~H~~
H~~w o'H
v~~ az~c~x ~ a~, d A ~ ~~ d~ ~ pecd7 ~ ~
v ~~~aH ~a ~~~~~~A~
a~..~>~ Hwv~~ ~~w~
o .
H ~ ~ ~ L7 ~ aC7, ~ a Ew-~ aa,. ~ H ~
o ,~a ~ ~-' ~ ~ ~ a ~ a ~ ~ ~ H ~
.,",, d H
~, ~~a~~ ~d~~~~~~a~ a w w ~ ~ ~ ~ ~ ~ ~ C7 ~ ~ ~
~ c7 ~ A
Uau ~ W ~ ~ ~'' ~ aw., ~ ~ ~ ~ a ~ q ~ L~ ~ ~ E-1 O' E-~ E-~ ~ ~ L7 ~Wd~~ W~~~~q a.,~~ w w~c~~w~a~N
U ~ dza ~wC7>~,~~'~~~ av~
'd ~~~tw7z jwH~~w~°'~P~ ~
dAW~A~x~~~ >~
'~~~~~~A~~~
awqw A a~~
ww ~dwwC7v, ~s ~ ~ H ~ C7 ~ ~ as C7 z va rr~ ~ ~ ~ as a. ~~~A~ ~a~~~~~ ~a ~a H~~~a~~~~~Z ~
w ~x~a,a,> ~A~Ha~a~~~ ~x~
c +' U U
O ~ O 7~
ai ~ ~ ~ N 4H
U ~ °' ~'o °' ~o r' y i'' N N
r'"
W P.i x ~ ~ o '~
~,,., .~ ~~

a~
da' U ..~ .~ :d a~
' ~ ~, '~"
V 'd O p ~ V n o ~ a ~ o b o ~n oz.°"'.~
M
v ~a~~~

~H~~ A
dHx~w a~~~dw~~z >~z~wAaa~~
'~'~~w ~ww~~a~Aw ~c~~z~ »~~~~~~,~
at~aa~ wNH~z z>
a r~ C7 A ~ C7 E-~ v~ E-~ ~ ~, ~ w E
a~x~jw~~
~~H~~
a~~a~~~xa~
~~~A~
v H~~~~~~~A
-~~- x a ~~~x~
°' ~'' ~ w ~ d d v~ w °' ~ A a, ~ ~ a-' w'~~a W A ~ o' ~1 ~1 W P; ~ ~ ~ ~ r~
o ~~~~~ ww~~~A~o,~H aa~, ~'~za ~wc7>A~~da~ a~
~ t~ H U ~ w w ~ ~ ~ a z ~AwW~~~w~~a ~
A
o ~A~~a ~~a, v >a w ~~~~w ~~~~~Z~~~~x~ a~,a ~~~~~~~~~w ~
w d~~,w~ ~A>~a~a~~~ d~
..., b 'o c~,a ego ,.c~ o P~ a~ p, ..
Rv d .-O N N O
:N
d w +~
W P.i o a~
~ ~ ~ o a 0 0 ~
eC m ~~ .~ ~ -G
C". _ bi0 d ~ .~ ~ b '.~'!-,'' ''~bD z '~ v a .''y' O N
Q. ~ ~ '~-~ .~ ~ a~
o z ~ .~
v ~a~ ob~.~b ~,C/.~~~~U~

cw7~wN w~'w -~~-a~~a~
~~~~~~~~>
c5~d~~ ~ww .-,~waw..,>
aw,H~x °,~x~~w~~x ~w'~'~w rid w aEw-'w~w ~~~q~~~'~a~
~~aA~a~~z~
w ~cw7da~ ~~w",H~~~v~,~~~
~~,>~
b ~' ~ ~ H w ~ ~ a, L7 ~ aw ~
~~x eon ~C~.7~~~ aw.~~~~~Hw~xa~, ~>~~x~ ~~~~Hw~H~~
o ~~a~H ~a~a~~~H~H
c. ~~~~~ ~d~~~~~~'o~ a w wW ~c7~ a~'.,~~~~~aa~,>~
~w~~o' ~~w~~~~~
~a~~
a ~~~U~ A~~ ~~>d w~~
w a ~x~daw~~~ a~.~~' ~wH~
~awU~~~~da ~w o ~~~Ha ~~~ v w waw~ ~ ~~~~w~w~ ~a w~~~~ ~~~~~~~ad.~~~ ~a ~ ~ ~ ~ ~ C7 ~ w ~l v~ ~
w ~~~~~x ~A~Ha~a~~~
N v c~
dp U U
U ~ ~ ~H
U ~ °' ~ ra ~'n w~ x 0 0 ~b ~ ~b ~°, o U
~, ~ ~.b. w w M pp p .~ ~ ~ a3 ayd p ..d wHH~ Wa~~~~H~a ~~w~ ~~~w~q~Ha O'~ x a ? O'w ate" ~ ~ w ~ ~
~ ~ ~ a ~ ~ az..~ H~ ~'' A a ~ c7 a;~ w~ ~~a,>~~wAW
W~~c~v,awa,~
a~~A~
~ c7 ~' w x ~'' w ~ ~ ~ ~ w ~
H
~a~,N~~ ~~xa>~~~~
Ha~.~~~~' Hc~~7~z~~Hx~w a~aA~~~~w~~
Ac~.7H~~-H ~7a~..~d~enHO,t~.7,.,~.~a~
~~~o,a~- ~~~p~~a~,~a~
H
>~~~
vya~ ~, ~~aaA~ ~~~rx ~r~r~~~C~7 ~C~7N~wH~''~~a~
~» ~,~,v~aH~~H~~
a pW.., ~ ~ ~ a ~ ~~ w ~ ~ ~ ~ w ~~a~~
A o~~~ ~>q~~~~~a~' a ww~~~ ~~~~~~aA~~
> A ~ v~ ~ C7 ~ d ~ a ~~~~~~~a~~
~A~~~ ~xa~~~~Wx~ ~;
~v ate, w~~~~a~o,dH ~a ~~~~a ~w~~~w~~~~ w A w w f~ W > A a ~ a ~w~'~~ ~~~~zC~7rwn~~ wa~.r ~a~>~~~~'~~ ~a ww> ~A~Hax~ddd .., .O ~~., ~ .sl ~ Q
N
c~ OA
a~
N ~ N
O
°~' o a~
a~
N b bn.~ ~
a~
'd V ~U
oz ~.~~
d .~ ~"'~on ~~ ~v~

wHH~, ~~~zH~Hxa ~ ~as ~ ~ A ~ H a x~~xa> a~~UwAa~~x ~'d~w~ ~~z~~~Hd~7 o~~dz >~a >~aw~~
aa~ dr~~r~~Z~
t~.7~a~~ ~a'w~'ww~~~
H
~~~'~~~~w~
~~H~~ a~aa~~~xa~
~d~'~~ a~t7~~~d~w~
~~.,~~a~ ~dd~q~°~~ca7q~
"' ~ ~ a~ ~ w H ~ ~ d C7 O'w ~
add ~da~.~d~ ~~ ~~~aw-.E-r~~
v~ ~ a ~ ~ ~ d ~ ~ ~ E~ w ~ ~ a, A~H~H~~H
A~o'dd ~ad d~~~a~' a ~'~~~A ~d~ ~~~~a~ >
w~~da ~,a~xH~c~a~~
~w~~~ ~~~ ~~d~d~
a ~ p~ ~ Ed-~ ~ > d d ~
~ W~ ~ ~ ~-1 ~ ~ ~ ~ ~ ~ ~ ~ ~ ran t" v~ pd.., ~ ~ ~ ~ ~ A ~ ~ p~ d E-~ a w ~~~~z ~x~~o,wp~~~~
~Aw.,~>~ a A ~ w A W ~ d O
~~~~~~A~v~ ~
~~~~~~w.~a ~ ~ ~ a~, oy a w ~ z ~ >
~~dd~; ~f~~(-~~aav~d~~~ ~
.'., N !~ O
.O
bn ,~ o U U
°
U O 4.a a~
Y
U '~ c~C
.fl N N
H
x ~
a>
o +~
N '~
.~ M .~ b N
r~ OJ
.-~ N O N V~
t"~ O '"'' O
O
d ~ ~'~ ~

Wo'~~x~~H~xa o,H x ~ w ~ ~ d w ~ ~ > H a o~w~U~w~~~
~ ~ z ~ w ~1 o~w E-H Cd.7 d Z a,, w E-~ ~ Ei d W
a x r~
ai~cw~7A~ ~dd~~>~wU
dc7awd ~~~~~~~a~~.,~
~~~~~aH~~w a Hx H
r~n~da~~~a~,~~ a' wr~~ ~ ~>~d~v,~~a ~~~~~r'~ncd7~d~
~w~dwtn A~dd~E-~~~dc7 w~~~~~~~~~ ~
~~d~W r,,,wC7>~1 ~~dd ~~d~~~
a ~~ ~>A
~ww>A W~da ~
~~A~v~
~~~~aC~7~~~~ w>
w ~~~d~~~~~~ a HdH~~'r"t~.7~ww ~A>~a~ad~~ t~~
.'., N !~ O
O
by ,s~ o r-v -;
p as a> o ,.'t,' ~ ~ o w a w M
U cd N m U b ~
N '~ O c~ d ~ O w y~ .~1 'b ON+~..
bD '"
~Z~~
~ '~ L7 ~~>x a~x~W ~~~~~~>Ha o~ w p~ U W w rx ~~z~~~a~
~H~o ~CO7aa~
C~7da~~ ~~wE-~~
~~xa~~~H~
~,wv~~ ~~~w~~
A~H~~ ~'o~z~~~x~w a~o°a~~~~w~
A~7~aH ~~~~~~c7~z H
A ~~ ~~ x ~~d~~ ~~~~~~w'~~x~~
~~~a~~
~d~~~'~~~a~ a ww~o~ ~,oa~x~aa,~~ w ~wx~~'~°s ~~w~x~~~p'' ~ >
a A~~~~~~~x ~ v' ~ ~ ~ ~ ~ ~ ~ G-1 a ~ ~ ~ ~ ~ w ~W~~°'w~a~
a ~ ~ w o a ~~~aw. ~ ~~w~>~?~~~d w a~~ ~o~~WC~7~
a w z ~~H~
~~~~x ~A>Na~a~~~
..., au ..~ o ~., a~ ~ o O
~, O
...
~~
U N ai rO N N
H
-i ~1 ~ O 4.~
N
a~ a~ O P~-~
M .~
U ~ ~ .~
0 oD v ~-' O c~ .~ b ~"
O 0 .~
~z~.~-a wHH~ WO'a~,~~'~''~N
~~~w~A~Ha oJ~xa> o~w~Uwwrx~~
r~ >~Z~~AO'w a, E-~ ~ H d C7 ~~-'p.''z"p'~P~w >w wHH~
~C7~'A~ ~~w~ W ~~~>
~a°~,H~~
r~
qw~~~ ~~~z~a~xa~
a~aa ~~~A~ ~C70'~W~HC~.7~Z~
~ H ~ ~ ~ ~ W7 ~~~~~~~H~~
~ C7 E-~ ~ H ~1 ~ rte; v~
~~~d~~d~~~~
A~~'~~ ~~A~~~~~a~ a ~~~~H~~~~~
~H~a qH~' ~~>~~~x ~Aw~~A wx~~~~ WxH a;~
w~~~~A~~~~
~~~ww ~W~~aw~"'~~
w~7z ~~~>~ ~~~~A~~x~~a ~
Hrx ~wx ~A~Ha a~.,w'~a~,,~ >~~ww~tw"w~~
~a~j~~~~~~ ~a pa ~ p,, U
~ ~ w w > ~ ~ ~ E-~ a ~ a ~ ~ ~
.., an ,.~ o N
a~ ~ ~ ~ o p, v o _ at r/~ fn o °' ~ ~n U '~
N ~
N
'~', ~ °~~~
m O ~.;
a~ u~
~.~.~v U ~
~t ,ta v .b ''~r O '~' o oz wHH~, v~~~zH~HxO~
'H w~O'w~~a~Ha d a> ~aw,a~,>w~~'~~
~a~.,H~o~~Aw ~a~~~~'a~~U
O'O > d d ~ ~ ~ ~ ~ >
~c~7aq~ Lw7H~~'~>w~~
c7dd t" wHwHww~d~
as vW ~ ~ ~ a a ~ '_' v~ ~ ~ W ~ x a ~
E-~ C7 d Z a~. v~, C~7 ~ d ~ ~ ~ d~ ~ A r~ ~ d ~ W

~ d a~ ~ ~~ ca7 ~
ate', ~ r~ d ~ c7 a w ~
d ~" w > rn v~ 0.' ~ a~ w a~..~ .~d., q H
~d~d~ ~~H~~a~~~~~d >d~0 ~c~7H~~a~.~~E~-~~
a awi~~ '~~d~~~~C~7~~~w ' ~ad d~a,v~aH a ~~a~a,~~~~~a~
as H~.,~r~~~~Cd7~dt°' ~~lw'w~ ~~d~~''E~>d~~
Cw7Ad~~1 A~~dd~ awi~~ ~ad..~
'n ~ ~~,, ~ ~ W ~ ~ ~1 A ~ O~ d E-~ a ~ C~7 d ~' a ~ ~' ~ > ~ W ~ "' d ~ ~
~ a~ ~ ~ ~"r x w ~ O' ~ ~ ~ ~ R' ~a~>~ A~e~~~~~~~ a ~q~Ha ~~~>~~~~~~
~~~~x~wwww~ ~a d w p. ~, ~ ~ d z a ~ ~, d > d a ~'' ~ A W
~,,.~~~~~>~dww ~a ~~~~~x ~A>~a~~~~~ ~
N O op., b0 ,s~ O
U U
p, ~ c~ ~ ~+~, N H N
°
N
N +~
+~ cad U ~ ~-~
m N N
o x o M ~ N
,~ .~ ~i ~t ,~ v :b o ~d ~~' O ''..' o d ~

[0266] The peptides in accordance with the invention can be a variety of lengths, and either in their neutral (uncharged) forms or in forms which are salts. The peptides in accordance with the invention can contain modifications such as glycosylation, side chain oxidation, or phosphorylation, generally subject to the condition that modifications do not destroy the biological activity ofthe peptides.
[0267] The peptides of the invention can be prepared in a wide variety of ways.
For the preferred relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. (See, for example, Stewart ~ Young, SoLm PHASE
PEPTIDE SYNTHESIS, 2D. ED., Pierce Chemical Co., 1984). Further, individual C35 peptide epitopes and C35 peptide epitope analogs can be joined using chemical ligation to produce larger homopolymer or heteropolymerpolypeptides that are still within the bounds of the invention.
[0268] Alternatively, recombinant DNA technology can be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989). Thus, recombinant polypeptides, which comprise one or more peptide epitope sequences of the invention, can be used to present the appropriate T cell epitope.
[0269] The nucleotide coding sequence for C35 peptide epitopes or C35 peptide epitope analogs of the preferred lengths contemplated herein can be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci, et al., J. Am. Chem. Soc. 103:3185 (1981). Peptide analogs can be made simply by substituting the appropriate and desired nucleic acid bases) for those that encode the native peptide sequence; exemplary nucleic acid substitutions are those that encode an amino acid defined by the motifs/supermotifs herein. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast, insect or mammalian cell hosts may also be used, employing suitable vectors and control sequences.
(0270] It is generally preferable that the peptide epitope be as small as possible while still maintaining substantially all of the immunologic activity of the native protein. When possible, it may be desirable to optimize HLA class I binding peptide epitopes of the invention to a length of about 8 to about 13 amino acid residues, preferably 9 to 10. It is to be appreciated that a longer polypeptide, e.g., a C35 polypeptide fragment or a synthetic polypeptide, can comprise one or more C35 peptide epitopes or C35 peptide epitope analogs in this size range (see the Definition Section for the term "epitope" for further discussion ofpeptide length).
HLA class II binding epitopes are preferably optimized to a length of about 6 to about 30 amino acids in length, preferably to between about 13 and about 20 residues. Preferably, the epitopes are commensurate in size with endogenously processed pathogen-derived peptides or tumor cell peptides that are bound to the relevantHLA molecules. The identification and preparation ofpeptides ofvarious lengths can be carried out using the techniques described herein.
[0271] An alternative preferred embodiment of the invention comprises administration of peptides of the invention linked as a polyepitopic polypeptide, e.g., homopolymers or heteropolymers, or as a minigene that encodes a polyepitopic polypeptide.

[0272] Another preferred embodiment is obtained by identifying native C35 polypeptide regions that contain a high concentration of class I and/or class peptide epitopes. Such a sequence is generally selected on the basis that it contains the greatest number of C35 epitopes per amino acid length. It is to be appreciated that epitopes can be present in a frame-shifted manner, e.g. a 10 amino acid long peptide could contain two 9 amino acid long epitopes and one amino acid long epitope; upon intracellular processing, each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide.
Thus a larger, preferably mufti-epitopic, polypeptide can be generated synthetically, recombinantly, or via cleavage from the native source.
Assays to Detect T-Cell Responses (0273] Once HLA binding peptides are identified, they can be tested for the abilityto elicit a T-cell response. The preparation and evaluation ofmotif bearing peptides are described, e.g., in PCT publications WO 94/20127 and WO
94/03205, the entire contents of which are hereby incorporated by reference.
Briefly, peptides comprising epitopes from a particular antigen are synthesized and tested for their ability to bind to relevant HLA proteins. These assays may involve evaluation of peptide binding to purified HLA class I molecules in relation to the binding of a radioiodinated reference peptide. Alternatively, cells expressing empty class I molecules (i. e. cell surface HLA molecules that lack any bound peptide) may be evaluated for peptide binding by immunofluorescent staining and flow microfluorimetry. Other assays that may be used to evaluate peptide binding include peptide-dependent class I assembly assays and/or the inhibition of CTL recognition by peptide competition. Those peptides that bind to an HLA class I molecule, typically with an affinity of 500 nM or less, are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with selected target cells associated with pathology.
(0274] Analogous assays are used for evaluation of HLA class II binding peptides. HLA class II motif bearing peptides that are shown to bind, typically at an affinity of 1000 nM or less, are further evaluated for the ability to stimulate HTL responses.
[0275] Conventional assays utilized to detect T cell responses include proliferation assays, lymphokine secretion assays, direct cytotoxicity assays, and limiting dilution assays. For example, antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL
responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells. Alternatively, mutant, non-human mammalian cell lines that have been transfected with a human class I
MHC gene, and that are deficient in their ability to load class I molecules with internally processed peptides, are used to evaluate the capacity of the peptide to induce in vitro primary CTL responses. Peripheral blood mononuclear cells (PBMCs) can be used as the source of CTL precursors. Antigen presenting cells are incubated with peptide, after which th.e peptide-loaded antigen-presenting cells are then incubated with the responder cell population under optimized culture conditions. Positive CTL activation can be determined by assaying the culture for the presence of CTLs that lyse radio-labeled target cells, either specific peptide-pulsed targets or target cells that express endogenouslyprocessed antigen from which the specific peptide was derived. Alternatively, the presence of epitope-specific CTLs can be determined by lFNy in situ ELISA.
[0276] Additionally, a method has been devised which allows direct quantification of antigen-specific T cells by staining with fluorescein-labelled HLA tetrameric complexes (Altman, J. D. et al., Proc. Natl. Acad. Sci. USA
90:10330, 1993; Altman, J. D. et al., Science 274:94, 1996). Other options include staining for intracellular lymphokines, and interferon release assays or ELISPOT assays. Tetramer staining, intracellular lymphokine staining and ELISPOT assays all appear to be at least 10-fold more sensitive than more conventional assays (Lalvani, A. et al., J. Exp. Med. 186:859, 1997; Dunbar, P.
R. et al., Curt. Biol. 8:413, 1998; Murali-Krishna, K. et al., Inamunity 8:177, 1998).
[0277] Helper T lymphocyte (HTL) activation may also be assessed using techniques known to those in the art, such as T cell proliferation or lymphokine secretion (see, e.g. Alexander et al., Immunity 1:751-761, 1994).
[0278] Alternatively, immunization of HLA transgenic mice can be used to determine irnmunogenicity ofpeptide epitopes. Several transgenic mouse strains, e.g., mice with human A2.1, Al l (which can additionally be used to analyze HLA-A3 epitopes), and B7 alleles have been characterized. Other transgenic mice strains (e.g., transgenic mice for HLA-A1 and A24) are being developed.
Moreover, HLA-DRl and HLA-DR3 mouse models have been developed. In accordance with principles in the art, additional transgenic mouse models with other HLA alleles are generated as necessary.
[0279] Such mice can be immunized with peptides emulsified in Incomplete Freund's Adjuvant; thereafter anyresulting T cells can be tested for their capacity to recognize target cells that have been peptide-pulsed or transfected with genes encoding the peptide of interest. CTL responses can be analyzed using cytotoxicity assays described above. Similarly, HTL responses can be analyzed using, e.g., T cell proliferation or lymphokine secretion assays.
Vaccine Compositions [0280] Vaccines that contain an immunologically effective amount of one or more C35 peptide epitopes and/or C35 peptide epitope analogs of the invention are a further embodiment of the invention. The peptides can be delivered by various means or formulations, all collectively referred to as "vaccine"
compositions. Such vaccine compositions, and/or modes of administration, can include, for example, naked cDNA in cationic lipid formulations; lipopeptides (e.g.,Vitiello, A. et al., J. Clin. Invest. 95:341, 1995), naked cDNA or peptides, encapsulated e.g., in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294,1991: Alonso et al., Vaccine 12:299-306,1994; Jones et al., Iraccine 13:675-681,1995); peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al.,Nature 344:873-875,1990; Huetal., ClinExplmmunol. 113:235-243,1998);
multiple antigen peptide systems (MAPs) (see e.g., Tam, J. P., Proc. Natl.
Acad.
Sci. U.S.A. 85:5409-5413, 1988; Tam, J.P., J. Immunol. Methods 196:17-32, 1996); viral, bacterial, or, fungal delivery vectors (Perkus, M. E. et al., In:
Concepts in vaccine development, Kaufinann, S. H. E., ed., p. 379, 1996;
Chakrabarti, S. et al., NatuYe 320:535, 1986; Hu, S. L. et al., Nature 320:537, 1986; Kieny, M.-P. et al., AIDS' BiolTechnology 4:790, 1986; Top, F. H. et al., J. Infect. Dis. 124:148, 1971; Chanda, P. K. et al., hif-ology 175:535, 1990);
particles of viral or synthetic origin (e.g., Kofler, N. et al., J. Immunol.
Methods.
192:25, 1996; Eldridge, J. H. et al., Sem. Hematol. 30:16, 1993; Falo, L. D., Jr.
et al., Nature Med. 7:649, 1995); adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. Annu. Rev. Immunol. 4:369, 1986; Gupta, R. K. et al., haccine 11:293, 1993); liposomes (Reddy, R. et al., J. Immunol. 148:1585,1992; Rock, K. L., Immunol. Today 17:131,1996); or, particle-absorbed cDNA (Ultner, J. B.
et al., Science 259:1745,1993; Robinson, H. L., Hunt, L. A., and Webster, R.
G., vaccine 11:957,1993; Shiver, J. W. et al., In: Concepts in vaccine development, Kaufinann, S. H. E., ed., p. 423,1996; Cease, K. B., and Berzofsky, J. A., Annu.
Rev. Immunol. 12:923, 1994 and Eldridge, J. H. et al., Sem. Hematol. 30:16, 1993), etc. Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) or attached to a stress protein, e.g., HSP 96 (Stressgen Biotechnologies Corp., Victoria, BC, Canada) can also be used.
[0281] Vaccines of the invention comprise nucleic acid mediated modalities.
DNA or RNA encoding one or more of the polypeptides of the invention can be administered to a patient. This approach is described, for instance, in Wolff et.

al., Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466;
5,804,566; 5,739,118; 5,736,524; 5,679,647; and, WO 98/04720. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No.
5,922,687). Accordingly, peptide vaccines of the invention can be expressed by viral orbacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. For example, vaccinia virus is used as a vector to express nucleotide sequences that encode the peptides of the invention.
Upon introduction into an acutely or chronically infected host or into a non-infected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848.
Another vector is BCG (Bacille Calinette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. adeno and adeno-associated virus vectors, alpha virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, are apparent to those skilled in the art from the description herein.
[0282] Furthermore, vaccines in accordance with the invention can comprise one or more C35 peptide epitopes of the invention. Accordingly, a C35 peptide epitope or C35 peptide epitope analog can be present in a vaccine individually or;
alternatively, the peptide epitope or analog can exist as multiple copies of the same peptide epitope or analog (a homopolymer), or as multiple different peptide epitopes or analogs (a heteropolymer). Polymers have the advantage ofincreased probability for immunological reaction and, where different peptide epitopes or analogs are used to make up the polymer, the ability to induce antibodies and/or T cells that react with different antigenic determinants of the antigen targeted for an immune response. The composition may be a naturally occurring region of an antigen or can be prepared, e.g:, recombinantly or by chemical synthesis.

[0283] Carriers that can be used with vaccines of the invention are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly z-lysine, poly z-glutamic acid, influenza virus proteins, hepatitis B virus core protein, and the like.
The vaccines can contain a physiologically tolerable diluent such as water, or a saline solution, preferably phosphate buffered saline. Generally, the vaccines also include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glyceryl-cysteinyl-Beryl-serine (P3CSS).
[0284] Upon immunization with a peptide composition in accordance with the invention, via injection (e.g., subcutaneous, intradermal, intramuscular, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal), or other suitable routes, the immune system of the host responds to the vaccine by producing antibodies, CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to subsequent exposure to the TAA, or at least partially resistant to further development of tumor associated antigen-bearing cells and thereby derives a prophylactic or therapeutic benefit.
[0285] In certain embodiments, components that induce T cell responses are combined with components that induce antibody responses to the target antigen of interest. A preferred embodiment of such a composition comprises class I
and class II epitopes in accordance with the invention. Alternatively, a composition comprises a class I and/or class II epitope in accordance with the invention, along with a PADRETM molecule (Epimmune, San Diego, CA).
[0286] Vaccine compositions of the invention can comprise antigen presenting cells, such as dendritic cells, as a vehicle to present peptides of the invention. For example, dendritic cells are transfected, e.g., with a minigene construct in accordance with the invention, in order to elicit immune responses. Minigenes -, are discussed in greater detail in a following section. Vaccine compositions can be created in vitro, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs in vitro.
[0287] The vaccine compositions of the invention may also be used in combination with antiviral drugs such as interferon-a, or immune adjuvants such as IL-12, GM-CSF, etc.
[0288] Preferably, the following principles are utilized when selecting epitope(s) for inclusion in a vaccine, either peptide-based or nucleic acid-based formulations. Each of the following principles can be balanced in order to make the selection. When multiple epitopes are to be used in a vaccine, the epitopes may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived.
[0289] 1) Epitopes are selectedwhich, upon administration, mimic immune responses that have been observed to be correlated with prevention or clearance of TAA-expressing tumors. For HLA Class I, this generally includes 3-4 epitopes derived from at least one TAA.
[0290] 2) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an ICSO of nM or less, or for Class II an ICso of 1000 nM or less. For HLA Class I it is presently preferred to select a peptide having an ICSO of 200 nM or less, as this is believed to better correlate not only to induction of an immune response, but to in vitro tumor cell killing as well.
[0291] 3) Supermotifbearing-peptides, or a sufficient arrayofallele-specific motif bearing peptides, are selected to give broad population coverage. In general, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth of population coverage.
[0292] 4) When selecting epitopes from cancer-related antigens, it can be preferable to include analog peptides in the selection, because the patient may have developed tolerance to the native epitope. When selecting epitopes for infectious disease-related antigens it is presently preferable to select either native or analog epitopes.
[0293] 5) Ofparticularrelevance are "nested epitopes." Nested epitopes (or epitope analogs) occur where at least two epitopes or analogs (or an epitope and an analog) overlap in a given polypeptide sequence. A polypeptide comprising "transcendent nested epitopes" is a polypeptide that has both HLA class I and HLA class II epitopes and/or analogs in it. When providing nested epitopes, it is preferable to provide a sequence that has the greatest number of epitopes or analogs per provided sequence. Preferably, one avoids providing a polypeptide that is any longer than the combined length of the peptide epitopes or analogs.
When providing a polypeptide comprising nested epitopes, it is important to evaluate the polypeptide in order to insure that it does not have pathological or other deleterious biological properties; this is particularly relevant for vaccines directed to infectious organisms. Thus, in a preferred embodiment, the vaccine compositions of the invention comprise one or more multi-epitope polypeptides selected from the group consisting of I105 to V 113 of SEQ ID N0:2 and FIG.
1B, T101 to V 113 of SEQ ID N0:2 and FIG.1B, E100 to V 113 of SEQ ID NO:2 and FIG.1B, G99 to V 113 of SEQ ID N0:2 and FIG.1B, I93 to V 113 of SEQ ID
N0:2 and FIG. 1B, D88 to V113 of SEQ H) N0:2 and FIG. 1B, P84 to V113 of SEQ ID NO:2 and FIG.1B, I~77 to V 113 of SEQ ID N0:2 and FIG. 1B, Q72 to V 113 of SEQ ID N0:2 and FIG.1B, F65 to V l 13 of SEQ ID NO:2 and FIG.1B, and L59 to V113 of SEQ ID NO:2 and FIG. 1B.
[0294] 6) If apolypeptide comprising more than one C35 peptide epitope or C35 peptide epitope analog is created, or when creating a minigene, an objective is to generate the smallest polypeptide that encompasses the epitopes/analogs of interest. This principle is similar, if not the same as that employed when selecting a polypeptide comprising nested epitopes. However, with an artificial polyepitopic polypeptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic polypeptide. Spacer or linker amino acid residues can be introduced to avoid functional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. functional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a functional epitope that is a "dominant epitope." A
dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed.
Minigene Vaccines [0295] A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding multiple C35 peptide epitopes or analogs are a useful embodiment of the invention; discrete .epitopes/analogs or polyepitopic polypeptides can be encoded. The epitopes or analogs to be included in a minigene are preferably selected according to the guidelines set forth in the previous section. Examples of amino acid sequences that can be included in a minigene include: HLA class I epitopes or analogs, HLA
class II epitopes or analogs, a ubiquitination signal sequence, and/or a targeting sequence such as an endoplasmic reticulum (ER) signal sequence to facilitate movement of the resulting peptide into the endoplasmic reticulum.
[0296] The use of multi-epitope minigenes is also described in, e.g., Ishioka et al., J. Immunol. 162:3915-3925, 1999; An, L. and Whitton, J. L., J. Tirol.
71:2292,1997; Thomson, S. A. et al., J. Immunol. 157:822,1996; Whitton, J. L.
et al., J. Tirol. 67:348,1993; Hanke, R. et al., Vaccine 16:426,1998. A
similar approach can be used to develop minigenes encoding TAA epitopes.
[0297] For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA

sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. However, to optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design such as one or more spacer or linker amino acid residues between epitopes. HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL or HTL epitopes; these larger polypeptides comprising the epitope(s)/analog(s) are within the scope of the invention.
[0298] The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene.
Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitopepolypeptide, can then be cloned into a desired expression vector.
[0299] Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells.
Several vector elements are desirable: a promoter with a downstream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; anE. coli origin ofreplication; and anE. cvli selectable marker (e.g.
ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S.
Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.
[0300] Optimized peptide expression and immunogenicity can be achieved by certain modifications to a minigene construct. For example, in some cases introns facilitate efficient gene expression, thus one or more synthetic or naturally occurring introns can be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.

[0301] Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate bacterial strain, and DNA is prepared using standard techniques.
The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA
sequence analysis. Bacterial cells harboring the correct plasmid can be stored as cell banks.
[0302] In addition, irnmunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence to enhance immunogenicity.
[0303] In some embodiments, a bi-cistronic expression vector which allows production ofboth the minigene-encoded epitopes and a second protein (e.g., one that modulates immunogenicity) can be used. Examples of proteins or polypeptides that, if co-expressed with epitopes, can enhance an immune response include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e.g., LeIF), costimulatory molecules, or pan-DR binding proteins ~~~,TM~ Epimmune, San Diego, CA). Helper T cell (HTL) epitopes such as ~P1ADRETM molecules can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes. This can be done in order to direct HTL epitopes to a cell compartment different than that of the CTL
epitopes, one that provides for more efficient entry of HTL epitopes into the HLA
class II pathway, thereby improving HTL induction. In contrast to HTL or CTL
induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF-J3) maybe beneficial in certain diseases.
[0304] Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in E. coli, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and are grown to saturation in shaker flasks or a bioreactor according to well known techniques. Plasmid DNA is purified using standard bioseparation technologies such as solid phase anion-exchange resins available, e.g., from QIAGEN, Inc. (Valencia, California). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.
[0305] Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as "naked DNA,"
is currentlybeing used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene vaccines, alternative methods of formulating purified plasmid DNA may be used. A variety of such methods have been described, and new techniques may become available.
Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., WO 93/24640; Mannino & Gould-Fogerite, BioTechniques 6(7): 682 (1988); U.S. Patent No. 5,279,833; WO 91/06309; and Felgner, et al., PYOC. Nat'lAcad. Sei. USA 84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) can also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.
[0306] Target cell sensitization can be used as a functional assay of the expression and HLA class I presentation of minigene-encoded epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is a suitable target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation, electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection.
A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). The transfected cells are then chromium-51 (5'Cr) labeled and used as targets for epitope-specific CTLs. Cytolysis of the target cells, detected by SiCr release, indicates both the production and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.
[0307] hz vivo irnmunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (11') for lipid-complexed DNA). Eleven to twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTLs, standard assays are conducted to determine if there is cytolysis of peptide-loaded, s'Cr-labeled target cells. Once again, lysis of target cells that were exposed to epitopes corresponding to those in the minigene, demonstrates DNA vaccine function and induction of CTLs. Immunogenicity of HTL epitopes is evaluated in transgenic mice in an analogous manner.
[0308] Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment for ballistic delivery, DNA can be adhered to particles, such as gold particles.
Combinations of CTL Peptides with Helper Peptides [0309] Vaccine compositions comprising CTL peptides of the present invention can be modified to provide desired attributes, such as improved serum half life, broadened population coverage or enhanced immunogenicity.
[0310] For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the CTL peptide to a sequence which contains at least one HTL epitope.
[0311] Although a CTL peptide can be directly linked to a T helper peptide, particularlypreferred CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, e.g., amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optional spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer.
When present, the spacer will usually be at least one or two residues, commonly three to 13, more frequently three to six residues. The CTL peptide epitope may be linked to the T helper peptide epitope, directly or via a spacer, at either it's amino or carboxyl terminus. The amino terminus of either the CTL peptide or the HTL peptide can be acylated.
[0312 In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in the majority of the population. This can be accomplished by selecting amino acid sequences that bind to many, most, or all of the HLA class II molecules. These are known as "loosely HLA-restricted" or "promiscuous" T helper sequences. Examples of amino acid sequences that are promiscuous include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE), Plasmodium falciparum CS protein at positions 378-398 (DIEKKTAKMEKASSVFNVVNS), and Streptococcus l8kD protein at positions 116 (GAVDS1LGGVATYGAA). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.
[0313] Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences that may not be found in nature. Synthetic compounds fall within the family of molecules called Pan-DR-binding epitopes (e.g. , PADRETM, Epimmune Inc., San Diego, CA). PADRETM peptides are designed to bind multiple HLA-DR (human HLA class Il) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVAAZTLKA.Aa, where "X" is either cyclohexylalanine, phenylalanine, or tyrosine; "Z" is either tryptophan, tyrosine, histidine or asparagine; and "a" is either D-alanine or L-alanine, has been found to bind to numerous allele-specific HLA-DR molecules. Accordingly, these molecules stimulate a T helper lymphocyte response from most individuals, regardless of their HLA type. Certain pan-DR binding epitopes comprise all "L"
natural amino acids; these molecules can be provided as peptides or in the form of nucleic acids that encode the peptide.
[0314] HTL peptide epitopes can be modified to alter their biological properties.
HTL peptide epitopes can be modified in the same manner as CTL peptides. For instance, they may be modified to include D-amino acids or be conjugated to other molecules such as lipids, proteins, sugars and the like. Peptides comprising D-amino acids generally have increased resistance to proteases, and thus have an extended serum half life.
(0315] In addition, polypeptides comprising one or more peptide epitopes of the invention can be conjugated to other molecules such as lipids, proteins or sugars, or any other synthetic compounds, to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or the carboxyl termini.
Combinations of CTL Peptides with T Cell Priming Materials [0316] In some embodiments it maybe desirable to include in the pharmaceutical compositions of the invention at least one component which primes cytotoxic T
lymphocytes. Lipids have been identified as agents capable of facilitating the priming in vitro CTL response against viral antigens. For example, palinitic acid residues canbe attached to the s- and a-amino groups of a lysine residue and then linked to an irnmunogenic peptide. One or more linking moieties can be used such as Gly, Gly Gly , Ser, Ser-Ser, or the like. The lipidated peptide can then be administered directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. A preferred immunogenic composition comprises palmitic acid attached to E- and a-amino groups of Lys via a linking moiety, e.g., Ser-Ser, added to the amino terminus of an immunogenic peptide.
[0317] In another embodiment of lipid-facilitated priming of CTL responses, E.
coli lipoproteins, such as tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine (P3CSS) can be used to prime CTL when covalently attached to an appropriate peptide.
(See, e.g., Deres, et al., Nature 342:561,199). Thus, peptides of the invention can be coupled to P3CSS, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P3CSS-conjugated epitopes, two such compositions can be combined to elicit both humoral and cell-mediated responses.
Vaccine Compositions Comprising Dendritic Cells Pulsed with CTL and/or HTL
Peptides [0318] An embodiment of a vaccine composition in accordance with the invention comprises ex vivo administration of a-cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A
pharmaceutical to facilitate harvesting of DC can be used, such as ProgenipoietinTM (Monsanto, St. Louis, MO) or GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes in HLA molecules on their surfaces.
[0319] The DC can be pulsed ex vivo with a cocktail of peptides, some of which stimulate CTL responses to one or more antigens of interest, e.g., tumor associated antigens (TAA) such as HER2lneu, p53, MAGE 2, MAGE3, and/or carcinoembryonic antigen (CEA). Collectively, these TAA are associated with breast, colon and lung cancers. Optionally, a helper T cell (HTL) peptide such as PADRETM, can be included to facilitate the CTL response. Thus, a vaccine in accordance with the invention comprising epitopes from HERZ/neu, p53, MAGE2, MAGE3, and carcinoembryonic antigen (CEA) is used to treat minimal or residual disease in patients with malignancies such as breast, colon or lung cancer; any malignancies that bear any of these TAAs can also be treated with the vaccine. A TAA vaccine can be used following debulking procedures such as surgery, radiation therapy or chemotherapy, whereupon the vaccine provides the benefit of increasing disease free survival and overall survival in the recipients.
[0320] Thus, in preferred embodiments, a vaccine of the invention is a product that treats a majority of patients across a number of different tumor types. A
vaccine comprising a plurality of epitopes, preferably supermotif bearing epitopes, offers such an advantage.
Administration of Vaccines for Therapeutic or Prophylactic Purposes [0321] The polypeptides comprising one or more peptide epitopes of the present invention, including pharmaceutical and vaccine compositions thereof, are useful for administration to mammals, particularly humans, to treat and/or prevent disease. In one embodiment, vaccine compositions (peptide or nucleic acid) of the invention are administered to a patient who has a malignancy associated with expression of one or more TAAs, or to an individual susceptible to, or otherwise at risk for developing TAA-related disease. Upon administration an immune response is elicited against the TAAs, thereby enhancing the patient's own immune response capabilities. In therapeutic applications, peptide and/ornucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective immune response to the TAA-expressing cells and to thereby cure, arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.
[0322] The vaccine compositions of the invention can be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000 ~,g of peptide and the higher value is about 10,000;
20,000; 30,000; or 50,000 pg of peptide. Dosage values for a human typically range from about 500 ~g to about 50,000 ~.g of peptide per 70 kilogram patient.
This is followed byboosting dosages ofbetween about 1.0 ~g to about 50,000 ~.g ofpeptide, administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine may be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood.
[0323] As noted above, polypeptides comprising CTL and/or HTL epitopes of the invention induce immune responses when presented by HLA molecules and contacted with a CTL or HTL specific for an epitope comprised by the peptide.
The manner in which the peptide is contacted with the CTL or HTL is not critical to the invention. For instance, the peptide can be contacted with the CTL or HTL
either in vitro or in vivo. If the contacting occurs in vivo, peptide can be administered directly, or in other forms/vehicles, e.g., DNA vectors encoding one or more peptides, viral vectors encoding the peptide(s), liposomes, antigen presenting cells such as dendritic cells, and the like, as described herein.
[0324] Accordingly,forpharmaceuticalcompositionsoftheinventionintheform of peptides or polypeptides, the peptides or polypeptides can be administered directly. Alternatively, the peptide/polypeptides can be administered indirectly presented on APCs, or as DNA encoding them. Furthermore, the polypeptides, peptide epitopes or DNA encoding them can be administered individually or as fusions of one or more peptide sequences.
[0325] For therapeutic use, administration should generally begin at the first diagnosis of TAA-related disease. This is followed by boosting doses at least until symptoms are substantially abated and for a period thereafter. In chronic disease states, loading doses followed by boosting doses may be required.
[0326] The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 ~g of peptide and the higher value is about 10,000; 20,000; 30,000; or 50,000 ~g of peptide. Dosage values for a human typically range from about 500 ~,g to about 50,000 p.g ofpeptide per 70 kilogram patient. Boosting dosages ofbetween about 1.0 wg to about 50,000 p.g of peptide, administered pursuant to a boosting regimen over weeks to months, can be administered depending upon the patient's response and condition. Patient response can be determined by measuring the specific activity of CTL and IiTL obtained from the patient's blood.
[0327] In certain embodiments, polypeptides, peptides and compositions of the present invention are used in serious disease states. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be desirable to administer substantial excesses of these peptide compositions relative to these stated dosage amounts.
[0328] For treatment of chronic disease, a representative dose is in the range disclosed above, namelywhere the lower value is about 1, 5, 50, 500, or 1,000 p.g of peptide and the higher value is about 10,000; 20,000; 30,000; or 50,000 ~,g of peptide, preferably from about 500 ~,g to about 50,000 ~,g of peptide per 70 kilogram patient. Initial doses followed by boosting doses at established intervals, e.g., from four weeks to six months, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic disease, administration should continue until at least clinical symptoms or laboratory tests indicate that the disease has been eliminated or substantially abated, and for a follow-up period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.
[0329] The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, intrathecal, or local administration.
Preferably, the pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly.
[0330] Thus, in a preferred embodiment the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable Garner, preferably an aqueous carrier.
A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8%
saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances or pharmaceutical excipients as may be required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
[0331] The concentration of peptides and polypeptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to SO% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
[0332] A human unit dose form of the peptide and polypeptide composition is typically included in a pharmaceutical composition that also comprises a human unit dose of an acceptable carrier, preferably an aqueous carrier, and is administered in a volume of fluid that is known by those of skill in the art to be used for administration of such compositions to humans (see, e.g., Remington's Pharmaceutical Sciences,17"' Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pennsylvania, 1985).
[0333] The peptides and polypeptides of the invention can also be administered via liposomes, which serve to target the peptides and polypeptides to a particular tissue, such as lymphoid tissue, or to target selectively to infected cells, as well as to increase the half life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptides and polypeptides to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells (such as monoclonal antibodies which bind to the CD45 antigen) or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions.
Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., Ann. Rev.
Bi~phys.
Bioeng. 9:467 (1980), andU.S. PatentNos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
[0334] Fortargeting compositions ofthe inventionto cells ofthe immune system, a ligand can be incorporated into the liposome, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells.
A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.
[0335] For solid compositions, conventional nontoxic solid carriers maybe used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 95% of active ingredient, that is, one or more peptides of the invention, often at a concentration of 25%-75%.
[0336] For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form, along with a surfactant and propellant.
Typical percentages ofpeptides are 0.01 %-20% byweight, often 1 %-10%. The surfactant must, of course, be pharmaceutically acceptable, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides maybe employed. The surfactant may constitute 0.1 %-20% byweight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant, although an atomizer may be used in which no propellant is necessary and other percentages are adjusted accordingly. A carrier can also be included, e.g., lecithin for intranasal delivery.
[0337] Antigenic peptides of the invention have been used to elicit a CTL
and/or HTL response ex vivo, as well. The resulting CTLs or HTLs can be used to treat chronic infections, or tumors in patients that do not respond to other conventional forms of therapy, or who do not respond to a therapeutic peptide or nucleic acid vaccine in accordance with the invention. Ex vivo CTL or HTL responses to a particular antigen (infectious or tumor-associated) are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-2~ days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (an infected cell or a tumor cell).

[0338] A number of computer algorithms have been described for identification of peptides in a larger protein that satisfy the requirements of peptide binding motifs for specific MHC class I or MHC class II molecules. Because of the extensive polymorphism of MHC molecules, different peptides will often bind to different MHC molecules. Tables 1-6 list C35 peptides predicted to be MHC
binding peptides using three different algorithms. Specifically, Tables 1 and 5 list C35 HLA Class I and II epitopes predicted using the rules found at the SYFPEITHI website (wysiwXg~//35/http~//134.2.96.221/scripts/hlaserver.dll/
EnPredict.htm) and are based on the book "MHC Ligands and Peptide Motifs" by Rammensee, H.G., Bachmann, J. and Stevanovic, S. (Chapman & Hall, New York 1997). Table 2 lists predicted MHC binding peptides derived from the C35 sequence using the NIH BIMAS program available on the web (httu-//bimas dcrt nih gov/c~i-bin/molbio/ken~arker comboform). Finally, Tables 3 and 6 list predicted C35 peptides identified by the Tepitope program, a program for prediction of peptides that may bind to multiple different MHC
class II molecules. Using Tepitope, four C35 peptides were identified as likely candidates for binding to a variety of HLA class II molecules. These peptides are, in general, longer than those binding to HLA class I and more degenerate in terms of binding to multiple HLA class lI molecules. Due to the relatedness of the HLA
molecules and the inherent limitations of the binding algorithms, it is expected that many of these C35 peptide epitopes predicted to bind to a specific HLA
molecules will also bind to one or more other HLA molecules.

C35 peptides predicted by SYFPEITHI website (score reflects ligation strength):
Class I MIIC

HLA-A*0201 nonamers Position Score SV APPPEEV

DLIEAIRRA

ATYLELASA

SNGETLEKI

ITNSRPPCV

SGEPGQTSV

AVKEQYPGI

TYLELASAV

GTGAFEIEI

YEKDLIEAI

FEIEINGQL

NSRPPCVIL

ELASAVKEQ

RLGGTGAFE

LGGTGAFEI

EIEINGQLV

EINGQLVFS

GGFPYEKDL

RRASN GETL

HLA-A~0201 decamers Pos Score RLGGTGAFEI

ASNGETLEKI

KITNSRPPCV

ATYLELASAV

VEPGS GVRIV

CGFEATYLEL

SAVKEQYPGI

AIRRASNGET

YLELASAVKE

IEIESRLGGT

FEIEINGQLV

ITNSRPPCVI

MSGEPGQTSV

GAFEIEINGQ

EINGQLVFSK

INGQLVFSKL

FPYEKDLIEA

DLIEAIRRAS

IRRASNGETL

QLVFSKLENG

LIEAIRRASN

TSV APPPEEV

EVEPGSGVRI

YPGIEIESRL

GGTGAFEIEI

GGFPYEKDLI

TNSRPPCVIL

HLA-A*0203 nonamers Pos Score FEATYLELA

HLA-A*0203 decamers Pos Score EATYLELASA

HLA-A1 nonamers Pos Score KLENGGFPY

SGEPGQTSV

SGVRIVVEY

EVEPGSGVR

YCEPCGFEA

LASAVKEQY

EPCGFEATY

GFEATYLEL

YLELASAVK

PYEKDLIEA

EIEINGQLV

PPEEVEPGS

VKEQYPGIE

GIEIESRLG

ASNGETLEK

decamers Pos Score GSGVRIVVEY

YCEPCGFEAT

.

SKLENGGFPY

SGEPGQTSVA

GIEIESRLGG

EIEINGQLVF

ELASAVKEQY

VKEQYPGIEI

EVEPGSGVRI

CEPCGFEATY

YLELASAVKE

KLENGGFPYE
EKDLIEAIRR

NGETLEKITN

GFEATYLELA

AFEIEINGQL

TLEKITNSRP

HLA-A26 nonamers Pos Score EINGQLVFS

ETLEKITNS

DLIEAIRRA

EIESRLGGT

ELASAVKEQ

AVKEQYPGI

EPCGFEATY

GFEATYLEL

LVFSKLENG

EVEPGSGVR

KLENGGFPY

EIEINGQLV

SGVRIVVEY

ATYLELASA

RIV VEYCEP

SVAPPPEEV

GVRIVVEYC

SI

PGIEIESRL

NGQLVFSKL

SRLGGTGAF

FEIEINGQL

IVVEYCEPC

EQYPGIEIE

IEINGQLVF

FSKLENGGF

GGFPYEKDL

KITNSRPP C

ITNSRPPCV

HLA-A26 decamers Pos Score ELASAVKEQY

EIEINGQLV F

EINGQLVFSI~

VVEYCEPCGF

EVEPGSGVRI

DLIEAIRRAS

ETLEI~ITNSR

VFSI~LENGGF

CGFEATYLEL

EIESRLGGTG

ESRLGGTGAF

GSGVRIVVEY

EPCGFEATYL

AFEIEINGQL

INGQLVFSKL

GTGAFEIEIN

LVFSKLENGG

SVAPPPEEVE

IVVEYCEPCG

AVKEQYPGIE

QLVFSKLENG

KLENGGFPYE

ENGGFPYEKD

EPGQTSVAPP

QTSV APPPEE

CEPCGFEATY

EATYLELASA

ATYLELASAV

SKLENGGFPY

LIEAIRRASN

HLA-A3 nonamers Pos Score YLELASAVK

KLENGGFPY

EVEPGSGVR

RLG GTGAFE

IEING~LVF

ASN GETLEK

.

AIRRASNGE

SV APPPEEV

TLEKITNSR

GVRIVVEYC

EPCGFEATY

AVKEQYPGI

QLVFSKLEN

SGVRIVVEY

EINGQLVFS

INGQLV~FSK

DLIEAIRRA

EAIRRASNG

IVVEYCEPC

ATYLELASA

IESRLGGTG

SRLGGTGAF

ENGGFPYEK
KDLIEAIRR

KITNSRPPC

RIVVEYCEP

LASAVKEQY.

EIEINGQLV

LIEAIRRAS

IEAIRRASN

RRASNGETL

decamers Pos Score EINGQLVFSK

EVEPGSGVRI

TYLELASAVK

ELASAVKEQY

EIEINGQLVF

SV APPPEEVE

RLGGTGAFEI

YLELASAVKE

AIRRASNGET

RASNGETLEK

AVKEQYPGIE

EIESRLGGTG
DLIEAIRRAS
LIEAIRRASN

VVEYCEPCGF

ATYLELASAV

GVRIVVEYCE

KLENGGFPYE

IRRASNGETL

IVVEYCEPCG

CEPCGFEATY

GIEIESRLGG

SKLENGGFPY

LENGGFPYEK

TLEKITNSRP

KITNSRPPCV

RIVVEYCEPC

QLVFSKLENG

HLA-B*0702 nonamers Pos Score EPGS GVRIV

NSRPPCVIL

EPGQTSVAP

APPPEEVEP

31.

EPCGFEATY

GFEATYLEL

RRASN GETL

PPPEEVEPG

PGSGVRIVV

PCGFEATYL

FPYEKDLIE

TNSRPPCVI

HLA-B* 0702 decamers Pos Score EP CGFEATYL

YPGIEIESRL

EP GS GVRIV V

FPYEKDLIEA

EPGQTSVAPP

APPPEEVEPG

IRRASNGETL

TNSRPPCVIL

INGQLVFSKL

CGFEATYLEL

AFEIEINGQL

HLA-B*08 octamers Pos Score FPYEKDLI

EIEINGQL

GIEIESRL

EPGSGVRI

EIESRLGG
14.

EAIRRASN

RASNGETL

ETLEKITN

CGFEATYL

AVKEQYPG

RLGGTGAF

EINGQLVF

GQLVFSKL

FSKLENGG

GFPYEKDL

NSRPPCVI

SRPPCVIL

HLA-B*08 nonamers Pos Score FSKLENGGF

FPYEKDLIE

AVKEQYPGI

YEKDLIEAI

NSRPPCVIL

ETLEKITNS

EIESRLGGT

.14 FEIEINGQL

EAIRRASNG

GSGVRIVVE

GFEATYLEL

PGIEIESRL

GGFPYEKDL

HLA-B*1510 nonamers Pos Score NSRPPCVIL

GFEATYLEL

PGIEIESRL

GGFPYEKDL

RRASNGETL

HLA-B*2705 nonamers Pos Score SRLG GTGAF

RRASNGETL

IEINGQLVF

KDLIEAIRR

PGIEIESRL

GGFPYEKDL

FEIEINGQL

INGQLVFSK

ASNGETLEK

EVEPGSGVR

GFEATYLEL

YP GIEIESR

NGQLVFSKL

TLEKITNSR

VRIVVEYCE

.14 P C GFEATYL

YLELASAVK

ENGGFPYEK

IRRASNGET

SGVRIVVEY

VEYCEPCGF

FSKLEN GGF

EKI?LIEAIR

NSRPPCVIL

VEPGSGVRI

EPCGFEATY

KLENGGFPY

HLA-B*2709 non amers Pos Score RRASN GETL

SRLGGTGAF

GGFPYEKl~L

GFEATYLEL

P GIEIE SRL

FEIEINGQL

VRIVVEYCE

NSRPPCVIL

HLA-B*5101 nonamers Pos Score EPGSGVRIV

GGFPYEKDL

PGIEIESRL

NGQLVFSKL

PGSGVRIVV

EPCGFEATY

SGEPGQTSV

LASAVKEQY

LGGTGAFEI

SGVRIVVEY

FPYEKDLIE

SNGETLEKI

PPEEVEPGS

TYLELASAV

~AVKEQYPGI

GAFEIEING

RRASN GETL

PPPEEVEPG

12.

CGFEATYLE

YPGIEIESR

EIEINGQLV

YEKDLIEAI

RASNGETLE

ITNSRPPCV

HLA-B*5101 octamers Pos Score FPYEKDLI

RASNGETL

VAPPPEEV

EPGSGVRI

CGFEATYL

NGETLEKI

PGSGVRIV

GGTGAFEI

TGAFEIEI

GAFEIEIN

GQLVFSKL

EQYPGIEI

IEINGQLV

TNSRPPCV

Class II MHC
HLA-DRBl*0101 15 -mers Pos Score QLVFSI~LENGGFPYE

ATYLELASAVKEQYP

V VEYCEPCGFEATYL

GAFEIEINGQLVFSK

RIVVEYCEPCGFEAT

EATYLELASAVI~EQY

YLELASAVKEQYPGI

IEIESRLGGTGAFEI

ESRLGGTGAFEIEIN

PEEVEPGSGVRIVVE

ASAVKEQYPGIEIES

GSGVRIVVEYCEPCG

TGAFEIEINGQLVFS

PCGFEATYLELASAV

KEQYPGIEIESRLGG

AFEIEINGQLVFSKL

GFPYEKDLIEAIRRA

GFEATYLELASAV KE

EIESRLGGTGAFEIE
90 ' IEAIRRASNGETLEK

GETLEKITNSRPP CV

EPCGFEATYLELASA

QYPGIEIESRLGGTG

RLGGTGAF,EIEINGQ

EIEINGQLVFSKLEN

IEINGQLVFSKLENG

EINGQLVFSKLENGG

PYEKDLIEAIRRASN

EKDLIEAIRRASNGE

FEATYLELASAVKEQ

VFSKLENGGFPYEI~D

KDLIEAIRRASNGET
EAIRRASNGETLEKI

MSGEPGQTSVAPPPE

EPGQTSVAPPPEEVE

APPPEEVEPGSGVRI

PPPEEVEPGSGVRIV

YCEPCGFEATYLELA

. 15 PGQTSVAPPPEEVEP

GQTSVAPPPEEVEPG

SAVKEQYPGIEIESR

GIEIESRLGGTGAFE

GTGAFEIEINGQLVF

YPGIEIESRLGGTGA

HLA-DRB1 *0301 (DR17) 15 - mers Pos Score AFEIEINGQLVFSKL

YLELASAVKEQYPGI

QLVFSKLENGGFPYE

TGAFEIEINGQLVF S

RIVVEYCEPCGFEAT

GQLVFSKLENGGFPY

EKDLIEAIRRASNGE

QTSVAPPPEEVEPGS

VRIVVEYCEPCGFEA

YPGIEIESRLGGTGA

IEAIRRASNGETLEK

GSGVRIVVEYCEPCG

KDLIEAIRRASNGET

GETLEKITNSRPPCV

EYCEPCGFEATYLEL

ATYLELASAVKEQYP

EQYPGIEIESRLGGT

LENGGFPYEKDLIEA

PEEVEPGSGVRIVVE

NGQLVFSKLENGGFP

ASAVKEQYPGIEIES

GIEIESRLGGTGAFE

EIESRLGGTGAFEIE

VF SKLENGGFPYEKD

GFPYEKDLIEAIRRA

HLA-DRB1 *0401 (DR4Dw4) 15 - mers Pos Score EATYLELASAVKEQY

TGAFEIEINGQLVFS

EKDLIEAIRRASNGE

KDLIEAIRRASNGET

IEAIRRASNGETLEK

QLVFSKLENGGFPYE

GFPYEKDLIEAIRRA

YPGIEIESRLGGTGA

GETLEKITNSRPPCV

V VEYCEPCGFEATYL

PCGFEATYLELASAV

KEQYP GIEIESRLGG

NGGFPYEKDLIEAIR

PEEVEPGSGVRIVVE

GSGVRIVVEYCEPCG

GVRIVVEYCEPCGFE

ATYLELASAVKEQYP

YLELASAVKEQYPGI

ESRLGGTGAFEIEIN

AFEIEINGQLVFSKL

EIEINGQLVFSKLEN

VAPPPEEVEPGSGVR

PPPEEVEPGSGVRIV

EVEPGSGVRIVVEYC

YCEPCGFEATYLELA

CEPCGFEATYLELAS

EPCGFEATYLELASA

GFEATYLELASAVKE

FEATYLELASAVKEQ

LASAVKEQYPGIEIE

EQYPGIEIESRLGGT

QYPGIEIESRLGGTG

IEIESRLGGTGAFEI

RLGGTGAFEIEINGQ

LGGTGAFEIEINGQL

GTGAFEIEINGQLVF

GAFEIEINGQLVFSK

IEINGQL.VFSKLENG

EINGQLVFSKLENGG

INGQLVFSKLENGGF

YEKDLIEAIRRASNG

IRRASNGETLEKITN

RRASNGETLEKITNS

ASNGETLEKITNSRP

SNGETLEKITNSRPP

expression is evidentlynot sufficient to tolerize all T cells with functional avidity for the level of deregulated iL3 expressed in some tumors. The observation that although B/C.N and BCB 13 express low levels of iL3, they are not susceptible to lysis by the tumor specific CTL suggests, however, that higher affinity T
cells have been tolerized. This appears to be the first instance in which a tumor antigen has been reported to be expressed in the thymus. These observations emphasize that tolerance to a self protein is not absolute but must be defined in relation to quantitative levels of expression (Targoni et al., J. Exp. Med. 187:2055 (1998);
C. J. Harrington et al., Immunity 8:571 (1998)).
[0531] If broadly effective vaccines are to be developed based on expression of shared tumor antigens, then it is critical to demonstrate that such antigens can be immunoprotective. The largest number of shared antigens have been identified for human tumors, but clinical Immunotherapy trials employing these antigens have so far been inconclusive, in part because of uncertainty regarding optimal vaccination strategies (Pardoll, D.M., Nat. Med. 4:525 (1998)). In mice, where immunotherapeutic strategies could be more thoroughly investigated, very few shared tumor antigens have been identified. It was, therefore, of considerable interest to determine whether immunization with iL3 recombinant vaccinia virus would induce tumor specific CTL and protect mice from tumor challenge (Overwijk et al., Proe. Natl. Acad. Sci. 96:2982 (1999); Moss, B., Science 252:1662 (1991); Irvine et al., J. Immunology 154:4651 (1995); McCabe et al., Cancer Reseaf~eh 55:1741 (1995); Estin et al., Pr~e. Natl. Acad. Sci. 85:1052 (1988); J. Kantor et al., JNC184:1084 (1992); V. Bronte et al., Proc. Natl.
Acad.
Sci. 94:3183 (19.97)). Immunization of Balb/c mice with vaccinia virus recombinant for the iL3 gene (H2.16) generated CTL that were able to lyse both BCA 34 and BCA 39 tumor cells, but not B/C.N in vitro (FIG. 9A). Mice immunized twice or even once with vaccinia virus recombinant for iL3 were able to reject challenge with BCA 34 tumor cells (FIGS. 9B and 9C). Mice immunized with empty viral vector, or control vaccinia recombinant for the Inhibitor Protein of cAMP-dependent Protein Kinase (PKIa) were unable to rej ect this tumor challenge (Olsen, S.R. and T.Jhler, M.D., J. Biol. Chem. 266:11158 (1991); Mueller et al., Manuscript in Preparation). These results demonstrate that the iL3 self protein is an immunoprotective tumor antigen.
(0532] The present inventors have developed a new strategy to identify genes that encode CTL epitopes based on CTL-mediated selection from a tumor cDNA
library in a modified vaccinia virus vector (Merchlinsky et al., Virology 23:444 (1997); E. Smith et al., manuscript inpreparation). We have applied this strategy to identify a deregulated housekeeping gene that encodes a tumor rejection antigen shared by three independently derived marine tumors. This ribosomal protein may be representative of a larger class of immunoprotective shared tumor antigens that become immunogenic as a result of deregulated expression of self proteins without compromising immune tolerance to normal tissues. Such antigens would be well suited for immunotherapy of cancer in vital organs.

Expression and Inununogenicity of C35 Tumor Antigen [0533] RNA transcripts of the novel C35 tumor gene are overexpressed in 70%
(12/17) ofprimaryhumanbreast carcinomas examined and 50% (5110) ofbladder carcinomas examined when compared to expression in normal human tissues.
The full-length gene encodes a novel 115 amino acid protein of unlmown function. A monoclonal antibody, 2C3, has been selected that stains the surface membrane of cells expressing C35 by flow cytometric analysis. In addition, human cytotoxic T lymphocytes (CTL) have been generated in vitro that specifically lyse C35+ breast and bladder tumors. The ability to generate C35-specific CTL in vitYO from normal human donors suggests the absence of tolerance to the overexpressed protein. Overexpression of C35 in tumors of different individuals and the ability to induce humoral and cellular immune responses make C35 a promising candidate for immunotherapy.

Material and Methods [0534] Cell lines: Human mammary carcinoma cell lines BT20, BT474, MCF7, MDA MB231, SKBR3, T47D (supplied by ATCC) were grown in RPMI-1640 (BioWhitaker, Walkersville, MD) supplemented with 10% fetal bovine serum (Biofluids, Rockville, MD). An immortalized line derived from normal breast epithelium, H16N2, two metastastic tumors, 21-MTl and 21-MT2, and two primary tumors, 21-NT and 21-PT all derived from the same patient, and grown in DFCI medium (Band, V. and Sager, R., "Tumor Progression in Breast Cancer"
in Neoplastic Transformation in Human Cell Culture, J.S. Rhim and A.
Dritschilo eds., The Human Press Inc., 'Totowa, NJ. (1991), pp. 169-78) were generously provided by Dr. Vimla Band, New England-Tufts Medical Center.
The bladder tumor cell line ppT11A3 was derived from the immortalized nontumorigenic cell line SV-HUC. These bladder cell lines were generously provided by Dr. Catherine Reznikoff, University of Wisconsin Clinical Cancer Center, and grown in F12 medium supplemented with 1% FBS, 0.025 units insulin, 1 ug hydrocortisone, 5 ug transferrin, 2.7 g dextrose, 0.1 uM non-essential amino acids, 2 mM L-glutamine, 100 units penicillin, and 100 ug streptomycin per 500 ml. Normal proliferating breast epithelial cells (MEC) were purchased from Clonetics (BioWhittaker) and maintained according to the supplier's directions.
[0535] RNA extraction andNorthern BlotAnal,~sis: Cell lines were harvested for RNA extraction at approximately 80% confluency. Cells were harvested and lysed in QG buffer from Qiagen RNAeasy kit. Total RNA was extracted as per manufacturer's protocol and stored at -80°C as precipitates with GITC
and alcohol. Tissue samples were provided by the Cooperative Human Tissue Network as snap frozen samples, which were homogenized in lysis buffer for use in the RNAeasy protocol. For Northern blots, mRNA was extracted from total RNA (30 ug total RNA/well) using Dynal's (Lake Success, NY) oligo-dT2s magnetic beads and electrophoresed in 0.8% SeaKemLE (FMC Bioproducts) with 3 % formaldehyde. The mRNA was blotted onto Genescreen Plus (NEN) in l OX
SSC overnight by capillary blot, then baked for 2 hours at 80°C.
Membranes were probed with random-primed 32P-labeled cDNA probes (Prime-It, Stratagene, LaJolla, CA) at 106 cpm/ml Quickhyb solution (Stratagene), at 68°C
as per manufacturer's protocol. Blots were exposed to Xray film and/or phosphorimager screens overnight. Expression on all blots was normalized to a housekeeping gene, such as GAPDH or beta actin.
(0536] Subtractive Hybridization: PCR Select cDNA Subtraction Kit (Clontech, Palo Alto, CA), based on Representational Difference Analysis as first described byLisitsyn et al.(Lisitsyn, N. and Wigler, N.M., Science 259:946-51 (1993)), v~ras employed as per manufacturer's protocol to generate cDNAs enriched for genes overexpressed in tumor compared to normal breast cell lines. Briefly, oligo-dT-primed double stranded cDNA was synthesized from 2 ug high quality, DNase-treated mRNA from tumor and normal cells. Adaptors were ligated to short blunt-end (Rsal digested) tumor sequences and hybridized with excess Rsal digested normal fragments. Following 32 hour hybridization, suppression PCR
(Clontech) allowed preferential amplification of overexpressed tumor sequences using adaptor sequences as primers. The products of the PCR amplification were cloned into pT7Blue3 (Novagen, Madison, WI) to generate a subtracted library.
Clones were grown in LB/ampicillin (100ug/ml) in 96-well format, inserts were PCR amplified from the overnight cultures and PCR products were spotted on Genescreen Plus using BioDot manifold (BioRad, Hercules, CA). Duplicate dot blots were then probed with random-primed tumor or normal cDNA, or, alternatively, the PCR products of the forward and reverse subtractive hybridizations. Clones that appeared to be overexpressed in the tumor cDNA and forward subtraction (tumor minus normal) were analyzed by Northern Blot (as described above) to confirm differential gene expression.
[0537] cDNA lib~afy and full length gene: Oligo-dT primed double stranded cDNA was generated from SKBR3 cell line using SMART cDNA Synthesis (Clontech Laboratories), followed by phenol:chloroform:isoamyl alcohol extraction. Primers were synthesized (C35 sense: 5'-GCGATGACGGGGGAGCC, and C35 antisense: 5'-CCACGGAATCTTCTATTCTTTCT; Fisher Oligos, The Woodlands, TX) to amplify the coding region of C35, based on the open reading frame deduced from EST homologies, Accession # W57569, in particular. PCR products were cloned into pT7Blue 3 (Novagen).
[0538] Yaccinia and Retroviral C35 recombinants: The coding sequence of C35 was subcloned from the library into vaccinia transfer plasmid, pVTI~O at BamHI/SaII sites in a defined orientation. Recombinant virus was generated by transfection of pVTI~0.C35 along with NotI and ApaI digested V7.5/TK viral DNA into fowlpox virus infected BSC-1 cells. As described elsewhere (U.S.
Utility Patent Application No. 08/935,377; PCT/LTS98/24029; T Cells Specific for Target Antigens and Vaccines Based Thereon), this is an efficient method for construction of vaccinia virus recombinants. The C35 gene was also cloned into a retroviral vector pLXSN, and viral stocks were generated by co-transfection of 293-GP cells with pVSVg for pseudotyping. Supernatants including infectious virus were collected 48 hours later.
[0539] Generati~n of C35-specific 2C3 monoclonal antib~dy andFACSanal~sis:
Linel mouse small cell lung carcinoma cells were infected with C35-retrovirus, and 103 - 2 x 104 cells were inj ected into three BALB/cByJ mice. Following 21 days, serum was harvested from retro-orbital bleeds and checked for reactivity with human tumor cells known to express low (MDA-MB-231) or very hig?n (21NT) levels of C35 mRNA. Spleens were also harvested for the production of hybridomas by the fusion of spleen cells with P3 myeloma cells using standard mouse hybridoma technology. ELISA was used to screen HAT resistant clones for the presence of Ig. High producers were isotyped, quantitated, and used to screen C35+ and C35- cell lines by flow cytometry. Hybridoma clone supernatants containing 1 ug IgG were incubated with 106 cells in PAB (PB S,1 BSA, 0.1% a.zide) for 30 min on ice, followed by 3 washes with PAB, and incubation with goat anti-mouse IgG conjugated to FITC (Southern Biotechnology, Birmingham, AL) for 30 minutes on ice. One hybridoma clone, 2C3, recapitulated the surface staining seen with the immune serum (FIGS.14A-14B) andwas selected for expansion and antibodypurification (BioExpress, West Lebanon, N~.
[0540] Generation of human C35-specific T Bell line: Peripheral blood derived from a healthy female donor (HLA A2, 11,. B35, 44) was separated into erythrocyte-rosette positive fraction~(a source of total T lymphocytes) and negative fraction (a source of monocytes). The T lymphocytes were cryopreserved for later use while the monocytes were incubated under conditions to generate dendritic cells (DC). Maturation of DCs was induced as described by Bhardwaj and colleagues (Bender, A. et al., J. Immunol. llleth. 196:121-35 (1996); Reddy, A. et al., Blood 90:3640-46 (1997); Engelmayer, J. et al., J.
Immunology 163:6762-68 (1999)) with some modifications. hGM-CSF and hIL-4 (1000U/ml) were added every other day. At day 7, non-adherent, immature DC
were incubated with a retrovirus recombinant for C35 for 6 hours in the presence of GM-CSF and 1L-4. At this point, the retroviral supernatant was washed out and immature dendritic cells were subjected to maturation conditions, which again included GM-CSF,1L-4 as well as 12.5% monocyte conditioned medium (MCM). After 4 days, these mature, C35-expressing DC were used to stimulate autologous T cells at a ratio of 1 DC:50 T cells for a period of 14 days. A
fresh pool of autologous DC were generated for restimulation of the T cells, but this time they were infected after 48 hours of maturation in MCM with a vaccinia virus recombinant for C35. Cytokines IL-2 (20 U/ml), IL-12 (20 U/ml) and IL-18 (10 ng/ml) were added and a 1:50 ratio of DC:T cells was maintained. Following 12 days culture, T cells were stimulated for 7 additional days with EBV-B
cells infected with C35 recombinant retrovirus and with addition of IL-2 (20 U/ml) and IL-7 ( 10 ng/ml). Cytokines were all purchased from R&D Systems (Minneapolis, MIA. At this point, the cells were >90% CD8+ and were tested for activity in a standard 5'CrRelease assay. Briefly, one million target cells were incubated with 100 uCi SICr, washed, then incubated with CTL effectors for 4 hours in RPMI-1640, supplemented with 10% human AB serum (BioWhittaker). Activity of the CTL is expressed as the percent of specific lysis, measured as (SiCr released into the supernatant upon lysis of labeled targets by CTL - spontaneous release)/(maximal release - spontaneous release).
Results [0541] Characte~izatioh of C35: The sequence of clone C35, differentially expressed in human breast tumor cells, is not homologous to any known gene in Genbank, but homologous EST sequences (prototype Accession# W57569) were identified. Homologous human EST fragments are present in NCI CGAP (Cancer Genome Anatomy Project) libraries, including tumors of brain, lung and kidney (A# AA954696), Soares ovary (A# AA285089) and parathyroid tumors (A#
W37432), an endometrial tumor (A#AA337071), and colon carcinoma (A#
AA313422). An open reading frame was identified that encodes a 115 amino acid protein (FIG. l0A). The full-length gene Was isolated from a cDNA library of the breast adenocarcinoma cell line SKBR3. Sequencing of full-length transcripts from the cell lines SI~BR3, 21MT2-D, and H16N2 confirmed that there were no point mutations in the cDNA; the transcript is 100% homologous in C35'" cell lines, as well as C35'° cell lines. The C35 gene aligns on human chromosome 17q12 (A# AC040933) and mouse chromosome 11 (A#
AC064803). Exons were deduced from homologies with cDNA EST sequences, as well as GRAIL predictions. Interestingly, the gene for C35 is within 1000 base pairs of the Her2/neu oncogene and within 2000 by of the gene for Growth Factor Receptor-Bound Protein 7 (GRB7), a tyrosine kinase that is involved in activating the cell cycle and that is overexpressed in esophageal carcinomas (Tariaka, S.
et al., J. Clin. Invest. 102:821-27 (1998)) (FIG. 10B). Her2/neu protein overexpression has been correlated with gene amplification in 30% breast tumors and is associated with poor clinical prognosis (Slamon, D.J. et al., Science 235:177-82 (1987)).

[0542] Predicted protein motifs in the C35 amino acid sequence include: casein kinase IIphosphorylation sites at amino acids 38 to 41 (TYLE), 76 to 79 (SKLE), and 97 to 100 (SNGE); an N-myristoylation site at amino acids 60 to 65 (GGTGAF); and a cAMP- and cGMP-dependent protein kinase phosphorylation site at amino acids 94 to 97 (RRAS). Finally, the C35 protein contains a prenylation motif at the COOH-terminus, amino acids 112 to 115 (CVIL).
Prenylation, the covalent attachment of a hydrophobic isoprenoid moiety, is a post-translational modification that promotes membrane association and also appears to mediate protein-protein interactions (Fu, H.-W. and Casey, P. J., RecentProg~ess in Hormone Research 54:315-43 (1999)). Prenylation has been shown to be required for localization and transforming potential of the oncogenic Ras family proteins to the cell surface (Jackson, J.H. et al., Proc. Natl.
Aead. S'ci.
U.S.A. 87:3042-46 (1990); Hancock, J.F. et al., Cell 57:1167-77 (1989)).
Inhibitors of prenylation have been shown to possess anti-tumor activities, such as slowing tumor growth (Gaxcia, A.M. et al., J. Biol. Chem. 268:18415-18 (1993)) and to promote rejection in animal models (Kohl, N.E. et al., Nature Med. 1:792-97 (1995)). Three O-glycosylation sites are predicted at or near the amino terminus -- thr8, ser2, and ser9 using NetOGlyc2Ø
[0543] C35 Transcript is Overexpressed in BYeast and Bladders Careiraorna: An ideal target antigen for tumor immunotherapy would be abundantly expressed in multiple independent carcinomas, and would be absent or minimally expressed in normal proliferating and vital tissues. Differential expression of C35 was confirmed by Northern blot analysis. C35 is expressed in 7/10 human tumor cell lines at levels 10-25X higher than expression in a normal immortalized breast epithelial cell line, H16N2 (FIG. 11A). Importantly, C35 expression is shared among lines derived from both primary (21NT, 21PT) and metastatic (21MT1, 21MT2) lesions of a single patient, suggesting its expression may be associated with early events in the process of tumor transformation. In addition, the overexpression of C35 is shared among independently derived human mammary carcinoma cell lines, including SKBR3, T47D, and BT474. Interestingly, the C35 expression pattern in SKBR3, MDA MB231, H16N2 and tumors derived from the same patient correlates with Her2/neu expression, which may be associated with the close genomic proximity of the two genes and the incidence of HER2/neu gene amplification.
[0544] To investigate whether C35 expression in patient derived tumors is clinically relevant for development of a cancer vaccine, mRNA was extracted from snap frozen human tissue samples obtained from the Cooperative Human TissueNetwork (CHTI~. 70% ofprimarybreasttumor samples overexpress C35 transcript (FIG. 11B), and 35% (7/20) of these breast adenocarcinomas overexpress at levels 10-70 fold higher than normal breast. Overexpression of C35 is also seen in 50% ofbladder carcinoma primary specimens examined (FIG.
12), while 20% (3114) ofprimarybladder carcinoma express at levels greater than fold higher than normal bladder. Overexpression of C35, at levels 9X or greater, was not detected in panels of ovarian (0/7), prostate (0/5), or colon (0/15) carcinomas (data not shown).
[0545] 2C3 Monoclonal Antibody reacts with C35+ cells: In order to confirm differential expression of the gene product encoded by C35, a monoclonal antibody against the shared tumor antigen was selected. Hybridomas were produced by immunizing mice with a poorly immunogenic BALB/cByJ tumor cell line, which had been transduced with a retroviral human C35 recombinant.
Hybridorna clones were screened for their ability to stain C35++ breast and bladder tumor cell lines (FIGS.13A and 13B). Non-tumorigenic breast H16N2 and bladder SV-HUC epithelial cell lines did not show a significant shift in fluorescence intensity when compared to the isotype control. In contrast, 2C3 monoclonal antibody specifically stained C35+ breast tumors, SKBR3 and 21-NT-D, and bladder tumor ppT11A3. The staining was earned out on cells that were neither fixed nor permeabilized, indicating that 2C3 antibody recognizes a surface molecule.

HLA peptide motif search results (- ~ User Parameters and coring In ormation (- met o selected to imrt num er explicit o results number num er o results requeste 20 HL,A mo ecu a type se ecte ,~1 ' length selected or su sequences9 to be score ..... . . __.__......_.__.__..
...______.___._..._._' echoing mo a selected or input _._ sequence ..._.__.. . ._._.__.___.____.__-_______.._..___..____._...
..._. .._. ......w_...__ ec omg ormat i num ere ~ mes ~~
~~

en o user's input peph a sequence~- 115 . ' -. _ _ _ .~ a ~
.. . _. _ . __ _____._.__ ;
. ~T~
.. ~
~~~~
~

~ 107 su sequencescorescalculate num ero ~
.

num ac m scoring output tab e;~_ er 20 sequences reporte o top-sconng su . ... .. . .. .. . . . . R ...___. . ______.._ .. _.___.____ . .. .
__.___..__...__.__.
Scoring esults RankStart Subsequence Score (Estimate of Half Pos~honResidue Time of Disassociation Listing of a Molecule Containing This Subsequence) 77 . _________. 22$.OOO ...._,..
. ____.. _..
_ _ KLENGGFPY
, lE~
;~EVEPGSGVR
___....
-._ __.
____.
_ ___._:

4$.000 ..
.._...
YCEPCGFEA.
.
....
..
........_...
.
__..___.
.........____......__._.._.:

~
YLELASAVK

.OOO

SGEPG(2TSV a.2$O

_ ._... .... .._. _.__....
. . ..1_~O___. _..._.._.
. _.. .: . .. _..
.

..
...
_..?I,_._ .
_.
_ VVEYCEPCG, .
.__.
_ 9Ex ,:
ASNGETLEK
1.$OO
' TLEKITNSR
O.9O0 IOl ;

LIEAIRRAS
~

.
EIESRLGGT
0.900 , .
$4 11 _..._... .
. EIEINGQLV, ' .. .__ .
66 .._.__._.....
. . O900....
. ..... . .
._: ......_' $2 O.9O0 _._. ._._._..

r 8~
EKDLIEAIR
O.
OO
.
.

..
.
.
.
.
LASAVKEQY, , .
.....
__.
O.S00.__.
.
.
.
...
.
..
.
.
..

~1$-~31 EPCGFEATY

, 6g -.
...i INGQLVFSK..
.
.
~__.....
.._:2~.._..
.
.
.
......__ , -~-..
.I
FEATYLEL__.....
.
._.._ .________ ~22$_"...__.._........._._-_.-, _ NGETLEKIT
~
.2 $
...:
..__.
.
__._._._ .._ .
.___ ..
...
.
_ .
.
.
.
..__ ._._.

19 ~ GTGAFEIEI
~ .125 .
_..
..
_.,_._.__._ __.
_. __.___.
__._.._,.-"
w..
.

.100 ENGGFPYEK
y ~
._.

Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results User Parameters and Scoring In ormation L
method selecte to hmri number o exphc>t resu is number num er o results requeste 20 HLA molecule type se ected Al eng se ecte or subsequences to be 10 scored ~.
....._........_. _ .. .. ... _-.. _.._.__...___..._........__....___-_.___~_..:

echoing mode se ecte or input sequence ___ .
..

_ ._.___._____..._____.._.._____. n~ ere._'u~i ec otng ormat__.
__V
-__._-.._~.._.~.-_I

! en o user's input peph a sequence- 115 ~ ;
. . _ ._ . _... . _ ..... ...______-__.__________..__.____._.___-_-_._._.___-__~

num er o su sequence scores ca c ate ; 10,...__ ' number o top-sconng su sequences reporte ack m sconng output to ~.e~ ~.... ., _, 20. a . . . ... .. .. - Scoring Results '.-_..... _...._._ .... . ... .
._..__._._..._....
RankStart ubsequence Score (Estimate of H alf PositionResidue Time of Disassociation Listing o a Molecule Containing This Subsequence) ;
.

EIEInGQLVF
, 45.

..
'...._ .._.__._._.__..__...____._..__ _ ......._..._.._.....
.._.__ EVEPgSGVRI
18.000 i ..
........_...._.....
_.
...
~....
.
.
._......_.____.._.....
.
......_...__.._.._..._ YCEPcGFEAT
9.000 ~
_.__._...____..____ _.__ .
.
__ ____.__._____....._._ ...
~

.

.
WEYcEPCGF
.
_.
....._.
_.
____.~
.
_.
...
_ ....

$2 GIEIeSRLGG
4.500 __....
.,SGEPgQTSVA
..
.
_..2-25~.~_.___,._..
.._.......
....
._.

LIEAiRRASN.
1.800 ~' ~
~
' 1.SOO
.
, GSGVrIVVEY
~
..' 1.2SO

EKDLiEAIRR
.
~~

i ~~8 1.12 .i 11 5 RASNgETLEK
i .
.-...
. ..
. .
._..,....._._.,.__.___._l~_,.~_....
. ..._...___._...__ 68 EINGqLVFSK
1.OOO
__..
. .._ _...
_._ ._...
....
.. .
_.._ _..._..
.

EIESrLGGTG
. . ._.. .
.... _ .._ .. ..._ .
. .._..._...._ __.,_ ....

14 41 ~ ELASaVKEQY O.S00 . T.' '~

ETLEkITNSA 0.2SO
.
~
~~

16 0.22_5 ~ _ 46 _ l !
VKEQyPGIEI .
~ ~

17 39 i YLELaSAVKE 0.1 0 s . .. . ..._. -' 1R 7I -. r" ,KLENgGFPYE.......__._._ ,..
._'1 O_.__..._...._....
_....__._.__~

1 76 SKLEnGGFPY 0.125 ._... _..... .... . .. ... ................._..._._._.._.____..
....... ....___.
...
..

20 . . 75 i ~.
_..
EQYPgIEIES

Echoed User Peptide Sequence (tength =115 residues) HLA peptide motif search results ser Parameters and Scoring In ormation-method selected to InuU num er o exp ~c~t resu is num er ~~ ~ ~ - ~

num er o rcsu is requeste 20 L mo ccule typc selecle A 0201 length selccte or subsequences to ~ 9 be scored ec omg mode se ected or input sequencey ec omg onnat _ num ere . mes ~

engt o user's input 115 peph a sequence ~. . _...
.. ...... .. _. . ........ .. _ num er o su sequence scores ca cu ate , num er o top-scoring su sequences 20 report ac m scoring output tab e Scoring Results RankStart ubsequence Score (Eshmate of Hal ~
PositionResidue ime of Disassoc~'ation Listing of a Molecule Containing This Subsequence) ~~ SVAPPPEEV2.9 2 KITNSRPPC2.391 ~3 I. 42 lOS 1.4 $
~
ITNSRPPCV
IVVEYCEPC

FEIEINGQL1. IH

47 KEQYPGIEI0.710 .

DLIEAIRRA0.7 LGGTGAFEI0.671 1 GTGAFEIEI.SSI
~

~1G~ GGFPYEKDLO.S16 gl II ATYLELASA.SOH
~

12 FEATYLELA.S 1.

13 EEVEPGSGV0.41 IS
~

14 VEPGSGVRI0.34$

I$ SNGETLEKI.315 ~)7 ~

NGQLVFSKLO.2 S

22 GVRIVVEYC.205 IH AVKEQYPGI0.196 .~ YEKDLIEAI.ISI
g5 ~

2U TYLELASAVO.1 7 ~

Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results explicit number leng se ected or subsequences to 10 ..
be scor .
~ '~
-~
~~

. ~~.Y
or input sequence e se ecte ~~ ec omg mo ' ~~ ~. ~
-echoing onnat ,num ere rues o user's rnput peptrde sequence ~._-~ i115 en -_ -~~~~~
~

_ 1l __ ~"
cu ate num er o~su -sequence scores c num er of top-sconng su sequences e20 reporte bac m sconng output to Scoring Results 'Rank.
Start Position:
uhsequence Resrdue ~ Score ~ stimate o Hal Trine of Disassociation of .
Listing a Molecule Containing This Suhsequence) 1 5 RLGGtGAFEI :SI
.... _....
~-_ KITNsRPPCV 33.472 ~S FEIEiNGQLV 25.SO
~ .
.

FPYEkDLIEA 4.502 $3 ~

5 33 r- .173 CGFEaTYLEL ._..-. ..... . .
~ _.' ~

s~ 3.1 5 sv 1 ~
-37 ATYLeLASAV __ 1 , SO YPGIeIESRL 0. 41 ~

INGQ1VFSKL 0.450 10 17 ~
. .,VEPGsGVRIV
, 11 24 RIVVeYCEPC ~ 0.335 ;
_...
.

12 53 IEIEsRLGGT ~ .302 ~~

13 ~~0 0.259 GGTGaFEIEI ~

14 8 TSVApPPEEV _222 ' ..
'~

SAVKeQYPGI .217 ~

1 21 ' .2 scvRiwEYC 1 .~ _...._........ .
~ ..__.. .
-..._.._ ;~ O-1 4 IESR1GGTGA .
'._ ' ~
, 18 ~
...-_-~._ ..
' y _ , -.123-_ _y__.
GGFPyEKDLI ..
~ . _ . __ _ _ _..... -. .. _. __.__ $1 ...
~ .....___.......
.._,..

2 105 ITNSrPPCVI 0.101 ' ... .._. . ...... .___ .
. . .. _ Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results User Parameters and Scoring Information method selecte to mnt number of results explicit number number o results requested ~ 20 HLA _molecule type selected A 0205 length seiecte or subsequences to be score ~

or input sequence .
echoing mode selecte ..__ g ___ .....
echom otmat ~ ; num ere mes t ..____.__. ..___.
. ~ ~

_. __ ._ _ q ~_....
~
e~uence ~
U a s len of user's m ut ~
P peP _. ~
~

_ 1 7 _ ;
num er o su sequence scores c cu ate ~~~~
~
' e!r _ ., 20 num er of top-sconng su sequences reporte ac m sconng output to Rank Start Position r7 ~ GS
2$ IVVEYCEPC
~ a.UbU

SVAPPPEEV
~~ 2.OOO
j .' lO4 1.SOO
~ KITNSRPPC .

Sl GGFPYEKDL .2EO
~
.. . ......

4S AVKEQYPGI 1.200 ..__. ..__.-_._._ ..__._.__...._ ' ~..._.._ ..... ... . ......,_..._.
~..
....
....
~

_ _ 7 . VFSKL ,.

4~ ~ KEQYPGIEI ~ 0.4~U
105 ITNSRPPCV ~ .'O.34O
3~ ~ATYLELASA
Echoed User Peptide Sequence (length =11 S residues) HLA peptide motif search results (~ - User Parameters and Scoring In ormation ~

~ exp ictt mct o selecte to ~mri num er o resultsnum er number o results requeste 20 HLA mo ecu a type selecte A_0205 .

engt se ecte or subsequences to 10 be score W
_ .. .. .. ..___. .___. .... _.~...
....._.._ ..__._.

ec omg mode se ecte or input sequence , Y
..... .._.. .__...__ ...__.... ..___..
._._... .___.. ____ ...__.. ..
_..___..._~.

ec omg onnat num ere~l'mes .. . ___. _ ..____ . _.__.. ._..-...;
._._ .~. .___ ...____. _____ ~ _..___._._.~

lengt o user's input pepi~ a sequence115 ;
. . . _._..._ ..._.._... .___._ ...._._ ... __..____ _______ ......__.___.' num er o su sequence scores ca eu , _. 106 ate ; i ~~

number o top-sconng subsequences reporte ac m sconng output tabled , , , Scoring esults Rank.Start Subsequenceg core stimate o alf T~me Position'esidue of Disassqoeiat~o)n of Listin a Molecule Containin This Subse uenee ' CGFEaTYLEL
.300 j ~ KITNsRPPCV

FEIEiNGQLV
2.5 I
E_IESRLGGT
1.428 .

FPYEkDLIEA
j.3 -58 .... . _ RLGGtGAFEL-~
. ,_.. .. .._.
__..__. I
_. _ ~ .
...___ .
. _._._._.
_ _____ _ ~ LIgO

St _~
YPGIeIESRL
1.

37 ATYLeLASAV

lO
~

MSGEpGQTSV
O.SIO

~
NGGFpYEKDL
0.42 ~

~

TNSRpPCVIL

13 0.30 ~

ftIVVeYCEPC

14 .200 ~~
SAVKeQYPGI
~

IS
r ;~
VEPGsGVRIV

16 j05 .,.
'~
ITNSrPPCVI
0.170 .._ .._.
.,.
. .
,._ I7 :
j50 ~ ..SNGEtLEKIT
. _..
_ ___ _-._.._..-_.._....
._._ ..,______..

Echoed t)ser Peptide Sequence (length =115 residues) HLA peptide motif search results I User Parameters and Scoring Information met od se ected to hm~t number expbcrt of results number number o results requeste HL mo ecu a type se ected A24 ~

eng se ected for subsequences 9 to be score .__ ._ . . ._ _._._. _.._.. .__._ .._.__. ._..._. ...__._.._ _.._~_ ec omg mo a selecte or input ~ y sequence ~ _ .__ _ .
_ ~_ _.. .
... . ... _.. ..
.__. ..______..._.___.... .___.__...____._..______.__~.-_ ec omg format i num eyed Imes ,ii _._ .. . ... .. ..._.._. _____..._-_.
.. .__.. _..___..._____._.-__ __~_:~_...__._.

ength o user's input pepU a sequencer 118 ..._... .._.. __..__..__._....___...__.__._._....__.....-___...~____-_.._~_~.~~~

num er o su sequence scores ca _ Sr , 107 cu ate ~

num er o top-sconng su sequences reported bac m scormg output table~~ 2b .. . _.. . ._.... _. g...__.._. ._.__.. .___._........__.._._._....
.._.____.__._.. __.__......__.._~
Scorin esults ;
Rank Score (Estrmate of Hal Start Time of D~sassocianon Pas~tion~ of ' Subsequence ~ a Molecule Containing Residue This Subsequence) j Listing '1 :

34 ~ GFEATYLEL 33.000 . ~

~2 QYPGIEIES 11.
4~ . 0 ."
.

NG,QLVFSKL 11.0 ~~
~
.

38 TY,LELASAV 10.

.

~$ GFPYEKDLI .

H1 ~GGFPYEKDL 4.800 ~
f ...._ _._ .... .___._.. .._.___...__ ..~ __ .~_.. ______ .
_ 7 IL , ~ NS ...
107 RPPCV _____ $OO
' 75 FSKLENGGF 2.000 ~~~

O SNGETLEKI 1.320 AvxEQYPGI 1.200 ' ...__. ._ 45 ~

11 GTGAFEIEI 1.10 ?
61 ..... _... ._ .__.... .____.. ._...__...,_ ~ ._..._ ...._.~
. ...

12 S9 LGGTGAFEI 1.1 O
' GS FEIEINGQL 1.00 14 SI PGIEIESRL 1.008 ~~.

1S TNSRPPCVI 1. O
~lO~

I6 PYEKDLIEA . 2S
.. ..._ ._._..~... ..__. . ..___.,_ _,._ ..._ ._._. ._.:

17.~~
RRASNGETL _ ._... _._. . _..._ ...
_.... ____ .._... ~.. .._._ ______ ...___.
..__..

_ .__.. ____._.
EYCEPCGFE . O i . . . .__. _.. . .__... ... _._. .
. _ ___ _._. .._.. . _.._. .. .

PCGFEATYL 400 ' _._. ._ .. .... . .. __...._ ...
-.. . _ _ __. ..._._.~. __.......
.. _.__.

0 47 QYPGIEI _ 3 . . _ ... .... 1 Echoed User Peptide Sequence (length= t25 residues]

HLA peptide motif search results User Parameters and Scoring In ormation method selecte to limn number explicit o resu is number num er o results requested 20 LA molecule type selected ~4 .

engt se ecte or su sequences to 1 be scor ..._ ... ....._... .___ ..__... .._........._,._ . __._. ._..__ .. ...__.

ec omg mo a select or input sequence; Y
._. .._ .. .. _... ...____._. ...-~..._____.__...__.__ .....~_....___._.. .,.__._ _.._ .__.-..____.....___ ec omg onnat , num er .... .. ... .. ......_ ..__. _ .._,tnes . ..-__.. ._.____. _._._. . _.___... -___ ____... ...____._ _____.' engt o user's input pepb a sequence i L5 .. . . .... _.__..__ ..___ ____._.~._ __-. _____.
._.._....

='_r . ~_ .-~
num er o su sequence scores c ~ ~
cu ate number o top-sconng su sequences e;..20 reporte bac m sconng output to Scoring Results ~

RankStart Subsequence Score (Estimate of al Ti Position;Residue ' D sassociation off:
Listing a Molecule Containing This Subsequence) ~4 .~
At;'EIeINGQL
42.

~, 2 LO.000 74 .. ._.... ., .. . ... .
VFSK1ENGGE') . .__ . __.'.

~~i 9.000 PYEKdLIEA~ ,~
~ ~~

.392 INGQIVFSta;
s ~r EYCEpCGFEI1~
~

! ..__. .... .__, .._____.._ ...... Sw._~~_.. . ___.._....
YPGIeIESRL . __.__......__.__ ...__.

3~ .280 CGFEaTYLEL
.

IOti~
TNSRpPCVIL
4.00 ~~31 EPCGfEATYL
4.000 I

SU
NGGFpYEKDL
4.OO
.

II 3. 00 2b . ,.___ _._... ...._..._....
VVEYCEPCGF __._.._... _ .. ____..
, _......_. ..
_.
._.
.
.
..
_ .._._..
._,__..
.
....
..

_ 3.
12 .. . . ... ...
~

EIEInGQLVF
' 13 58 RLGGtGAFEI 2.200 ... ..._ .. . . ._.. ....

14 ~ 56 2.0 ESRLgGTGAF

.r I~~
EVEPgSGVRI
I.
O

ASNGeTLEKI
1.

...
_ ..._..
.......
.
..__.
.._.
_.___.

. ITNSrPPCVI

...' .. . __..
__.__. _.
__... ___.
.....__....
..-:._..._._____..
. _._.__..___._.

I8 ~ .SAVKeQYPGI
~ . ~__._ ____..
~ __ 1.500.,__._..__....._..
._..._,.._ GGFPyEKDLI,.
~.
.
.
._.
___..
.._i-....
~.__.._...
.
...
_,_.
._.....__ .,._.

GGTGaFEIEI
1.100 !

Echoed User Peptide Sequence (length =1x 5 residues) HLA peptide motif search results User Parameters and coring nformation met o selecte to ~m~t number of expbcrt resu is num er number of results requested 20 11LA mo ecule type selected ~ .
~

lengt se ecte _'~ 9 or su V
sequences to a score ~~
~
~
~~ ~ ~ ~~
~
.
~~

ec om mo , e se ~~ Y
eete .__ ....__~._..__.__..
or m ut s uence g P ~l _.._ ..._... ..__. __. ._____._.__.__.~_.~._..___..~__ .___...-. _____...._ ec omg ormat num erg;
.__._.. .___. ._... _~. '-. _~_____....~______.._~~_.-._.
_~. .___..~__..____...._ _-.

en of user's input peptz a sequence~ ._ 115 ___....__.._..,___._....___.___,_...~_...___._____..~....._...,_,___ __~

num er o su sequence scores c c 1 7 ated ~ . _ .. . _._. . . .... _ . . ..

number o top-sconng su sequences e~~2 report ac m sconng output to _. .... . . .. ...... ._g _.... _____. ._.. ..__.. ._._. .. ,.__...... ._.__._ ______.._~
Scorin Results RankStart Subsequenee core (Estrmate o )Ialf' Positiomesidue 'line o Disassociation Listing of a Molecule Containing This Subsequence) ...._ . .._. ._._......_.._' .

77 (,OOO
~ KLENGGFPY
.. .. ..._..
..
__..
: ..._ _..
. _... ..___..
._._.. ..._____.
..__._. .___._ 39 _ _ . . .Y~ELASAVK
: 20. 00 . .. . ..
_.__.. ._._ _..._. ._.....
_.__.

r .
I . . .... .
[ _... . .
~1 .... . .
. . ,......~_o~
. ....._ .
.._...._...__._...._._.

bl G
,AFEIES.

~ .

.3 0 69 .
T~7GQLVFSK:

9G 0.300 ~ . . .... _ ASNGETLEK .__... . . . ..___ ..._..
.. _..__. -__. .._._._. ._.___....____ ~
...
.
.._..
.....
...
..._...
_ .
_...
.

~7 .270 GvRIVVSYC

ENGGFPYEK
0.162 25 ~ IVVEYCEPC
.135 , '-AVKEQYPGI
0.090 0.075 .. _.._._ ., ,.. __ . __ _ ...
. _. .._~_...
. _.._ .
__..._._ ..__..._____..__.

12 ~ 42 LASAVKEQY
O.O 0 .

13 0.0 KITNSRPPC
~

YPGIEIESR
~
.

IS ~Z ~
. QLVESKLEN

1S ~ .. .054 '.
EVEPGSGVR

I7, ~ .._.. __.. ..._~.~5._._ .. . -___. ____ ..,__ ..
..

....
~......
._ EPCGFEATY
...
:

1H 0. 45 j 9 __. _._ ._ .._._ _.___ SVAPPPEEV ..~__. .__._... __.__.
'~__ __.._ .._ .
..._ _..._.
._..
.

19. .... ... ._._ ..._. . __.'..~-..36 . _.r... _.__._ ___ g~ .030 ...,.
....
..
~KaLIEAIRR
...
._ .

'-vEYCEPCGF

Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring In ormahon method selected to tmrt num er o resu is exp tctt num er number o results requested r' 20 HLA molecule type selected A3 ength selecte or su sequences to 10 be score _... _ __.. ...._.. .,._. ..___.
_.___. _.. ._. .____._ __ ..._..
..

ec omg mode se ected or input sequencey , _.. ___. _... . _ .., _~_.._ ___.._.
.__...~__ .__. ..__..-_ .__. -ec otng ormat num ere ..... _ . .. ..._... _.._. .___ mes _.__. ._... .._. ...._ ..._.. ___ .._.___.
____..-_._. _1 en o user's input peph a sequence 11 S
; ~__....-. . ... . ... ...__.__ ____....__..._ ___._~._..__. ____..~..._ ,__-_..._____:._.._._:

num er o su sequence scores a cu ~1 fi at .__ .
. ..

number o top-sconng su sequences reported bac tn scoring output tab e~ 20 ... . .._ .__ ~ _ __._.

... ... _. __ ,.. ._. .___ __ _...._.. ...._.___ ..____ ...____...___ _____ coring Results RankStart sequence Residuecore ( ~ s6mate of Half PositionListing Time o ' Dtsassociaa'o 03'-:
a Molecule Containing This Subsequence) .

EINGqLVFSK 8.100 -...-~._.
_ .._ _. ..' .
-._' __ $8 ~RLGGtGAFE2 2-;~00 ...,_ ,_.
-._ ...
.,., .._..

ELASaVKEQY 1. 00 .
~.-4 ~NGgFPYEK O.81O
:

~S ~ RASNgETLEK

20 ~ ._. . GSGVrIVVEY.__.__ _.. ~_. .__ ._.__ ..~;2 .._. : Ø____..... ...__._..
..___..__..._~

IO ETLEkITNSR 0.20 ~~

26 VVEYcEPCGF 0.200 , ~

KLENgGFPYE O.1 O
.

EIEInGQLVF 0.120 ~

11 RIVVeYCEPC O. O
24 ._.. ..... ._._...._. .-.....__....__.,.__...__.___ ._ _...___...._____ ___.
. _._ _ KITNsRPPCV - 60 ~~12 f ATYLeLASAV O.0$0 ~

14.~ TYLElASAVK 0.045 t$ . FPYEkDLIEA . 4 0 $3 ...

I ITNSrPPCVI
IO$ . . . .._ .. .... . .._ __......___ , . ... . ~ .__~__ ..___.. ...._ ._...
._ . i 17 QLVFsKLENG 0.045 72 ._. ..._ ._........ ... _... _.._. ..~.
._. _-.....-_. .__-.. ..._.__.._._..
_.. .,_ 18 CEPCgFEATY 0.03 30 _ . . _ ._. . . ._. .. ..,- ...__..____.__._...___..._._..
~ __ .._.. .

22 : . .._ , .. .____ _.., .___.....__._ . GVRIvVEYCE. ~27._.__.. .__._. ____.
. _..._ ...__.;
~

2O ... EVEPgSGVRI. . ..... .._. 027.. ._._._.
16 . ____. ._. _.. .._..

Echoed User Pegtide Sequence (length = l I5 residues) HLA peptide motif search results User Parameters and coring Information metho se ected to ~m~t num er o exphc~t results number number o results requeste 20 HLA molecule type se ecte A 1 l0i -lengt se ecte or subsequences to be score ~
_ ~~
~
~

or enput sequence ~~ Y
echomg mode selecte _. .._._._. . . . ____.. ._.____._.____...,~_.
____ -.._. _...__..-__ ._.____.
_. __u___ .._____._.__ ec omg ormat _ f~ ~"er~ed~Imes ....... . .___ . .._._. .__ ..._ ~_. ..~._ ___.. ...

;
p 115 a ti a se uen engt o user's m ut p p q ce __ ' ~ ~ ~ ' ~'~-~. __ ~
~
~
, ca cu ated sequence scores number o su ~

e; 20 number o top-sconng su sequences reported ac m sconng output tab ..._ .. . _._ . . ... ..._._ __... ....... ..___. .._._..,_.__. .... . .._.__.. _____ .__. .
.__.__.___. ,_~_. .._ Scoring Results Rank:Start ubsequence core ( stimate of~alf Time PositionResidue ~ of isassociahon~~
Listing a Molecule Containing This Subsequence) '. .
.
..
...

~1 , .400 39 ,; .__..
YJJELASAVK . . .. .. ..._..
.. .__.. ..._._ .....' ~
INGQLVFSK, 0.120 EVEPGSGVR
~' .
.
..
.
..
.._ ....012 _.
.
....
..

lOl ~
TI,EKITNSR~
O.O$O

GTGAFEIEI
O.
'.
' ~

SO .~
. , YPGIEIESR.
,.
. ~~~
._._..
...__..
..____, ..~~040..
___ _..
._~_.__.
..__.____._._...~

ASNGETLEK
O.

' , ~

0.036 $7 KDLIEAIRR~
~

KLENGGFPY

.

~ENGGFPYEK
0.024 :
7~

L1 ~ SVAPPPEEV
~ . O. ZO
_. __ ____..
____. . _..
. _. .. ._.
... _._ ...__.__......_.._..
___. ._.__ 4S .O2O
~

0.

~~
A'PYLELASA
~
~
..

, .
.
GFEATYLEL, .
_ .
.
.
_, ._...

2_._ ..
_...
_.
_.
...
.
.

IS
~~
ITNSRPPCV
O.
~
..

1 ~ i 22 ._... ...__.. .._ _ _ ...
GVRIVVEYC .._...
; .._. ..
..
_ 17 TYLELASAV .00 i ~, ; _. .. .___, .~. ..___....___._-.__.
_ _. .~. __. .___.__. ___. _.-._ .__ .~ __.__..
.._.

1$ ,$2 ~ . GFPYEKDLIO.O ;
, ~ __. ..._ _.. . _._. ._. ..__.. ._-.____ ... . .._.__ _____ . __..
~ ..__ ._.. . CGFEA _ . . _.. ._.... ._ ..__._.~'..__6....____ . . . .__. ..YCEP..~._. _._.._. __.._ ., _.._ ... ..

73 .. __ O' : .O4 , . ..._ ....

Echoed User Peptide Sequence (length =11 S residues) -29~-HLA peptide motif search results User Parameters and Scoring Information met od sc ecte to emit num er ' exphcrt o results n i---~--~~---~ numbero resultsrequeste;~ 20 H A molecule type selecte A 3101 i lengt se ecte or su sequences ._!~9 to a score .._ _. _... . ..
~ , ~~

or input sequence ~- Y--echoing mo a se ect .____~~:
.. _._.. .__-.. .__... ~. ...__.
~_. ..___.._y....

ec omg ormat ; num ere .._ ._.. . ._.._. .___........_._..tes ;
...___. .__.. _-. _..._.. ~_._...._._-ength of user s input pepri a 1 sequence ___... __... ._.... _.___...___.._..
_._.___...___._...________....___...____~__~

num er o su sequence scores ca "~~ 107 c at ~

ac m sconng output to lei 2 number o top-sconng su sequences reporte _.. . ...__ _._...__._... . ..__.._.._.__.. . ._._..__.. ______._ .._.___.._ coring Results _.' iRaStart Subsequence core ~ st~mate of Half PositionResidue Time of D~sassocsation Listing of i a Molecule Containing This Subsequence) .
TLEKITNSR.
..
.
.
_..
__.
2:_...~..
...___ .
_._..
.._.

~~16 ~
EVEPGSGVR
0.600 SO YPGIEIESR
.400 .

$7 KDLIEAIRR

YLELASAVK
.

~ENGGFPX
0.1 ...
.
...
...
.,..,_ .
._.
.___...
_ ._____..
...___...
.____.
.___....
i ATYLELASA

INGQLV
FSK
O.OZ4 4~~
AVKEQYFGI
O.O2O

IO
~
GTGAFEIEI
O

I
I, ~.
' .
SVAPPPEEV
.._.
._ ___..
....
____..~_.
Z__~..._....
_..__ _.___,.____ ._.

24 O.O1Z

14 0.0 2 73 ' .
LVFSKLENG

15 ~ TYLELASAV O. 2 ~ .~

lOS ~ ITNSRPPCV
. '~

Z
QLVFSKLEN
I
__ .
__.._ __ .
____ .
__ .._ .
..
_ _ ._.....
___..
.
~

0:
O
I
$Z
GFPYEKDLI
_ _ _ __ ..
, ~

lO4 _ , _. ..KITNSRPPC
. . ... . _..
._... ___._'.OO
__ . .__.
r____._..._.

ZO ENGGFPYEK
7~ . .... .
: ..__~OO_._...
. . ___ ._ ....

Echoed User Peptide Sequence (length = l l5 residues) HLA peptide motif search results ser Parameters and coring Information h met od selected to limit number explicit o resu is ~ num er num er o resu is requeste r 20 HLA molecule type se ect ;~A 3302 ~

_ ~;
leng selecte or su sequences to be score _ __ .. .. _____... ._.______ .-.. .___'_. _____._..._.
~

q ~
p i . ~_~___..__-g n mode selected or m ut se uence ec of ... .. _~...._ ..__ _.. ._~__.____.__......____......
~. .__..__.._.._.. _.

ec omg ormat i num er ... ..__.._. _-_..__.__ _..~.._. es-!
___. .~_._.__.______ __=

length o user's input peptide sequenceI 15 j ~ .._ .. ._.._.__.__.~____...___._.___-._..~._..___.__.__~..____..~..:

num er o su sequence scores c cu .. 107..
ate '.; _, I
~~ _...

m sconng output to e; 2 number o top-sconng su sequences report ac ._... _.._ .._ ._.._.. ____..._._. . ....._._.._ ...._...___._...
.._____._.___._._.__ coring esults Rank Start Score ~ stimate of Hal Position. Time o Disassociation Subsequence of , Residue ~a Molecule Containing Listing This Subsequence) ~
~~

r] 16 ~ EVEPGSGVR 4S.OOO
.... .. ......_..
........._. .._... ._:

.. . ... _....... '00_._ _....
. .__..._.. ..

50 , YPGIEIESR
....._..
... _.__.._..
....
-_.
.... ._... ,. ' ~

EIEINGQLV :
:
:
s .
I.SOO

ESRLGGTGA 1.SOO
'. . .. ...... ....
. ~

S4 . . . ..... EIESRLGGT1.S O
,....... .._.. __.... ....._.._.._..
S . ......__..___,....._.~.__.
, .__..._.

INGQLVFS I.SO

( $ 86 EKDLIEAIR

ELASAVKEQ

lO BS DLIEAIRRA
.. .'.

l l 96 . .__._.. ASNGETLEK500 . ..__ .___ . .. _.._.._..
.. ..~___._........._..._._.
____._..

I2 22 GVRIWEYC _ O.SOO _ 13 ~ . MSGEPGQTS ~ O.SOO

l4 ~(~ LIEAIRRAS 0.500 . '...:_.. .___..
..._....
'._...

; .. ..
IS ~O7 _~NSRPPCVIL : ..

I6 ~~ ,_'_ SVAPPPEEV .
. _ .. . . ....... ._........_.
.._.. ..._ ... .__...

17 38 . , TYLELASAV O.SOO _ _ - ... _I
'._ ...
. '_-- _ 25 : ._ . _._.~.'. OO..._._._.
.,IVVEYCEPC_... ___._. .____.
_... ._ 19 45 '~ AVKEQYPGI 0. O
.. . ... ... ._.... ...__._..._.__~..__ .__.___.. ..._...____..

20 (~~: QYPGIEIES . OO

Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results User Parameters and coring nformahon metho se ected to limit number exp ic~t o resu is number ( ~ number o resu is requeste ~ 20 HLA molecule type se ected ~ A 3302 .

leng se ecte or subsequences to , _.
a scored ._.__ _ ._._._.... ...__.._...._.___ _.___ . . . ...___... ...~_..__ ec omg mo a se ect or input sequence; Y i . ... .: _-_.._. .____ .__-__..__......___.__ _' .... __y. .__.._____.__ ec omg_ormat _ _ i num er __ _ _ nes iI
~
~ y o user's input peptide sequence ( 11S
leng .. _ _ __..____ ~
~
~~
~
~
y~
~

cu ate 107 i num _._ _.
er ~
o su sequence scores c ~.

m sconng output to number o top-sconng su sequences .
reporte ac e; 2 . __.. ..___ ....._ . __..__ __._.._._. . ........__... ......___._...... .._-__.._....._.___ coring esu is RankStart Subsequence core Estima#e of I~alf Position.Residue Time of Disassociation Listing of .
a Molecule Containing Tbis Subsequence) ~~
~.
. ~

1 EVEPGSGVR 4S.O O
16 .... . . ...._.. .._._........_.
.._... .:

lOl TLEKITNSR 9.OOO
.. ... _....... ..__......
. ..._....... .._ 3 SO _ 3.OO
YPGIEIESR ._. _... . . ..._._._.
.... ...._....._.._.. . .._ __....

66 ETEINGQLV 1.SOO
.

ESRLGGTGA 1.SO
. ..... ....... ..._.

6 EIESRLGGT _.... ____. .__..1~.. O.
S4 : .._.__.._........ .___..._..
-.. . . .. .______ _ EINGQLVFS 1.S
68 ~~
.

86 ~EKDLIEAIR

lO DLIEAIRRA
~
BS

11 ....,_.. ASNGETLEK..._ .__.. ... .._..~_,~~
96 ... ..___..._........._.._...
.. .._,_..;

12 GvRIwEYC O.SOO . _ ._ 13 ~ MSGEPGQTS ~ O.SOO
la ~ s~ LIEAIRRAS o.so 1S lO7 . .~NSRPPCVIL .
16 ~i ..._ SVAPPPEEV .. .., . ._.... ._:..~._. ..... ..,_ _. . .._...
17 3S ~ .__. TYLELASAV .._. ~~ .... . ~_SOO... . _..~__. ._._ . _.' Echoed User Peptide Sequence (length =11 S residues) HLA peptide motif search results User Parameters and Scoring Information .

method selecte to lima num er o exp results icit number T' ~ ' number o results requested 20 HLA molecule type select AGB. t , , length se ected or su sequences 9 to be scored ~
.. .... . .. . ._. . ....__ . ...__._..
... ... ....._.. ..._.._.

echoing mode se ected or input sequenceY ;
_... ._ .. . _.__ .._.. .__,~ _._.._..~____._......._.
.__.___... __..__.. .. ... ..._...__...' ec omg ormat num ere . .._ . . __._ ._...._. ____. ____...es ._.__.. _.__ ..__.___ ____. .a len o use s Input pepti a sequence 115 __.._. ... _.. ... ,.____._... .....__..._._~_._..____.___-...____..-____......____..._:~ _...~..__ num er o su sequence scores ca cu ate !
~
~
~

number o top-scoring su sequences reported ~..
ac m scoring output tab e.
_ .. :

.. . . __.. .... .. __.... ._.... .. _ ______... __.._.._._ _ _..___........_____ 1 Scoring Results RankStart Subsequence Score (Estimate of Half PositionResidue Time of DisassocWahon Listing of ;
a Molecule Containing This Subsequence) G
I
GVEPGSGVR
90O.OO
-lz.OOO

SVAPPPEEV
__ ._.
..
.._.._.
.
_ ....
_ SO
YPGIEIESR
lO.OO
_.
.
._ .
_.
..
.
.
._.......
_...~..
.
..._.
.

.
oo ~
ASNGETLEK

S S.OOO
lOl -TLEKITNSR

.. . .__.. ..... ..__._.4'OOOy.
AVKEQYPGI. _._.._ . .,...___._...____...._ _...' ~
ENGGFPYEK
3.
O

YLELASAVK

Gl ~
GTGAFEIEI

8~
~
EKDLIEAIR
2.25 .

11 .200 69 .... _. _.. __ .._.__ .
. .____.._.. _. _.___.__.-_..._____...
INGQLVFSK .__.__:
' ..._..
...
..
..
.

_ 1.00 ~12 ~

KDLIEAIRR

' I.OOO

ITNSRPPCV

14 37 ~ 1.000 ATYLELASA . ~

15 ~ ESRLGGTGA 0.90 E
~
.

O.BO
~S
IVVEYCEPC
"....
._.._ .._ :..
....

0.800 1~
73, LVFSKLENG
_.
.._ .._.
...
..__..
.__..
.
.._.__...
__.._.__._ _._.,._..__ _____._.._____...._r B
DLIEAIRRA
O.
OO
..
....
.
.
_.
.
.__.
.....__ ...__._..
.___.__..
..._..__..
.._.._ EPGSGVRIV
.. .. ..
. .. ........
.___.;."~._-._....
.~._.....____.
.____' VVEYCEPCG
_. ~. 00.____.
_ ___.. __.
....__.

Echoed User Peptide Sequence (length =1 IS residues) HLA peptide motif search results -' ~ sex Parameters and Scoring Information method selecte to hmtt num er o results explicit number number o results requested HLA molecule type se ected AG8.1 lengt se ected or su sequences to , be score .._.. . .._.. _.___...__.__. ......
....._.. .__.....

echotng mode selected or input sequence ..... _ .. . __._ .__... ._____ ~__ ....._.
___._.. .__.____ __._.... ~. ...
..__.__...' ec omg ormat ~ num ere ._ . .__.... ._...... ____ ___._._ ies i ._.._..._. __._..._...._.-____. __~____.__.__~-r .J

len o user's input pepti a sequence115 ..._. ..... _.. ... , ..__._.. ...__..._ . _.. ___.. ____. __.~...__.___..._~
.. .. ._.___..__.~

num er o su sequence scores ca cu at I
. . . ..... _ _.. ....

number o top-scoring su sequences 20 reporte ac m scoring output to e.

.. . .. _._.. .... .. ....__... ._.._ .. _ _._.___... _._.._,... _ _. ..._.
coring Results RankStart Subsequence Score (Estimate of Half PositionResidue Time o Disassociation Listing of .
a Molecule Containing This Subsequence) I
I
G
EVEPGSGVR
9OO.OO
...
.
.
_..
.
...
...
.
_____ _.....

1Z.OO0 __.
. ...._.
. _ .._.
._ . .._.., . ___.:

r3 SO .
YPGIEIESR
lO.
O
.__ . _.
. ._.
. .
_..._.
....
._.._....
_._.._..
. ...._ oo ASNGCTLEK
.

r r TLEKITNSR
S.O
O

S
.
AVKEQYPGI
4.

...
..
..
_..__.
_.
._...'.
..,_...
....
...___..
.
..__..___.
....._____.....__ ~ENGGFPYEK
3.
O
~
..
.
__.
.
....

__ YLELASAVK
3.OOO
..
_..
.
.
.
..
._ _..
_..
.
._.:

GTGAFEIEI
;~
3.OOO

.10 EKDLIEAIR
2.250 11 1.2 O ' 6~ .... __ ...., _.__... .,.___._..._.
,__' _....._.__.__.. .___._..
INGQLVFSK _____.
v ..._..
..
.

12 1.OOO ' 8~
KDLIEAIRR

13 ~ ITNSRPPCV
10$ I. OO
~

14 ATYLELASA 1.OOO

IS
~
SG
ESRLGGTGA

IVVEYCEPC
.800 ' ..
...
~
' "....
...., ._._.._ .._:

O.BOO

~
LVFSKLENG
i ' .
_.
__ .._.
_..
_ ..
.__..
.__..
.
....____ .
____.__._ .~__.._..
_.__._...
.._-..._:

DLIEAIRRA
.
OO
' _.
.
~__.
._.__.
...__._..
.___..__..
...__.___ .._..

18 . . EPGSGVRIV ... .. . .. ....... ..___:...
.. ' ~__.._.... .__._....___..

20 ~ . VVEYCEPCG
~ . 00 i Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results -- ser Parameters and Scoring Information met o selecte to limit number o results explicit number "- number of results requested ~20 LA mo ecu a type se ected ~ A68.1 eng se ecte or subseque_nces to . .10 a scored ,_.' ~y"
"
.

sequence X
echoing mo a se~ ected ~ or mput ;
____ _. ._. __.. _.__ ____. .~_. num ere .__.__.-____ ~. .._. _.__._ _._. mes ~
.__. _.._. ._.
g ormat ~
ec om ~
~

_ y5 'T
_e sequence __ s mputpe_ph ~o~ us eng~
~~
~

_ 10 ..
_ !
cu ate num er o ~su~sequence scores c num er o top-sconng su ~ sequences -reporte bac . m scoring output to e Scoring esults Rank Start Position Subsequence esadue ~
Score (Estimate of Half Time of Disassociation of Listing a Molecule Containing This Subsequence) I E:TLEkITNSR O
lOO _.

2 EVEPgSGVRI I .~_ 16 ~~

68 EINGqLVFSK

1S EEVEpGSGVR
~

S 3.OO0 9S ~
~SNgETLEK

SS YEKD1IEAIR _ .aS~_ ._..
~'.

9 SVAPpPEEVE 1.800 ~
~~

EKDLiEAIRR 1.5 73 ~ 1.200 LVFSkLENGG
, ~ 1.2~
2S ~
, IWEyCEPCG
_ :

11 1.OO0 105 .. .
_.' _.
_,_ ITNS_rPPCVI
~..
~~

: LOOO
ATYLeLASAV ~ , f~IZ .
3~

13 78 LENGgFPYEK O. OO.
i .

14 TSVApPPEEV
~ 8 ~

~2 .
_GVRIvVEYCE , ~ ..

18 O. OO
~EPGSgVRIW ...
.. . .
~. _. ..

.

MSGEpGQTSV
__.
..
_ _ .
.__ _._.
~
..
' _~~
.
.
._ lA
_ _ , .
~
..TY

y, '.., .' .._ ..._ __, ,- -__ PGiEIESR ._ .-... .
... ' ._ ..
.
..
_ "
~

:
_.
.
:
rv ._ A
y .
.
, '0,400 _,_ ~qYPGIE
.

Echoed User Peptide Sequence øength = I IS residues) HLA peptide motif search results ser Parameters and Scoring Information "met god selected to tmrt number o results explicit number num er o resu is requested ~ 20 HLA mo ecule type se ected ~ B14 ength se ecte or su sequences to a scored 9 .. .._._ . .... .._.... ........
_..__. ....__.._ ____...__.. .._._...._...
__ ._.....:~....-ec omg mo a selecte or input sequenceY
! ~.___.
_.. . ..._.. _. _.._ .__.. ..-. _..__.
._~ ~._ .___.._. .___.. _.._ ..._.____.__ ._.__._.. __._ ec omg onnat ; num ere _....._ mes _._ . ...._. . _... __ .__._.. ___._....___.~__ ._ .._____.__...
~ --..___ _-_ .
~
~

u~ Ii h _ S
i ~~
e se_ ~~
uenc_e en o user's mp pep q ~
~ ~~
~
.~

i 107.
sequence scores ca cu at ~
num er of su ~

bac m scoring output to e. 20 ., num er o top-sconng su sequences reporte _.. ..._ .__ g ~ .. . .._ _. ___.. __... ._._._.. ..._..._ .. _ Seorm esu RankStart Subsequence core (Estimate o a f Time Position:Residue of Disassociation of , Listing a Molecule Containing This Subsequence) RRASNGETL
20.

....
._.
_.
...
..
..
..
..._ ___..
_.
.

SRLGGTGAF
5.000 _ .
..
_, ..
..
.
.
.
.

, ETLEKITNS
. 3.375 ' .'~
~

lOS
ITNSRPPCV
2.
' , DLIEAIRRA
1.35 y EPGSGVRIV
....
.
v _..
__ .._.__...,._._1.2._.__._.
__......
._ ._.
.._._...._._' NGQLVFSKL
1.O
.

~8 GGFPYEKDL
81 1.00 EIESRLGGT
.

lO
:

SNGETLEKI
0.600 ..EAIRRASNG . ... __. .__ ____ ......~.45___., , ._ .., ._... . _ ____ .._ 68 r EINGQLVFS 0. 5 13 0.300 ~

_.
FEIEINGQL

14 3 VRIVVEYCE .30 ' .

IS 0.300 21 ' SGVRIWEY
~

I6 SI 0.300 _ ' PGIEIESRL
. ..
.
' ~

17 ITNSRPPC .25 1~4' ; ~
._.. ..__ .. __ ._. ~
. ...... ._ ___. ._._. ___._ _..._ .. ..._ a .:

. _ .225 18 EQYPGIEIE _.. __ .. _.__. .. __.
48 . .._ _.. .__ _._. _.. __. .__:
; ~

SNGET .. .... . ___. .__ 2~._.__..
_... ._ . . _. .. ...._... __ _.. .

~ _ . ...,.
IO7 , 0.2 _..
. . .. . _ Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results I Uscr Parameters and coring Information met oei selected to lima num er explictt of results ~ num er -' ~

number of resu is requeste ~ 20 HLA molecu a type selected . B14 lengt se ected or su sequences to ,___10 a scored ! _ "___ ~ ~ ~
. ~~~~

ec omg mo a se ect Y '?
or input sequence ~...._ ~
_ .. . . . . ...__. .__._. .__._..
__ . .... ._._ . ._. .._... __.
__~

ec omg onnat ; num ere _ _ . . ..._... ....._ ____.. ...__...mes __ .._.__..._._ ..~ .__..__. _____:

en of user's input pepti a sequence11 . . _ __.__....._.... ___.__._....__....._...__.....__._._.~ ____~_~, . . ____.. _...___....._.i num er o su sequence scores ca culate~!
;

num er o top-sconng su sequences reporte ac m sconng output tab e; " , 20...

... .... . _...Resu .~°._ ___.. ....__ .. _._.._.._.... . __._._.
.._._.__....~
Sconng is RankStart nbseqnenee core ( ~ shmate of Hal Position,Residue ime o isassociah ol' j Listing a Molecule Containing TLis Subsequence) lO3 .750 EKITnSRPPC

r 5.0 CGFEaTYLEL

I-IRRAsNGETL
.000 EPGSgVRIW
3.00 ~"

DLIEaIRRAS
.

, _ ITNsRPPCV
2.
OO
i W
~.
.
"

.000 TNSRpPCVIL

SO
~
YPGIeIESRL
1.

~

1.000 ~
ATYLeLASAV
1.O
.

31 0.90 .
,.~
EPCGfEATYL

12 O. O
~H
EQYPgIEIES

13 76 ~~
SKLEnGGFPY
0.750 14 83 ; . FPYEkDLIEA
~ O.

8 .TSVApPPEEV
.

ASNGeTLEKI
_ .
...
.
.
_.
__.
.
.._..
._...
.
__..._ ..._.
.
.
..

17 O. 00 44 ._._ SAVKeQYPGI
_....
..__.
.
..

_ ~
SRLGgTGAFE

19 53 IEIEsRLGGT 0.45 _ C-f~..~_._.~... ._. ~ ._. . _... .._3..._. .____.._ _..___... _._.._..__..
20 ~l ~ SGVAiVVEYC
Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results ser Parameters and Sconng Information met od selecte to limit num er o resu is . exp ic~t number number o resu is requeste HLA mo ecu a type selected B 2705 englh se ected or subsequences to 9 a score ;
... ... ....._. .._.. .__... __ ...__.. ..___.._ ...._.

echoing mo a se ecte or input sequence~Y-._ p~ .._ _' ._ ..___.. ,_._ ____. ......___.
_..__ . ._,. ...
~
~

~ oat ~
e_c o g number _ ' ii nes _ ...__~....__.___ .. .___.__.______~
_..
. . ...
..

._ 1~ 5 es uence engt er's input p tid eq ~
o us.._.___..__..__~
_ _ ... _ ~
~ ~

num er o su sequence scores ca cu 1 7 at num er o top-sconng subsequences 20 reporte ac m sconng output to ei ~.
.. ._.. . ._.._ .. .._.. _.. . ._.. ......._.. .___._...._...~~ "__ ._.~_... ______-__..._.._ Scoring Results RankStart Subseduence Score (Estimate of Half PositionResidue Time of isassociahon o Listing .
a Molecule Containing ~_ 'his Subsequence) ~ . . . .__.__ _ _-.... _...
RRASNGETL . ..._._ ___.._. ..___.
~
..-.

57 .. __. ... .__..I .~..
SRLGGTGAr ... .. ____.__ ..
'.
.

~, IRRASNGET
..
.......
..
_ .__.
_._ .
.
.__.

oo ,...
..
, ..
~4 ~~
VEYCEPCGF
.' S ~ 4S. OO

KLENGGFPY
, _ 3~J ~~O.OO,. "_. _.. .__...
. _._......___ _' , YLELASAVK
...J

~S
FEIEINGQL ..

27.OOO

~QYPGIEI
~
.~

2O.
OO
INGQLVFSK

23 ~
vRIwEYCE
20.OO0 --.11~ .101 ..
._ TLEKITNSR, ..__.
..._.......
IS.V
_..._.
__...
_._.
.._ _.~.
. __.

~

~EINGQLVF
S.OOO

107 1 .OOO
. ' 14 O.OOO

'_.

YEKDLIEAI
.O

17 .000 .' .~
VEPGSGVRI .

17 S1 ,. .5 ~ ~ GGFPYEKDL . ._-__.
.._ _~
... _-.

1~ '~
~ .
, TNSRPPCVI
~
' ,_ _.

Y
OOO
.
, _.
SNGETLEKL.

.
FSKLENGGF
_.r -.
O

Echoed User Peptide Sequence (length =115 residues) VILA peptide motif search results User Parameters and conng In ormation metho selected to limit num er exp rcit o resu is num er num er o results requeste ~ 20 HLA molecu a type select B 2705 ;

engt se ect or su sequences to 1 be scor _ __ _ v ... ___.....
~u ~

! Y t ... ' ;
a select ~~ or m ut s uence __ ec om . mo ; num ere g p ~! mes .._. ..__. .. ...____.___.. _.____...
g __. __~ _... ___ . ___. .____.._-_..__ ec_om ormat _ _ _ _ _ _ 115 , len o~~user's m_pu_t peph a sequence __ _ _ _ ' -~-_ ..~:
cu at ~
number o su sequence scores c num er o top-scoring su sequences e!~ 20 reporte ac m scoring output to . -I.._..___...._ . . ..._... .. _ ...

_. . _ ._... ... .__. .._... ._...._. ._._... .._.___.._ __...__._ ....._._.._.__. ___.__.. ....__~
conngResults ,--._ .
RankStart Subsequenceg Score (Estimate of Half Position:es~due : T~me of Disassqociati Listin ~ of !
a Molecule Cantainin This Subse uence .~
'.~

3 ._._. .._.
IRRAsNGETL .._._.:_.
i ~.. .._._.. .-~.. ~.-~~.__.

RRASnGETLE ~
... fi0.000 .. ... .... .__._.. ___._._ . ....__~ .__.. ..._ 3 30.00 78 ...
LENGgFPYEK .

RASNgETLEK 30.000 ' ~ .
~

SH ~C7.OOO
RLGGtGAFEI ~~

6 25.000 33 -__.___. . ____.. ..__-.
CGFEaTYLEL _,_ ,_.... _. __ ..... .
..
...
.._:

TNSRpPCVIL ~
ZO.
~
.... .___.. ..__. ___ ._._ 11 69 ._ .
Echoed User Peptide Sequence (length = I15 residues) -30~-HLA peptide motif search results User Parameters and Scorrng nformation I- method se ected to limit numberexplicit o results num er _ __ num er o results requested ~

H molecu a type se ected B
~ 3501 or su sequences to be scored lengt se ecte ....~ ._ .
_ .
~
.
~

sequence ; Y
selecte or mput ...
ec omg mode _..___. .___...__.._ .___._.._.__....__.
_ ._. ..__......____ .________ ..

g ; num ere _.. .. ___.,uses _ --.-.._..-____.
ec om ormat _._. _. ... . _.... ..__._. ._~_..~__~.._.____.
_......___._.. . .___..__._ leng o user's input pepti a sequence 11S
_ ____ _ __..J___...._..__.-__...._s Y~

number o su sequence scores ca t~
cu2at ~

m sconng output to Iei 20.
number o top-sconng su sequences reporte ac ... . . . . .. . .~ __.. . ..:

... _... .._ ..._._. ._. .._. .._ . ___ __ ...___ . ____.. ..__.... ....~_ ..___.__._ coring Results ,.,... _..
RankStart Position Su Score (Estimate of Half sequence esidue Time of Disassociation Listing ~ of a Molecule Containing This Subsequence) 31 ' ,. EPCGFEATY 4(}.0 . .

~S ~ . FSKLENGGF , .22.500 Echoed User Peptide Sequence (length =1l5 residues) HLA peptide motif search results XJser Parameters and coring nformation met od se ected to imrt num er o resu is cxp ~ctt num er number o resu is requeste 20 HLA mo ecu a type selected B 3501 ength selected for su sequences ~ 10 to a score i ..__._ . ._.. . _._.....
__ __. ..
'.'_. . ..~.
"
-.
~"

~
p ted or zn ut s uence ode se ~
ec o g m m . .__ .. _.__._. __- _.___ ..._.__...
__._. _.___. ..____ . ___ ..___ .
~

_ . num ere ~ mes i ec omg ormat _ _ _ _ ~
~ ~

T_.j ~_ I 1 eng o user's input peph a sequence _'- i ~
~
.
~~

_. i ~l U
su sequence scores ca cu ate num er o ~.
~ ~
~ ~

m sconng output ta 2 e, ac num er o top-sconng su sequences reported .. .. ..... .._. ... ...._. ._...
._ . _ _ ... ..._.. Sconng Results ~ .........__.. ._._ .._... ._ _ ......._...
____._ .....~
.RankStart Subsequence Score (Estimate of Half PositionResidue ~ Time of Disassociation of Listing a Molecule Containing This Subsequence) .
.

31 EPCGfEATYL 30.00 r YPGIeIESRL 20.0 2 ~1 ESRLgGTGAF 1 .000 ...
' .__... . ._.
..

20 ,.~
GSGVrIWEY -...-.i.:

y. 18 ~7 33 Echoed User Peptide Sequence (length = x 15 residues) HLA peptide motif search results ser Parameters and coring Information method se ected to hm~t number of resu is exphcn number num er o resu is request 20 L mo ecu a type selected ~Ol ' eng se ecte or su sequences to a ~
scor ~~
~-or input sequence ec omg mo a se ecte ......_. ._.____. .___. _.-... ...__._....._..__.
_. ____ _.._ .....___ _.__...._____..

;
ec omg at ' um ere nes ._ ..__._ .___ _...._ .-. ._..._ .__..._ . _. _ .. ..__.
~

~ ut peptt a sequence 1 en o user's t p .. _ .. .. .... .. _ _..... . .._~..
___,....._.._._ ___...___ .__.___ ...._.__._.., num er o su sequence scores c eu ate 107 ~
~

in sconng output t e. ZO
ac num er o top-sconng su sequences report .. .. . _.. . . . _. .._g . ....__.. .. .__. ._.. _ _. ._. . _._._ Sconn esu is RankStart Subsequence core (Estimate of Half PositionResidue Time of Disassociation Listing of ' a Molecule Containing This Subsequence) ..
RRASNGETL
1S.OOO
~

GFGATYI,EL

TYLELASAV

~~6 EIEINGQLV

SGEPGQTSV
3.OOO
...
.

.
3.OOO

.._ ...
._...
~...
._..
_._.__ .._____.
,_.
_..
...._.._:

NGQLVFSKL
'_.

GGFPYEKDL
3.00 EPGSGVRIV

lO 1.~OO
y$
FEIEINGQL

SRLGGTGAF
.O~
_a ._ ......
.._ _..
.._.
.
.._._.._ .___._ __ ....
__..

lOf>
TNSRPPCVI
1.OO

~ 1. OO

~ 1.O O

,~.
ITNSRPPCV
1.

, NSRPPCVIL
0.900 _...
__ .
.
..
..
_.
.._.
....._ .
...
.._.
.__ AVKEQYPGI
.
.
.
_ __ ._..
...
.
.
.
.
__ .
.
..___.
____.
.
_.
.
___..
....

,1H
SI
, PGIEIESRL
O.C>OO
~
..
_..
.._..
_..._;
-~..
..__._ ~
..
..

~LIEATRRA ~
19 O. OO
88 .. ... ... _.__. .... .__...
...... ... .. _____. _.
..._ ..
.
.
.
,.

20 . ._. .., O ..

ETLEKITNS

Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results User Parameters and coring Information ~ iucthod se ected to limit number o results exp icit number number o resu is requested HLA mo ecule type selecte 3 Ol ength se ecte or su sequences to 1 a scored E
.. ... ..__... _._._ ..__. ..._._.
~
~~

e selecte or input sequence Y
echoing mo n -~

v...___.. ..._ ~. .___ __..._~ es:
. __ _n~ ere ._.._~_..e~.._otng._~at-leng o user's mpu_f peptide sequenceI15 ~ ~___._._._...
_._' _ ~~~ ~
~
' .
-~

eacuate _. 106 sequencescores num ero su I, num er o top-sconng su sequences 20 reporie ac in sconng output t e;

Scoring Results RankStart ubseguence Score (Estimate of Half PositionResidue Time of Disassociation Listing of a Molecule Containing This Subsequence) I CGFEaTYLEL 12.00 33 _ 64 _ ,. AFEIeINGQL
.

~3 IRRAsNGETL
.~93 4.500 VKEQyPGIEI
3.OO0 ~
EVEPgSGVRI
3.000 TNSRpPCVIL
3.
O
....
..
_.._..
_..
_.
._._._ ._.,....__.....
..____.
.._..
.
...._ ..._.:

~INGQ1VFSKL
3.
OO

~8 Y;PCGfEATYL
.OO

SAVKeQYPGI
2.OOO

( yMSGEpGQTSV
2.0 ~
~..
~._...
TSVApPPEEVs __ :
...
.
..._._.
..._ ......
._2.OO0 , .
.
.___ ._:

~37 ATYLeLASAV
2.
O

sO
NGGFpYEKDL

_S

~
SO
YPGIeIESRL

~S I
~~~ASNGeTLEKI

S~ LO
, . _..
_ RLGGtGAFEI

1~ ITNSrPPCVI
IOS _._,. _...
_.. ._. ..
..___._._.....___.__....
.. . ._.

I~ ~GGFPyEKDI~I
HI I.
. __. _.. .__ ' ..._ , ~-- - . .,...
; _.._. ._..
.._.

I 1.00 4 ..._. _..... .. ._.-_ _.._ ~~ . ____. _... .... ._ KITNsRPPCV
.
.
.
..
_._..
__..._ .___ ...
..

- O E

.y FPYEkDLIEA

Echoed User Peptide Sequence (length =115 residues) DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

Claims (18)

1 . An isolated polypeptide comprising a peptide comprising two or more C35 peptide epitopes, wherein said peptide is selected from the group consisting of amino acids T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2, and wherein said isolated polypeptide is not SEQ ID NO: 2, SEQ ID NO: 153, SEQ ID NO: 155, or amino acids E100 to R109 of SEQ ID NO:2.
2. An isolated polypeptide comprising at least one C35 peptide epitope analog, wherein said C35 peptide epitope analog is selected from the group consisting of:
for the peptide epitope G22 to C30 of SEQ ID NO:2 and FIG. 1B, the analogs with either alanine or glycine substituted for cysteine at the ninth amino acid residue; for the peptide epitope I25 to C33 of SEQ ID NO:2 and FIG. 1B, the analogs with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG. 1B, the analog with valine substituted for tyrosine at the ninth amino acid residue; for the peptide epitope K104 to C112 of SEQ ID NO:2 and FIG. 1B, the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope K104 to V113 of SEQ ID NO:2 and FIG. 1B, the analogs with alanine, serine, glycine or leucine substituted for cysteine at the ninth amino acid residue;
for the peptide epitope I105 to V113 of SEQ 1D NO:2 and FIG. 1B, the analogs with either leucine or methionine substituted for threonine at the second amino acid residue and/or alanine, serine or glycine substituted for cysteine at the eighth amino acid residue; and for the peptide epitope N107 to L115 of SEQ ID NO:2 and FIG. 1B, the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue.
3. An isolated polypeptide according to claim 1, wherein said peptide is amino acids T101 to V113 of SEQ ID NO:2.
4. An isolated polypeptide according to claim 1, wherein said peptide is amino acids E100 to V113 of SEQ ID NO:2.
5. An isolated polypeptide according to claim 1, wherein said peptide is amino acids G99 to V113 of SEQ ID NO:2.
6. An isolated polypeptide according to claim 1, wherein said peptide is amino acids I93 to V113 of SEQ ID NO:2.
7. An isolated polypeptide according to claim 1, wherein said peptide is amino acids D88 to V113 of SEQ ID NO:2.
8. An isolated polypeptide according to claim 1, wherein said peptide is amino acids P84 to V113 of SEQ ID NO:2.
9. An isolated polypeptide according to claim 1, wherein said peptide is amino acids K77 to V113 of SEQ ID NO:2.
10. An isolated polypeptide according to claim 1, wherein said peptide is amino acids Q72 to V113 of SEQ ID NO:2.
11. An isolated polypeptide according to claim 1, wherein said peptide is amino acids F65 to V113 of SEQ ID NO:2.
12. An isolated polypeptide according to claim l, wherein said peptide is amino acids L59 to V113 of SEQ ID NO:2.
13. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope G22 to C30 of SEQ ID NO:2 and FIG.

1B, the analog with either alanine or glycine substituted for cysteine at the ninth amino acid residue.
14. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope I25 to C33 of SEQ ID NO:2 and FIG.
1B, the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue.
15. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope K77 to Y85 of SEQ 1D NO: 2 and FIG.
1B, the analog with valine substituted for tyrosine at the ninth amino acid residue.
16. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope K104 to C112 of SEQ ID NO:2 and FIG. 1B, the analog with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue.
17. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope K104 to V113 of SEQ ID NO:2 and FIG. 1B, the analog with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue.
18. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope I105 to V113 of SEQ ID NO:2 and FIG. 1B, the analog with either leucine or methionine substituted for threonine 12. An isolated polypeptide according to claim l, wherein said peptide is amino acids L59 to V113 of SEQ ID NO:2.

13. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope G22 to C30 of SEQ ID NO:2 and FIG.

1B, the analog with either alanine or glycine substituted for cysteine at the ninth amino acid residue.

14. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope I25 to C33 of SEQ ID NO:2 and FIG.
1B, the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue.

15. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope K77 to Y85 of SEQ 1D NO: 2 and FIG.
1B, the analog with valine substituted for tyrosine at the ninth amino acid residue.

16. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope K104 to C112 of SEQ ID NO:2 and FIG. 1B, the analog with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue.

17. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope K104 to V113 of SEQ ID NO:2 and FIG. 1B, the analog with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue.

18. An isolated polypeptide according to claim 2, wherein said C35 peptide epitope analog is, for the peptide epitope I105 to V113 of SEQ ID NO:2 and FIG. 1B, the analog with either leucine or methionine substituted for threonine 27. An isolated polypeptide according to any one of claims 1-12, which is not more than 65 amino acids in length.

28. An isolated polypeptide according to any one of claims 1-12, which is not more than 60 amino acids in length.

29. An isolated polypeptide according to any one of claims 1-12, which is not more than 55 amino acids in length.

30. An isolated polypeptide according to any one of claims 1-12, which is not more than 50 amino acids in length.

31. An isolated polypeptide according to any one of claims 1-12, which is not more than 45 amino acids in length.

32. An isolated polypeptide according to any one of claims 1-12, which is not more than 40 amino acids in length.

33. An isolated polypeptide according to any one of claims 1-12, which is not more than 35 amino acids in length.

34. A fusion protein comprising an isolated peptide comprising two or more C35 peptide epitopes, wherein said isolated peptide is selected from the group consisting of amino acids T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F6S to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

35. A fusion protein according to claim 34, wherein said isolated peptide is amino acids T101 to V113 of SEQ ID NO:2.

36. A fusion protein according to claim 34, wherein said isolated peptide is E 100 to V113 of SEQ ID NO:2.

37. A fusion protein according to claim 34, wherein said isolated peptide is G99 to V113 of SEQ ID NO:2.

38. A fusion protein according to claim 34, wherein said isolated peptide is amino acids I93 to V113 of SEQ ID NO:2.

39. A fusion protein according to claim 34, wherein said isolated peptide is amino acids D88 to V113 of SEQ ID NO:2.

40. A fusion protein according to claim 34, wherein said isolated peptide is amino acids P84 to V113 of SEQ ID NO:2.

41. A fusion protein according to claim 34, wherein said isolated peptide is amino acids K77 to V113 of SEQ ID NO:2.

42. A fusion protein according to claim 34, wherein said isolated peptide is ammo acids Q72 to V113 of SEQ ID NO:2.

43. A fusion protein according to claim 34, wherein said isolated peptide is amino acids F65 to V113 of SEQ ID NO:2.

44. A fusion protein according to claim 34, wherein said isolated peptide is amino acids L59 to V113 of SEQ ID NO:2.

45. A fusion protein according to claim 34, comprising a homopolymer of said isolated peptide.

46. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids T101 to V113 of SEQ ID NO:2.

47. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids E100 to V113 of SEQ ID NO:2.

48. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids G99 to V113 of SEQ ID NO:2.

49. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids I93 to V113 of SEQ ID NO:2.

50. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids D88 to V113 of SEQ ID NO:2.

51. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids P84 to V113 of SEQ ID NO:2.

52. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids K77 to V113 of SEQ ID NO:2.

53. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids Q72 to V113 of SEQ ID NO:2.

54. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids F65 to V113 of SEQ ID NO:2.

55. A fusion protein according to claim 45, wherein said homopolymer is a homopolymer of amino acids L59 to V113 of SEQ ID NO:2.

56. A fusion protein according to claim 34 comprising a heteropolymer of said isolated peptides.

57. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids T101 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

58. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids E100 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids T101 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

59. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids G99 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of: amino acids T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

60. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids I93 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2 D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 5 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

61. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids D88 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ 117 NO:2, GI93 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID
NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

62. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids P84 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

63. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids K77 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

64. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids Q72 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

65. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids F65 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

66. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids Q72 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of: amino acids:
T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2.

67. A fusion protein according to claim 56, wherein said heteropolymer is a heteropolymer of amino acids L59 to V113 of SEQ ID NO:2 linked to at least one other isolated peptide selected from the group consisting of amino acids:

T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, T93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, and F65 to V113 of SEQ ID NO:2.

68. A fusion protein according to claim 34, fused to a T helper peptide.

69. A fusion protein according to claim 34, fused to a carrier.

70. A fusion protein according to claim 34, linked to a lipid.

71. An isolated polypeptide consisting of two or more C35 peptide epitopes, wherein said isolated polypeptide is selected from the group consisting of:
amino acids T101 to V113 of SEQ ID NO:2, E100 to V113 of SEQ ID NO:2, G99 to V113 of SEQ ID NO:2, I93 to V113 of SEQ ID NO:2, D88 to V113 of SEQ ID NO:2, P84 to V113 of SEQ ID NO:2, K77 to V113 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to V113 of SEQ ID NO:2, and wherein said isolated polypeptide is not SEQ ID NO: 2, SEQ ID NO:153, SEQ ID NO:155, or amino acids E100 to R109 of SEQ ID
NO:2.

72. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids T101 to V113 of SEQ ID NO:2.

73. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids E100 to V113 of SEQ ID NO:2.

74. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids G99 to V113 of SEQ ID NO:2.

75. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids I93 to V113 of SEQ ID NO:2.

76. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids D88 to V113 of SEQ ID NO:2.

77. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids P84 to V113 of SEQ ID NO:2.

78. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids K77 to V113 of SEQ ID NO:2.

79. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids Q72 to V113 of SEQ ID NO:2.

80. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids F65 to V113 of SEQ ID NO:2.

81. An isolated polypeptide according to claim 71, wherein said polypeptide is amino acids L59 to V113 of SEQ ID NO:2.

82. An isolated polypeptide comprising a peptide comprising at least one C35 peptide epitope analog, wherein said peptide is selected from the group consisting of the analog of peptide T101 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twelfth residue, the analog of peptide E100 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirteenth residue, the analog of peptide G99,to V113 of SEQ ID NO:2 having either alanine or glycine substituted for cysteine at the fourteenth residue, the analog of peptide I93 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twentieth residue, the analog of peptide D88 to V113 of SEQ ID
NO:2 having either alanine or glycine substituted for the cysteine at the twenty-fifth residue, the analog of peptide P84 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty-ninth residue, the analog of peptide K77 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirty sixth residue, the analog of peptide Q72 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty first residue, the analog of peptide F65 to V113 of SEQ
ID
NO:2 having either alanine or glycine substituted for the cysteine at the forty eighth residue, and the analog of peptide L59 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue.

83. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to the analog of peptide T101 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twelfth residue.

84. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitome analog is the analog of peptide E100 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirteenth residue.

85. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitome analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fourteenth residue.

86. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twentieth residue.

87. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty fifth residue.

88. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty-ninth residue.

89. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirty-sixth residue.

90. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-first residue.

91. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-eighth residue.

92. An isolated polypeptide according to claim 82, wherein said peptide comprising at least one C35 peptide epitope analog is the analog of peptide to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue.

93. A fusion protein comprising a peptide comprising at least one C35 peptide epitope analog, wherein said peptide is selected from the group consisting of for the peptide epitope G22 to C30 of SEQ ID NO:2 and FIG. 1B, the analogs with either alanine or glycine substituted for cysteine at the ninth amino acid residue; for the peptide epitope I25 to C33 of SEQ ID NO:2 and FIG.
1B, the analogs with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG. 2B, the analog with valine substituted for tyrosine at the ninth amino acid residue; for the peptide epitope K104 to C112 of SEQ ID NO:2 and FIG. 1B, the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope K104 to V113 of SEQ ID NO:2 and FIG. 1B, the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue;
for the peptide epitope I105 to V113 of SEQ ID NO:2 and FIG. 1B, the analogs with either leucine or methionine substituted for threonine at the second amino acid residue and/or alanine, serine or glycine substituted for cysteine at the eighth amino acid residue; and for the peptide epitope N107 to V113 of SEQ ID
NO:2 and FIG. 1B, the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue, the analog of peptide T101 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twelfth residue, the analog of peptide E100 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for cysteine at the thirteenth residue, the analog of peptide G99 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for cysteine at the fourteenth residue, the analog of peptide I93 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twentieth residue, the analog of peptide D88 to V113 of SEQ ID
NO:2 having either alanine or glycine substituted for the cysteine at the twenty fifth residue, the analog of peptide P84 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty ninth residue, the analog of peptide K77 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirty sixth residue, the analog of peptide Q72 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-first residue, the analog of peptide F65 to V113 of SEQ
ID
NO:2 having either alanine or glycine substituted for the cysteine at the forty-eighth residue, and the analog of peptide L59 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue.

94. A fusion protein according to claim 93 comprising a homopolymer of said peptide comprising at least one C35 peptide epitope analog.

95. A fusion protein according to claim 93 comprising a heteropolymer of said peptides comprising at least one C35 peptide epitome analog.

96. A composition comprising an isolated polypeptide according to any one of claims 1-33 or 71-92 and a pharmaceutically acceptable carrier.

97. A composition comprising a fusion protein according to any one of claims 34-70 or 93-95 and a pharmaceutically acceptable carrier.

98. An isolated peptide comprising at least one C35 peptide epitope analog, wherein said peptide epitope analog is K104 to V113 of SEQ ID NO:2 and FIG.
1B, wherein the cysteine at the ninth amino acid residue is cysteinylated.

99. An isolated peptide comprising at least one C35 peptide epitope analog, wherein said peptide epitope analog is I105 to V113 of SEQ ID NO:2 and FIG.
1B, wherein the cysteine at the eighth amino acid residue is cysteinylated.
CA2488682A 2002-06-10 2003-06-10 Gene differentially expressed in breast and bladder cancer and encoded polypeptides Expired - Fee Related CA2488682C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38673802P 2002-06-10 2002-06-10
US60/386,738 2002-06-10
US43224102P 2002-12-11 2002-12-11
US60/432,241 2002-12-11
US46465003P 2003-04-23 2003-04-23
US60/464,650 2003-04-23
PCT/US2003/018252 WO2003104428A2 (en) 2002-01-21 2003-06-10 Gene differentially expressed in breast and bladder cancer and encoded polypeptides

Publications (2)

Publication Number Publication Date
CA2488682A1 true CA2488682A1 (en) 2003-12-18
CA2488682C CA2488682C (en) 2014-04-01

Family

ID=29740818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2488682A Expired - Fee Related CA2488682C (en) 2002-06-10 2003-06-10 Gene differentially expressed in breast and bladder cancer and encoded polypeptides

Country Status (8)

Country Link
US (4) US7563882B2 (en)
EP (2) EP2070949B1 (en)
JP (1) JP4643255B2 (en)
CN (1) CN100418981C (en)
AU (2) AU2003274463B2 (en)
CA (1) CA2488682C (en)
NZ (1) NZ537579A (en)
WO (1) WO2003104428A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5311901A (en) * 2000-04-04 2001-10-15 Univ Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
CN100418981C (en) * 2002-06-10 2008-09-17 瓦西尼斯公司 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
WO2005055936A2 (en) * 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US8354380B2 (en) * 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
CN101932333A (en) 2007-12-26 2010-12-29 瓦西尼斯公司 Anti-c 35 antibody combination therapies and method
BRPI0924556A2 (en) * 2009-06-09 2015-06-30 Vaxon Biotech "identification, optimization and use of shared hla-b * 0702 epitopes for immunotherapy"
WO2014140176A1 (en) * 2013-03-15 2014-09-18 Vaccibody As Targeting vaccines for veterinary use
EP3013789B1 (en) * 2013-06-28 2020-03-04 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CA2939305A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2016103192A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
JP6255360B2 (en) * 2015-03-04 2017-12-27 ヴァクソン バイオテックVaxon Biotech Identification, optimization and use of immunotherapy for shared HLA-B * 0702 epitopes
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
MX2017016134A (en) 2015-06-11 2018-08-15 Lycera Corp Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
SG10201913659SA (en) * 2015-10-08 2020-03-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
CN108884020A (en) 2016-02-26 2018-11-23 奥克兰联合服务有限公司 Amino acid and peptide conjugates and conjugation process
KR102251584B1 (en) * 2018-11-21 2021-05-14 가톨릭대학교 산학협력단 Method for measuring and predicting antigen-specific T cell response restricted by HLA molecules

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5081029A (en) 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
PT90959B (en) 1988-06-24 1995-05-04 Dow Chemical Co PROCESS FOR THE PREPARATION OF BIFUNCTIONAL MACROCYCLIC CHELANTES, OF THEIR COMPLEXES AND THEIR CONJUGATES WITH ANTIBODIES
EP0353450B1 (en) 1988-06-24 1995-03-29 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE151110T1 (en) 1988-09-02 1997-04-15 Protein Eng Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (en) 1990-03-20 1997-10-15 Univ Columbia CHIMERIC ANTIBODIES WITH RECEPTOR-BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE69128253T2 (en) 1990-10-29 1998-06-18 Chiron Corp SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
EP1149913A1 (en) 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
ES2093778T3 (en) 1991-04-26 1997-01-01 Surface Active Ltd NEW ANTIBODIES AND METHODS FOR USE.
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JPH07503124A (en) 1991-06-14 1995-04-06 ゾーマ・コーポレーション Antibody fragments and their complexes produced by microorganisms
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
JPH08501085A (en) 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ Use of cytokine IP-10 as an antitumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
NZ263050A (en) 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
PT744958E (en) 1994-01-31 2003-11-28 Univ Boston BANKS OF POLYCLONE ANTIBODIES
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5516717A (en) 1995-04-19 1996-05-14 United Microelectronics Corporation Method for manufacturing electrostatic discharge devices
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5972622A (en) 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
DE19639601A1 (en) 1996-02-28 1997-09-04 Bayer Ag Parapox viruses that contain foreign DNA, their production and their use in vaccines
US5935801A (en) 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US6828426B1 (en) 1996-07-15 2004-12-07 Chugai Seiyaku Kabushiki Kaisha VEGF-like factor
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
DE69739469D1 (en) 1996-08-23 2009-07-30 Vegenics Ltd Recombinant vascular endothelial growth factor D (VEGF-D)
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US5856131A (en) 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
DE69800716T2 (en) 1997-04-14 2001-09-20 Micromet Ges Fuer Biomedizinis NEW METHOD FOR PRODUCING ANTI-HUMAN ANTIGENT RECEPTORS AND THEIR USE
EP1992640A1 (en) 1997-12-24 2008-11-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US5958660A (en) 1997-12-31 1999-09-28 Eastman Kodak Company Hydrophilic colloid composition
WO1999037775A2 (en) 1998-01-26 1999-07-29 Genquest, Inc. Compositions and methods for detecting and treating breast cancer
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20020052308A1 (en) 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2392510A1 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US6489101B1 (en) 1999-11-30 2002-12-03 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
AU5311901A (en) 2000-04-04 2001-10-15 Univ Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1274852A2 (en) * 2000-04-12 2003-01-15 University Of Rochester Targeted vaccine delivery systems
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20050196755A1 (en) 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7858559B2 (en) 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
IL161418A0 (en) 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
CN100418981C (en) * 2002-06-10 2008-09-17 瓦西尼斯公司 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2003270909A1 (en) 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US20050042218A1 (en) 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
WO2005055936A2 (en) 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer

Also Published As

Publication number Publication date
US7879990B2 (en) 2011-02-01
EP1531848A2 (en) 2005-05-25
CN1684700A (en) 2005-10-19
US20080089886A1 (en) 2008-04-17
AU2003274463B2 (en) 2009-10-29
NZ537579A (en) 2006-10-27
US20090297440A1 (en) 2009-12-03
JP4643255B2 (en) 2011-03-02
EP2070949B1 (en) 2013-01-16
AU2003274463A1 (en) 2003-12-22
US20090305350A1 (en) 2009-12-10
AU2009217460A1 (en) 2009-10-15
WO2003104428A3 (en) 2004-04-08
US20040063907A1 (en) 2004-04-01
CA2488682C (en) 2014-04-01
JP2005528914A (en) 2005-09-29
US7750125B2 (en) 2010-07-06
WO2003104428A2 (en) 2003-12-18
EP1531848A4 (en) 2007-03-28
CN100418981C (en) 2008-09-17
US7563882B2 (en) 2009-07-21
EP2070949A2 (en) 2009-06-17
US7968688B2 (en) 2011-06-28
EP2070949A3 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
CA2488682A1 (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20220072113A1 (en) Antigen specific multi epitope vaccines
US9447144B2 (en) MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
US20040037843A1 (en) Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US20070020327A1 (en) Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
TR201909021T4 (en) Personalized immunotherapy against various neuronal tumors and brain tumors.
EP1568373A2 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
US20040121946A9 (en) Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
EP1242049A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
US20040146519A1 (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
US20030224036A1 (en) Hla class I a2 tumor associated antigen peptides and vaccine compositions
JP2003517310A (en) Induction of a cellular immune response against MAGE2 / 3 using peptide and nucleic acid compositions
US20040048790A1 (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
US6664232B1 (en) HLA-A2 restraint tumor antigen peptide originating in SART-1
US20040053822A1 (en) Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
JPWO2003037917A1 (en) Tumor antigen
NZ548918A (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190610